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ABSTRACT 
 
Kyunghee Yang:  Mechanisms of Drug-Induced Liver Injury: The Role of Hepatic Transport Proteins 
(Under the direction of Kim L.R. Brouwer) 
 
The objectives of this research were to investigate mechanisms of drug-induced liver injury 
(DILI) that involve drug-bile acid (BA) interactions at hepatic transporters, and develop a novel strategy 
to reliably predict human DILI. Troglitazone (TGZ), an antidiabetic withdrawn from the market due to 
severe DILI, was employed as a model hepatotoxic drug. Pharmacokinetic modeling of taurocholic acid 
(TCA, a model BA) disposition data from human and rat sandwich-cultured hepatocytes (SCH) revealed 
that species differences exist in TCA hepatocellular efflux pathways; in human SCH, TCA biliary 
excretion predominated, whereas biliary and basolateral excretion contributed equally to TCA efflux in 
rat SCH. This finding explains, in part, why rats are less susceptible to DILI compared to humans after 
administration of drugs that inhibit BA biliary excretion. The present study also revealed for the first time 
that TGZ sulfate (TS), a major TGZ metabolite, inhibits BA basolateral efflux in addition to biliary 
excretion. These findings support the hypothesis that TS is an important mediator of altered hepatic BA 
disposition; increased hepatic TS exposure due to impaired canalicular transport function might 
predispose a subset of patients to hepatotoxicity. A novel in vitro model system, rat SCH lacking selected 
canalicular transporters [breast cancer resistance protein (Bcrp) and multidrug resistance-associated 
protein 2 (Mrp2)] was established to test this hypothesis; biliary excretion of hepatically-generated TS 
was not significantly altered, suggesting that alternate transporters can excrete TS into bile, and loss of 
Bcrp and/or Mrp2 function would not necessarily be risk factors for increased hepatocellular TS 
accumulation in rats. To translate experimental data to in vivo humans, a mechanistic model that 
incorporated TGZ/TS disposition, BA physiology/pathophysiology, hepatocyte life cycle, and liver injury 
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biomarkers was developed; intracellular BA concentrations and toxicity measured in SCH were used to 
link BA homeostasis and hepatotoxicity. This mechanistic model adequately predicted the incidence, 
delayed presentation, and species differences in TGZ hepatotoxicity. This dissertation research revealed a 
number of important and novel findings that improve our understanding about mechanisms underlying 
BA-mediated DILI, and establish a framework to integrate biological information and experimental data 
to evaluate DILI mechanisms and predict hepatotoxic potential of chemical entities. 
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CHAPTER 1.  Introduction  
 
An Updated Review on Drug-Induced Cholestasis: Mechanisms and Investigation of 
Physicochemical Properties and Pharmacokinetic Parameters1 
 
INTRODUCTION 
The liver is the major organ responsible for the metabolism and excretion of endogenous and 
exogenous compounds, including drugs. The liver is predisposed to drug toxicity because of its 
anatomical location and the expression of uptake transporters that facilitate accumulation of drugs in 
hepatocytes. Drug-induced liver injury (DILI) is the most common cause of acute liver failure (1), and is 
one of the primary reasons for the failure of pharmaceutical agents during drug development. 
Unfortunately, current in vitro screening approaches or in vivo preclinical studies do not adequately 
predict the likelihood of DILI. Even Phase III clinical trials that involve a few thousand patients often fail 
to detect DILI. In some cases, instances of severe liver injury and death only were observed after drug 
approval and administration to tens or hundreds of thousands of patients. These unexpected findings led 
to blackbox warnings, or in severe cases, withdrawal of the drug from the market. Recent examples 
include troglitazone and bromfenac (withdrawn), and bosentan and diclofenac (blackbox warnings).  
DILI is classified into hepatocellular, mixed, or cholestatic injury based on the major underlying 
mechanism (2). Among 784 DILI cases reviewed by the Swedish adverse drug reactions advisory 
committee between 1970 and 2004, almost one-half of the cases had either cholestatic or mixed 
cholestatic hepatic toxicity (3). Acute cholestatic injury comprised approximately 16% of all hepatic 
                                                     
1This chapter has been published in Journal of Pharmaceutical Sciences, and is presented in the style of that Journal: 
J Pharm Sci 2013 Sep;102(9):3037-57. 
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adverse drug reactions in a Danish study of 1100 DILI cases from 1978 to 1987 (4). In the United States, 
drugs were responsible for approximately 20% of cases of jaundice in the elderly population (5). 
However, reported reactions are thought to be only a small fraction of all the instances of drug-related 
cholestasis in the community because drug-induced cholestasis can present with asymptomatic disease 
where the only clinical manifestation is an elevation in liver enzymes, which often is not detected or 
reported.  Therefore, the actual number of cases and medical costs associated with drug-induced 
cholestasis could exceed what has either been reported or estimated. In the present paper, the clinical 
presentation and mechanisms of bile-acid mediated drug-induced cholestasis are reviewed. In addition, 
we investigated whether the physicochemical properties or pharmacokinetic parameters of selected drugs, 
or the ability of these compounds to inhibit BSEP, influenced the type of cholestatic liver injury (impaired 
bile formation vs. obstruction of bile flow).  Furthermore, existing in silico models developed to predict 
drug effects on bile acid transporters and nuclear receptors that are involved in bile acid homeostasis are 
reviewed.  
 
CLINICAL FEATURES OF DRUG-INDUCED CHOLESTASIS 
Diagnosis  
Biochemical tests (liver function tests) typically are used to define drug-induced cholestasis. The 
Council of International Organizations of Medical Sciences (CIOMS) defines cholestatic injury as an 
elevation of serum alkaline phosphatase (AP) to greater than 2x the upper limit of normal (ULN) 
combined with a major elevation of γ-glutamyl transpeptiase (GGT) in the presence of a normal alanine 
transaminase (ALT) value.  Alternatively, cholestasis is thought to be present when there is an increase in 
both ALT and AP, but with an ALT/AP ratio of < 2. In severe cases of cholestasis, an increase in serum 
conjugated bilirubin also is observed. Mixed hepatocellular/cholestatic injury is defined as an ALT/AP 
ratio of 2 – 5, whereas hepatocellular injury is defined as ALT > 2x ULN or ALT/AP ≥ 5 (6). An accurate 
diagnosis of DILI also requires careful causality assessment, interpretation of clinical features and 
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laboratory tests including liver biopsy findings, if available, and the exclusion of other potential causes 
for liver injury.  
Clinical Presentation 
Drug-induced cholestasis may present as an acute illness that promptly diminishes after 
withdrawal of the offending drug. Drug-induced cholestasis may present with or without jaundice, and 
symptoms may occur weeks or months after the start of treatment. Nonspecific symptoms such as nausea, 
malaise, anorexia, and fatigue may be elicited due to parenchymal liver injury. For some drugs (e.g., 
amoxicillin-clavulanate, erythromycin), abdominal pain or discomfort has been reported (7). Chronic 
drug-induced cholestasis can result in the development of xanthomas, pruritus, and melanoderma. 
Symptoms often resolve following withdrawal of the offending drug, but in some cases, if there is 
significant loss of the interlobular bile ducts, chronic liver disease may develop and even progress to liver 
failure (8). Rarely, drugs can induce cholelithiasis (gall stones) or mimic large duct sclerosing cholangitis, 
resulting in extrahepatic obstruction (9). Drug-induced cholestasis can be classified into the following 
categories: 
Acute Drug-Induced Cholestasis without Hepatitis (Bland Cholestasis): This is a rare type of 
drug-induced cholestasis that typically is produced by estrogens or anabolic steroids, and manifests 
histologically as pure canalicular cholestasis.  Bland cholestasis causes abnormal biliary secretions 
without hepatocellular damage. 
Acute Drug-Induced Cholestasis with Hepatitis (Cholestatic Hepatitis): This type of drug-
induced cholestasis is associated with concomitant hepatic parenchymal damage. Cholestatic hepatitis is 
characterized by portal inflammation and varying degrees of hepatocyte injury and necrosis. 
Acute Drug-Induced Cholestasis with Bile Duct Injury: This type of drug-induced cholestasis 
involves bile duct injury (ductular, cholangiolar, or cholangiolytic) but minimal parenchymal liver cell 
injury. 
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Chronic Drug-Induced Cholangiopathies: These drug-induced cholestatic disorders vary from 
mild, nonspecific bile duct injury (mild elevation in AP or GGT) to vanishing bile duct syndrome 
(VBDS), sclerosing cholangitis, and cholelithiasis (10). 
 
PHYSIOLOGY OF BILE ACID HOMEOSTASIS 
Cholestasis may occur if there is impaired formation of bile or if there is a physical obstruction to 
the flow of bile after it has been secreted from hepatocytes. To understand the pathogenesis of cholestasis, 
it is important to understand the physiological principles involved in bile flow. 
Synthesis and Conjugation 
Primary bile acids are synthesized from cholesterol in hepatocytes. Approximately 16 enzymes 
are involved in this process; the rate limiting step is 7α-hydroxylation by Cytochrome P450 7A1 
(CYP7A1) (11, 12). Chenodeoxycholic acid (CDCA) and cholic acid (CA) are the most common primary 
bile acids in humans while rodents have high levels of muricholic acid (MCA) and hyocholic acid (HCA). 
Secondary bile acids are formed by gut bacteria-mediated dehydroxylation of primary bile acids. The 
most common secondary bile acids include lithocholic acid (LCA) and deoxycholic acid (DCA), which 
are formed by 7-dehydroxylation of CDCA and CA, respectively. Bile acids are conjugated extensively 
with glycine or taurine in the liver, and more than 98% of bile acids excreted from the liver are amidated. 
Bile acids also may undergo sulfation or glucuronidation. Conjugated bile acids are more water soluble 
and therefore, are excreted more readily into feces and urine. Bile acid synthesis has been 
comprehensively reviewed elsewhere (11, 13). 
Hepatobiliary Transport 
Bile acids undergo vectorial transport from sinusoidal blood across the basolateral membranes 
into hepatocytes, and across the canalicular membranes into bile. Bile acids are taken up from the 
sinusoidal blood into hepatocytes by the uptake transport proteins sodium taurocholate cotransporting 
polypeptide (NTCP) and organic anion transporting polypeptides (OATPs) (Figure 1A). NTCP is 
responsible for sodium-dependent bile acid uptake, while sodium-independent transport is mediated by 
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OATPs. The efficiency of hepatic uptake varies depending on the bile acid structure: trihydroxy > 
dihydroxy bile acids, and conjugated  > unconjugated bile acids (14). Individual bile acids may use 
different uptake transporters. The uptake of conjugated bile acids such as taurocholic acid (TCA) is 
mediated predominantly (>75%) by sodium-dependent NTCP. In contrast, sodium-dependent uptake 
accounts for less than half of the uptake of unconjugated bile acids (15-18). Within hepatocytes, bile acids 
are translocated by diffusion or undergo carrier-mediated transport after binding to cytosolic proteins such 
as glutathione S-transferases, liver fatty acid binding protein (L-FABP), and dehydrogenases (19). 
Vesicular transport of bile acids has been suggested, but confocal microscopy studies of fluorescent bile 
acid analogs in hepatocyte couplets showed no intracellular vesicular structure containing bile acids (20). 
However, characteristics and intracellular disposition of fluorescent bile acid analogs may differ between 
individual bile acids, and the significance of vesicular transport of bile acids in hepatocytes remains to be 
investigated. At the canalicular membrane, bile acids are excreted into bile predominantly via the bile salt 
export pump (BSEP) in an ATP-dependent manner (Figure 1A). Multidrug resistance-associated protein 
(MRP) 2, which is the main driving force for bile salt-independent bile flow through canalicular excretion 
of reduced glutathione, also transports glucuronide and sulfate conjugates of bile acids (21). The osmotic 
forces that are generated by bile acid secretion, coupled with the coordinated contraction of the actin 
filaments that surround the canaliculus, generate the pressure necessary to force bile to flow down the bile 
duct. The biliary tract itself is composed of a network of small to large ducts that are lined by 
cholangiocytes (bile duct epithelial cells). Cholangiocytes also express ion and organic anion transporters 
on the apical [i.e. apical sodium-dependent bile salt transporter (ASBT), OATP1A2] and basolateral [i.e. 
organic solute transporter (OST)α/β, MRP3] membranes that modify the composition of bile before it 
passes into the larger bile ducts (21-23). In humans, bile acids enter the gallbladder where they are stored 
and expelled into the duodenum in response to hormonal signals such as cholecystokinin. In addition to 
canalicular excretion, hepatocytes also are capable of effluxing bile acids across the basolateral membrane 
into sinusoidal blood via MRP3, MRP4, and a recently identified heteromeric organic solute transporter, 
OSTα-OSTβ (Figure 1A). Human MRP3 and rat Mrp3 transported glycocholic acid (GCA) and 
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taurolithocholate 3-sulfate (TLC-S), whereas TCA was transported to a significant degree only by rat 
Mrp3 (24). Unconjugated (CA, DCA) and conjugated bile acids [TCA, GCA, taurochenodeoxycholic acid 
(TCDCA), glycochenodeoxycholic acid (GCDCA)] were transported by MRP4 in the presence of 
glutathione with higher affinity than MRP3 (25), suggesting that MRP4 may play an important role in 
basolateral efflux of bile acids in humans. OSTα-OSTβ transports glycine and taurine conjugated bile 
acid species by facilitated diffusion; OSTα-OSTβ mediates cellular efflux or uptake depending on the 
electrochemical gradient (26, 27). The contribution of basolateral efflux to overall hepatic bile acid 
excretion is small under normal conditions, but expression of these transporters is up-regulated under 
cholestatic conditions as an important part of adaptive response to serve as a compensatory route of bile 
acid excretion (28-32). Assem et al. reported that Mrp4 and sulfotransferase (Sult) 2a1 are both 
upregulated during cholestasis suggesting that increased sulfation and hepatic basolateral efflux of 
sulfated bile acids leads to increased renal excretion as a compensatory excretion route (33). In healthy 
humans, the proportion of sulfated bile acids in the serum is less than 2% of bile acids, and the amount of 
total bile acids excreted in urine is minimal, whereas in patients with hepatobiliary/cholestatic disease, 
urinary excretion of bile acids increased more than 100-fold, with 25 – 80% of urinary bile acids excreted 
in the sulfated form (34). These studies demonstrate that sulfation and glucuronidation of bile acids are 
important detoxification pathways; conjugation increases the hydrophilicity of bile acids and, in most 
cases, decreases the toxicity and facilitates the urinary excretion of bile acids. 
Intestinal Transport 
Bile acids undergo efficient enterohepatic recirculation. The bile acid pool size is only about 2 – 3 
g in humans, but 12 – 18 g of bile acids are secreted into bile per day because the pool recycles several 
times after each meal (35). Just a small fraction of the bile acid pool is lost in the feces (0.2 – 0.6 g/day), 
and about 0.3 g/day of bile acids are synthesized in hepatocytes to replace the portion that is excreted 
(35). In the intestinal lumen, taurine- or glycine-conjugated bile acids are de-conjugated by gut bacteria. 
Bile acids are reabsorbed by ASBT in the terminal ileum (Figure 1B) or by passive diffusion (36). From 
the enterocyte, bile acids enter the mesenteric blood via basolateral transport proteins such as MRP3 and 
7 
 
OSTα-OSTβ (Figure 1B) (16, 23, 37-41), and return to the liver in portal blood followed by efficient 
uptake by hepatocyte transporters, as described above. It has been reported that MRP4 is expressed in the 
basolateral membrane of Caco-2 cells (42), but its expression and contribution to basolateral transport of 
bile acids in enterocytes remain to be investigated. Sulfate-conjugates of bile acids are not deconjugated 
readily and only a limited amount of sulfated bile acids are re-absorbed (34). Bile acids that are not 
absorbed from the colon are eliminated in the feces; fecal elimination is balanced by biosynthesis from 
cholesterol in the liver.  
Bile Acid Toxicity  
Bile acids are required for the digestion and absorption of fats and fat-soluble vitamins and they 
facilitate the excretion of bile pigments, cholesterol, and other medium-sized molecules by micellar 
solubilization. Bile acids induce biliary lipid secretion and solubilize cholesterol in bile, thereby 
promoting cholesterol elimination. Bile acids are potent activators of nuclear receptors such as farnesoid-
X receptor (FXR) and pregnane X receptor (PXR), and they play an important role in the regulation of 
lipid homeostasis (43, 44).  
However, bile acids can be cytotoxic when present in abnormally high concentrations in 
hepatocytes. Therefore, defects in bile acid excretion may lead to cholestasis. Defects in hepatocytes 
(especially at the canalicular membrane), altered fluidity of bile, impaired contraction of the actin 
filaments in the pericanalicular region, and changes in bile duct patency can reduce bile flow. 
Importantly, drugs also can affect bile flow at one or more of these steps, which will be discussed in more 
detail in the following sections. Bile acid toxicity is thought to be highly correlated with hydrophobicity; 
more hydrophobic bile acids are more cytotoxic.  The rank order of bile acid cytotoxicity, from greatest to 
least is:  LCA> CDCA, DCA > CA > ursodeoxycholic acid (UDCA) (45). Under normal conditions, it is 
likely that the unbound concentration of bile acids in the cytosol of hepatocytes is low because bile acids 
are highly bound to cytosolic proteins. However, if hepatic concentrations exceed the binding capacity of 
the cytosolic proteins, unbound bile acid concentrations would be expected to increase markedly. 
Accumulation of bile acids in hepatocytes leads to mitochondrial damage and ultimately to apoptosis or 
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necrosis (46, 47). LCA has been shown to induce biliary tract injury; oral administration of LCA to mice 
resulted in cholangitis (48).  
 
MECHANISMS OF DRUG-INDUCED CHOLESTASIS 
Cholestatic drugs may disrupt bile acid homeostasis by direct inhibition of bile acid transport 
(Figure 2A), or by indirect processes, which may include regulation of transporter localization (Figure 
2B) or expression (Figure 2C). In the following section, the physiological mechanisms of drug-induced 
cholestasis that are associated with altered bile acid homeostasis are reviewed. 
Role of hepatic transport proteins in drug-induced cholestasis 
Hepatic biliary and basolateral transport proteins regulate the physiologic/pathophysiologic 
effects of endogenous compounds such as bile acids as well as exogenous compounds.  Increasing 
evidence supports the hypothesis that drug-mediated functional disturbances in hepatic bile acid 
transporters can lead to intracellular accumulation of potentially harmful bile acids and subsequent 
development of cholestatic hepatocyte damage.  In an effort to avoid drug-induced cholestasis, an in vitro 
test for BSEP inhibition during drug development may prove beneficial to screen for hepatotoxic 
compounds. However, bile acid-drug interactions are more complicated. The intracellular accumulation of 
bile acids is dependent upon both uptake and efflux (basolateral and canalicular) processes. Furthermore, 
the sensitivity of each transport protein to administered drugs may differ. Thus, to predict the hepatic 
exposure to bile acids, inhibitory effects of drugs on each transport protein, as well as drug concentrations 
at the site of interaction should be considered when translating in vitro data to in vivo. For the inhibition 
of uptake transporters, systemic concentrations of drugs are important, whereas intracellular drug 
concentrations are important when considering the inhibitory effects of drugs on bile acid efflux. 
However, measurement of intracellular hepatocyte drug concentrations is challenging, and these data 
typically are not available, particularly in humans. Additionally, most major human bile acids are >80% 
bound to plasma proteins (49), so it is likely that bile acids are highly bound to cytosolic proteins in 
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hepatocytes; total as well as unbound intracellular bile acid concentrations may be important in predicting 
drug-bile acid interactions.  
Several transport proteins have been identified as potential loci for drug-induced cholestasis. 
These include the basolateral uptake transporters (NTCP and OATPs), canalicular efflux transporters 
(BSEP, MRP2, and MDR3), and basolateral efflux transporters (MRP3 and MRP4). The potential role(s) 
of each of these transport proteins in drug-induced cholestasis will be discussed in detail in the following 
paragraphs. 
Hepatic Canalicular Efflux Transport Proteins.  The rate-limiting step in bile formation is 
transport of biliary constituents across the canalicular membrane. This process is mediated predominantly 
by BSEP, a hepatic transport protein that is a member of the ATP-binding cassette (ABC) gene 
superfamily. Impaired BSEP function due to defects in gene coding or gene regulation can lead to 
inherited and acquired cholestatic disorders such as progressive familial intra-hepatic cholestasis type 2 
(PFIC2), benign recurrent intrahepatic cholestasis type 2 (BRIC2), and intrahepatic cholestasis of 
pregnancy (50-52). Many drugs that cause either cholestatic or mixed hepatocellular/cholestatic liver 
injury (e.g., troglitazone, bosentan, cyclosporine, rifampin, sulindac, and glibenclamide) inhibit 
BSEP/Bsep-mediated biliary excretion of bile acids, potentially leading to increased hepatic exposure to 
cytotoxic bile acids (53-58). Two recent studies that systematically compared the potency of BSEP 
inhibition between cholestatic and non-cholestatic drugs revealed that drugs that caused cholestatic/mixed 
DILI in humans exhibited a markedly higher incidence and potency of BSEP inhibition compared to 
drugs that were non-cholestatic or caused hepatocellular liver damage (59, 60). In these studies, the 
inhibitory effects of test compounds on TCA uptake into inside-out membrane vesicles prepared from 
insect cells over-expressing BSEP/Bsep were investigated, and BSEP inhibition was demonstrated to be 
one of the risk factors for drug-induced cholestasis. These studies also showed a close correlation between 
inhibition potency for human BSEP- and rat Bsep-mediated TCA transport (59, 60). In most of the BSEP 
inhibition studies, including the above studies, TCA was used as a model bile acid. However, Kis et al. 
showed that troglitazone and glibenclamide inhibited the BSEP/Bsep-mediated transport of different bile 
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acids (TCA, GCA, TCDCA, and GCDCA) with similar potencies (IC50), whereas cyclosporine A 
exhibited a 10-fold more potent inhibition of GCA and TCDCA transport compared to TCA and GCDCA 
(57). Thus, extrapolation of the results of transport inhibition from one bile acid to another may not be 
accurate. Also, one should note that membrane vesicles do not express metabolizing enzymes, thus 
inhibitory effects of metabolites cannot be detected unless the metabolite(s) are tested directly.   
Whereas most of the BSEP inhibitors directly cis-inhibit BSEP, estradiol 17β-glucuronide and 
progesterone metabolites indirectly trans-inhibit Bsep after secretion into the bile canaliculus by Mrp2 
(61). Bosentan stimulated Mrp2-dependent bilirubin excretion and bile salt-independent bile flow, while 
phospholipid and cholesterol secretion were markedly inhibited and uncoupled from bile salt secretion 
(62). Inhibition of biliary lipid secretion was not observed in Mrp2-deficient TR- rats, which suggested 
that translocation of organic anions across the canalicular membrane is a prerequisite for the occurrence 
of the uncoupling effect (62). 
MDR3, an ATP-dependent phospholipid flippase, translocates phosphatidylcholine from the 
inner to the outer leaflet of the canalicular membrane (63). Subsequently, canalicular phospholipids are 
solubilized by canalicular bile salts to form mixed micelles, thereby protecting cholangiocytes from the 
detergent properties of bile salts. Mutations in MDR3 result in impaired biliary excretion of 
phosphatidylcholine and cause PFIC3, a severe pediatric liver disease that usually requires liver 
transplantation (64). Yoshikado et al. noted that two patients with itraconazole-induced cholestatic liver 
injury exhibited markedly high serum itraconazole concentrations (65). In itraconazole-treated rats, 
biliary phospholipids, rather than bile acids, were markedly decreased compared to control rats (65). 
Itraconazole decreased MDR3-mediated efflux of phosphatidylcholine in MDR3-overexpressing cells, but 
did not alter BSEP-mediated TCA transport (65). These results suggest that inhibition of MDR3-mediated 
biliary phospholipid secretion can be a risk factor for drug-induced cholestasis even if bile acid excretion 
is not altered. In vitro, MDR3 transported verapamil and cyclosporine, which could potentially lead to 
competitive inhibition of phospholipid flippase activity and cholestatic injury (66).  
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Hepatic Basolateral Efflux Transport Proteins.  As described above, BSEP inhibition is a risk 
factor for drug-induced cholestasis. However, not all drugs that inhibit BSEP cause cholestasis.  This 
suggests that screening for BSEP inhibition alone cannot accurately predict the hepatotoxic potential of 
drugs. This might be due to compensatory mechanisms of bile acid transport. The basolateral efflux 
transporters, MRP3 and MPR4, play a minor role in bile acid efflux under normal conditions, but they 
are up-regulated under cholestatic conditions to compensate for impaired biliary excretion (67-72).  
Compensatory basolateral efflux prevents hepatic bile acid accumulation and enables subsequent renal 
elimination of bile acids. Thus, impaired function of MRP3 and MRP4 by drugs, or genetic 
polymorphisms resulting in reduced-function variants may result in accumulation of toxic bile acids in 
hepatocytes. Troglitazone sulfate (TS), a major metabolite of troglitazone and a potent BSEP inhibitor, 
also inhibits MRP4-mediated dehydroepiandrosterone (DHEAS) transport; potent inhibition of both 
canalicular and basolateral efflux of bile acids by TS may predispose hepatocytes to toxicity (73). Our 
group has investigated the inhibitory effects of 88 compounds on MRP3 and MRP4, and reported that 
MRP4 inhibition was associated with an increased risk of cholestatic potential for drugs that are not 
BSEP inhibitors (74, 75). These results suggest that MRP4 inhibition also may represent a risk factor for 
the development of cholestatic DILI in humans. 
Hepatic Uptake Transport Proteins.  Basolateral uptake transporters are important in controlling 
hepatic and systemic exposure to drugs and toxins. The hepatic accumulation of bile acids is regulated by 
both uptake and efflux (basolateral and canalicular) processes, thus inhibition of hepatic bile acid uptake 
may exert protective effects by preventing the hepatic accumulation of bile acids. Bosentan, a potent 
inhibitor of human BSEP and rat Bsep, caused hepatic injury in humans, but bosentan-treated rats did not 
develop hepatotoxicity (54). Species difference in bosentan-induced hepatotoxicity might be explained by 
differential inhibition of human NTCP and rat Ntcp. Bosentan was a more potent inhibitor of sodium-
dependent TCA uptake in rat (IC50 = 5.4 µM) than human (IC50 = 30 µM) suspended hepatocytes, 
resulting in less hepatocyte accumulation of TCA in rats after administration of bosentan (76). Drugs also 
may exert differential inhibitory effects on individual bile acids. Marion et al. reported that troglitazone 
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differentially affected the uptake and accumulation of CDCA species (CDCA and metabolites) compared 
with TCA in rat SCH, causing an intracellular increase in CDCA species but not TCA (18). Troglitazone 
inhibited both uptake and biliary excretion of TCA in rat and human hepatocytes, leading to unchanged or 
even decreased intracellular accumulation (18, 77-79). Hepatic accumulation of CDCA species was not 
altered after incubation with 10 µM troglitazone, but was significantly increased with 100 µM 
troglitazone suggesting that biliary excretion of CDCA species was inhibited to a greater extent than 
uptake processes by higher concentrations of troglitazone. CDCA is more abundant in humans, and is 
known to be more cytotoxic compared to TCA (80, 81). These results suggest that one should consider 
species differences as well as differential inhibitory effects of drugs on individual bile acids when 
predicting hepatotoxicity in humans. 
Role of intestinal transport proteins in drug-induced cholestasis 
Bile acid concentrations in enterocytes are important in the bile acid regulatory loop. Once 
activated by bile acids, intestinal FXR induces an intestinal hormone, fibroblast growth factor 19 (FGF19; 
or Fgf15 in mice), which migrates to the liver and activates hepatic FGF receptor 4 (FGFR4) signaling to 
inhibit hepatic bile acid synthesis (13). Activation of hepatic FXR also down-regulates bile acid synthesis 
by activation of small heterodimer partner (SHP) (13). In ASBT null mice, which were unable to absorb 
bile acids in the ileum, intestinal and hepatic FXR activity was impaired resulting in decreased Fgf15 and 
Shp in the ileum and liver, respectively (82). Because Fgf15 and Shp play important roles in the 
regulatory feedback loop of bile acid synthesis, mRNA levels of Cyp7a1and bile acid synthesis were 
increased in ASBT null mice compared to wild-type mice (82). Similarly, inhibition of bile acid 
absorption in the intestine by ASBT inhibitors or bile acid sequestrants interrupted the normal feedback 
inhibition of bile acid synthesis, leading to increased hepatic Cyp7a1 expression and bile acid synthesis 
(82). On the other hand, inhibition of basolateral bile acid transport in enterocytes of OSTα null mice 
increased intestinal Fgf15 expression and decreased bile acid synthesis in hepatocytes (40). Interruption 
of bile acid absorption by surgical procedures (i.e. partial external biliary diversion, partial ileal bypass) 
or bile acid sequestrants (i.e. cholestyramine, cholespitol) have been used to treat cholestasis and/or 
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pruritus (83-85). Bile acid sequestrants are non-digestible resins that bind to intestinal bile acids and form 
an insoluble complex, reducing absorption of bile acids. They are used to treat primary 
hypercholesterolemia, and also as a second-line treatment for pruritus in patients with incomplete biliary 
obstruction. ASBT inhibitors have been investigated to treat hypercholesterolaemia, but the effects on 
cholestatic liver disease have not been evaluated fully. Reduced absorption of bile acids through the 
enterohepatic circulation may have therapeutic effects in certain types of cholestatic liver disease, but 
effects on the feedback loop of bile acid synthesis also must be considered. 
Indirect Interactions: Effects on Expression/Activity/Localization of Transport Proteins and 
Enzymes Involved in Bile Acid Homeostasis  
Due to the critical physiological and pathophysiological role of bile acids, homeostasis is tightly 
regulated through multiple nuclear receptors including FXR, the retinoid-X receptor (RXR), the liver 
receptor homologue-1 (LRH-1), the constitutive androstane receptor (CAR) and the liver-X-receptor 
(LXR), as well as the cell surface bile acid receptors including the G-protein coupled receptor TGR5.  In 
addition, bile acid transporters undergo post-transcriptional regulation including insertion/retrieval of 
transporters into/from the plasma membrane. These mechanisms allow fine tuning of bile acid synthesis 
and transport and, under normal physiological conditions, maintain enterohepatic circulation and regulate 
intracellular concentrations of bile acids through repression of bile acid synthesis, induction of bile acid 
metabolism (e.g. induction of phase I and II hydroxylation, sulfation and conjugation) as well as 
inhibition of hepatic bile acid uptake, and stimulation of bile acid efflux. The importance of nuclear 
receptors in the adaptive response to bile acids has been demonstrated in numerous knockout rodent 
models.  For example, PXR or CAR knockout mice are more susceptible to cholestatic liver injury than 
wild-type mice (31, 86, 87). Nuclear receptor-mediated adaptive changes are likely caused by compounds 
normally excreted into bile (e.g. bile acids, hormones, drugs, or bilirubin) that are retained during 
cholestasis and act as nuclear receptor ligands (88, 89).  
Drugs that act as nuclear receptor activators (e.g. rifampicin, dexamethasone) can increase the 
clearance of other drugs or induce the formation of reactive metabolites that can cause hepatotoxicity. For 
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example, acetaminophen liver toxicity was exacerbated by increased phase I-mediated oxidation to the 
reactive metabolite N-acetyl-p-benzoquinone-imine by CYP inducers (90, 91).   
Several anticholestatic compounds such as UDCA, phenobarbital, and rifampicin are nuclear 
receptor agonists, which could explain their anticholestatic properties. In recent years, FXR agonists have 
been proposed as a treatment for cholestatic liver disease because they repress bile acid uptake and 
synthesis, and promote bile acid excretion by activation of canalicular bile acid transporters. However, the 
utility of FXR agonists in the treatment of cholestasis might depend on the type of cholestasis, and 
changes in the expression of transport proteins that are induced. For conditions that are characterized by 
bile duct destruction such as primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC), 
stimulation of canalicular bile acid excretion may worsen liver injury. Interestingly, FXR knockout mice 
but not wild-type mice adapted to bile duct obstruction by increasing expression of Mrp4 mRNA and 
were protected from liver injury after ligation of the common bile duct (92). It was suggested that FXR 
acts as a negative regulator of the basolateral bile acid transport protein MRP4, whose increased 
expression normally protects the liver from accumulation of potentially toxic bile acids through 
basolateral efflux and subsequent renal elimination. FXR competes with CAR for binding at the MRP4 
promoter and represses MRP4 induction by CAR activation; activation of FXR could impair the MRP4-
mediated basolateral efflux of bile acids (93). Because of this, FXR antagonists might be beneficial in 
certain types of cholestasis (e.g. total biliary obstruction) where increased renal bile acid excretion is 
desired.  For more detail about FXR and PXR and their role as potential targets for cholestasis, see the 
review of Jonker et al (43).  
Estrogen-induced cholestasis.  While decreased expression or impaired function of transport 
proteins can contribute to or cause cholestasis, most changes in transport protein expression observed in 
cholestatic patients or animal models represent compensatory mechanisms providing alternate routes of 
excretion in response to the retention of bile acids. There are only a few examples where changes in 
transport protein expression or localization (as opposed to inhibition) due to drug treatment or other 
cholestatic agents, such as hormones and proinflammatory cytokines, are the primary cause of 
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cholestasis. The most prominent example of this type of cholestasis is estrogen- and C17-alkylated 
steroid-induced cholestasis, which causes a clinical picture that is similar to intrahepatic cholestasis of 
pregnancy in susceptible women who use oral contraceptives or postmenopausal estrogen replacement 
therapy. Estrogen-induced cholestasis can be induced experimentally in rodents with estradiol-17β-D-
glucuronide (E217G) or the synthetic estrogen ethinylestradiol (94, 95). Although trans-inhibition of 
BSEP-mediated bile acid transport by E217G has been demonstrated (61), the internalization of Bsep and 
Mrp2, which impairs the excretory function within minutes by reducing the amount of protein in the 
canalicular membrane, appears to be a key mechanism of cholestasis (96-98).  E217G activates classical, 
Ca2+-dependent protein kinase C and phosphoinositol 3-kinase signaling pathways, which are 
cooperatively involved in internalization and intracellular retention of Bsep/Mrp2 (99, 100). Furthermore, 
E217G activates the estrogen receptor α (ERα) in isolated perfused rat liver (101). This might explain why 
chemical inhibition or knock-down of ERα partially prevented decreased Bsep/Mrp2 activity and reduced 
transporter internalization (101). This finding is substantiated further by the observation that Erα(-/-) mice 
are resistant to ethinylestradiol-induced hepatotoxicity (102). At the moment, it is not quite clear how the 
activation of the ERα leads to internalization of transporter proteins. Recent data suggest that 
phosphoinositol 3-kinase is not directly involved in this process, and it was shown that activation of 
protein kinase C actually precedes activation of ERα, suggesting that other yet unknown mediators are 
involved (101).  Interestingly, the upregulation of Mrp3 expression and activity in rat liver after 
administration of ethinylestradiol was independent of cholestasis and required the estrogen receptor (103). 
Inflammation-induced cholestasis.  Inflammation often contributes to liver injury during 
cholestasis. However, cholestasis also can be induced by inflammation itself. This phenomenon is 
common in patients with extrahepatic infections or inflammatory processes in which inflammatory 
cytokines or bacterial endotoxins lead to profound reductions in bile flow (104, 105). The prototypical 
example of inflammation-induced cholestasis is sepsis-associated cholestasis. Lipopolysaccharide (LPS), 
an endotoxin from the cell wall of gram-negative bacteria, is a potent causal agent in inflammation. LPS 
often is released at extrahepatic sites and cleared from the systemic circulation by Kupffer cells in the 
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liver, which respond by producing proinflammatory cytokines and/or nitric oxide (NO). These cytokines 
and NO activate membrane receptors and after intracellular signal transduction, they alter hepatic and 
renal transport protein expression and function.  
Most of our knowledge about inflammation-induced changes in hepatic transport proteins is 
based on animal models; reduced expression of the bile acid uptake proteins Ntcp and Oatp, decreased 
expression of the canalicular bile acid efflux pumps Bsep and Mrp2, and downregulation of phase I and II 
metabolizing enzymes have been described. There is also some regulation through internalization of Bsep 
and/or Mrp2 from the canalicular membrane to intracellular vesicles (106, 107).  However, the key factor 
appears to be translational regulation resulting in reduced mRNA transcription and hence protein 
synthesis. Interestingly, signal transduction of inflammatory cytokines targets regulatory transcription 
factors (e.g. through phosphorylation or decreased binding of nuclear transcription factors) resulting in 
reduced nuclear quantities and function of these nuclear receptors. This has, for example, been 
demonstrated for RXRα, an important heterodimerization partner for numerous nuclear receptors such as 
FXR, RAR, PXR and CAR, in response to LPS or IL-1β treatment (108-110).   
So far, only a few studies have investigated the effects of inflammation-induced cholestasis in 
human disease.  In PBC and PSC, cholestasis develops with a substantial inflammatory component; 
decreased expression of NTCP, OATP1B1, MRP2, and BSEP have been reported, whereas MRP3, 
MRP4, and OSTα/β expression were increased (30, 32, 111). Furthermore, in patients with advanced 
stage PBC, the canalicular localization of MRP2 was disrupted and the expression of the uptake 
transporters, OATP1B1, OATP1B3, and NTCP was decreased (112). In another study, an increase in the 
severity of inflammation and the fibrosis score in patients with viral hepatitis was associated with 
decreased hepatic MRP2, MDR1, and OATP1B1, but not MRP3, mRNA expression (113). 
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ASSESSMENT OF PHYSICOCHEMICAL PROPERTIES AND PHARMACOKINETIC 
PARAMETERS OF DRUGS WITH DIFFERENT MECHANISMS OF CHOLESTASIS 
In previous sections, direct and indirect mechanisms of drug-induced cholestasis mediated by 
interruption of bile acid homeostasis were reviewed. Since multiple processes are involved in bile acid 
homeostasis, an accurate prediction of the cholestatic potential of drugs mediated by these pathways is not 
straightforward. Several studies have investigated risk factors for the development of drug-induced 
cholestasis based on the drugs’ inhibitory effects on BSEP and physicochemical properties and 
pharmacokinetic parameters (59, 60). In this type of analysis, it is critical to establish well-defined 
phenotypes (i.e. cholestasis).  In general, there are two major mechanisms of drug-induced cholestasis:  
(1) impaired formation of bile due to drugs that interact with bile acid formation and/or hepatic bile acid 
transport (hepatic cholestasis), and (2) physical obstruction of bile flow after bile has been secreted from 
hepatocytes, which might be caused by drugs that damage the bile duct itself (ductular/ductal cholestasis). 
If cholestatic drugs with different mechanisms of cholestasis are all considered as one group, it may 
confound the study results and lead to inaccurate predictions of cholestatic potential. In the present 
investigation, we compared the physicochemical properties and pharmacokinetic parameters of 77 
cholestatic drugs. The compounds selected for investigation included 50 drugs reported to cause 
cholestasis due to impaired bile acid formation (bland cholestasis or cholestatic hepatitis; classified into 
Group 1) and 27 drugs reported to cause cholestasis by obstruction of bile flow (classified into Group 2) 
(Table 1.1) (6, 114-117). Eleven drugs, including glyburide and carbamazepine, were reported to cause 
both impaired bile formation and obstruction of bile flow; these drugs were classified into Group 3 
(“Mixed Cholestasis”; Table 1.1), and were not included in the statistical analysis (6, 114-117).  
Relationship between Mechanism of Cholestasis and Physicochemical Properties of Drugs 
To explore the relationship between the mechanism of cholestasis and physicochemical 
properties, we compared the molecular weight, lipophilicity, and solubility of the Group 1 and Group 2 
cholestatic drugs. The physicochemical properties of the investigated compounds are summarized in 
Table 1.1; if experimentally determined logP and logS values were not available, then they were obtained 
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from Dragon Ver.5.5 (Talete SRL, Milano, Italy). The molecular weight distribution of these compounds 
ranged from 114.2 to 1202.8 g/ml. The median (range) molecular weights for Group 1 and Group 2 
cholestatic drugs were 346.9 (114.2 – 1202.8) and 295.8 (136.1 – 814.1) g/mol, respectively. The log P 
value, which is an indicator of lipophilicity, varied from -1.8 to 8.6, with median (range) values of 2.6 (-
1.4 – 8.6) and 2.3 (-1.8 – 5.1) for Group 1 and Group 2, respectively. The solubility, indicated by logS, 
ranged from -10.2 to 0.4, with median (range) values of -3.5 (-10.2 – 0.4) and -2.8 (-5.7 – -0.1) for Group 
1 and Group 2, respectively. There were no statistically significant differences between drugs from these 
two different cholestatic groups with regard to any of the physicochemical properties discussed above.  
Relationship between Mechanism of Cholestasis and Plasma Concentrations of Drugs 
To explore the relationship between the mechanism of cholestasis and systemic exposure, we 
investigated the maximum plasma concentrations (Cmax), maximum unbound plasma concentrations 
(Cmax,u), and standard and maximum daily doses of the cholestatic drugs in humans. Information about 
Cmax, standard and maximum daily doses were retrieved from Thompson’s Micromedex DRUGDEX 
index, Lexicomp database, and PubMed. The Cmax,u was calculated for each drug using the Cmax and 
experimentally determined plasma protein binding values available from published sources. If protein 
binding data were not available, estimated values were used (118); estimated and experimentally 
determined protein binding values were comparable for the drugs with available protein binding data. The 
Cmax distribution ranged from 0.00004 to 492 µg/ml (Table 1.1). The median (range) Cmax values for 
Group 1 and Group 2 cholestatic drugs were 1.1 (0.00028 – 492) and 2.0 (0.004 – 150) µg/ml, 
respectively. Cmax,u values ranged from 0.00001 to 231.6 µM  (Table 1.1), with median (range) values of 
0.4 (0.00003 – 80.6) and 2.2 (0.0005 – 231.6) µM for Group 1 and Group 2, respectively. Plasma protein 
binding ranged from 0 to 99.8 %; median (range) values were 88 (0 – 99.8) and 90 (0.5 – 99) for Group 1 
and Group 2, respectively. The median standard daily doses were 300 (4 – 6750) and 440 (1.3 – 6500) 
mg/day, whereas the maximum daily doses were 450 (8 – 12000) and 600 (15 – 12000) mg/day for Group 
1 and Group 2, respectively. There were no significant differences in Cmax, Cmax,u, plasma protein binding, 
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standard daily doses or maximum daily doses between the two groups of cholestatic drugs, indicating that 
these values, by themselves, were not predictive of the mechanism of cholestasis.  
Relationship between Mechanism of Cholestasis and the Metabolism and Excretion of Drugs 
To explore the relationship between the mechanism of cholestasis and drug disposition, we 
investigated the extent of metabolism, renal excretion and biliary excretion of cholestatic drugs. Drugs 
were categorized as high, intermediate or low, if the extent of metabolism/excretion was ≥ 70%, between 
30% and 70%, and < 30%, respectively. The relationship between the mechanism of cholestasis and the 
biopharmaceutics drug disposition classification system (BDDCS) class also was investigated. The 
BDDCS categorizes drugs into four classes; class 1 represents drugs with high solubility and extensive 
metabolism, whereas class 2 drugs have low solubility and extensive metabolism. Drugs with high 
solubility and poor metabolism are categorized into class 3, and class 4 is composed of drugs with low 
solubility and poor metabolism (119). Information on metabolism, the routes of excretion, BDDCS class, 
and clinical parameters were retrieved from Thompson’s Micromedex DRUGDEX index, Lexicomp 
database, PubMed, and WOMBAT-PK 2007 (120), and are presented in Table 1.1. Among the 50 
cholestatic drugs categorized in Group 1, 26 (52%) drugs were classified as low with respect to the extent 
of metabolism. Among 27 cholestatic drugs categorized in Group 2, information about metabolism was 
available for 25 drugs; 60% (15 out of 25) of these were metabolized to a minimal extent. Drugs with low 
renal excretion accounted for 44% (22 out of 50) of Group 1 cholestatic drugs and 48% (13 out of 27) of 
Group 2 cholestatic drugs. Importantly, 64% (32 out of 50) of Group 1 and 78% (21 out of 27) of Group 2 
cholestatic drugs were excreted extensively into bile (≥70%).  However, the classification of cholestatic 
drugs (Group 1 vs. 2) was not associated with the extent of metabolism or the extent of renal or biliary 
excretion when examined using the chi-square test (Table 1.2). Cholestatic drugs were categorized evenly 
as BDDCS class 1 – 3, with fewer drugs in BDDCS class 4. This is consistent with the previous report 
that only a small number of the approved drugs are categorized as BDDCS class 4 (119). There was no 
significant association between BDDCS class and the type of cholestasis when examined using the chi-
square test (Table 1.2). 
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Relationship between Mechanism of Cholestasis and Inhibition of Bile Acid Transport Proteins by 
Drugs 
Inhibition of bile acid transport is one important mechanism of drug-induced cholestasis. Thus, 
the relationship between the mechanism of cholestasis and the ability of drugs to inhibit bile acid 
transport was investigated. BSEP is a major transport protein responsible for the biliary excretion of bile 
acids. Inhibition data for BSEP is relatively abundant compared to inhibition of other bile acid transport 
proteins based on recent publications describing high-throughput screening approaches to analyze for 
BSEP inhibition (59, 60, 121). Information about BSEP inhibition was available for 41 cholestatic drugs 
(Table 1.1). Drugs with IC50 values less than 133 µM were defined as BSEP inhibitors as reported 
previously (59). Chi-square analysis revealed that BSEP inhibitors are more abundant in Group 1 
compared to Group 2 cholestatic drugs (61% vs 20%, p=0.023; Table 1.2); among the 31 Group 1 
cholestatic drugs, 19 drugs (61%) were BSEP inhibitors. On the other hand, only 2 out of 10 Group 2 
cholestatic drugs were BSEP inhibitors. Although this analysis was performed with only a limited number 
of drugs, the data suggest that BSEP inhibition might not play a major role in cholestasis that is caused by 
bile duct obstruction. Inhibition data for other bile acid transporters such as ASBT, NTCP, OATP and 
MRP4, as well as substrate information on major drug transporters such as OATP, MRP2, BCRP, and P-
gp, might be necessary to understand the complex interplay of bile acid homeostasis, the pharmacokinetic 
behavior of drugs, and direct and indirect regulation of the pathogenesis of different types of cholestasis.  
 
IN SILICO MODELING TO PREDICT DIRECT AND INDIRECT EFFECTS OF DRUGS ON 
BILE ACID HOMEOSTASIS 
Interruption of bile acid homeostasis plays a key role in the development of cholestasis.  
Therefore, in order to improve the prediction of cholestatic potential, it is important to understand how 
drugs affect bile acid disposition. However, for a large number of drugs, experimental data documenting 
an interaction with bile acid transporters are not available; high-throughput screening methods to test the 
inhibition potential of drugs have not been available until recently (59, 60, 122). Data regarding drug 
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effects on nuclear receptors involved in bile acid homeostasis are even more scarce because the role of 
nuclear receptors in bile acid homeostasis has been revealed only recently (123, 124). In silico modeling 
can be used to fill this data gap; existing datasets can be used to build in silico models based on the 
structural properties of drugs, and these models can be used to predict drug effects on bile acid 
homeostasis. When large datasets are available and resulting in silico models are well-validated, they can 
help reduce the financial burden in early drug discovery and development by limiting the need for 
extensive laboratory experiments.  In the following section, in silico models to predict drug effects on bile 
acid transporters and nuclear receptors such as PXR and FXR are reviewed.   
In Silico Modeling to Predict Drug Interactions with Bile Acid Transport Proteins 
The 3D structures of membrane transport proteins remain scarce.  Thus, current computational 
transporter studies rely on a series of experimentally measured interactions of small molecules with 
membrane transporters and employ statistical learning approaches, such as quantitative structure-activity 
relationship (QSAR) and ligand-based pharmacophore construction. Available computational models of 
bile acid transporters (i.e., MRP2, MRP3, MRP4, BSEP, NTCP, ASBT, OATPs) are summarized in Table 
1.3. Due to the great heterogeneity of experimental reports (e.g., from diverse assay types, test 
concentrations and experimental conditions), most of the computational studies present classification 
models (e.g., inhibitors vs. non-inhibitors). The few available quantitative models (such as for binding 
affinity or inhibition) usually are limited to small sets of compounds with the measurements from the 
same source. 
For the canalicular efflux transporters BSEP and MRP2 (Table 1.3), Warner et al. reported 
classification of BSEP inhibitors (defined by an IC50 threshold of 300M) by a recursive partitioning 
QSAR for over 600 chemicals using molecular descriptors as covariates (121). An earlier study by Saito 
et al. reported a multiple linear regression model of BSEP inhibition (measured in % of taurocholate 
transport at 100M test concentration) for 37 diverse drug-like compounds using chemical fragment 
descriptors, but this model has not been validated further (125). Several groups reported QSAR models 
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for MRP2 inhibition at various potency thresholds (Table 1.3) using linear (e.g., PLS – partial least 
squares regression and discriminant analysis) and non-linear modeling methods (SVM – Support Vector 
Machine, kNN – k Nearest Neighbors, RF – Random Forest) (126-128). The accuracy of these models on 
external data (judged by test sets) ranged from 70 to 90%. In addition, Ng et al. developed a QSAR model 
of binding affinity to rat Mrp2 for 25 methotrexate analogues as well as a pharmacophore for their 
binding model (129). Zhang et al. have constructed a pharmacophore for MRP2 inhibitors, which 
performed slightly worse than their SVM QSAR model (127). 
Due to lack of experimental measurements, very few computational studies exist for the 
basolateral bile acid efflux transporters MRP3 and MRP4 (Table 1.3). Sedykh et al. reported classification 
models of MRP4 inhibitors at a 10M threshold with external accuracy of 70%, however, the modeling 
was based on a rather small set of 64 molecules (128). In a recent study, Akanuma et al. attempted 
structural analysis of MRP4 transport for several groups of -lactam antibiotics (130). 
For the bile acid uptake transporters, there were appreciably more studies on ASBT and OATPs 
than on NTCP (Table 1.3), which reflects the importance of the former to the absorption, distribution, 
metabolism, excretion and toxicity  of pharmaceuticals because they also are expressed in gut and kidney 
(131). Karlgren et al. reported classification models of OATP1B1, OATP1B3, and OATP2B1inhibitors at 
a 20M potency threshold, with expected accuracy of 75-93% (132). Several QSAR models of ASBT 
binding affinity as well as pharmacophores were developed by Zheng et al., Rais et al., and Gonzalez et 
al. with squared correlation coefficient (R2) values of 0.68-0.89, albeit all were trained on small 
congeneric series of conjugated bile acid derivatives (133-137). Sedykh et al. and Zheng et al. reported 
classification QSARs of ASBT inhibitors based on 10M and 100M potency thresholds respectively 
(128, 133). In a recent study, Greupink et al. developed a 3D-pharmacophore model based on five NTCP 
substrates, which were then applied to screen large chemical libraries. Several NTCP inhibitors were 
identified among the top selected hits (138). 
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Based on the data presented in Table 1.3, the small size of the modeling data sets is the major 
limitation to accurate in silico prediction of drug interactions with bile acid transporters. Conformational 
flexibility of membrane transporters, their broad substrate specificity, as well as noisiness and limitations 
of experimental assays all require large and diverse sets of chemical structures for proper statistical 
learning. Large and diverse modeling sets also are necessary for the broad applicability of the resulting 
models, so that more structural classes of chemicals can be covered and reliably predicted. Presently, 
there are too few compounds with experimental data available for MRP3, MRP4 and NTCP transporters. 
Even though OSTα/β is essential for bile acid transport, adequate data for in silico modeling is not yet 
available (27). 
In Silico Models of Drug Interactions with the Nuclear Receptors, FXR and PXR 
A number of the resolved 3D protein structures of FXR and PXR are publicly available (e.g., 
1OSH, 1OSV for FXR, 3R8D, 2QNV for PXR at www.pdb.org), which allows for application of 
modeling techniques such as docking and structure-based pharmacophore construction. However, 
accurate characterization of a drug-protein interaction by structure-based methods can be difficult, which 
is the case for PXR with its large and flexible pocket leading to promiscuous binding and poor docking 
results (139, 140). Therefore, statistical knowledge-inference methods, such as QSAR, are still applied 
widely. Currently available computational models of FXR and PXR are reviewed in Table 1.4. Although 
stand-alone docking yielded modest results (~60% accuracy), as demonstrated by Khandelwal et al., 
Kortagere et al.,  and Ekins et al., docking was used routinely to impute bound conformations of 
chemicals for the subsequent 3D-QSAR modeling studies (139, 141-144). Most of the classification 
models of PXR agonists have external accuracy in the 70-85% range (Table 1.4). A few quantitative 
models for the potency of PXR activation (measured as EC50) also have been reported (139, 145), 
although it is important to note that these do not take into account the extent of activation (i.e., efficacy), 
which can vary substantially among the agonists. 
Relatively few in silico studies are available for FXR activation, likely due to the limited 
availability of experimental data. Several quantitative models of FXR activation (Table 1.4) achieve 
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correlations in the 0.76-0.93 range (square of Pearson’s correlation coefficient), albeit on rather small data 
sets. Recent studies by Shuster and Grinke employed a set of pharmacophores for classification of FXR 
agonists with accuracy of ~70% (146, 147). While diverse models for PXR activation currently are 
available (e.g., see the recent review by Kortagere et al.(140)) and further improvements are likely to be 
incremental, in the case of FXR, new models based on larger data samples definitely are needed for 
reliable use in drug design and risk assessment.  
 
CONCLUSIONS AND FUTURE DIRECTIONS 
Disruption of bile acid homeostasis is an important mechanism of drug-induced cholestasis. In 
order to accurately predict the cholestatic potential of drugs, an understanding of the molecule’s effects on 
the many processes involved in bile acid homeostasis appears to be necessary. In silico modeling, which 
will diminish the time and resources required for laboratory experiments, is a promising approach to 
obtain this mechanistic information. Drugs may inhibit bile acid transporters directly, or alter the 
expression, function and/or localization of transporters by indirect interactions mediated by nuclear 
receptors and intracellular signaling pathways. In addition, patient-specific factors including genetic 
polymorphisms, underlying disease, and pregnancy may alter the function of bile acid transporters and 
predispose individuals to cholestasis. These data can be integrated and incorporated into mechanistic, 
mathematical models to improve predictions. Multi-scale modeling approaches incorporating both drug 
disposition and physiological processes (i.e. systems biology) is an exciting, emerging area. Recent 
efforts using mechanistic, mathematical modeling approaches have successfully predicted the 
hepatotoxicity induced by drugs such as acetaminophen and methapyrilene (148, 149). The same 
approach can be taken to predict drug-induced cholestatic injury, thereby allowing more accurate 
predictions during the early stages of drug development. 
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Table 1.1. Physicochemical and pharmacokinetic properties of drugs with different mechanisms of cholestasis. 
Drug MW logP
a 
logSa PPBa 
(%) 
Cmaxb 
(µg/ml)  
Cmax,uc 
(uM) 
Std 
Daily 
Dosed,e 
(mg 
/day) 
Max 
Daily 
Dosed 
(mg/ 
day) 
Meta-
bolismf 
Renal 
Excre-
tionf 
Fecal/ 
biliary 
Excre-
tionf 
BDD
-CSg 
BSEP 
Inhibi
-tionh 
IC50 for 
BSEP 
Inhibition 
(µM) 
Group 1: Impaired Formation of Bile (n=50)  
6-Mercapto-
purine 
152.2 -0.4 -1.3 19.0 0.073 0.39 225 350 H I L 2 - - 
Acitretin 326.5 6.4 -6.7 99.0 0.42 0.013 37.5 75 I I I 2 Y 18(60) 
Atorvastatin 540.7 5.7 -7.4 98.5 0.019 
0.0005
3 
45 80 H L H 2 - - 
Azithromycin 749.1 4.0 -1.3 28.5 0.40 0.38 875 1500 I L H 3 N 
>1000 
(121) 
Bupropion 239.8 3.6 -2.9 84.0 0.14 0.093 300 450 H H L 1 N 
>1000 
(121) 
Captopril 217.3 0.3 -0.1 27.5 0.93 3.1 234 450 I H L 3 - - 
Celecoxib 381.4 3.9 -4.9 97.0 1.2 0.091 400 600 H I I 2 - - 
Cephalexin 347.4 -0.7 -1.5 12.5 32 81 2500 4000 L H L 3 - - 
Cetirizine 388.9 1.7 -3.6 93.0 0.31 0.056 7.5 10 L H L 3 - - 
Chlorambucil 304.2 3.3 -1.4 99.0 492 16 15.0 28 H I L 1 - - 
Clarithro-
mycin 
748.1 3.2 -2.6 50.5 3.7 2.4 1000 1500 H I L 3 Y <13(121) 
Cyclosporine 1203 3.0 -5.2 93.7 0.93 0.049 525 1260 H L H 2 Y 
0.3-10 
(59, 60, 
121, 150-
152) 
Danazol 337.5 0.5 -5.6 96.2* 0.025 0.0028 450 800 H L I 2 Y <10 (121) 
Dapsone 248.3 1.0 -3.1 75.3 0.93 0.93 175 300 H H L 2 N 
>1000 
(60, 121) 
Dextro-
methorphan 
271.4 3.6 -1.3 74.8* 0.0077 0.0071 120 180 H H L 1 - - 
Dicloxacillin 470.4 2.9 -5.1 96.9 91 6.0 1750 2000 L I I 3 Y 
<10(121), 
70(60) 
  
 
2
6
 
Fenofibrate 360.9 5.3 -5.7 99.0 4.4 0.12 100 160 I I L 2 Y 15(59) 
Fosinopril 563.7 6.3 -4.4 94.4 0.37 0.037 22.5 40 I I I 2 Y <13(121) 
Gabapentin 171.3 -1.1 -1.2 1.5 2.5 14 2700 3600 L H L 3 N 
>1000 
(121) 
Gemcitabine 263.2 -1.4 -1.2 6.4 7.0 25 1912.5 2125 H H L 1 - - 
Glimepiride 490.7 3.5 -5.6 99.5 0.55 0.0056 4.5 8 I I I 2 Y 
<10(121), 
16(59) 
Griseofulvin 352.8 2.2 -4.6 83.8* 1.6 0.73 540 750 H I I 2 - - 
Hydrochloro-
thiazides 
297.8 -0.1 -2.7 67.9 0.49 0.53 56.25 100 L H L 3 - - 
Isoniazid 137.2 -0.8 0.0 5.0 11 73 300 300 H H L 1 N 
>1000 
(60, 121) 
Itraconazole 705.7 5.7 -8.9 99.0 2.0 0.028 450 800 H I L 2 Y 18(59) 
Ketoconazole 531.5 4.4 -4.9 99.0 3.5 0.066 700 1200 I L I 2 Y 
2.9-65 
(59, 60, 
121, 153) 
Loracarbef 349.8 0.5 -0.9 25.0 13 27 500 800 L H L 3 - - 
Mesalamine 153.2 1.2 -2.2 43.0 5.0 19 3600 4800 H L H 2 N 381(121) 
Metformin 129.2 -0.5 0.0 2.5 1.0 7.5 1250 2550 L H L 3 N 
>1000 
(121) 
Methimazole 114.2 -0.3 0.4 0.0 0.21 1.9 37.5 60 H H L 1 N 
>1000 
(60, 121) 
Methyldopa 211.2 0.4 -1.3 20.0 3.1 12 1750 3000 I H L 3 N 
>1000 
(60) 
Metolazone 365.9 2.5 -3.8 95.0 22 3.1 10.25 20 L H L 4 - - 
Nevirapine 266.3 1.8 -3.4 60.0 2.3 3.4 300 400 H H L 2 N 295(121) 
Nifedipine 346.4 2.2 -4.8 96.0 0.094 0.011 45 180 H H L 2 Y 
19-40 
(60, 121, 
154) 
Nitro-
furantoin 
238.2 -0.1 -3.1 60.0 0.50 0.84 300 400 I I L 4 N 
>1000 
(60, 121) 
Norfloxacin 319.4 -1.0 -2.6 12.5 2.4 6.6 800 800 L I L 4 - - 
Ofloxacin 361.4 -0.4 -2.0 22.5 2.8 5.9 700 800 L H L 3 N 
>1000 
(121) 
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Orlistat 495.8 8.6 
-
10.2* 
99.0 0.10 0.0020 270 360 L L H 4 - - 
Oxacillin 401.5 2.4 -4.5 92.0 43 8.6 6750 12000 I H L 3 - - 
Propafenone 341.5 3.2 -3.6 96.0 
0.0002
8 
0.0000
32 
675 900 H I I 2 Y 54(121) 
Propyl-
thiouracil 
170.3 0.4 -2.2 80.0 6.5 7.6 500 900 H I L 1 - - 
Repaglinide 452.7 5.9 -5.9* 98.0 0.051 0.0023 8.5 16 H L H 2 - - 
Risperidone 410.5 3.0 -3.2 89.0 0.033 0.0088 8.5 16 H H L 1 Y <10(121) 
Rofecoxib 314.4 3.2 -3.5 87.0 0.32 0.13 31.25 50 H H L 2 Y 95(121) 
Rosiglitazone 357.5 2.4 -4.0 99.8 0.37 0.0021 4 8 I I L 1 Y 
4.4-6.4 
(56, 57, 
118)  
Roxithro-
mycin 
837.2 2.8 -3.9 86.0 12 2.0 387.5 600 I L I 4 - - 
Tamoxifen 371.6 7.1 -6.3 99.0 0.060 0.0016 30 40 H L I 1 Y 
10-23 
(121, 150, 
153) 
Ticlopidine 263.8 2.9 0.0 98.0 2.1 0.16 500 500 I I L 1 Y 
27-74 (60, 
121) 
Troglitazone 441.6 3.6 -5.9* 99.0 2.8 0.064 400 600 H L H 4 Y 
4-66 
(121, 153, 
154) 
Warfarin 308.4 2.6 -4.2 99.5 1.5 0.026 6 10 H H L 2 Y 115(121) 
Group 2: Obstruction of Bile Flow (n=27)  
Ajmaline 326.5 1.8 -2.8 46.0 1.5 2.4 42.5 50 H L H 1.5 - - 
Allopurinol 136.1 -0.6 -2.4 0.5 1.9 14 450 800 H H L 2 - - 
Amineptine 337.5 5.1* -4.7* 95.3* 0.77 0.11 150 200 - H L - - - 
Amitriptyline 277.4 4.9 -4.5 94.8 0.029 0.0054 187.5 300 H I L 1 - - 
Ampicillin 349.5 1.4 -1.7 24.0 107 232 6500 12000 L H L 3 - - 
Carmustine 214.1 1.5 -1.8 80.0 1.7 1.6 297.5 340 I I L 1 N.D. 
97(121), 
>1000 
(60) 
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Chloro-
thiazide 
295.8 -0.2 -2.8 50.0 0.50 0.85 750 1000 L H L 4 - - 
Cimetidine 252.4 0.4 -1.6 17.5 1.1 3.7 800 1600 I I L 3 N 
>1000 
(121, 153) 
Ciprofloxacin 331.4 0.3 -3.3 30.0 3.8 8.0 1000 1500 I H L 4 N 
>1000 
(121) 
Clindamycin 425.1 2.2 -1.1 93.0 4.5 0.73 1600 2600 H L H 1 - - 
Cromolyn 468.4 1.9 -0.4 69.5 0.0092 0.0060 440 800 L L H 3 N 
>1000 
(57, 118) 
Cypro-
heptadine 
287.4 4.7 -1.9 90.1* 30 10 12 20 H I I 1 - - 
Diazepam 284.8 2.8 -3.7 96.8 0.17 0.019 22 40 H H L 1 - - 
D-
penicillamine 
149.2 -1.8 -0.1 80.6 5.6 7.3 187.5 4000 L H L 3 N 
>1000 
(60) 
Floxuridine 246.2 -1.4 -1.3 7.7* 3.3 12 24.5 42 H L L - - - 
Haloperidol 375.9 4.3 -4.0 92.0 0.020 0.0043 1.25 15 H H L 2 Y 23(121) 
Ibuprofen 206.3 4.0 -3.7 99.0 57 2.8 1000 3200 H H L 2 N 
>790 
(121, 
154), 
599(60) 
Imipramine 280.5 4.8 -4.2 92.0 0.025 0.0070 162.5 300 H H L 1 - - 
Methyl-
testosterone 
302.5 3.5* -4.8* 98.0 0.032 0.0021 30 50 H H L 2 - - 
Phenyl-
butazone 
308.4 3.2 -2.6 98.5 150 7.3 450 600 I I L 1 - - 
Phenytoin 252.3 2.5 -4.1 90.0* 5.5 2.2 450 600 H L H 2 - - 
Prochlor-
perazine 
374.0 4.9 -3.6 95.2* 0.0040 
0.0005
1 
27.5 40 H L H 1 Y <10(121) 
Tenoxicam 337.4 1.9 -2.6 98.5 2.0 0.089 30 40 I I L 1 - - 
Tetracycline 444.5 -1.3 -2.4 65.0 9.3 7.3 1125 2000 L I L 3 N 
>1000 
(121) 
Thiaben-
dazole 
201.3 2.5 -3.6 74.6* 5.0 6.3 3000 3000 H H L 2 N 560(121) 
Tolbutamide 270.4 2.3 -3.4 96.0 100 14.8 1125 3000 H H L 2 N 
>1000 
(57, 118) 
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Troleando-
mycin 
814.1 4.2* -5.7* 61.6* 2.0 0.94 1500 2000 - I L - - - 
Group 3: Mixed Cholestasis (n=11)  
Azathioprine 277.3 0.1 -1.4 30.0 1.0 2.5 192.5 350 H H L 1 N 
>1000 
(57, 118)  
Carbama-
zapine 
236.3 2.5 -3.0 74.0 12 13 1000 1600 H H L 2 N 
>1000 
(121) 
Chlor-
promazine 
318.9 5.4 -5.0 97.5 0.30 0.024 400 2000 H I L 1 N.D. 
31-91 
(121, 
153), 
148(60) 
Chlor-
propamide 
276.8 1.9 -2.1 92.0 150 43 300 750 L H L 0 N 
>1000 
(57, 118)  
Erythromycin  734.1 3.1 -2.5 60.0 1.3 0.72 1000 1000 L L H 3 N.D. 
>983 
(121), 4.1-
13 (59, 
60) 
Estradiol 272.4 4.0 -3.5 93.5* 
0.0000
43 
0.0000
1 
15.5 30 H H L 1 - - 
Flucloxacillin 453.9 2.6 -5.8* 94.0 8.0 1.1 3500 6000 L H L 4 N.D. 
<10(121), 
209(60) 
Glyburide 494.1 4.7 -5.1 99.0 0.22 0.0045 10.6 20 H I I 2 Y 
5.3-60 
(57, 118, 
152-154) 
Pioglitazone 356.5 2.3 -4.6* 99.0 1.1 0.029 22.5 45 H L H 2 Y 
0.3 (56, 
57, 118) 
Propoxy-
phene 
339.5 4.2 -4.3 78.0 0.085 0.055 325 390 H L H 2 - - 
Terbinafine 291.5 6.0 -6.4* 99.0 1.0 0.034 625 1000 H H L 2 - - 
MW, molecular weight; PPB, plasma protein binding; BDDCS, biopharmaceutics drug disposition classification system; 
aObtained from Dragon Ver.5.5, measured data if not stated otherwise (*calculated). 
bRetrieved from Thompson’s Micromedex DRUGDEX index and Lexicomp database if not stated otherwise. 
cCalculated using Cmax, MW, and PPB. 
dRetrieved from Thompson’s Micromedex DRUGDEX index and Lexicomp database. Administered orally if not stated otherwise. 
eIf a dose range was recommended (e.g. for different indications), the average of minimum and maximum recommended daily dose was calculated. 
If dosing was given as mg/kg or mg/m2, the maximum and average doses were calculated based on a 70 kg adult with a body surface area of 1.7. 
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fThe extent of metabolism, renal excretion, and fecal/biliary excretion. H, High (≥70%); I, Intermediate ( ≥30% and <70%); L, Low (<30%). 
Retrieved from Thompson’s Micromedex DRUGDEX index and Lexicomp database if not stated otherwise. 
gClass 1, high solubility/extensive metabolism; class 2, low solubility/extensive metabolism; class 3, high solubility/poor metabolism; class 4, 
low solubility/poor metabolism. 
hDrugs with IC50 < 133 µM are defined as BSEP inhibitors.(59) 
iN.D: Inhibitory effects of chlorpromazine, erythromycin, flucloxacillin, and carmustin were not determined because reported IC50 values of these 
drugs spanned the cutoff value of 133 µM.  
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Table 1.2. Relationship between mechanism of cholestasis (impaired formation of bile and 
obstruction of bile flow) and the extent of metabolism and excretion, BDDCS, and BSEP inhibition 
for 77 cholestatic compounds. 
Drugs with no information were excluded from the analysis. P-values from chi-square tests are presented. 
Metabolism (n=75)a 
 Group 1 
(Impaired formation of bile) 
Group 2 
(Obstruction of bile flow) 
P-value 
High  11 5 
0.7881 Intermediate  13 5 
Low 26 15 
Renal Excretion (n=77)a 
 Group 1 
(Impaired formation of bile) 
Group 2 
(Obstruction of bile flow) 
P-value 
High  11 6 
0.9186 Intermediate  17 8 
Low 22 13 
Biliary Excretion (n=77)a 
 Group 1 
(Impaired formation of bile) 
Group 2 
(Obstruction of bile flow) 
P-value 
High  32 21 
0.1065 Intermediate  11 1 
Low 7 5 
BDDCS (n=73)b 
 Group 1 
(Impaired formation of bile) 
Group 2 
(Obstruction of bile flow) 
P-value 
Class I 20 7 
0.503 
Class II 13 5 
Class III 11 9 
Class IV 6 2 
BSEP Inhibition (n=41)c 
 Group 1 
(Impaired formation of bile) 
Group 2 
(Obstruction of bile flow) 
P-value 
Yes 19 2 
0.023 
No 12 8 
aHigh (≥70%); Intermediate ( ≥30% and <70%); Low (<30%) 
bClass 1, high solubility/extensive metabolism; class 2, low solubility/extensive metabolism; class 3, high 
solubility/poor metabolism; class 4, low solubility/poor metabolism. 
cDrugs with IC50 < 133 µM are defined as BSEP inhibitors.  
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Table 1.3. Computational models of small molecule interactions with bile acid transporters. 
Transporter Model description 
External 
Accuracya 
Data sizeb 
(train/test) 
Reference 
BSEP %inhibition at 100 M R2=0.95 37/0 Saito et al 2009(125) 
BSEP 
Classification of inhibitors at 
300 M 
87% 437/187 
Warner  et al 
2012(121) 
MRP2 Binding affinity, Ki R2=0.82 20/5 Ng et al 2005(129) 
MRP2 
Classification of inhibitors at 80 
M 
72% 79/39 
Pedersen et al 
2008(126, 127) 
MRP2 Classification of inhibitors 74-77% 257/61 
Zhang et al 
2009(127) 
MRP2 Classification of substrates 87% 150/38 
Sedykh et al 
2013(128)  
MRP2 
Classification of inhibitors at 10 
M 
89% 77/19 
Sedykh et al 
2013(128)  
MRP3 Classification of substrates 98% 50/12 
Sedykh et al 
2013(128)  
MRP4 Classification of substrates 92% 74/18 
Sedykh et al 
2013(128)  
MRP4 
Classification of inhibitors at 10 
M 
70% 51/13 
Sedykh et al 
2013(128)  
ASBT Binding affinity, Ki R2=0.73 29/1 
Gonzalez et al 
2009(137) 
ASBT 
Classification of inhibitors at 
100 M 
54-88% 38/19-30 
Zheng et al 
2009(133) 
ASBT Binding affinity, Ki R2=0.68 23/4 
Zheng et al 
2010(134) 
ASBT 
Binding affinity, Ki 
Transport constraints, Km/Vmax 
R2=0.89 
R2=0.68 
32/1 
Rais et al 2010(135, 
136) 
ASBT Classification of substrates 93% 80/20 
Sedykh et al 
2013(128)   
ASBT 
Classification of inhibitors at 10 
M 
92% 120/30 
Sedykh et al 
2013(128)   
NTCP 
Ligand-based 3D 
pharmacophore 
60% 5/10 
Greupink et al 
2012(138) 
OATP1B1 
Classification of inhibitors at 20 
M 
81-93% 98/48 
Karlgren et al 
2012(132, 155) 
OATP1B1 79% 134/67 
Karlgren et al 
2012(132) 
OATP1B3 92% 125/62 
Karlgren et al 
2012(132) 
OATP2B1 75% 118/60 
Karlgren et al 
2012(132) 
OATP2B1 
Classification of inhibitors at 
100 M 
80% 109/27 
Sedykh et al 
2013(128)    
OATP2B1 Classification of substrates 75% 42/11 
Sedykh et al 
2013(128)    
aAccuracy of the model when evaluated on external data (i.e., data not known to the model) 
bNumber of data points (i.e., distinct molecules) available for modeling 
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Table 1.4. Computational models of PXR and FXR activation. 
Model description 
External 
Accuracya 
Data sizeb 
(train/test) 
Reference 
Pregnane X Receptor (PXR) 
Classification of agonists  at 100M 73-87% 175/15 Ung  et al 2007(156) 
Classification of agonists  at 100M 63-67% 177/145 
Khandelwal et al 
2008(141) 
Classification of agonists  at 100M 72-81% 168/130 
Kortagere  et al 
2009(142) 
Classification of agonists  at 10M 77% 
95/20 
Ekins et al 
2009(139) Activation, EC50 R2=0.45 
Classification of agonists (0.5nM – 
38.3M) 
82-85% 316/315 
Dybdahl et al 
2012(157) 
Classification of agonists at 100M 
85% 405/29 
Matter  et al 
2012(145) 
78% 586/50 
Activation, EC50 R2=0.45 273/33 
Farnesoid X Receptor (FXR) 
Activation by non-steroidal agonists, 
EC50 
R2=0.76 82/20 
Honorio et al 
2005(143, 158) 
Activation by non-steroidal agonists, 
EC50 
R2=0.77 77/20 
Honorio et al 
2007(143) 
Activation by non-steroidal agonists, 
EC50 
R2=0.93 58/10 
Zhang et al 
2007(144) 
Structure-Activity relationship analysis - 50/0 
Genet et al 
2010(159) 
Classification of agonists at 100M by 
structure-based pharmacophores 
73% -/221 
Shuster  et al 
2011(146) 
Grienke et al 
2011(147) 
aAccuracy of the model when evaluated on external data (i.e., data not known to the model) 
bNumber of data points (i.e., distinct molecules) available for modeling 
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Figure 1.1. Localization of bile acid transporters in human hepatocytes (A) and enterocytes (B). 
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Figure 1.2. Mechanisms of altered bile acid transport by cholestatic drugs.  
(A) Direct inhibition of transport proteins. Cholestatic drugs might directly interfere with bile acid 
transport through inhibition of transporter function. (B) Altered localization of transport proteins. 
Certain cholestatic drugs can activate membrane-bound and intracellular receptors resulting in activation 
or inhibition of intracellular signal transduction and increased insertion into or internalization from the 
plasma membrane. Internalized proteins can be degraded or undergo recycling to the plasma membrane. 
(C) Altered transport protein expression. Bile acids and certain cholestatic drugs are activators of 
nuclear receptors (NR). Binding of ligands results in dissociation of heat-shock proteins from the NR, 
homo-dimerization and subsequent translocation to the nucleus where they bind to response elements of 
target genes and activate gene transcription. 
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Project Rationale and Specific Aims 
The objectives of this research project were to investigate the mechanisms of drug-induced liver 
injury (DILI) that involves transporter-mediated drug-bile acid interactions, and develop a novel strategy 
to reliably predict DILI liability of drugs in humans. This includes improving our understanding of 
species differences in bile acid disposition, specifically differential effects of transporter inhibitors on 
hepatic bile acid exposure in humans and rats, and impact of altered transport function on hepatic 
disposition of drugs. A mechanistic model that incorporates bile acid physiology and drug disposition was 
developed to translate data from in vitro systems to in vivo, and from preclinical species to humans, for 
the reliable prediction of human DILI. Troglitazone, an anti-diabetic drug withdrawn from worldwide 
markets due to severe DILI, was used as a model hepatotoxic drug. TGZ and its major metabolite, TGZ 
sulfate (TS) are potent inhibitors of multiple bile acid transporters. The experimental and analytical 
methods to study hepatic transporters are discussed in the next chapter (Chapter 2). 
  The first aim (Aim #1) of this dissertation research was to characterize the species differences in 
hepatobiliary disposition of taurocholic acid (TCA, a prototypical model bile acid) and its interaction with 
TGZ and TS using experimental data obtained in human and rat sandwich-cultured hepatocytes (SCH) 
combined with pharmacokinetic modeling and simulation (Chapter 3). The second objective (Aim #2) 
was to evaluate the impact of loss-of-function of canalicular transporters, which is a potential risk factor 
for DILI, on disposition of TS that is predominantly eliminated into bile. To this end, a novel in vitro 
model system, rat SCH lacking breast cancer resistance protein (Bcrp) and multidrug resistance-
associated protein 2 (Mrp2), was established (Chapter 4), and altered disposition of TGZ and derived 
metabolites was evaluated (Chapter 5). Finally, a mechanistic, mathematical model was developed to 
improve our predictability of DILI caused by altered hepatobiliary disposition of bile acids (Aim #3). The 
quantitative relationship between the intracellular concentrations of bile acids and toxicity, which was 
critical for the model development, was determined in human and rat SCH, and incorporated into the 
mechanistic model (Chapter 6). This mechanistic model was used to assess the contribution of bile acid 
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transport inhibition associated with TGZ hepatotoxicity in humans and to investigate the mechanism(s) 
for differential hepatotoxicity of TGZ in humans and rats (Chapter 7). 
 
Aim #1. Characterize the species differences in hepatobiliary disposition of taurocholic acid (TCA) 
and the influence of hepatic transport protein modulation by troglitazone (TGZ) and TGZ sulfate 
(TS) on TCA disposition. 
Hypothesis: Species differences in hepatic disposition of bile acids may be responsible for poor 
predictability of human DILI using preclinical animals. Bile acid disposition data from human and rat 
SCH combined with pharmacokinetic (PK) modeling/simulations will provide insights regarding species 
differences in transporter-mediated drug-bile acid interactions.   
1.a.  Characterize the hepatobiliary disposition (basolateral uptake and efflux, canalicular efflux) of TCA 
and predict altered TCA disposition by functional modulation of transporters in human and rat SCH 
using PK modeling and simulation. 
1.b.  Determine the impact of TGZ and TS on the hepatobiliary disposition of TCA using human and rat 
SCH and isolated membrane vesicles. 
Aim #2. Elucidate the mechanisms responsible for increased cellular accumulation of TS, which is a 
potential risk factor of TGZ-induced hepatotoxicity.  
Hypothesis: TS, a potent bile acid transport inhibitor, is mainly excreted into bile via breast cancer 
resistance protein (Bcrp) and multidrug resistance-associated protein 2 (Mrp2). Impaired biliary 
transport (due to genetic polymorphisms, drug-drug interactions, and underlying disease) will increase 
hepatocellular exposure to TS and further inhibit bile acid transport, leading to hepatotoxicity in 
susceptible patients. 
2.a.  Establish an in vitro model system to evaluate the impact of loss-of-function of Bcrp and/or Mrp2 
using SCH from WT and Mrp2-deficient (TR-) rats and RNA interference (RNAi).   
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2.b. Quantify the consequences of impaired function of Bcrp and/or Mrp2 on hepatocellular 
accumulation of TS using SCH from WT and TR- rats, in the absence and presence of Bcrp 
knockdown. 
Aim #3. Develop a mechanistic, mathematical model to predict DILI caused by altered 
hepatobiliary disposition of bile acids. 
Hypothesis: A mechanistic, mathematical model incorporating dynamic interactions between drug(s) and 
the biological system will improve the understanding and the prediction of bile acid-mediated 
hepatotoxicity in humans.  
3.a.  Determine the quantitative relationship between the intracellular concentrations of bile acids 
[lithocholic acid (LCA) and chenodeoxycholic acid (CDCA)] and toxicity in human and rat SCH. 
3.b. Develop a mechanistic, mathematical model to predict altered hepatic disposition of bile acids and 
subsequent hepatotoxicity using TGZ as a model hepatotoxic drug. 
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CHAPTER 2.  Analysis of Hepatic Transport Proteins1 
 
INTRODUCTION 
The liver is one of the major organs responsible for the metabolism and excretion of endogenous 
and exogenous compounds. Hepatocytes contain transport proteins that facilitate the influx of many 
compounds from sinusoidal blood. Once inside the hepatocyte, compounds may be biotransformed by 
metabolizing enzymes and/or excreted. Hepatocytes are polarized cells with distinct apical and basolateral 
domains (Figure 2.1); transport proteins on the apical membrane are responsible for excretion of 
compounds into the bile canaliculus, whereas basolateral transport proteins mediate influx into 
hepatocytes and efflux back to sinusoidal blood. Biliary excretion of drugs and metabolites is an active 
process that requires energy, usually in the form of adenosine triphosphate (ATP); the multidrug and toxin 
extrusion (MATE) transporter is one exception that does not require ATP for drug transport into the bile 
canaliculus. ATP-dependent transport proteins also are located on the basolateral membrane, and are able 
to efflux drugs and metabolites from hepatocytes into sinusoidal blood.  
In this chapter, the hepatic transport proteins important for drug disposition in humans are 
introduced based on their localization and function. The nomenclature and substrate specificity of hepatic 
transport proteins are summarized in Tables 2.1 and 2.2. In vitro and in vivo model systems and tools used 
to answer questions related to hepatic transport proteins are discussed, and more sophisticated approaches 
under development are introduced as future directions. 
 
                                                     
1This chapter has been published in Transporters in Drug Development, and is presented in the style of that book: 
Chapter 9: Analysis of hepatic transport proteins. Sugiyama Y and Steffansen B (eds.), in: Transporters in Drug 
Development, Springer, pp201-233 (2013). 
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HEPATIC TRANSPORT PROTEINS  
Hepatic Influx Transport Proteins 
The solute carrier (SLC) and solute carrier organic anion (SLCO) gene families are two 
representative families of transport proteins that mediate the hepatic influx of xenobiotics across the 
basolateral hepatocyte membrane (Figure 2.1). The list of hepatic influx transporters and example 
substrates are included in Table 2.1. 
NTCP (SLC10A1) The sodium-taurocholate cotransporting polypeptide (NTCP) is expressed 
exclusively in hepatocytes and plays a major role in the Na+-dependent hepatic influx of conjugated bile 
acids such as glycocholate and taurocholate (1). NTCP also is capable of transporting 
bromosulfophthalein (BSP), estrone 3-sulfate (E1S), and drugs such as pitavastatin and rosuvastatin, 
although the contribution of NTCP to the uptake of drug substrates into hepatocytes in vivo remains to be 
determined (Table 2.1). In rats, Ntcp also may be capable of transporting the thyroid hormones, and the 
mushroom toxin α-amanitin (2).  
OATPs (SLCO, previously SLC21A) The family of organic anion transporting polypeptides 
(OATPs) plays an essential role in sodium-independent influx of endogenous and exogenous compounds 
into hepatocytes, and may be the rate-limiting step in the hepatobiliary clearance of some drugs, such as 
statins. OATPs exhibit broad and overlapping substrate specificity; the spectrum of OATP substrates 
includes organic anions, bulky organic cations (previously referred to as type II cations), and neutral 
steroids. Some OATP isoforms have been hypothesized to function as glutathione or bicarbonate 
antiporters (3-5), employing the high intracellular glutathione or bicarbonate concentrations as a driving 
force for hepatic influx of substrates with high efficiency.  
Eleven human OATP isoforms have been identified so far; OATP1B1, OATP1B3, and OATP2B1 
are the major human OATPs that play an important role in the hepatic influx of drugs across the 
basolateral membrane domain. OATP1B1 and 1B3 are liver-specific, whereas OATP2B1 is widely 
expressed (e.g. in intestine, brain, and kidney). OATP1B1 exhibits the largest diversity of substrates 
including bilirubin, BSP, bile salts, many antibiotics, angiotensin receptor antagonists, 3-hydroxy-3-
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methyl-glutaryl Coenzyme A (HMG-CoA) reductase inhibitors (statins), and anticancer drugs (Table 2.1). 
OATP1B1 is the major human liver transport protein that is involved in sodium-independent bile salt and 
bilirubin influx. Inhibition of OATP1B1-mediated influx by drugs has been correlated with the incidence 
of hyperbilirubinemia (6). OATP1B1 is important in the hepatic influx of statins; genetic polymorphisms 
in SLCO1B1 have been shown to be associated with increased systemic exposure of statins and increased 
risk of statin-induced myopathy (7). While OATP1B3 has overlapping substrate specificity with 
OATP1B1, distinct substrate specificity has been reported; repaglinide and troglitazone sulfate are more 
selective substrates for OATP1B1, while digoxin, cholecystokinin-8, and paclitaxel show selectivity for 
OATP1B3 (Table 2.1). Bile acids are known to be transported by OATP1A2, OATP1B1, and OATP1B3, 
but OATP2B1-mediated bile acid transport has not been investigated.  
OATs (SLC22A) Organic anion transporters (OATs) mediate transport of small anionic 
compounds in exchange for dicarboxylate ions. Among six human OATs that have been functionally 
characterized, OAT2 (SLC22A7) is expressed in the basolateral membrane of hepatocytes and renal 
proximal tubule cells, while OAT7 (SLC22A9) is expressed exclusively in the liver (8). The known 
substrates for human OAT2 include prostaglandins, dehydroepiandrosterone sulfate (DHEAS), E1S, and 
anticancer drugs such as 5-fluorouracil and methotrexate (Table 2.1). OAT7, a recently characterized 
OAT, has been shown to transport sulfated hormones such as E1S and DHEAS when expressed in X. 
Laevis oocytes (9). Interestingly, typical OAT substrates such as para-aminohippurate, α-ketoglutarate, 
prostaglandins, cyclic nucleotides, and salicylic acid were not transported by OAT7, while OAT7 could 
transport the short-chain fatty acid butyrate (9). 
OCTs (SLC22A) Organic cation transporters (OCTs) are electrogenic uniporters that primarily 
mediate the transport of small cations (previously referred to as type I cations) in a sodium-independent 
fashion. Human OCT1 (SLC22A1) is expressed exclusively at the basolateral membrane of the 
hepatocytes (10). OCT1 is known to transport antiviral drugs such as acyclovir and ganciclovir, as well as 
the H2-receptor antagonists famotidine and ranitidine (Table 2.1). OCT3 (SLC22A3) and OCTN2 
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(SLC22A5) also are expressed in the liver, but expression levels are relatively low compared to OCT1 and 
the functional role of these proteins in hepatic drug transport remains to be elucidated (8).  
OSTα/β (SLC51A/51B) Organic solute transporter (OST) α/β is a heteromeric transporter that is 
expressed widely in the liver, small intestine, kidney, testis, and adrenal gland. In hepatocytes, OSTα/β is 
expressed in the basolateral membrane, and is able to transport bile acids, E1S, and DHEAS. Since 
OSTα/β mediates substrate transport by facilitated diffusion, OSTα/β-mediated transport is bidirectional 
depending on the substrate’s electrochemical gradient (10). Gene expression levels of SLC51A and 
SLC51B are positively regulated by bile acids through farnesoid X receptor (FXR), and it has been shown 
that hepatic OSTα/β is up-regulated in patients with chronic cholestatic disease such as primary biliary 
cirrhosis (PBC) (11). 
Hepatic Canalicular Efflux Transport Proteins 
Biliary excretion is an important elimination pathway for many endogenous and exogenous substances. 
Canalicular transport proteins responsible for biliary excretion of substances primarily belong to the ATP-
binding cassette (ABC) family of proteins that mediate ATP-dependent transport of solutes.  
P-glycoprotein (MDR1, ABCB1) P-glycoprotein (P-gp) was first identified in multidrug-
resistant (MDR) tumor cells (12), and is the most well characterized ABC transport protein. P-gp is 
widely distributed in liver, intestine, kidney, and brain. In hepatocytes, P-gp is expressed in the 
canalicular membrane and is responsible for biliary excretion of bulky hydrophobic and cationic 
substrates including many chemotherapeutic agents (e.g., daunorubicin, doxorubicin, etoposide, 
paclitaxel, vinblastine, vincristine), cardiac glycosides (e.g., digoxin), rhodamine 123, cyclosporine A, 
and protease inhibitors (e.g., amprenavir, indinavir, nelfinavir, ritonavir, saquinavir). Substrate specificity 
of P-gp largely overlaps with that of CYP3A4, resulting in synergistic defense mechanisms against 
xenobiotics. The ABCB1 gene is highly polymorphic, and hepatic expression levels of P-gp are highly 
variable between different individuals. 
MDR3 (ABCB4) MDR3, a phospholipid flippase, is involved in the biliary secretion of 
phospholipids and cholephilic compounds that form micelles with bile acids. Biliary excretion of 
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phospholipids protects the lumen of the bile canaliculus by solubilizing toxic bile acids (13). A deficiency 
in the ABCB4 gene leads to progressive familial intrahepatic cholestasis type 3 (PFIC3), a disease that is 
characterized by increased γ-glutamyltranspeptidase levels, ductular proliferation, and inflammatory 
infiltrate that can progress to biliary cirrhosis. Individuals with decreased MDR3 activity are susceptible 
to cholesterol gallstone formation, which is known as low-phospholipid associated cholelithiasis (14). 
Inhibition of MDR3-mediated biliary phospholipids excretion is one proposed mechanism of 
hepatotoxicity induced by drugs such as itraconazole. 
BSEP (ABCB11) The bile salt export pump (BSEP) is the major transport protein that mediates 
the biliary excretion of conjugated and unconjugated bile acids. Some drugs such as pravastatin may be 
substrates for BSEP based on membrane vesicle studies (15); however, the relative role of BSEP versus 
other canalicular transport proteins in the biliary excretion of pravastatin in hepatocytes or the intact liver 
remains to be determined (16). PFIC2 patients do not express BSEP protein due to a genetic 
polymorphism in the ABCB11 gene; this leads to hepatocellular injury and necrosis caused by increased 
intracellular concentrations of detergent-like bile acids (17). Inhibition of BSEP-mediated bile acid 
transport is purported to be one mechanism of drug-induced liver injury associated with hepatotoxic drugs 
such as troglitazone, bosentan, and cyclosporine. 
MRP2 (ABCC2) Multidrug resistance-associated protein (MRP) 2 plays an important in the 
biliary excretion of organic anions, including bilirubin-diglucuronide, glutathione conjugates, sulfated 
bile acids, and divalent bile acid conjugates, as well as numerous drugs such as sulfopyrazone, 
indomethacin, penicillin, vinblastine, methotrexate, and telmisartan (Table 2.2). The absence of functional 
MRP2 due to genetic mutations in ABCC2 results in Dubin-Johnson syndrome (DJS), which is 
characterized by decreased biliary excretion of bilirubin conjugates and hyperbilirubinemia (18). 
BCRP (ABCG2) Breast cancer resistance protein (BCRP) is highly expressed in the canalicular 
membrane of hepatocytes as well as in the intestine, breast, and placenta. BCRP is a half-transport protein 
that forms a functional homodimer, and is responsible for transport of glucuronide and sulfate conjugates 
(e.g., E1S, estradiol-17β-D-glucuronide (E217G), SN38-glucuronide), anticancer drugs (e.g., irinotecan, 
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SN-38, methotrexate, daunorubicin, doxorubicin), and some statins (e.g., pitavastatin, rosuvastatin) (Table 
2.2). 
MATE1 (SLC47A1) Human MATE1 is expressed predominantly in the canalicular membrane of 
hepatocytes and the luminal membrane of renal tubular cells. MATE1 has been shown to transport 
organic cations across the membrane in a bidirectional manner dependent on the proton gradient. 
Substrate specificity of MATE1 primarily overlaps with the OCTs; MATE1 substrates include acyclovir, 
N-methylpyridinium, and tetraethylammonium (Table 2.2). 
Hepatic Basolateral Efflux Transport Proteins   
Xenobiotics in the liver also may be excreted across the basolateral membrane into sinusoidal 
blood. MRP1, 3, 4, 5, and 6 are involved in cellular transport of both hydrophobic uncharged molecules 
and hydrophilic anionic compounds. OATPs also may function as basolateral efflux transport proteins 
under certain conditions, although the in vivo role of OATPs in basolateral efflux remains to be elucidated 
(4). 
MRP3 (ABCC3) MRP3 was first localized in human and rat hepatocytes, and is also expressed 
widely in kidney, pancreas, enterocytes, cholangiocytes, and the gallbladder (19). The expression level of 
MRP3 in hepatocytes is low in normal liver, but markedly increased in patients with DJS who lack 
functional MRP2, and in patients with cholestatic liver disease, consistent with the important 
compensatory role of MRP3 when the function of biliary transport proteins is impaired (20-22). MRP3 is 
responsible for the basolateral efflux of glutathione and glucuronide conjugates (e.g., acetaminophen 
glucuronide), methotrexate, and E217G.  
MRP4 (ABCC4) MRP4 is localized in many different tissues including liver, kidney, brain, and 
prostate (19). The expression level of MPR4 in normal hepatocytes is low, but is markedly induced under 
cholestatic conditions. MRP4 is responsible for the basolateral efflux of bile acids when the normal 
vectorial transport of bile acids from the hepatocyte into bile is compromised (23). MRP4-mediated bile 
acid transport requires glutathione, because bile acids and glutathione are co-transported by MRP4 (24). 
MRP4 also transports cyclic nucleotides (e.g., cAMP and cGMP), nucleoside analogs (e.g., zidovudine, 
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lamivudine, and stavudine), purine analogs (e.g., 6-mercaptopurine and 6-thioguanine), and non-
nucleotide substrates such as methotrexate (25). 
Other MRPs MRP1 (ABCC1) is expressed in several tissues including liver, lung, testis, kidney, 
skeletal and cardiac muscle, placenta, and macrophages (19). MRP1 is responsible for the efflux of 
various organic anions, such as glucuronide, glutathione, and sulfate conjugates of drugs. MRP5 (ABCC5) 
transports cyclic nucleotides (e.g., cAMP and cGMP) and purine analogs (e.g., 6-mercaptopurine and 6-
thioguanine). The expression levels of MRP1 and MRP5 in healthy liver are relatively low, but protein 
levels of hepatic MRP1 and MRP5 were significantly increased in patients with PBC (26). Protein 
expression of hepatic MRP5 also was increased in acetaminophen-induced liver failure, suggesting a 
protective role for this protein in hepatic injury (26). MRP6 (ABCC6) is localized in the basolateral 
membrane of hepatocytes and transports glutathione conjugates and the endothelin receptor antagonist 
BQ-123 (Table 2.2). Expression of MRP6 was not altered in patients with PBC or acetaminophen-
induced liver failure, and the functional roles of MRP6 remain to be explored (26). 
  
IN VITRO MODELS AND METHODS TO STUDY HEPATOBILIARY DRUG TRANSPORT  
Membrane Vesicle System 
With the development of membrane vesicle assays, it became possible to perform functional 
studies to identify and characterize distinct efflux transport systems. Historically, vesicle transport assays 
were performed using membranes isolated from hepatic tissue from the relevant species. Functional 
studies of hepatic efflux transporters in either canalicular liver plasma membrane (cLPM) or basolateral 
liver plasma membrane (bLPM) vesicles were enabled by the development of a method to separate these 
two membrane leaflets in the early 1980s (27, 28). This assay system was used to identify and 
characterize bile acid and bilirubin glucuronide transport across the canalicular membrane, and led to the 
discovery of BSEP and MRP2 (29, 30). The isolation of high-purity apical and basolateral membranes 
from tissue is labor intensive and technically challenging. Since inside-out and right-side-out vesicles 
coexist, ATP-dependent basolateral efflux data generated with bLPMs may be confounded by influx 
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transporters. Naturally, these membranes contain multiple transport proteins; therefore, it is impossible to 
identify specific substrates for ABC efflux proteins.  
Due to evolving molecular biology techniques and identification of individual transport proteins, 
this tissue-based assay system has been replaced by vector-transfected and virus-infected cell lines 
expressing a single ABC-transporter. In the early 1990s, baculovirus-infected insect cells (Spodoptera 
frugiperda, Sf9) were used widely to generate membrane vesicles containing the transport protein of 
interest because this system allowed high expression of transport proteins (31). Disadvantages of these 
membrane vesicles are the different glycosylation pattern and a lower cholesterol content in Sf9 cells 
compared to mammalian cell lines (32), which may affect the localization and function of transporters. 
For example, MRP2-mediated transport and ATPase activity were altered by membrane cholesterol 
content (32). Therefore, either transiently or stably transfected mammalian cell lines from human 
embryonic kidney (HEK) 293, Madin-Darby canine kidney (MDCK) II, or porcine kidney epithelial 
(LLC-PK1) cells are now used more frequently for preparation of membrane vesicles for transporter 
studies. These systems are suitable for high-throughput screening of substrates and inhibitors for a single 
transport protein.  
The most commonly used membrane system for efflux transporters is the vesicular transport 
system that detects direct translocation of substrates into inside-out vesicles (Figure 2.2). Substrates taken 
up into inside-out vesicles are separated from the incubation solution using rapid filtration and quantified 
by high performance liquid chromatography (HPLC), liquid chromatography mass spectrometry 
(LC/MS), scintillation counting, or fluorescence detection. ATP-dependent transport is calculated by 
subtracting the transport of substrate in the presence of AMP from that in the presence of ATP; 
endogenous transporter-mediated transport is excluded by subtracting ATP-dependent transport of 
substrate in control vesicles from that in transporter-expressing vesicles. This method detects direct 
transport of substrate, and kinetic parameters such as the Michaelis-Menten constant (Km) and the 
maximal transport velocity (Vmax) can be calculated. This method is ideal for the detection of drug-drug 
interactions (DDIs) or drug-endogenous compound interactions using a probe substrate. However, it is 
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difficult to detect the transport of highly permeable compounds due to passive diffusion out of the 
membrane vesicles.  
The ATPase method, which detects the hydrolysis of ATP in the presence of an interacting 
compound, is more suitable for determining the transport of highly permeable compounds. The ATPase 
method is based on the principle that ABC transporters utilize the chemical energy of ATP cleavage to 
mediate the transport of substrates across membranes. The inorganic phosphate produced during this 
process is directly proportional to the activity of the transporter and can, for example, be monitored by 
colorimetric detection. This method is most commonly used for high-throughput screening for P-gp and 
BCRP, although it also is available commercially for other ABC efflux transporters. However, ATPase 
systems are indirect measures of transport, and are not always suitable for distinguishing between 
potential substrates, inhibitors or modulators. Major applications of the membrane vesicle systems as well 
as their advantages and disadvantages when used to study hepatobiliary drug transport are summarized in 
Table 2.3. 
Transfected Cells 
Bacterial, insect as well as mammalian cells have been transfected with vector constructs 
allowing overexpression of transport proteins for identification of transport processes. The transfected cell 
model is illustrated in Figure 2.2. Non-polarized cells such as Sf9 and HEK293 cells have been used for 
overexpression of a single transport protein, while polarized cells have been employed for the 
overexpression of one or more basolateral proteins in concert with apical protein(s). Transfected cell 
models can be used for high-throughput screening of substrates and inhibitors of a specific over-expressed 
transport protein. The major limitation of this model is that generally it is not suitable for the study of 
efflux transporters. Hypothetically, in transfected cells expressing a single efflux protein, transported 
substrates should demonstrate lower cellular accumulation, and inhibitors should increase drug 
accumulation compared to the parental cell line. However, substrates of drug efflux transporters are 
usually organic anions that do not easily penetrate into the cell in the absence of influx transport proteins. 
To overcome this limitation, polarized mammalian cells (e.g., MDCKII, LLC-PK1) have been used for 
 62 
 
transfection of one or more influx and/or efflux transport proteins. Depending on the transporter, the 
protein will be routed to the apical or basolateral membrane in polarized cells; expression of influx 
transporters allows import of the substrates transported by the ABC efflux transporters. Furthermore, the 
combined expression of influx and efflux proteins enabled the analysis of vectorial transport, which is a 
key step in hepatobiliary elimination (33, 34). These double-transfected polarized cell lines were first 
developed by Cui et al. in the early 2000s (34) and are now valuable tools to study transcellular transport. 
Using MDCKII cells expressing both Oatp1b2 and Mrp2, Sasaki et al. demonstrated a good correlation 
between the clearance values obtained from in vitro transcellular transport and in vivo biliary clearance 
(35). Triple and quadruple transfected cell lines OATP1B1/MRP2/MRP3 or MRP4, as well as 
OATP1B1/OATP1B3/OATP2B1/MRP2 have been developed to better predict hepatobiliary processes 
(36, 37). Recently, a triple-transfected cell line expressing influx and efflux transporters as well as the 
drug-metabolizing enzyme uridine diphosphate glucuronosyl transferase (UGT) 1A1 has been described 
to study transporter-metabolism interplay (38). As our understanding of the role of influx and efflux 
transporters in facilitating the vectorial transport of xenobiotics across the hepatocyte has evolved, the use 
of polarized mammalian cells has become more popular to identify substrates and inhibitors of hepatic 
transport proteins. However, protein trafficking or localization in transfected cells may differ from human 
hepatocytes, depending on the species or type of transfected cells. Also, it is difficult to standardize the 
relative expression levels of transporters, and the relative contribution of a particular transport protein to 
overall transport of the substrate cannot be determined. The major applications of transfected cells 
together with their advantages and disadvantages when used to study hepatobiliary drug transport are 
summarized in Table 2.3.   
Hepatocytes 
Freshly isolated hepatocytes are the most comprehensive cell-based model to study hepatic drug 
transport and remain the gold standard. However, the scarcity of fresh, healthy human liver tissue suitable 
for hepatocyte isolation is a significant limitation, and isolation of human hepatocytes is technically 
challenging. Recent advances in technology have made good-quality cryopreserved human hepatocytes 
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commercially available at the user’s convenience. Cryopreserved human hepatocytes have been used 
widely to study drug metabolism (39) and substrate influx in suspension (40-42); cryopreserved 
hepatocytes cultured in a sandwich configuration repolarize and form bile canalicular networks (43). Both 
the suspended and sandwich-cultured hepatocyte models are illustrated in Figure 2.2. However, not all 
batches of cryopreserved hepatocytes are qualified for sandwich-culture due to limitations in cell 
attachment and the loss of expression, localization, and/or function of transport proteins and metabolizing 
enzymes. Thus, further research is needed to improve the cryopreservation process.  
Suspended Hepatocytes Fresh or cryopreserved suspended hepatocytes are a useful tool to 
characterize hepatic influx and metabolism processes, and inhibition studies can be performed with this 
system. However, suspended hepatocytes cannot be used for induction studies because the viability of 
hepatocytes in suspension cannot be maintained longer than several hours. Additionally, hepatocytes lose 
their cellular polarity during isolation and internalization of canalicular transport proteins has been 
demonstrated, which precludes the use of suspended hepatocytes to predict biliary clearance (44). 
Sandwich-Cultured Hepatocytes In contrast to conventionally plated hepatocytes, hepatocytes 
cultured between two layers of gelled collagen (“sandwich-configuration”) develop functional canalicular 
domains with proper localization of transport proteins and metabolic enzyme expression. (45) Liu et al. 
demonstrated that rat sandwich-cultured hepatocytes (SCH) could be used to investigate the hepatobiliary 
disposition of substrates using Ca2+ depletion methods (46, 47). This method involves pre-incubation of 
SCH with Hanks’ balanced salt solution (HBSS) containing Ca2+ (standard HBSS) or Ca2+-free HBSS for 
10 minutes. Ca2+-free HBSS disrupts tight junctions and opens the bile canalicular networks, while 
incubation with standard HBSS maintains tight junction integrity. Subsequently, cells are rinsed and 
incubated with substrate in standard HBSS for a predetermined period of time. Accumulation of substrate 
in cells+bile vs. cells can be determined in standard and Ca2+-free HBSS buffers, respectively. The 
amount of substrate excreted into the bile canaliculi can be estimated as the difference in accumulation in 
standard and Ca2+-free HBSS buffers, and in vitro biliary clearance may be obtained by dividing the 
amount of drug in the bile compartment by the area under the concentration-time curve (AUC) in the 
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dosing medium. This system has been applied to hepatocytes from many species, and has been used 
extensively to assess biliary clearance as a measure to improve hepatic clearance predictions (45). Biliary 
clearance values scaled from in vitro intrinsic biliary clearance measurements obtained in SCH have been 
shown to correlate well with in vivo biliary clearance data in rats (48-51) and humans (52, 53). 
To determine the contribution of a specific transport protein to the disposition of a substrate, a 
transporter-specific reference compound can be employed in hepatocytes as well as transport protein 
overexpressing cells (54). Basically, this method compares the ratio of influx clearances of the test and 
the reference compound in both systems. However, the results are based on the assumption that the 
reference compound is specific for the respective transport protein, which – due to the overlapping 
substrate spectrum of transport proteins – is hardly ever the case.  
SCH from naturally occurring, genetically deficient rodents lacking a specific transport protein, 
such as the Mrp2-deficient Wistar (TR-) and Eisai-hyperbilirubinemic Sprague-Dawley (SD) rats 
(EHBR), and the Mdr1a-deficient CF-1 mice, have been useful tools to evaluate the role of a transporter 
in the disposition of substrates (48). Also, genetically modified animals that lack specific transporter(s) 
can be used to assess the potential involvement of specific transport protein(s) in drug-drug interactions or 
polymorphisms that impair the function of drug transport proteins. However, care must be taken in 
interpreting the results of these studies because compensatory changes in drug metabolizing enzymes 
and/or other transport proteins may exist. Also, species difference in the expression, localization, and 
function of transport proteins between humans and genetically modified animals may limit clinical 
applicability of the data.   
RNA interference (RNAi) of single or multiple transport proteins is a powerful tool to explore the 
consequences of loss of transport protein function. Synthetic small interfering RNA (siRNA) was 
transfected into rat SCH to specifically knock down Mrp2 and Mrp3 (55). Infection of rat SCH with 
adenoviral vectors expressing short hairpin RNA (shRNA) targeting Bcrp showed a significant decrease 
in protein expression and activity of this canalicular transport protein (56).  Recently, Liao et al. 
successfully knocked down OATP1B1, 1B3, and 2B1 in sandwich-cultured human hepatocytes using 
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special delivery media containing siRNA (57). These studies have demonstrated the utility of knock down 
of specific transport proteins in SCH. However, careful optimization is required because knock down of 
one transport protein may alter the expression/function of metabolic enzymes and other transport proteins.  
Other Hepatocyte Models Limited exposure of liver tissue to collagenase results in hepatocyte 
couplets preserving closed canalicular vacuoles and hepatocyte polarity (58). Hepatocyte couplets have 
been used to study hepatobiliary transport mechanisms underlying bile secretion (59, 60). HepaRG cells, 
a human hepatoma cell line, maintain specific liver functions such as drug metabolizing enzymes and 
transport proteins. In HepaRG cells, mRNA expression levels and functional activity of basolateral and 
canalicular transport proteins were comparable to those of human hepatocytes (61). Also, expression 
levels of transport proteins were up-regulated by known inducers, indicating that HepaRG cells maintain 
transactivation pathways that regulate expression of transport proteins (61). Since HepaRG cells are 
readily available compared to human hepatocytes, they may be a useful system to study hepatobiliary 
transport of compounds. However, HepaRG cells differentiate into biliary epithelial cells as well as 
hepatocytes, and the fraction of cells that differentiate into hepatocytes varies among different cultures 
and plates. In addition, more characterization is warranted including cell polarity and polarized expression 
of relevant transport proteins. Human inducible pluripotent stem (iPS) cells have been successfully 
differentiated into hepatocyte-like cells that exhibit human hepatocyte function such as inducible CYP450 
activity (62). Although the expression and function of transport proteins still needs to be characterized, 
hepatocytes derived from individual-specific iPS cells may serve as a novel tool to study hepatobiliary 
transport of compounds in specific individuals. Newer three-dimensional microfluidic models (e.g. 
liverchip, Hµrel) that more closely resemble in vivo liver physiology are currently under development. 
Further investigations are needed to explore the utility of these more complex models. The major 
applications of hepatocytes as well as their advantages and disadvantages when used to study 
hepatobiliary drug transport are summarized in Table 2.3.  
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Isolated Perfused Liver Models 
For decades, in situ or isolated perfused liver (IPL) studies have been used to investigate the 
physiology and pathophysiology of the liver. The model is illustrated in Figure 2.2. Publications 
regarding the use of IPLs date back to the 1950s, when the metabolism of drugs and endogenous 
compounds was first studied using this approach. In contrast to in vitro models such as isolated 
hepatocytes and liver slices, the IPL preserves hepatic architecture, cell polarity and bile flow. 
Furthermore, this model enables simultaneous sampling of bile as well as inflow and outflow perfusate; 
liver tissue may be obtained at the end of the study. Thus, the IPL provides a rich dataset amenable to 
pharmacokinetic modeling, and makes this system useful for mechanistic studies of hepatobiliary 
transport.  
In IPL studies, the liver may be perfused in a single-pass or recirculating mode. A single-pass 
perfusion system is used to determine directly the steady-state hepatic extraction ratio of a compound. In 
the single-pass system, outflow perfusate from the liver does not re-enter the system, and the perfusion 
medium is pumped into the liver at a constant rate. Thus, steady-state conditions can be achieved readily, 
and drug and metabolite disposition can be examined at different dose levels in a single preparation. Also, 
experiments can be designed so that each liver serves as its own control. Hemoglobin-free oxygenated 
perfusate often is used in the single-pass perfusion system because a large volume of perfusate is 
required. Furthermore, flow rates that are 2 - 3 times higher than physiologic blood flow are required to 
maintain adequate oxygen delivery. In recirculating systems, blood-containing pefusate is oxygenated and 
recirculated through the liver at a constant flow rate that is similar to liver blood flow in vivo. The hepatic 
clearance of the drug can be determined from the dose introduced into the reservoir and the AUC in the 
reservoir. In recirculating systems, the only route of metabolite elimination is via biliary excretion, and 
metabolites usually accumulate in hepatocytes or in the perfusate, if they are able to flux across the 
hepatic basolateral membrane. Accumulation of metabolites may be advantageous in mass-balance 
determination of metabolite formation and kinetic evaluation of hepatic influx of metabolites. However, 
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potential drug-metabolite interactions may be magnified in the recirculating system compared with the 
single-pass IPL. 
The IPL model can be applied to transporter knock-out animals in combination with chemical 
inhibitors to investigate the contribution of specific hepatic drug efflux transporters (63, 64). However, 
these experiments are relatively expensive and low-throughput. Furthermore, species-specific differences 
between human and rodent transport proteins may significantly limit the clinical applicability of 
information generated using this approach. Whether or not the results obtained from IPL analyses can be 
extrapolated to in vivo findings in humans remains compound-dependent. The major applications of the 
IPL models as well as advantages and disadvantages when applied to studying hepatobiliary drug 
transport are summarized in Table 2.3. 
 
IN VIVO MODELS AND METHODS TO STUDY HEPATOBILIARY DRUG TRANSPORT  
In vivo pharmacokinetic/pharmacodynamic studies in humans are the gold standard for 
investigating the role of hepatic transporters. However, the complexity of the hepatobiliary system and 
considerable substrate overlap for many of the transporters makes it difficult to identify the function of 
specific transport proteins based on in vivo studies. Genetically-modified animals and patients with 
polymorphisms in transporter genes are valuable in evaluating the function of transport proteins, but 
species differences in transport protein function, and compensatory up-regulation of other transport 
proteins, may confound the translation of in vivo data generated in preclinical species to humans. 
In Vivo Biliary Excretion Studies 
Biliary excretion is an important route of elimination for some drugs and a potential site of drug 
interactions that may alter hepatic and/or systemic drug exposure. Accurate measurement of biliary 
clearance and understanding the mechanism(s) of biliary excretion are very important in evaluating the 
contribution of biliary clearance to total systemic clearance, predicting DDIs, identifying the contribution 
of enterohepatic recirculation to overall systemic and intestinal exposure, and elucidating potential 
mechanisms of hepatobiliary toxicity. 
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Bile Duct-Cannulation Animals, primarily rodents, often are used to determine the extent and 
the mechanisms of biliary excretion in vivo. Complete collection of bile is possible in bile duct-cannulated 
animals, which generates information about the extent of biliary excretion and the potential involvement 
of enterohepatic recirculation in overall systemic exposure. Proper study design is critical to obtain useful 
information from bile-duct cannulated animals.  For example, if bile flow is exteriorized for extended 
periods of time to obtain complete bile collection, intravenous or intestinal supplementation with bile 
acids should be considered to replenish the bile acid pool. In vivo biliary clearance data has been used to 
assess the accuracy of in vitro methods of estimating biliary clearance; reasonable in vitro-in vivo 
correlations have been obtained (49, 51, 52, 65). Genetically modified animals that are deficient in 
specific transport proteins has improved our understanding of the complex molecular processes involved 
in excretion of endogenous and exogenous compounds into bile. However, significant interspecies 
differences in substrate specificity and regulation of transport proteins have been reported, which 
complicates the direct extrapolation of animal data to humans (66).  
Aspiration of Duodenal Fluids Determining the biliary clearance of drugs in vivo in humans is 
challenging because it is difficult to access bile for sample collection from healthy human subjects. Bile 
samples can be collected in postsurgical patients with underlying hepatobiliary disease via a T-tube or 
nasobiliary tube (67, 68). However, it is difficult to rule out the effects of underlying heapatobiliary 
disease (e.g. altered protein expression, function, localization, and/or bile flow) in these patients. In 
healthy subjects, feces often are used as a surrogate to quantify the amount of drug excreted via non-renal 
pathways. However, this method cannot distinguish between biliary excretion, intestinal secretion, and 
unabsorbed drug following oral administration. Moreover, unstable drugs may not be recovered in feces 
due to the long exposure to the intestinal contents and colonic flora.  Furthermore, drugs that are 
reabsorbed in the intestine and undergo enterohepatic recycling will not be recovered completely in the 
feces.  
Oroenteric Tube Sampling duodenal fluids in healthy volunteers using an oroenteric tube 
alleviates some of the above mentioned problems. Duodenal bile is representative of gallbladder bile in 
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terms of bile composition, and collecting bile upon discharge from the biliary tract into the small 
intestines excludes the contribution of intestinal excretion and minimizes loss associated with metabolism 
and/or reabsorption. Oroenteric tubes have been commonly used to withdraw pancreatico-biliary 
secretions from the duodenum in medical practice, and have been used to study the biliary excretion of 
drugs (69, 70). Use of an occlusive balloon can facilitate more complete bile collection, and incomplete 
bile collection can be corrected by perfusing nonabsorbable markers. The most challenging part of this 
method is incomplete and highly variable recovery of compounds excreted into bile. Cholecystokinin 8 
(CCK-8) may be administered intravenously to pharmacologically stimulate gall bladder empting, but 
inter-individual response is variable. Ghibellini et al. introduced a novel method to evaluate the degree of 
gallbladder contraction and to detect any leakage of bile due to partial occlusion of the intestine (71). 
Subjects were administered a hepatobiliary imaging agent (e.g., 99mTc-mebrofenin), and the gall bladder 
ejection fraction was calculated from the abdominal gamma images of the study participants during 
gallbladder contraction. Incorporation of the ejection fraction as a correction factor in the calculation of 
the amount of drug excreted into the duodenum accounted for the variability in biliary excretion of the 
drug (72). This type of study provides direct evidence for biliary excretion and more precise 
quantification of biliary clearance, but is not used widely due to requirements for a gamma camera and 
personnel with expertise in gamma scintigraphy. The major applications of the in vivo biliary excretion 
models as well as advantages and disadvantages when used to study hepatobiliary drug transport are 
summarized in Table 2.4.  
Hepatobiliary Imaging Techniques 
Although techniques are available to study genetic polymorphisms and the expression of drug 
transporters at the mRNA and protein level, these data do not necessarily correlate with transporter 
function. Thus, there continues to be considerable interest in studying transporter function non-invasively. 
Pharmacokinetic analyses based on plasma concentrations in clinical studies provide information on 
overall hepatic clearance; however, differentiation between influx and canalicular efflux is not possible. 
While variations in influx activity of transporters might have a profound influence on systemic 
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concentrations, altered canalicular efflux might significantly affect liver concentrations without having 
measureable effects upon systemic exposure. This is especially relevant for drugs where the target site for 
effect or toxicity is within the hepatocyte. Therefore, quantitative estimations of tissue concentrations in 
vivo are necessary to investigate variations in efflux caused by DDIs or transporter polymorphisms. 
Furthermore, assessing the functional transport activity of P-gp, MRP2, or BCRP in the human liver 
might benefit the diagnosis of transporter deficiency-related diseases (e.g. PFIC3 and DJS). Several 
noninvasive imaging techniques such as magnetic-resonance imaging (MRI), single-photon emission 
computed tomography (SPECT) using 99mTc-labeled compounds, and positron emission tomography 
(PET) using short-lived 11C, 13N, 15O or 18F- isotopes have been employed to visualize and measure 
hepatic transporter activity in vivo.  
Magnetic-Resonance Imaging The first MRI contrast agents were developed in the early 1980s 
(e.g. gadopentetate dimeglumine, gadodiamide, gadoteridol). These extremely hydrophilic compounds 
distributed primarily into the extracellular fluid and were excreted predominantly via the kidney. Because 
of this distribution pattern, these contrast agents have been used primarily for angiography and to detect 
lesions in the brain. The development of gadobenate dimeglumine (Gd-BOPTA) and gadolinium-
ethoxybenzyl-diethylenetriamine pentaacetic acid (GD-EOB-DPTA, gadoxetic acid) allowed liver 
imaging and facilitated the distinction between normal and pathological tissue. Using these imaging 
agents, most hepatic tumors appear as hypointense lesions because they do not possess functional 
hepatocytes, while positive hepatocyte-enhancement may be observed in patients with tumors of 
hepatocellular origin (e.g. hepatocellular carcinoma, HCC). Hepatocyte influx of gadolinium compounds 
is thought to be mediated by OATPs (73, 74), while MRP2 mediates biliary excretion (75). Indeed, 
studies indicated that the degree of expression and localization of OATP1B1/1B3 and MRP2 affect the 
degree of hepatocyte-specific enhancement in HCC (73, 76). 
SPECT and PET imaging For quantitative determination of drug transporters, the 
radionucleotide-based molecular imaging techniques SPECT and PET hold great promise. Initially, PET 
was used to quantify P-gp function in the blood-brain-barrier; several 11C-labeled tracers have been 
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developed for this purpose (verapamil, carvedilol, N-desmethyl-loperamide, daunorubicin, paclitaxel). 
However, PET imaging also can be employed to study influx and excretion in other tissues. In 1995, 
Guhlmann et al. determined the hepatobiliary and renal excretion of N-[11C] acetyl-leukotriene E4 in rats 
and monkeys by PET analysis. In rats, cholestasis due to bile duct obstruction as well as Mrp2 deficiency 
(TR- rats) led to prolonged organ storage, metabolism, transport back into the blood and subsequently 
enhanced renal elimination compared to wild-type rats (77). Currently, compounds are being developed to 
evaluate hepatobiliary transport (78). In order to be useful clinically, such probes will need to be 
metabolically stable in humans, and ideally, the probes should be a substrate for a specific hepatic influx 
and/or efflux transport protein.  
Cholescintigraphy studies with 99mTc-N(2,6-dimethylphenyl carbamoylmethyl) iminodiacetic acid 
(99mTc-HIDA) were performed in patients with liver disease in the late 70s/early 80s for diagnostic 
imaging of hepatobiliary disorders (79). Furthermore, 99mTc-mebrofenin has been used widely to diagnose 
cholestasis, gallbladder function, and bile duct leakage. In 2004, Hendrikse et al. proposed that both 
compounds were useful tools to evaluate the function of Mrp1, Mrp2 and P-gp in-vivo (80). Another 
compound, 99mTc-sestamibi, has been suggested to be a probe for P-gp function (81). This compound 
originally was developed for imaging of myocardial ischemia and is a positively charged, lipophilic 
compound that readily enters cells and accumulates in mitochondria. In vivo studies with 99mTc-sestamibi 
showed that this substance is retained in the liver and kidneys after P-gp inhibition with PSC833, 
suggesting that inhibition of P-gp transport in these organs can be imaged with 99mTc-sestamibi (81). 
However, 99mTc-sestamibi is also a substrate for MRP1 (82). The major applications of in vivo imaging 
together with advantages and disadvantages when used to study hepatobiliary drug transport are 
summarized in Table 2.4. 
 
CONCLUSIONS  
Hepatic transport proteins play important roles in the hepatic influx and biliary excretion of drugs 
and metabolites, thus affecting the therapeutic efficacy and toxicity of many drugs. Therefore, it is 
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important to understand the roles of hepatic transport proteins in the disposition of drugs and metabolites 
during the drug development process. Table 2.5 summarizes preferred approaches that can be used to 
answer specific questions regarding hepatobiliary drug transport. It is relatively straightforward to 
determine which transport proteins are capable of transporting drugs and metabolites by using membrane 
vesicle systems or cell lines expressing a single transport protein. However, determining the contribution 
of each transport protein to the hepatic influx or efflux of a specific compound in the whole cell/intact 
organ is not as straightforward, and may require the use of several model systems (e.g., transfected cell 
lines and SCH) and scaling factors (e.g., relative activity factor) (83). Moreover, reference compounds 
used to obtain the scaling factor between different systems are often not specific to a single transporter, 
which makes it difficult to determine the precise contribution of a single transporter to overall disposition.  
Accurate predictions of clinically relevant drug interactions in hepatobiliary transport [either 
DDIs, drug-endogenous compound interactions (e.g. competition with bilirubin for influx or excretion) or 
drug-transporter interactions] are critical in drug development. Direct competitive interactions with a 
single protein can be predicted from membrane vesicle or transfected cell assays; however, accurate 
extrapolation to the in vivo setting requires an understanding of the unbound concentration at the site of 
transport. The ability of other transport proteins or drug metabolizing enzymes to compensate for drug 
interactions cannot be predicted accurately from these simplistic systems, and intact hepatocytes 
(suspended for influx studies; sandwich-cultured for hepatic efflux and overall hepatobiliary disposition) 
or whole organ and/or in vivo studies are required. More complex drug-transporter interactions involving 
signaling cascades and/or regulatory mechanisms, or interactions that involve generated drug metabolites 
require the complex machinery of the intact cell.  
Drug-induced liver injury (DILI) is one of the most common reasons for withdrawal of drugs 
from the market, or failure of new drugs in clinical trials. Inhibition of canalicular BSEP, which leads to 
elevated hepatic exposure of detergent-like bile acids, has been reported as one mechanism of DILI. Some 
hepatotoxic drugs also are potent inhibitors of NTCP and/or MRPs. Thus, determining whether drug 
and/or generated metabolite(s) inhibit(s) bile acid transport would provide key information about the 
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drug’s potential for DILI. High-throughput screening is possible to determine the inhibitory effects of a 
specific compound on bile acid transport in membrane vesicles expressing a single transporter. However, 
model systems that enable the generation of metabolites, and allow for direct measurement of bile acids 
accumulated in hepatocytes (e.g., SCH or IPL) provide more information to determine the potential for 
DILI. Hepatic exposure of the drug is important in predicting efficacy and toxicity, but this cannot be 
measured directly in vivo in humans nor predicted based on systemic exposure. Human SCH will provide 
invaluable information about the hepatic accumulation potential of drugs and generated metabolites, and 
how hepatic exposure changes when the function of transport proteins are altered due to disease states, 
drug interactions, or changes associated with genetic polymorphisms in transport proteins. Because only 
unbound drugs are available to interact with transporters, it is important to determine the intracellular 
unbound concentration. However, our current knowledge about intracellular unbound concentrations is 
limited, and development of in vitro systems to characterize hepatocellular binding/sequestration and the 
unbound concentration in the intact cell is needed.  
Many tools and model systems are available to analyze the role of hepatic transport proteins in 
drug development. Current efforts are focused on assessing which tools should be appropriately used at 
defined steps in the drug development process, as well as how the resulting information can be used most 
efficiently to answer the key questions before the compound reaches the clinic. Important work continues 
to focus on mathematical modeling and simulation based on data generated from the various in vitro and 
in vivo models to accurately predict the role of hepatic transport proteins in drug disposition, and how 
alterations in hepatic transport could alter efficacy and/or toxicity.  
 
  
 
  
 74 
 
Table 2.1. Human hepatic influx transporter proteins. 
Protein/ 
Trivial Names 
Gene Substrate/References 
NTCP SLC10A1 cholate; E1S;glycoursodeoxycholate; pitavastatin; rosuvastatin; 
taurocholate; tauroursodeoxycholate [U], BSP; glycocholate; 
taurochenodeoxycholate (85) 
OATP1B1 
OATP-C 
LST-1 
OATP2 
SLCO1B1 
(SLC21A6) 
atorvastatin; bilirubin; bisglucuronosyl bilirubin; bosentan; BSP; cholate; 
CGamF; DHEAS; E217G; E1S; fluo-3; fluvastatin; 
glycoursodeoxycholate; methotrexate; monoglucuronosyl bilirubin; 
olmesartan; pitavastatin; pravastatin; rifampicin; rosuvastatin; 
tauroursodeoxycholate; valsartan [U], benzylpenicillin (86), BQ-123; 
DPDPE; LTC4; PGE2; T3; T4 (87), caspofungin (88), cerivastatin (89, 90), 
SN-38 (91), microcystin-LR (92), phalloidin (93), repaglinide (94, 95), 
simvastatin (90), troglitazone-sulfate (96) 
OATP1B3 
OATP-8 
LST-2 
SLCO1B3 
(SLC21A8) 
amantinin; bilirubin; bosentan; BSP; CCK-8; CGamF; digoxin; E217G; 
E1S; fexofenadine; fluo-3; fluvastatin; glycoursodeoxycholate; 
methotrexate; monoglucuronosyl bilirubin; olmesartan; paclitaxel; 
pitavastatin; rifampicin; rosuvastatin; taurocholate; tauroursodeoxycholate; 
telmisartan; telmisartan glucuronide; T3; valsartan [U], BQ-123; deltorphin 
II; DHEAS; DPDPE; LTC4; ouabain; T4 (87), CCK-8 (97), microcystin-LR 
(92), phalloidin (93)  
OATP2B1 
OATP-B 
SLCO2B1 
(SLC21A9) 
atorvastatin; bosentan; BSP; E1S; fexofenadine; fluvastatin; glyburide; 
pitavastatin; pravastatin; rosuvastatin; taurocholate; telmisartan 
glucuronide [U], DHEAS (87), pregnenolone sulfate (98) 
OAT2 SLC22A7 2’-deoxyguanosine; 5-fluorouracil; bumetanide; cyclic GMP; 
erythromycin; paclitaxel; PGE2; PGF2α; tetracycline; theophylline; 
zidovudine [U], allopurinol; L-ascorbic acid; DHEAS; E1S; glutarate (99), 
methotrexate (100), ranitidine (101) 
OAT 7 SLC22A9 DHEAS; E1S (9) 
OCT1 SLC22A1 DASPMI; acyclovir; furamidine; ganciclovir; metformin; N-
methylpyridinium; oxaliplatin; pentamidine; PGE2; PGF2α; ranitidine; 
tetraethylammonium; YM155 [U], ganciclovir (102), azidoprocainamide 
methoiodide; n-methylquinidine; n-methylquinine; 
tributylmethylammonium (103), choline (104), imatinib (105), MPP+; N-
methylnicotinamide (106, 107), famotidine (108) 
OCT3 
EMT 
SLC22A3 Epinephrine; etilefrine; histamine; metformin; N-methylpyridinium; 
norepinephrine [U], adrenaline; noradrenaline; tyramine (109), agmatine; 
MPP+; tetraethylammonium (110-112), atropine (113), histamine (104) 
OCTN2 SLC22A5 acetyl-L-carnitine; D-carnitine; ipratropium; L-carnitine; quinidine; 
verapamil [U], cephaloridine; TEA; choline; purilamine (8) 
[U] From UCSF-FDA TransPortal webpage (http://bts.ucsf.edu/fdatransportal/); the information about 
transporter substrates is listed by transporters or compounds under the “Transporter Data Index”. 
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BSP, bromosulphthalein;  BQ-123, cyclo(D-Trp-D-Asp-L-Pro-D-Val-L-Leu);  CCK-8, cholecystokinin 8;  
CGamF, cholyl-glycyl amido-fluorescein;  DASPMI, 4-(4-dimethylamino)styryl-N-methylpyridinium;  
DHEAS, dehydroepiandosterone;  DPDPE, [D-penicillamine2,5]-enkephalin; E1S, estrone 3-sulfate;  
E217G, estradiol-17β-D-glucuronide;  GMP, guanosine monophosphate; LTC4, leukotriene C4;  MPP+, 1-
methyl-4-phenylpyridinium;  PGE2, prostaglandin E2; PGF2α, prostaglandin F2;T3, triiodothyronine; T4, 
thyroxine   
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Table 2.2. Human hepatic efflux transporter proteins. 
Protein/ 
Trivial Names 
Gene Substrates [Reference] 
Hepatic canalicular efflux transport proteins 
MDR1 
P-gp 
ABCB1 berberine; biotin; colchicine; dexamethasone; digoxin; doxorubicin; 
etoposide; fexofenadine; indinavir; irinotecan; loperamide; nicardipine; 
paclitaxel; rhodamine 123; ritonavir; saquinavir; topotecan; valinomycin; 
verapamil; vinblastine; vincristine [U], amprenavir; nelfinavir (114, 115), 
aldosterone; corticosterone (116), cyclosporin A; mitoxanthrone (117), 
debrisoquine; erythromycin; lovastatin; terfenadine (118), quinidine 
(119), levofloxacin; grepafloxacin (120), losartan (121), tacrolimus 
(122), talinolol (123), norverapamil (124) 
MDR3 
Phospholipid     
       flippase 
MDR2/3 
ABCB4 digoxin; paclitaxel; verapamil; vinblastine [U], phospholipids (125) 
BSEP 
Sister P-gp 
ABCB11 glycochenodeoxycholate; glycocholate; pravastatin; 
taurochenodeoxycholate; taurocholate [U] 
MRP2 
CMOAT 
cMRP 
ABCC2 DHEAS; E217G; etoposide; irinotecan; methotrexate; olmesartan; para-
aminohippurate; SN-38; SN-38 glucuronide; valsartan; vinblastine [U], 
LTC4; bisglucuronosyl bilirubin; monoglucuronosyl bilirubin; ochratoxin 
A; cholecystokinin peptide; E1S; cholyl-L-lysyl-fluorescein (19) 
acetaminophen glucuronide; carboxydichlorofluorescein (126), 
camptothecin; doxorubicin (127), cerivastatin (128), cisplatin; vincristine 
(129), glibenclamide; indomethacin; rifampin (130), pravastatin (33) 
BCRP 
MXR 
ABCP 
ABCG2 4-methylumbelliferone sulfate; daunorubicin; doxorubicin; E217G; E1S; 
hematoporphyrin; imatinib; methotrexate; mitoxantrone; pitavastatin; 
rosuvastatin, SN-38; SN-38 gucuronide; sulfasalazine; topotecan [U], 
mitoxanthrone glucuronides and sulfate conjugates (131), irinotecan 
(132), prazosin; rhodamine 123 (133), testosterone; tamoxifen; estradiol 
(134) 
MATE1 SLC47A1 acyclovir; cimetidine; E1S; ganciclovir; guanidine; metformin; N-
methylpyridinium; paraquat; procainamide; tetraethylammonium; 
topotecan [U]  
Hepatic basolateral efflux transport proteins 
MRP3 
MOAT-D 
MLP1 
cMOAT1 
ABCC3 E217G; ethinylestradiol-glucuronide; fexofenadine; folic acid; 
glycoholate; hyocholate-glucuronide; hyodeoxycholate-glucuronide; 
leucovorin; LTC4; methotrexate; S-(2,4-dinitrophenyl)-glutathione; 
taurocholate [U], bisglucuronosyl bilirubin; monoglucuronosyl bilirubin; 
DHEAS (19), acetaminophen glucuronide (18), monovalent and sulfated 
bile salts (22), etoposide (135) 
MRP4 
MOAT-B 
ABCC4 adefovir; chenodeoxycholylglycine; chenodeoxycholyltaurine; cholate; 
cholyltaurine; cyclic AMP; cyclic GMP; DHEAS; deoxycholylglycine; 
 77 
 
E217G; folic acid; methotrexate; olmesartan; para-aminohippurate; 
PGE1; PGE2; tenofovir; topotecan [U], cholylglycine; 
ursodeoxycholylglycine; ursodeoxycholyltaurine; urate; ADP; PMEA; 
fluo-cAMP (19), azidothymidine (136) 
[U] From UCSF-FDA TransPortal webpage (http://bts.ucsf.edu/fdatransportal/); the information about 
transporter substrates is listed by transporters or compounds under the “Transporter Data Index”. 
BQ-123, cyclo(D-Trp-D-Asp-L-Pro-D-Val-L-Leu);  CCK-8, cholecystokinin 8;  DHEAS, 
dehydroepiandosterone; E1S, estrone 3-sulfate; E217G, estradiol-17β-D-glucuronide;  LTC4, leukotriene 
C4; LTD4, leukotriene D4; PGE1, prostaglandin E1; PGE2, prostaglandin E2; PMEA, 9-(2-
phosphonomethoxyethyl)adenine 
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Table 2.3. Summary of advantages and disadvantages of in vitro models used to study hepatobiliary drug transport. 
In Vitro Model  Major Applications Advantages Disadvantages 
Membrane vesicle system    
Plasma membrane vesicles from 
tissue  
- Determine the transport of 
compounds at particular 
membrane domain 
- All relevant transporters 
expressed 
- No interference from metabolism 
- Isolation of high-purity 
membranes is labor intensive and 
technically challenging 
- Difficult to determine the 
contribution of a single 
transporter 
- Activity of efflux transporters 
may be confounded by influx 
transporters 
Membrane vesicles prepared from 
non-mammalian cells (Sf9) 
- Functional characterization of 
new transporters for which a 
stable cell line has not been 
developed 
- Low interference by background 
activity of endogenous 
transporters 
- Lower levels of glycosylation or 
phosphorylation of target protein 
than in mammalian cell lines 
- Lower cholesterol content in 
lipid bilayer compared to 
mammalian cell lines  
  Membrane vesicles prepared from 
transfected mammalian cells 
- High-throughput screening for 
substrates and inhibitors of a 
single transporter 
- High-throughput 
- Interference with background 
activity of endogenous 
transporters 
- Difficult to determine the 
transport of highly-diffusable 
compounds  
- Difficult to assess the relative 
contribution of multiple transport 
proteins. 
Transfected cells    
  Nonpolarized cells 
- High-throughput screening for 
substrate and inhibitors. 
- High-throughput cell-based 
model. 
- Not optimal for study of efflux 
transport proteins 
  Polarized cells 
- Vectorial transport across whole 
cells can be investigated. 
- Polarized phenotype mimics 
hepatocyte polarity 
- Species or cell type differences 
in protein trafficking or 
localization may exist 
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- Multiple transfections can be 
conducted 
- Difficult to standardize relative 
expression levels 
- Difficult to determine the relative 
contribution of a specific 
transport protein  
Hepatocytes    
  Suspended hepatocytes 
- Investigate kinetics and 
mechanisms of hepatic influx  
- Metabolic enzymes are intact 
- Applicable to hepatocytes from 
species of interest, including 
humans 
- Only used for short-time influx 
studies because hepatocyte 
viability decreases over time 
- Canalicular (apical) transport 
proteins may be internalized  
- Not suitable for study of 
canalicular efflux transport 
  Sandwich-cultured hepatocytes 
- Mechanistic studies on 
hepatobiliary disposition, drug 
interactions, and transporter 
regulation  
- Sandwich culture allows for 
optimal transporter expression 
- Most hepatic transport proteins 
and drug-metabolizing enzymes 
are expressed and functional 
- Static model with respect to 
blood flow 
- Inherent variability among 
donors in protein expression, 
function, and canalicular network 
formation 
Isolated Perfused Liver    
  Single-pass 
- Study mechanisms of hepatic 
influx,  metabolism, biliary 
excretion, and basolateral efflux 
- Intact organ physiology (retains 
hepatic architecture and bile 
flow) 
- Rodents can be pretreated in vivo 
prior to liver isolation to examine 
effects of inducers or inhibitors 
on hepatobiliary clearance 
- Direct measurement of steady-
state extraction ratio is possible 
- Low throughput 
- Labor- and animal-intensive 
- Limited to ~3 hours after liver 
isolation 
- Most amendable to rodents due 
to technical difficulties in 
perfusing livers from larger 
species 
  Recirculating 
- Study mechanisms of hepatic 
influx, metabolism, and biliary 
excretion  
- Intact organ physiology (retains 
hepatic architecture and bile 
flow) 
- Rodents can be pretreated in vivo 
prior to liver isolation to examine 
- Low throughput 
- Labor- and animal-intensive 
- Limited to ~3 hours after liver 
isolation 
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effects of inducers or inhibitors 
on hepatobiliary clearance 
- Metabolites accumulate in 
perfusate allowing mass-balance 
determination of metabolite 
formation and kinetic evaluation 
of hepatic influx of metabolites 
- Most amendable to rodents due 
to technical difficulties in 
perfusing livers from larger 
species 
- Potential drug-metabolite 
interaction 
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Table 2.4. Summary of advantages and disadvantages of in vivo models used to study hepatobiliary drug transport. 
In vivo Model  Major Applications Advantages Disadvantages 
In vivo biliary excretion    
  Bile duct cannulation 
- Direct measure of biliary 
excretion in animals 
- Studies may be conducted in 
freely moving animals 
- Most physiologically relevant 
model 
- Low throughput 
  Oroenteric tube 
- Direct measure of biliary 
excretion in humans 
- DDI study using probe drug 
- Direct measure of biliary 
excretion 
- Most physiologically relevant 
model 
- Low throughput 
- Requires specialized personnel 
and equipment 
- Correction for gallbladder 
ejection fraction is required to 
accurately quantify biliary 
excretion  
In vivo imaging    
  MRI - Anatomical imaging 
- Safer compared to radiation 
based imaging  
- Parent drug and metabolites not 
differentiated 
  Cholescintigraphy (HIDA scan) 
- Evaluate the function of 
gallbladder 
- Investigate the function of 
transporters or drug interactions 
at transporter level 
- 2D image 
- Non-invasive, real-time 
quantitative estimation of tissue 
concentration of drugs in vivo 
- Radionuclide-labeled probe 
- Parent drug and metabolites not 
differentiated 
  SPECT, PET 
- Investigate the function of 
transporters or drug interactions 
at transporter level 
- 3D image 
- Noninvasive, real-time 
quantitative estimation of tissue 
concentration of drugs in vivo 
- Radionuclide-labeled probe 
- Parent drug and metabolites not 
differentiated 
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Table 2.5. Preferred approaches to answer specific questions regarding hepatobiliary drug transport. 
 Membrane 
vesicles* 
Transfected 
cells 
Suspended 
hepatocytes 
Sandwich-
cultured 
hepatocytes 
Isolated 
perfused 
liver 
In vivo bile 
collection 
In vivo 
imaging 
Which influx transporters 
are capable of transporting 
the NCE? 
NA 1 2a 2a 2a NA 2a, c 
Which efflux transporters 
are capable of transporting 
the NCE? 
1 2 NA 2 a 2 a NA 2a, c 
What is the Clbiliary of the 
NCE?  
NA NA NA 1 2 1 NA 
Is the NCE subject to 
transporter-based DDIs in 
the liver? 
2 2 2 1 1 2 1c 
Is the NCE subject to DDIs 
at a specific transporter? 
1 1 2b 2b 2b NA 2b 
Is the NCE likely to inhibit 
bile acid excretion?   
1b 
 
NA NA 1b 1b 2 NA 
Is the NCE likely to 
accumulate in the liver?  
NA NA NA 1 1 NA 1 
Is the NCE subject to 
transporter-enzyme 
interplay?  
NA 2 NA 1 1 2 NA 
NCE: new chemical entity 
*Membrane vesicles overexpressing transporter(s) 
1, preferred;  2, possible;  NA, not applicable 
a, if used with a specific inhibitor; b, if used with a specific probe; c, NCE needs to be labeled or fluorescent 
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Figure 2.1. In vivo architecture of polarized hepatocytes with distinct apical and basolateral 
domains facing respectively the bile canaliculus and bloodstream. 
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Figure 2.2. In vitro models and the related methods to study hepatobiliary drug transport. 
 
 
  
 85 
 
REFERENCES 
 
(1) Stieger, B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the 
bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp 
Pharmacol, 205-59 (2011). 
(2) Gundala, S., Wells, L.D., Milliano, M.T., Talkad, V., Luxon, B.A. & Neuschwander-Tetri, B.A. 
The hepatocellular bile acid transporter Ntcp facilitates uptake of the lethal mushroom toxin 
alpha-amanitin. Arch Toxicol  78, 68-73 (2004). 
(3) Briz, O. et al. OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway 
for organic anions from hepatocytes? J Biol Chem  281, 30326-35 (2006). 
(4) Li, L., Meier, P.J. & Ballatori, N. Oatp2 mediates bidirectional organic solute transport: a role for 
intracellular glutathione. Mol Pharmacol  58, 335-40 (2000). 
(5) Satlin, L.M., Amin, V. & Wolkoff, A.W. Organic anion transporting polypeptide mediates 
organic anion/HCO3- exchange. J Biol Chem  272, 26340-5 (1997). 
(6) Campbell, S.D., de Morais, S.M. & Xu, J.J. Inhibition of human organic anion transporting 
polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact  
150, 179-87 (2004). 
(7) Link, E. et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J 
Med  359, 789-99 (2008). 
(8) Hagenbuch, B. Drug uptake systems in liver and kidney: a historic perspective. Clin Pharmacol 
Ther  87, 39-47 (2010). 
(9) Shin, H.J. et al. Novel liver-specific organic anion transporter OAT7 that operates the exchange 
of sulfate conjugates for short chain fatty acid butyrate. Hepatology  45, 1046-55 (2007). 
(10) Soroka, C.J., Ballatori, N. & Boyer, J.L. Organic solute transporter, OSTalpha-OSTbeta: its role 
in bile acid transport and cholestasis. Semin Liver Dis  30, 178-85 (2010). 
(11) Boyer, J.L. et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter 
OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver 
Physiol  290, G1124-30 (2006). 
(12) Juliano, R.L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese 
hamster ovary cell mutants. Biochim Biophys Acta  455, 152-62 (1976). 
 86 
 
(13) Oude Elferink, R.P. & Paulusma, C.C. Function and pathophysiological importance of ABCB4 
(MDR3 P-glycoprotein). Pflugers Arch  453, 601-10 (2007). 
(14) Rosmorduc, O., Hermelin, B., Boelle, P.Y., Parc, R., Taboury, J. & Poupon, R. ABCB4 gene 
mutation-associated cholelithiasis in adults. Gastroenterology  125, 452-9 (2003). 
(15) Hirano, M., Maeda, K., Hayashi, H., Kusuhara, H. & Sugiyama, Y. Bile salt export pump 
(BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther  314, 
876-82 (2005). 
(16) Kullak-Ublick, G.A., Stieger, B., Hagenbuch, B. & Meier, P.J. Hepatic transport of bile salts. 
Semin Liver Dis  20, 273-92 (2000). 
(17) Kullak-Ublick, G.A., Stieger, B. & Meier, P.J. Enterohepatic bile salt transporters in normal 
physiology and liver disease. Gastroenterology  126, 322-42 (2004). 
(18) Tsujii, H., Konig, J., Rost, D., Stockel, B., Leuschner, U. & Keppler, D. Exon-intron organization 
of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. 
Gastroenterology  117, 653-60 (1999). 
(19) Keppler, D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and 
drug therapy. Handb Exp Pharmacol, 299-323 (2011). 
(20) Konig, J., Rost, D., Cui, Y. & Keppler, D. Characterization of the human multidrug resistance 
protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology  29, 1156-
63 (1999). 
(21) Wagner, M., Zollner, G. & Trauner, M. New molecular insights into the mechanisms of 
cholestasis. J Hepatol  51, 565-80 (2009). 
(22) Hirohashi, T., Suzuki, H. & Sugiyama, Y. Characterization of the transport properties of cloned 
rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem  274, 15181-5 (1999). 
(23) Wang, R., Sheps, J.A. & Ling, V. ABC transporters, bile acids, and inflammatory stress in liver 
cancer. Curr Pharm Biotechnol  12, 636-46 (2011). 
(24) Rius, M., Nies, A.T., Hummel-Eisenbeiss, J., Jedlitschky, G. & Keppler, D. Cotransport of 
reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte 
membrane. Hepatology  38, 374-84 (2003). 
 87 
 
(25) Sampath, J. et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci  4, 
E14 (2002). 
(26) Barnes, S.N. et al. Induction of hepatobiliary efflux transporters in acetaminophen-induced acute 
liver failure cases. Drug Metab Dispos  35, 1963-9 (2007). 
(27) Meier, P.J., Sztul, E.S., Reuben, A. & Boyer, J.L. Structural and functional polarity of canalicular 
and basolateral plasma membrane vesicles isolated in high yield from rat liver. J Cell Biol  98, 
991-1000 (1984). 
(28) Blitzer, B.L. & Donovan, C.B. A new method for the rapid isolation of basolateral plasma 
membrane vesicles from rat liver. Characterization, validation, and bile acid transport studies. J 
Biol Chem  259, 9295-301 (1984). 
(29) Jedlitschky, G., Leier, I., Buchholz, U., Hummel-Eisenbeiss, J., Burchell, B. & Keppler, D. ATP-
dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its 
hepatocyte canalicular isoform MRP2. Biochem J  327 ( Pt 1), 305-10 (1997). 
(30) Gerloff, T. et al. Differential expression of basolateral and canalicular organic anion transporters 
during regeneration of rat liver. Gastroenterology  117, 1408-15 (1999). 
(31) Germann, U.A., Willingham, M.C., Pastan, I. & Gottesman, M.M. Expression of the human 
multidrug transporter in insect cells by a recombinant baculovirus. Biochemistry  29, 2295-303 
(1990). 
(32) Pal, A. et al. Cholesterol potentiates ABCG2 activity in a heterologous expression system: 
improved in vitro model to study function of human ABCG2. J Pharmacol Exp Ther  321, 1085-
94 (2007). 
(33) Sasaki, M., Suzuki, H., Ito, K., Abe, T. & Sugiyama, Y. Transcellular transport of organic anions 
across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human 
organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated 
protein 2 (MRP2/ABCC2). J Biol Chem  277, 6497-503 (2002). 
(34) Cui, Y., Konig, J. & Keppler, D. Vectorial transport by double-transfected cells expressing the 
human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol  60, 
934-43 (2001). 
(35) Sasaki, M., Suzuki, H., Aoki, J., Ito, K., Meier, P.J. & Sugiyama, Y. Prediction of in vivo biliary 
clearance from the in vitro transcellular transport of organic anions across a double-transfected 
Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting 
polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol  66, 450-9 (2004). 
 88 
 
(36) Kopplow, K., Letschert, K., Konig, J., Walter, B. & Keppler, D. Human hepatobiliary transport of 
organic anions analyzed by quadruple-transfected cells. Molecular pharmacology  68, 1031-8 
(2005). 
(37) Hirouchi, M., Kusuhara, H., Onuki, R., Ogilvie, B.W., Parkinson, A. & Sugiyama, Y. 
Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 
1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for 
analysis of the sinusoidal function of MRP3 and MRP4. Drug metabolism and disposition 37, 
2103-11 (2009). 
(38) Fahrmayr, C., Konig, J., Auge, D., Mieth, M. & Fromm, M. Identification of drugs and drug 
metabolites as substrates of MRP2 using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 
cells. Br J Pharmacol,  (2011). 
(39) Lau, Y.Y., Sapidou, E., Cui, X., White, R.E. & Cheng, K.C. Development of a novel in vitro 
model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured 
hepatocytes. Drug Metab Dispos  30, 1446-54 (2002). 
(40) Houle, R., Raoul, J., Levesque, J.F., Pang, K.S., Nicoll-Griffith, D.A. & Silva, J.M. Retention of 
transporter activities in cryopreserved, isolated rat hepatocytes. Drug Metab Dispos  31, 447-51 
(2003). 
(41) Shitara, Y. et al. Function of uptake transporters for taurocholate and estradiol 17beta-D-
glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet  18, 33-41 (2003). 
(42) De Bruyn, T. et al. Determination of OATP-, NTCP- and OCT-mediated substrate uptake 
activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci  
43, 297-307 (2011). 
(43) Bi, Y.A., Kazolias, D. & Duignan, D.B. Use of cryopreserved human hepatocytes in sandwich 
culture to measure hepatobiliary transport. Drug Metab Dispos  34, 1658-65 (2006). 
(44) Hoffmaster, K.A., Turncliff, R.Z., LeCluyse, E.L., Kim, R.B., Meier, P.J. & Brouwer, K.L. P-
glycoprotein expression, localization, and function in sandwich-cultured primary rat and human 
hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res  21, 
1294-302 (2004). 
(45) Swift, B., Pfeifer, N.D. & Brouwer, K.L. Sandwich-cultured hepatocytes: an in vitro model to 
evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev  
42, 446-71 (2010). 
 89 
 
(46) Liu, X. et al. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich 
configuration. Am J Physiol  277, G12-21 (1999). 
(47) Liu, X., LeCluyse, E.L., Brouwer, K.R., Lightfoot, R.M., Lee, J.I. & Brouwer, K.L. Use of Ca2+ 
modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp 
Ther  289, 1592-9 (1999). 
(48) Abe, K., Bridges, A.S., Yue, W. & Brouwer, K.L. In vitro biliary clearance of angiotensin II 
receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-
cultured rat hepatocytes: comparison with in vivo biliary clearance. J Pharmacol Exp Ther  326, 
983-90 (2008). 
(49) Fukuda, H., Ohashi, R., Tsuda-Tsukimoto, M. & Tamai, I. Effect of plasma protein binding on in 
vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat 
hepatocytes. Drug Metab Dispos  36, 1275-82 (2008). 
(50) Liu, X., Chism, J.P., LeCluyse, E.L., Brouwer, K.R. & Brouwer, K.L. Correlation of biliary 
excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos  27, 637-
44 (1999). 
(51) Li, N., Singh, P., Mandrell, K.M. & Lai, Y. Improved extrapolation of hepatobiliary clearance 
from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary 
transporters. Mol Pharm  7, 630-41 (2010). 
(52) Abe, K., Bridges, A.S. & Brouwer, K.L. Use of sandwich-cultured human hepatocytes to predict 
biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug 
Metab Dispos  37, 447-52 (2009). 
(53) Ghibellini, G. et al. In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin 
Pharmacol Ther  81, 406-13 (2007). 
(54) Kouzuki, H., Suzuki, H., Ito, K., Ohashi, R. & Sugiyama, Y. Contribution of organic anion 
transporting polypeptide to uptake of its possible substrates into rat hepatocytes. The Journal of 
pharmacology and experimental therapeutics  288, 627-34 (1999). 
(55) Tian, X., Zamek-Gliszczynski, M.J., Zhang, P. & Brouwer, K.L. Modulation of multidrug 
resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering 
RNA in sandwich-cultured rat hepatocytes. Mol Pharmacol  66, 1004-10 (2004). 
(56) Yue, W., Abe, K. & Brouwer, K.L. Knocking down breast cancer resistance protein (Bcrp) by 
adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a 
 90 
 
novel tool to assess the contribution of Bcrp to drug biliary excretion. Mol Pharm  6, 134-43 
(2009). 
(57) Liao, M. et al. Inhibition of hepatic organic anion-transporting polypeptide by RNA interference 
in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-
drug interactions. Drug Metab Dispos  38, 1612-22 (2010). 
(58) Milkiewicz, P., Roma, M.G., Elias, E. & Coleman, R. Pathobiology and experimental 
therapeutics in hepatocellular cholestasis: lessons from the hepatocyte couplet model. Clin Sci 
(Lond)  102, 603-14 (2002). 
(59) Boyer, J.L. Isolated hepatocyte couplets and bile duct units--novel preparations for the in vitro 
study of bile secretory function. Cell Biol Toxicol  13, 289-300 (1997). 
(60) Coleman, R., Wilton, J.C., Stone, V. & Chipman, J.K. Hepatobiliary function and toxicity in vitro 
using isolated hepatocyte couplets. Gen Pharmacol  26, 1445-53 (1995). 
(61) Le Vee, M., Jigorel, E., Glaise, D., Gripon, P., Guguen-Guillouzo, C. & Fardel, O. Functional 
expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human 
hepatoma HepaRG cell line. Eur J Pharm Sci  28, 109-17 (2006). 
(62) Song, Z. et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem 
cells. Cell Res  19, 1233-42 (2009). 
(63) Hoffmaster, K.A., Zamek-Gliszczynski, M.J., Pollack, G.M. & Brouwer, K.L. Hepatobiliary 
disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): 
pharmacokinetic consequences of the interplay between multiple transport systems. J Pharmacol 
Exp Ther  311, 1203-10 (2004). 
(64) Zamek-Gliszczynski, M.J. et al. Multiple mechanisms are involved in the biliary excretion of 
acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab Dispos  33, 1158-65 
(2005). 
(65) Nakakariya, M., Ono, M., Amano, N., Moriwaki, T., Maeda, K. & Sugiyama, Y. In Vivo Biliary 
Clearance Should Be Predicted by Intrinsic Biliary Clearance in Sandwich-Cultured Hepatocytes. 
Drug Metab Dispos,  (2011). 
(66) Ishizuka, H. et al. Species differences in the transport activity for organic anions across the bile 
canalicular membrane. J Pharmacol Exp Ther  290, 1324-30 (1999). 
 91 
 
(67) Brune, K., Nuernberg, B. & Schneider, H.T. Biliary elimination of aspirin after oral and 
intravenous administration in patients. Agents Actions Suppl  44, 51-7 (1993). 
(68) Verho, M., Luck, C., Stelter, W.J., Rangoonwala, B. & Bender, N. Pharmacokinetics, metabolism 
and biliary and urinary excretion of oral ramipril in man. Curr Med Res Opin  13, 264-73 (1995). 
(69) Galatola, G., Jazrawi, R.P., Bridges, C., Joseph, A.E. & Northfield, T.C. Direct measurement of 
first-pass ileal clearance of a bile acid in humans. Gastroenterology  100, 1100-5 (1991). 
(70) Northfield, T.C. & Hofmann, A.F. Biliary lipid output during three meals and an overnight fast. I. 
Relationship to bile acid pool size and cholesterol saturation of bile in gallstone and control 
subjects. Gut  16, 1-11 (1975). 
(71) Ghibellini, G., Johnson, B.M., Kowalsky, R.J., Heizer, W.D. & Brouwer, K.L. A novel method 
for the determination of biliary clearance in humans. AAPS J  6, e33 (2004). 
(72) Ghibellini, G., Vasist, L.S., Hill, T.E., Heizer, W.D., Kowalsky, R.J. & Brouwer, K.L. 
Determination of the biliary excretion of piperacillin in humans using a novel method. Br J Clin 
Pharmacol  62, 304-8 (2006). 
(73) Narita, M. et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular 
carcinoma. Journal of gastroenterology  44, 793-8 (2009). 
(74) Leonhardt, M. et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-
DTPA: role of human organic anion transporters. Drug metabolism and disposition  38, 1024-8 
(2010). 
(75) Pascolo, L. et al. Abc protein transport of MRI contrast agents in canalicular rat liver plasma 
vesicles and yeast vacuoles. Biochemical and biophysical research communications  282, 60-6 
(2001). 
(76) Tsuboyama, T. et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic 
acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular 
transporters and bile accumulation. Radiology  255, 824-33 (2010). 
(77) Guhlmann, A. et al. Noninvasive assessment of hepatobiliary and renal elimination of cysteinyl 
leukotrienes by positron emission tomography. Hepatology  21, 1568-75 (1995). 
(78) Takashima, T. et al. Positron emission tomography studies using (15R)-16-m-[11C]tolyl-
17,18,19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport. J 
Pharmacol Exp Ther  335, 314-23 (2010). 
 92 
 
(79) Stadalnik, R.C., Matolo, N.M., Jansholt, A.L. & Vera, D.R. Clinical experience with 99mTc-
disofenin as a cholescintigraphic agent. Radiology  140, 797-800 (1981). 
(80) Hendrikse, N.H. et al. In vivo imaging of hepatobiliary transport function mediated by multidrug 
resistance associated protein and P-glycoprotein. Cancer Chemother Pharmacol  54, 131-8 
(2004). 
(81) Luker, G.D., Fracasso, P.M., Dobkin, J. & Piwnica-Worms, D. Modulation of the multidrug 
resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. Journal of nuclear 
medicine : official publication, Society of Nuclear Medicine  38, 369-72 (1997). 
(82) Gomes, C.M., Abrunhosa, A.J., Pauwels, E.K. & Botelho, M.F. P-glycoprotein versus MRP1 on 
transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi 
and [99mTc]tetrofosmin. Cancer Biother Radiopharm  24, 215-27 (2009). 
(83) Hirano, M., Maeda, K., Shitara, Y. & Sugiyama, Y. Contribution of OATP2 (OATP1B1) and 
OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther  311, 
139-46 (2004). 
(84) Kock, K. & Brouwer, K.L. A perspective on efflux transport proteins in the liver. Clin Pharmacol 
Ther  92, 599-612 (2012). 
(85) Ho, R.H. et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, 
expression, and pharmacogenetics. Gastroenterology  130, 1793-806 (2006). 
(86) Tamai, I. et al. Molecular identification and characterization of novel members of the human 
organic anion transporter (OATP) family. Biochem Biophys Res Commun  273, 251-60 (2000). 
(87) Kullak-Ublick, G.A. et al. Organic anion-transporting polypeptide B (OATP-B) and its functional 
comparison with three other OATPs of human liver. Gastroenterology  120, 525-33 (2001). 
(88) Sandhu, P. et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos  
33, 676-82 (2005). 
(89) Shitara, Y., Itoh, T., Sato, H., Li, A.P. & Sugiyama, Y. Inhibition of transporter-mediated hepatic 
uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J 
Pharmacol Exp Ther  304, 610-6 (2003). 
(90) Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional 
characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and 
 93 
 
SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. 
Pharmacogenet Genomics  15, 513-22 (2005). 
(91) Nozawa, T., Minami, H., Sugiura, S., Tsuji, A. & Tamai, I. Role of organic anion transporter 
OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-
hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug 
Metab Dispos  33, 434-9 (2005). 
(92) Fischer, W.J., Altheimer, S., Cattori, V., Meier, P.J., Dietrich, D.R. & Hagenbuch, B. Organic 
anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin. 
Toxicol Appl Pharmacol  203, 257-63 (2005). 
(93) Meier-Abt, F., Faulstich, H. & Hagenbuch, B. Identification of phalloidin uptake systems of rat 
and human liver. Biochim Biophys Acta  1664, 64-9 (2004). 
(94) Kajosaari, L.I., Niemi, M., Neuvonen, M., Laitila, J., Neuvonen, P.J. & Backman, J.T. 
Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther  78, 
388-99 (2005). 
(95) Niemi, M. et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant 
of repaglinide pharmacokinetics. Clin Pharmacol Ther  77, 468-78 (2005). 
(96) Nozawa, T. et al. Involvement of organic anion transporting polypeptides in the transport of 
troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab 
Dispos  32, 291-4 (2004). 
(97) Ismair, M.G. et al. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting 
polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology  121, 1185-90 (2001). 
(98) Grube, M. et al. Modification of OATP2B1-mediated transport by steroid hormones. Mol 
Pharmacol  70, 1735-41 (2006). 
(99) Kobayashi, Y., Ohshiro, N., Sakai, R., Ohbayashi, M., Kohyama, N. & Yamamoto, T. Transport 
mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J 
Pharm Pharmacol  57, 573-8 (2005). 
(100) Sun, W., Wu, R.R., van Poelje, P.D. & Erion, M.D. Isolation of a family of organic anion 
transporters from human liver and kidney. Biochem Biophys Res Commun  283, 417-22 (2001). 
 94 
 
(101) Tahara, H. et al. A species difference in the transport activities of H2 receptor antagonists by rat 
and human renal organic anion and cation transporters. J Pharmacol Exp Ther  315, 337-45 
(2005). 
(102) Takeda, M. et al. Human organic anion transporters and human organic cation transporters 
mediate renal antiviral transport. J Pharmacol Exp Ther  300, 918-24 (2002). 
(103) van Montfoort, J.E., Muller, M., Groothuis, G.M., Meijer, D.K., Koepsell, H. & Meier, P.J. 
Comparison of "type I" and "type II" organic cation transport by organic cation transporters and 
organic anion-transporting polypeptides. J Pharmacol Exp Ther  298, 110-5 (2001). 
(104) Grundemann, D., Liebich, G., Kiefer, N., Koster, S. & Schomig, E. Selective substrates for non-
neuronal monoamine transporters. Mol Pharmacol  56, 1-10 (1999). 
(105) Thomas, J., Wang, L., Clark, R.E. & Pirmohamed, M. Active transport of imatinib into and out of 
cells: implications for drug resistance. Blood  104, 3739-45 (2004). 
(106) Gorboulev, V. et al. Cloning and characterization of two human polyspecific organic cation 
transporters. DNA Cell Biol  16, 871-81 (1997). 
(107) Zhang, L., Gorset, W., Dresser, M.J. & Giacomini, K.M. The interaction of n-
tetraalkylammonium compounds with a human organic cation transporter, hOCT1. J Pharmacol 
Exp Ther  288, 1192-8 (1999). 
(108) Bourdet, D.L., Pritchard, J.B. & Thakker, D.R. Differential substrate and inhibitory activities of 
ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), 
hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther  315, 1288-97 (2005). 
(109) Grundemann, D., Schechinger, B., Rappold, G.A. & Schomig, E. Molecular identification of the 
corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci  1, 349-51 (1998). 
(110) Hayer-Zillgen, M., Bruss, M. & Bonisch, H. Expression and pharmacological profile of the 
human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol  136, 829-36 
(2002). 
(111) Grundemann, D., Hahne, C., Berkels, R. & Schomig, E. Agmatine is efficiently transported by 
non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic 
cation transporter 2 (OCT2). J Pharmacol Exp Ther  304, 810-7 (2003). 
(112) Wu, X. et al. Structure, function, and regional distribution of the organic cation transporter OCT3 
in the kidney. Am J Physiol Renal Physiol  279, F449-58 (2000). 
 95 
 
(113) Muller, J., Lips, K.S., Metzner, L., Neubert, R.H., Koepsell, H. & Brandsch, M. Drug specificity 
and intestinal membrane localization of human organic cation transporters (OCT). Biochem 
Pharmacol  70, 1851-60 (2005). 
(114) Kim, R.B. et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of 
HIV-1 protease inhibitors. J Clin Invest  101, 289-94 (1998). 
(115) Polli, J.W. et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV 
protease inhibitor. Pharm Res  16, 1206-12 (1999). 
(116) Ueda, K. et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but 
not progesterone. J Biol Chem  267, 24248-52 (1992). 
(117) Marie, J.P., Helou, C., Thevenin, D., Delmer, A. & Zittoun, R. In vitro effect of P-glycoprotein 
(P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous 
leukemia (AML). Exp Hematol  20, 565-8 (1992). 
(118) Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R. & Kim, R.B. OATP and P-glycoprotein 
transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos  27, 
866-71 (1999). 
(119) Fromm, M.F., Kim, R.B., Stein, C.M., Wilkinson, G.R. & Roden, D.M. Inhibition of P-
glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between 
digoxin and quinidine [seecomments]. Circulation  99, 552-7 (1999). 
(120) Yamaguchi, H., Yano, I., Hashimoto, Y. & Inui, K.I. Secretory mechanisms of grepafloxacin and 
levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther  295, 360-6 (2000). 
(121) Soldner, A., Christians, U., Susanto, M., Wacher, V.J., Silverman, J.A. & Benet, L.Z. Grapefruit 
juice activates P-glycoprotein-mediated drug transport. Pharm Res  16, 478-85 (1999). 
(122) Floren, L.C. et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. 
Clin Pharmacol Ther  62, 41-9 (1997). 
(123) Spahn-Langguth, H. et al. P-glycoprotein transporters and the gastrointestinal tract: evaluation of 
the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin 
Pharmacol Ther  36, 16-24 (1998). 
(124) Pauli-Magnus, C. et al. Characterization of the major metabolites of verapamil as substrates and 
inhibitors of P-glycoprotein. J Pharmacol Exp Ther  293, 376-82 (2000). 
 96 
 
(125) Smith, A.J. et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several 
cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide 
trapping. J Biol Chem  275, 23530-9 (2000). 
(126) Xiong, H., Turner, K.C., Ward, E.S., Jansen, P.L. & Brouwer, K.L. Altered hepatobiliary 
disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-
associated protein 2-deficient TR(-) rats. J Pharmacol Exp Ther  295, 512-8 (2000). 
(127) Koike, K. et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA 
enhances drug sensitivity in human hepatic cancer cells. Cancer Res  57, 5475-9 (1997). 
(128) Matsushima, S. et al. Identification of the hepatic efflux transporters of organic anions using 
double-transfected Madin-Darby canine kidney II cells expressing human organic anion-
transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, 
OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol 
Exp Ther  314, 1059-67 (2005). 
(129) Kawabe, T. et al. Enhanced transport of anticancer agents and leukotriene C4 by the human 
canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett  456, 327-31 
(1999). 
(130) Payen, L., Courtois, A., Campion, J.P., Guillouzo, A. & Fardel, O. Characterization and 
inhibition by a wide range of xenobiotics of organic anion excretion by primary human 
hepatocytes. Biochem Pharmacol  60, 1967-75 (2000). 
(131) Kawabata, S. et al. Breast cancer resistance protein directly confers SN-38 resistance of lung 
cancer cells. Biochem Biophys Res Commun  280, 1216-23 (2001). 
(132) Maliepaard, M. et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected 
ovarian tumor cell line. Cancer Res  59, 4559-63 (1999). 
(133) Ozvegy, C. et al. Functional characterization of the human multidrug transporter, ABCG2, 
expressed in insect cells. Biochem Biophys Res Commun  285, 111-7 (2001). 
(134) Janvilisri, T., Venter, H., Shahi, S., Reuter, G., Balakrishnan, L. & van Veen, H.W. Sterol 
transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus 
lactis. J Biol Chem  278, 20645-51 (2003). 
(135) Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G.A. & Meier, P.J. Drug- and estrogen-
induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat 
liver. Gastroenterology  118, 422-30 (2000). 
 97 
 
(136) Schuetz, J.D. et al. MRP4: A previously unidentified factor in resistance to nucleoside-based 
antiviral drugs. Nat Med  5, 1048-51 (1999). 
 
 
 
 
  
 98 
 
 
CHAPTER 3.  Species Differences in Hepatobiliary Disposition of Taurocholic acid in Human and 
Rat Sandwich-Cultured Hepatocytes; Implications for Drug-Induced Liver Injury1  
 
INTRODUCTION 
Bile acids are important endogenous molecules that are involved in digestion and absorption of 
fats, and regulation of lipid and glucose homeostasis (1, 2). However, bile acids can exert toxic effects at 
supra-physiologic concentrations through disruption of mitochondrial ATP synthesis, necrosis, and 
apoptosis (3, 4); thus, defects in excretion may lead to hepatic accumulation of bile acids and subsequent 
hepatotoxicity.  
Hepatic transporters play important roles in vectorial transport of bile acids. Sodium taurocholate 
cotransporting polypeptide (NTCP) and organic anion transporting polypeptides (OATPs) are responsible 
for sodium-dependent and sodium-independent uptake of bile acids from sinusoidal blood into 
hepatocytes, respectively. Bile acids in hepatocytes are excreted into bile across the canalicular 
membrane, predominantly via the bile salt export pump (BSEP). Consistent with the important role of 
BSEP in bile acid excretion, impaired BSEP function due to genetic polymorphisms has been shown to 
induce liver injury (e.g., progressive familial intrahepatic cholestasis type II) (5). Also, there has been 
increasing evidence that inhibition of BSEP by drugs is associated with cholestatic/mixed type drug-
induced liver injury (DILI) (6-9).  
In addition to BSEP-mediated canalicular excretion, bile acids also are transported back into 
sinusoidal blood via basolateral efflux transporters, including multidrug resistance-associated protein 
(MRP) 3, MRP4, and organic solute transporter (OST)α-OSTβ. Expression levels of MRP3 and MRP4 
                                                     
1This work has been presented, in part, at the 2012 AAPS Annual Meeting and Exposition, Chicago, IL, October 14-
18, 2012, and will be submitted to Journal of Pharmacology and Experimental Therapeutics. 
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are up-regulated under cholestatic conditions, suggesting that they function as a compensatory route of 
bile acid excretion and thereby serve as an important part of adaptive response (10-12). OSTα-OSTβ 
mediates basolateral efflux of bile acids from enterocytes into the portal circulation by facilitated 
diffusion (13), but the role of OSTα-OSTβ in hepatic bile acid efflux remains to be further characterized. 
Recently, Morgan et al. reported that prediction of DILI was improved by considering the inhibitory 
effect of a drug on MRP2, MRP3 and MRP4, compared to BSEP inhibition alone (8). In addition, studies 
from our laboratory demonstrated that MRP4 inhibition was associated with cholestatic/mixed DILI 
among BSEP non-inhibitors, emphasizing the role of MRP4 in DILI (14). 
DILI is one of the primary reasons for withdrawal of approved drugs from the market and a major 
concern during drug development (15). One prominent example is troglitazone (TGZ), the first of the 
thiazolidinedione class of antidiabetic drugs that was withdrawn from worldwide markets due to severe 
DILI. (16, 17). Although mechanisms of TGZ-mediated hepatotoxicity remain unclear, in vitro vesicular 
transport assays demonstrated that TGZ and its major metabolite, TGZ sulfate (TS), are potent BSEP 
inhibitors, suggesting a cholestatic component in TGZ-induced hepatotoxicity (6, 7, 18). TGZ also 
inhibits NTCP, MRP3, and MRP4 (8, 19); although TS accumulates extensively in hepatocytes (20, 21), 
the effect of TS on basolateral efflux transporters has not been investigated.  
Due to extensive biliary excretion, it generally has been accepted that the contribution of 
basolateral efflux to hepatocellular bile acid excretion is minimal under normal conditions. However, as 
proposed in the “hepatocyte hopping” theory of bilirubin glucuronides (22), it is plausible that bile acids 
may undergo extensive basolateral efflux (through MRP3/4) and re-uptake into downstream hepatocytes 
(through NTCP/OATP). This would prevent saturation of biliary transporters in upstream hepatocytes and 
transfer bile acids to downstream hepatocytes, protecting hepatocytes from bile acid toxicity.  To our 
knowledge, the contribution of basolateral efflux vs. biliary excretion to hepatocellular bile acid 
disposition has not been precisely characterized. Jemnitz et al. (2010) investigated basolateral efflux and 
biliary excretion of TCA in human and rat sandwich-cultured hepatocytes (SCH) by measuring efflux of 
TCA from pre-loaded SCH into the standard or Ca2+-free buffer (23). However, these investigators did 
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not account for the “flux” of TCA accumulated within bile networks into the buffer, which results from 
regular “pulsing” of the bile canaliculi in SCH (24). Regular, ordered contraction of bile canaliculi, has 
been reported previously in isolated couplets and cultured hepatocytes (25, 26), and also has been shown 
to facilitate bile flow in vivo in rat liver (27).  
The purpose of the present studies was to characterize TCA hepatobiliary disposition (basolateral 
uptake, basolateral efflux, biliary excretion, flux from canalicular networks) in human and rat SCH using 
a novel uptake and efflux protocol developed by our laboratory combined with pharmacokinetic modeling 
(28). Results from the current investigation revealed that species differences exist in cellular TCA efflux 
pathways in human vs. rat SCH; differential hepatobiliary disposition of TCA in human and rat SCH in 
the presence of inhibitors of canalicular excretion and/or basolateral efflux was predicted by simulations. 
This study also investigated the effects of TGZ and its metabolites on the disposition of TCA in human 
and rat SCH, and the inhibitory effects of TS on MRP4, a basolateral efflux transporter that mediates bile 
acid transport. 
 
METHODS 
Materials   
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.  TGZ 
was purchased from Cayman Chemical Company (Ann Arbor, MI). TS was kindly provided by Daiichi-
Sankyo Co, Ltd. (Tokyo, Japan). TS also was synthesized from TGZ in-house as described by Saha et al. 
(29). [3H]TCA (5 Ci/mmol) and [3H]dehydroepiandrosterone sulfate (DHEAS; 79.5 Ci/mmol) were 
purchased from Perkin Elmer (Waltham, MA). Dimethyl sulfoxide (DMSO) was obtained from Fisher 
Scientific (Fairlawn, NJ). GIBCO brand fetal bovine serum, recombinant human insulin, and Dulbecco’s 
modified Eagle’s medium (DMEM) were purchased from Life Technologies (Carlsbad, CA). 
Insulin/transferrin/selenium (ITS) culture supplement, BioCoatTM culture plates, and MatrigelTM 
extracellular matrix were purchased from BD Biosciences Discovery Labware (Bedford, MA). 
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Sandwich-Cultured Hepatocytes (SCH)   
Rat hepatocytes were isolated from male Wistar rats (234–245 g, Charles River Laboratories, 
Inc., Wilmington, MA) using a two-step collagenase perfusion method as previously described (LeCluyse 
et al., 1996). Animals had free access to water and food before surgery and were allowed to acclimate for 
at least five days. All animal procedures complied with the guidelines of the Institutional Animal Care 
and Use Committee (University of North Carolina, Chapel Hill, NC). Rat hepatocytes were seeded onto 
6-well BioCoatTM culture plates at a density of 1.75×106 cells/well in seeding medium (DMEM 
containing 5% fetal bovine serum, 10 µM insulin, 1 µM dexamethasone, 2 mM L-glutamine, 1% MEM 
nonessential amino acids, 100 units of penicillin G sodium, and 100 µg of streptomycin) as described 
previously (30). Hepatocytes were incubated for 2 h at 37ºC in a humidified incubator (95% O2, 5% CO2) 
and allowed to attach to the collagen substratum, after which time the medium was aspirated to remove 
unattached cells and replaced with fresh medium. On the next day, cells were overlaid with BD 
MatrigelTM at a concentration of 0.25 mg/ml in ice-cold feeding medium (DMEM supplemented with 0.1 
µM dexamethasone, 2 mM L-glutamine, 1% MEM nonessential amino acids, 100 units of penicillin G 
sodium, 100 µg of streptomycin, and 1% ITS). The culture medium was changed daily until experiments 
were performed on day 4. Human SCH, seeded onto 24-well BioCoatTM culture plates and overlaid with 
MatrigelTM, were purchased from Triangle Research Labs (Research Triangle Park, NC). Human 
hepatocytes were obtained from two Caucasian females (31 years old, BMI 29.05 kg/m2; 56 years old, 
BMI 22.30 kg/m2), and one African American female (48 years old, BMI 24.9 kg/m2). The culture 
medium (the same feeding medium used for rat SCH) was changed daily until experiments were 
performed on day 7. 
Uptake and Efflux Studies in SCH   
Uptake and efflux studies of TCA were performed in human and rat SCH as previously described 
(28). Briefly, on day 4 (rat) or day 7 (human) of culture, SCH were pre-incubated for 10 min in 0.3 
mL/well standard (Ca2+-containing) or Ca2+-free (Ca2+/Mg2+-free buffer containing EGTA) HBSS. 
Incubating SCH in Ca2+-free HBSS disrupts the tight junctions that form the bile canalicular networks (B-
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CLEAR® technology, Qualyst Transporter Solutions, Research Triangle Park, NC). For uptake and efflux 
studies with TCA, SCH were treated with 1 μM [3H]TCA (400 nCi/mL) in 0.3 mL/well standard HBSS 
for 20 min at 37°C. After the 20-min uptake phase, buffers containing TCA were removed, cells were 
washed twice with 0.3 mL/well standard or Ca2+-free HBSS buffer at 37°C, and the third application of 
buffer was added to SCH for the 15-min (rat) or 10-min (human) efflux phase (Figure 3.1). For 
determination of TGZ effects on TCA disposition, SCH were pre-incubated with 10 µM TGZ for 30 min 
before 10-min application of standard or Ca2+-free HBSS. The rest of experiment (uptake and efflux) was 
performed as described above. Pre-incubation was selected to minimize the inhibitory effects of TGZ and 
its metabolites on TCA uptake, and to allow enough time for the formation of TS, a potent BSEP 
inhibitor. TCA accumulation in cells+bile (standard HBSS) and cells (Ca2+-free HBSS) during uptake (2, 
5, 10, and 20 min in human SCH; 2, 5, 10, 15, and 20 min in rat SCH) and efflux (2, 3.5, 5, and 10 min in 
human SCH; 2, 3.5, 5, 10, and 15 min in rat SCH) phases were determined by terminal sampling of n=3 
wells at each time point. During the efflux phase, incubation buffer (standard HBSS or Ca2+-free HBSS) 
also was collected at the end of the each incubation period. Cells were washed twice in ice-cold HBSS, 
and were solubilized in 0.3 mL (24-well; human SCH) or 1 mL (6-well; rat SCH) 0.5% Triton X-100. 
Radioactivity in cell lysates and buffer samples was quantified by liquid scintillation counting (Packard 
TriCarb, Perkin-Elmer, Waltham, MA). 
Pharmacokinetic Modeling   
Pharmacokinetic modeling was employed to evaluate the hepatobiliary disposition of TCA 
(Control), and to determine the effects of TGZ on TCA disposition (+TGZ) in human and rat SCH. A 
model scheme incorporating linear parameters governing TCA disposition (Figure 3.2) were fit to mass 
versus time data from individual SCH experiments (Figure 3.3). The model fitting was performed with 
Phoenix WinNonlin, v6.1 (Certara, St. Louis, MO) using the stiff estimation method and a power model 
to account for residual error.  The following differential equations, which were developed based on the 
model scheme depicted in Figure 3.2, were fit simultaneously to data generated in SCH in the presence of 
intact and disrupted bile canaliculi for each condition (human and rat; Control and +TGZ): 
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Mass in standard HBSS buffer: 
dXBuffer
+
dt
 = CLBL×CCell
+  + KFlux×XBile − CLUptake×CBuffer
+ − KWash×XBuffer
+             XBuffer
+        ° = Xdose 
Mass in Ca2+-free HBSS buffer: 
dXBuffer
−
dt
 = (CLBL+ CLBile)×CCell
− − CLUptake×CBuffer
− − KWash×XBuffer
−                    XBuffer
−        ° = Xdose 
Mass in cells: 
dXCell
+or−
dt
 = CLUptake×CBuffer
+or−  −  (CLBL+ CLBile)×CCell
+or−                                               XCell
+or− ° = 0 
Mass in bile (standard HBSS): 
dXBile
dt
 = CLBile×CCell 
+ −  KFlux×XBile                                                                               XBile
       ° = 0 
Mass in cells+bile (standard HBSS): 
dXCells+Bile
dt
 = 
dXBile
dt
+ 
dXCell
+
dt
                                                                                           XCells+Bile
° = 0 
where variables and parameters are defined as in Figure 3.2, and Kwash was activated for 1 minute at the 
end of the 20-min uptake phase and fixed at 1x104 min-1 based on simulations to eliminate the TCA dose 
from the buffer compartment and represent the wash step. CCell represents the intracellular concentration, 
calculated as XCell/VCell, where cellular volume (VCell) was estimated based on the protein content of each 
preparation, using a value of 7.4 μL/mg protein (31). CBuffer represents the buffer concentration, calculated 
as XBuffer/VBuffer where the buffer volume (VBuffer) was constant (0.3 mL). Initial parameter estimates were 
obtained from noncompartmental analysis of SCH data, where CLUptake was estimated from the initial (2 
min) uptake data as follows, CLUptake = (dXcells+bile/dt)/CBuffer. CLBL and CLBile were estimated from efflux 
phase data under Ca2+-free conditions, where (CLBL + CLBile) = X-Buffer,0-15min/AUCcells,0-15min. KFlux, which 
represents the flux of substrate out of bile networks in standard HBSS conditions, was estimated initially 
from simulations using Berkeley-Madonna. The impact of impaired function of canalicular and/or 
basolateral efflux transporters on hepatic TCA exposure in human and rat SCH was simulated using the 
TCA model and parameter estimates (Figure 3.2 and Table 3.1); parameters representing transport-
 104 
 
mediated efflux (CLBL and CLBile) were decreased by 10-fold in isolation, or in combination, in human 
and rat SCH; the resulting changes in predicted cellular TCA concentrations are plotted in Figure 3.5. To 
determine the net effect of impaired function of uptake and/or efflux (basolateral and canalicular) 
transporters on hepatic TCA exposure in human SCH, simulations were performed by decreasing CLUptake 
and CLEfflux (CLBL + CLBile) gradually by 10 to 100-fold in combination; it was assumed that both efflux 
pathways (CLBL and CLBile) were impaired to the same extent. Simulated cellular TCA concentrations are 
presented in Figure 3.6. All simulations were performed using Berkeley-Madonna v.8.3.11. 
Membrane Vesicles   
Human MRP4 plasmid (pcDNA3.1(-)-MRP4) was kindly provided by Dr. Dietrich Keppler 
(German Cancer Research Center, Heidelberg, Germany). HEK293T cell lines stably transfected with 
pcDNA3.1(-)-MRP4 or an empty plasmid vector (control) were established as previously described (14). 
Membrane vesicles were prepared from these cell lines, and transport experiments were carried out by a 
rapid filtration assay as described previously (32). Briefly, membrane vesicles (5 μg protein) were 
incubated at 37°C in Tris-sucrose buffer (TSB; 50 mM Tris-HCl/250 mM sucrose) containing 10 mM 
MgCl2, 10 mM creatine phosphate, 100 μg/mL creatine kinase, 4 mM ATP or AMP, and [3H]DHEAS 
(0.7 μCi/mL) in the absence and presence of TS, in a volume of 50 μL. After incubation for 2 min, the 
reaction was stopped by the addition of 0.8 mL ice-cold TSB and immediately applied to a glass fiber 
filter (type A/E, Pall Corp., Port Washington, NY) and washed twice with 2 mL ice-cold TSB.  Filters 
were mixed by vortexing in 5 mL of scintillation fluid and radioactivity was quantified by liquid 
scintillation counting (Packard TriCarb, Perkin-Elmer, Waltham, MA). The ATP-dependent uptake of 
substrate was calculated by subtracting substrate uptake in the presence of AMP from substrate uptake in 
the presence of ATP. The MRP4-dependent uptake of substrate was calculated by subtracting ATP-
dependent uptake in MRP4-overexpressing vesicles from that in control vesicles. Initially, the inhibitory 
effect of TS (10 μM) on MRP4-dependent transport of [3H]DHEAS (2 μM) was evaluated in the presence 
or absence of 3 mM GSH. Further studies were performed using concentration ranges of [3H]DHEAS (0.5 
- 20 μM) and TS (5 - 50 μM) in the absence of GSH to determine the inhibition constant (Ki). Type of 
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inhibition and kinetic parameters (Km, Vmax, and Ki) were determined by fitting competitive, 
noncompetitive, and uncompetitive models by nonlinear regression using Phoenix WinNonlin, v6.1. 
Representative data from n=2 independent experiments in triplicate are presented in Figure 3.4. 
Data Analysis   
TCA accumulation was corrected for nonspecific binding to the BioCoatTM plate without cells, 
and normalized to protein concentration measured by the BCA protein assay (Pierce Chemical, Rockford, 
IL). The intracellular concentration of TCA was obtained by dividing TCA accumulation (pmol/mg 
protein) by the previously reported hepatocyte volume (7.4 µl/mg protein) (31). Apparent (CLBile,app) and 
intrinsic (CLBile,int) biliary clearance values were calculated using B-CLEAR® technology (Qualyst 
Transporter Solutions, LLC, Durham, NC) based on the following equations: 
CLBile,app =  
AccumulationCells+Bile − AccumulationCells
AUCBuffer,0−t
 
CLBile,int =  
AccumulationCells+Bile − AccumulationCells
AUCCells,   0−t
 
Where AUCBuffer,0−t is the area under the TCA buffer concentration – time curve, which is the product of 
initial TCA buffer concentration (1 µM) and incubation time (t), assuming that sink conditions of TCA in 
the buffer are maintained (concentration changes < 10% during the uptake phase). AUCCell,0−t is the area 
under the TCA cellular concentration – time curve, which was obtained using the linear trapezoidal rule. 
Paired Student’s t-test was used to compare parameters in the presence or absence of TGZ pre-incubation. 
In all cases, P < 0.05 was considered statistically significant. All statistical analyses were performed using 
SigmaStat 3.5 (San Jose, CA). 
 
RESULTS 
TCA Disposition in Human and Rat SCH with and without TGZ Pre-incubation   
TCA uptake and efflux studies were conducted as described in Figure 3.1. The mass-time profiles 
of TCA in cells+bile and cells (during the uptake and efflux phases), and buffer (during the efflux phase) 
 106 
 
in human and rat SCH in the absence (Control) and presence (+TGZ) of TGZ pre-incubation are 
presented in Figure 3.3. Under all conditions, TCA accumulation in cells+bile and cells increased during 
the uptake phase and decreased during the efflux phase. Appearance of TCA in the standard and Ca2+-free 
HBSS buffer increased during the efflux phase. TGZ pre-incubation decreased TCA accumulation in 
cells+bile, cells, and the efflux into buffers in both human and rat SCH. CLBile,app of TCA during the 
uptake phase was also significantly decreased after pre-incubation with TGZ compared to the Control 
group, indicating that TGZ decreased uptake and/or biliary excretion of TCA; in human SCH, CLBile,app 
values after 10 min uptake (standard B-CLEAR® method) in Control and +TGZ groups were 11.9 ± 3.8 
µl/min/mg protein and 1.1 ± 0.24 µl/min/mg protein, respectively (P = 0.035). The corresponding values 
in rat SCH were 4.3 ± 0.7 µl/min/mg protein and 0.7 ± 0.12 µl/min/mg protein, respectively (P = 0.008). 
TCA CLBile,int was also significantly decreased after TGZ pre-incubation, suggesting that TGZ decreased 
TCA biliary excretion; in human SCH, CLBile,int values after 10 min uptake in Control and +TGZ groups 
were 3.4 ± 0.83 µl/min/mg protein and 1.7 ± 0.98 µl/min/mg protein, respectively (P = 0.004). The 
corresponding values in rat SCH were 5.5 ± 0.95 µl/min/mg protein and 2.0 ± 0.68 µl/min/mg protein, 
respectively (P = 0.049). 
Parameter estimates recovered from fitting differential equations (see Methods) based on the 
model scheme in Figure 3.2 to TCA accumulation data from independent SCH preparations are presented 
in Table 3.1. In the absence of TGZ pre-incubation (Control), human SCH showed greater CLUptake, 
slightly lower CLBile and notably lower CLBL relative to rat SCH. This is consistent with greater cellular 
accumulation of TCA observed in human SCH (Figure 3.3). Interestingly, CLBile was about 3.3-fold 
greater than CLBL in human SCH, whereas CLBile and CLBL showed a similar contribution to the total 
cellular efflux of TCA in rat SCH in the absence of TGZ. In human SCH, TGZ pre-incubation 
significantly decreased CLUptake (P = 0.017); there were trends toward decreased CLBL and CLBile after 
TGZ pre-incubation compared to the Control groups. In rat SCH, CLBile was significantly decreased after 
TGZ pre-incubation (P = 0.017); there were trends toward decreased CLUptake and CLBL after TGZ pre-
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incubation compared to the Control groups. However, these differences failed to reach statistical 
significance due to large variability in mean differences. 
Inhibitory Effects of TS on MRP4-Mediated [3H]-DHEAS Transport in Membrane Vesicles   
The inhibitory effects of TS on MRP4, a basolateral bile acid efflux transporter, were evaluated 
using membrane vesicles prepared form HEK293T cells overexpressing MPR4 or control cells. TS (10 
μM) inhibited MRP4-mediated transport of [3H]-DHEAS (2 µM) by 78 and 72% in the absence and 
presence of GSH, respectively (Figure 3.4A). Inhibition of MRP4-mediated [3H]-DHEAS transport by TS 
was determined in membrane vesicles over a range of substrate concentrations (DHEAS, 0.5 – 20 µM) 
and inhibitor concentrations (TS, 5 – 50 µM), with a Ki value of 8.0 μM based on a non-competitive 
inhibition model (Figure 3.4B). 
Impact of Impaired Function of Canalicular vs. Basolateral Efflux Transporters on Hepatic TCA 
Exposure    
The altered hepatobiliary disposition of TCA due to impaired function of bile acid efflux 
transporters was simulated based on the TCA model described in this report (Figure 3.2 and Table 3.1). 
Simulated hepatic TCA concentrations –up to and including steady-state (CH,ss) in human and rat SCH are 
shown in Figures 3.5A and 3.5B, respectively. CLUptake of TCA in rat SCH might have been 
underestimated compared to rats in vivo because it has been reported that TCA uptake clearance was 
decreased by 5-fold on day 4 compared to day 0 due to decrease in Ntcp protein expression, whereas TCA 
uptake clearance remained unchanged over time in human SCH (33-35). To account for decreased Ntcp 
function over days of culture, simulations also were performed with 5-fold higher CLUptake in rat SCH 
(Figure 3.5C). TCA CH,ss was higher in human SCH (11.1 µM) compared to rat SCH (1.9 µM) (Figures 
3.5A and 3.5B); this is consistent with the observed higher cellular TCA accumulation during uptake and 
efflux studies compared to rat SCH (Figure 3.3). However, TCA CH,ss in rat SCH with 5-fold greater 
CLUptake (9.1 µM) is comparable to that in human SCH (Figures 3.5A and 3.5C). In human SCH, a 10-fold 
decrease in CLBile increased TCA CH,ss by 2.9-fold compared to control, whereas there was an 1.3-fold 
increase in TCA CH,ss relative to control when CLBL was decreased by 10-fold (Figure 3.5A). 
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Interestingly, a 10-fold decrease in both CLBile and CLBL increased TCA CH,ss by 7.0-fold compared to 
control, which is a greater-than proportional increase compared to inhibiting either pathway in isolation. 
In rat SCH, TCA CH,ss was increased by 2.0- and 1.6-fold when CLBile and CLBL were decreased by 10-
fold, respectively, relative to Control (Figure 3.5B). TCA CH,ss increased by 9.3-fold relative to control 
when both CLBile and CLBL were decreased by 10-fold; similar to human SCH simulations, the increase in 
CH,ss is greater than proportional compared to when either pathway is impaired in isolation. The same 
trends were observed in rat SCH with 5-fold greater CLUptake (Figure 3.5C); the fold increase in TCA CH,ss 
was 1.9, 1.6, and 7.3 relative to control when CLBile, CLBL, and both CLBile and CLBL were decreased 10-
fold, respectively. 
Impact of Impaired Function of Uptake vs. Efflux Transporters on Hepatic TCA Exposure in 
Human SCH 
Hepatic bile acid concentrations are determined by both hepatic uptake and efflux, and drugs that 
inhibit efflux transporters often also inhibit uptake transporters. To understand the net effects of impaired 
function of uptake and efflux transporters on hepatic TCA exposure, TCA CH,ss in human SCH was 
simulated based on various values of CLUptake and CLEfflux (CLBile + CLBL) (Figure 3.6). When CLUptake 
remained unchanged (fractional inhibition of CLUptake = 0), TCA CH,ss increased exponentially as the 
fractional inhibition of CLEfflux increased. On the other hand, CH,ss decreased proportionally as the 
fractional inhibition of CLUptake increased, when CLEfflux remained unchanged (fractional inhibition of 
CLEfflux = 0). When the fractional inhibition of CLUptake and CLEfflux were the same, TCA CH,ss remained 
unchanged (fold-change = 1). If the fractional inhibition of CLUptake > the fractional inhibition of CLEfflux, 
then TCA CH,ss was decreased (fold-change < 1). If the fractional inhibition of CLUptake < the fractional 
inhibition of CLEfflux, then the fold-change in TCA CH,ss was greater than 1; TCA CH,ss increased 
exponentially with increasing fractional inhibition of CLEfflux, but the fold-increase in TCA CH,ss decreased 
with increasing fractional inhibition of CLUptake. Notably, a greater than 10-fold increase in TCA CH,ss was 
observed only when the fractional inhibition of CLUptake was less than 0.6. 
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DISCUSSION 
The present study determined the hepatobiliary disposition of TCA in human and rat SCH using a 
novel uptake and efflux protocol recently developed in our laboratory combined with pharmacokinetic 
modeling (28). The results demonstrated that species differences exist in the hepatocellular excretion of 
TCA; in human SCH, biliary excretion predominated, whereas biliary excretion and basolateral efflux 
contributed equally to hepatocellular TCA excretion in rat SCH (Table 3.1). Jemnitz et al. reported that 
basolateral and biliary excretion contribute equally to TCA efflux in human SCH, whereas basolateral 
efflux was the dominant cellular efflux pathway of TCA in rat SCH (23). The likely reason for these 
discrepancies is that TCA “flux” from the canalicular spaces into the buffer (KFlux in Figures 3.1 and 3.2) 
was not considered by Jemnitz et al. In their study, basolateral efflux was evaluated by measuring TCA in 
standard buffer during the efflux phase. However, the amount of TCA that appeared in the buffer during 
the efflux phase was actually the sum of basolateral efflux and flux from the bile canalicular spaces, 
which led to an overestimation of basolateral efflux. To circumvent these issues and accurately estimate 
the relative contributions of CLBL, CLBile, and KFlux, pharmacokinetic modeling was employed in the 
current study. 
After pre-incubation with TGZ, CLBile was significantly decreased (rat SCH) or tended to 
decrease (human SCH) compared to Control (Table 3.1), consistent with reported inhibitory effects of 
TGZ and TS on BSEP (6, 20). Interestingly, CLBL tended to decrease after TGZ pre-incubation compared 
to Control, suggesting that TGZ and/or TS might also inhibit basolateral efflux of TCA. TGZ has been 
reported to inhibit basolateral efflux transporters, MRP3 and MRP4, but with less potency compared to its 
effects on BSEP (8). However, hepatic concentrations of TGZ are minimal whereas TS accumulates in 
hepatocytes due to extensive hepatic metabolism of TGZ (20, 21).  To test the hypothesis that TS inhibits 
hepatic efflux transporters, the effects of TS on MRP4-mediated transport were investigated using 
membrane vesicles prepared from HEK293T cells overexpressing MRP4 or control cells. MRP4 was 
selected because TCA is transported by human MRP4, but not by human MRP3 (36, 37). Since GSH is 
co-transported with bile acids by MRP4 (36), the inhibitory effect of TS at a single concentration (10 µM) 
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was tested initially in the absence and presence of GSH. TS inhibited MRP4-mediated transport of [3H]-
DHEAS to a similar extent regardless of GSH, suggesting that the inhibitory effects of TS on MRP4 are 
independent of GSH (Figure 3.4A). Further studies were performed in the absence of GSH, and revealed 
that TS inhibited MRP4-mediated [3H]-DHEAS transport by non-competitive inhibition with a Ki value 
of 8 µM (Figure 3.4B).  
In addition to efflux inhibition, CLUptake was significantly decreased (human SCH) or showed 
trends towards a decrease (rat SCH) compared to Control after TGZ pre-incubation (Table 3.1). Although 
TGZ is a potent inhibitor of NTCP/Ntcp-mediated bile acid uptake (19), TGZ concentrations in the buffer 
were minimal during the uptake phase because TGZ-containing buffer was removed and replaced with 
TGZ-free buffer during the 10-min pre-incubation (standard or Ca2+-free buffers ) as well as the 20-min 
uptake phase. These data suggest that TGZ might inhibit NTCP/Ntcp by mechanisms other than direct 
inhibition; further studies are needed to characterize the precise mechanism(s) of inhibition. 
Preclinical animals often are less sensitive to bile acid-mediated DILI compared to humans, and 
thus, do not reliably predict human hepatotoxicity. Potential reasons include species differences in toxic 
bile acid composition, substrate and/or inhibitor specificity of bile acid transporters, and 
metabolism/detoxification pathways of bile acids (38-41). In addition, differential inhibition of 
hepatocellular excretion pathways, as demonstrated in the current study, may contribute to species 
differences in bile acid-mediated hepatotoxicity. Simulations revealed that impaired function of 
canalicular and/or basolateral efflux transporters led to differential hepatobiliary disposition of TCA in 
human and rat SCH. In human SCH, hepatic TCA concentrations, which are relevant to hepatotoxicity, 
were increased by 2.9-fold relative to control when canalicular transporter function was impaired, 
whereas impaired function of basolateral efflux transporters minimally increased hepatic TCA 
concentration (1.2-fold) (Figure 3.5A).  This was expected due to the predominant role of biliary 
excretion and the minor contribution of basolateral efflux to the overall hepatocellular excretion of TCA 
in human SCH. Interestingly, impaired function of both canalicular and basolateral efflux transporters 
further increased hepatic TCA concentrations by 2.4-fold compared to impaired function of canalicular 
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transport alone (7.3-fold increase compared to control) (Figure 3.5A), suggesting that basolateral efflux, 
despite serving as a minor route of hepatic excretion under normal conditions, plays an important role as a 
compensatory efflux pathway when canalicular excretion is impaired in human hepatocytes. 
Expression and/or function of Ntcp have been reported to decrease over days of culture in rat 
SCH, whereas it remains constant in human SCH; in rat SCH, TCA uptake clearance was decreased by 5-
fold on day 4 compared to day 0 (33-35). Thus, the CLUptake of TCA is likely underestimated in rat SCH, 
but not in human SCH. Although robust functional or quantitative proteomics data for BSEP and MRP3/4 
in SCH over time do not exist, available data suggest that protein expression of Bsep in rat SCH, and 
MRP3/4 in rat and human SCH remain relatively unchanged over days of culture (30, 34). To account for 
the decreased function of Ntcp in day 4 rat SCH, simulations were performed in rat SCH with a CLUptake 
estimate obtained in day 4 rat SCH (1X CLUptake) as well as a 5-fold greater CLUptake (5X CLUptake). When 
5X CLUptake was employed, hepatic TCA concentrations were comparable between rat and human SCH 
(Figures 3.5B and 3.5C). In both human and rat SCH, an exponential increase in hepatic TCA 
concentrations was only observed when the function of both efflux pathways was decreased (Figure 3.5). 
These results are consistent with the mathematical relationship that governs fold-change in cellular 
exposure: 1/(1 - fe), where fe is the total fraction excreted by all pathways (biliary or basolateral) (42). 
Zamek-Gliszczynski et al. demonstrated that if multiple excretion pathways exist, minor changes in 
exposure (<2-fold) are expected when a transport pathway that contributes to less than 50% of total 
excretion is impaired, as noted when biliary excretion (rat) or basolateral efflux (human and rat) pathways 
alone are decreased in the current study. However, hepatic exposure increases exponentially in response 
to loss-of-function of transport pathways that contribute to >50% of total excretion, as noted in the current 
study when both biliary excretion and basolateral efflux transporters are impaired.  
Bile acids undergo efficient enterohepatic recirculation; only ~5% of the bile acid pool is 
synthesized in hepatocytes, while the remaining 95% is re-absorbed from the intestinal lumen after biliary 
excretion, and taken up into hepatocytes (43). Therefore, in addition to canalicular and basolateral efflux 
transporters, hepatic bile acid exposure also is regulated by hepatic uptake transporters. Inhibition of bile 
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acid efflux transporters by drugs is reported to be associated with cholestatic/mixed type DILI, but often, 
these drugs also inhibit uptake transporters, which may exert protective effects (38); the net effect will be 
determined by the relative extent (potency) of uptake inhibition vs. efflux inhibition. As might be 
expected, simulations suggest that hepatic TCA exposure increases only when the extent of efflux 
inhibition exceeds that of uptake inhibition (Figure 3.6). Notably, fractional inhibition of CLUptake >0.6 
prevents hepatic TCA exposure from increasing by more than 10-fold, thereby confirming the protective 
effects of uptake inhibition. Simulations in the current study were performed using a constant fractional 
inhibition of uptake and efflux transporters throughout the simulation, assuming steady-state drug 
(inhibitor) concentrations in the medium and in the cell. In reality, drug concentrations change over time. 
Thus, dynamic changes in inhibitor concentrations should be considered by incorporating drug disposition 
into the model in order to more accurately predict altered bile acid disposition by a drug.  
In the current study, species differences in hepatic excretion of TCA in human and rat SCH were 
identified. In human SCH, biliary excretion predominated, whereas biliary excretion and basolateral 
efflux contributed equally to TCA efflux in rat SCH. As a result, the hepatic accumulation of TCA in rat 
SCH due to inhibition of BSEP alone might not be as extensive as that observed in human SCH. In 
human and rat SCH, inhibition of both excretion pathways led to exponential increases in hepatic TCA 
exposure, suggesting that inhibition of both excretion pathways might have increased DILI liability. 
Alternatively, administration of a drug that inhibits one excretion pathway may predispose individuals 
with impaired transport function (due to disease or genetic polymorphisms) in the alternate pathway to 
hepatic bile acid accumulation and subsequent DILI. Simulations confirmed that uptake inhibition plays a 
protective role by helping to minimize hepatic bile acid accumulation. This work emphasizes that the 
inhibitory effects of a drug on bile acid transporters mediating uptake as well as multiple efflux pathways 
should be considered when evaluating the hepatotoxic potential of a drug. 
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Table 3.1. Summary of parameter estimates based on the model scheme depicted in Figure 3.2 
describing taurocholic acid (TCA) disposition in human and rat sandwich-cultured hepatocytes 
(SCH) without (Control) or with 10 µM Troglitazone (+TGZ) pre-incubation. 
Human and rat SCH were treated with 1 µM TCA (see Figure 3.1 for details of incubation conditions) and 
the model was fit simultaneously to all data from each preparation. 
 CLUptake  CLBile  CLBL  KFlux 
Conditions: (mL/min/g liver)  (mL/min/g liver)  (mL/min/g liver)  (min-1) 
Human SCH        
Control  4.8 ± 0.94    0.31 ± 0.09†   0.094 ± 0.042†‡  0.043 ± 0.015*† 
+TGZ 0.51 ± 0.08*    0.19 ± 0.15†   0.050 ± 0.041†  0.070 ± 0.036†* 
 
Rat SCH 
       
Control 2.1 ± 0.83      0.61 ± 0.13*†   0.47 ± 0.13  0.053 ± 0.015† 
+TGZ 0.36 ± 0.07      0.33 ± 0.09**†   0.39 ± 0.11  0.077 ± 0.038* 
Data are presented as mean ± SD of individual fits from n=3 SCH preparations; *, significantly different 
from Control (P < 0.05) 
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Figure 3.1. Schemes depicting the uptake and efflux protocol. 
(A) Uptake and efflux studies were conducted in the presence of standard (+Ca2+) Hanks’ balanced salt 
solution (HBSS). (B) Tight junctions remained open throughout the study period by pre-incubating with 
Ca2+-free HBSS, then performing an uptake phase in standard HBSS to provide relief from the removal of 
Ca2+, followed by a brief wash and efflux in Ca2+-free HBSS. Dashed box represents pre-incubation with 
10 µM troglitazone (TGZ) for TGZ-treated groups. Gray shading represents inclusion of the substrate, 1 
µM taurocholic acid (TCA), in Standard HBSS during the uptake phase. Black shading represents 1 min 
wash. Cell schemes on the right represent the intended condition of the SCH system during the efflux 
phase, with arrows depicting the potential pathways leading to substrate efflux from cells + bile (A) and 
cells (B); CLBL, CLBile, and KFlux represent basolateral efflux, biliary excretion, and flux from the bile 
networks (depicted by the dashed arrow), respectively.   
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Figure 3.2. Model schemes depicting the disposition of taurocholic acid (TCA) in sandwich-cultured 
hepatocytes (SCH) studies based on the experimental design depicted in Figure 3.1. 
X, V, and C denote mass of TCA, compartmental volume, and compartmental concentration, respectively. 
Subscripts on mass, volume, and concentration terms denote the corresponding compartment in the model 
scheme. Superscripts represent the presence (+, intact tight junctions; cells + bile) and absence (-, 
modulated tight junctions; cells) of Ca2+ in the pre-incubation and efflux buffer. CLuptake, CLBL, and CLBile 
represent clearance values for uptake from buffer into hepatocytes, efflux from hepatocytes into buffer, 
and canalicular excretion from hepatocytes, respectively. KFlux represents the first order rate constant for 
flux from bile networks into buffer. 
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Figure 3.3. Taurocholic acid (TCA) mass versus time data in rat and human sandwich-cultured 
hepatocytes (SCH) in the absence (Control) or presence of 10 µM troglitazone (TGZ) pre-
incubation. 
Closed symbols/solid lines represent TCA in cells + bile (standard HBSS), and open symbols/dashed lines 
represent TCA in cells (Ca2+-free HBSS). The simulated mass-time profiles were generated from the 
relevant equations based on the model scheme depicted in Figure 3.2, and the final parameter estimates 
are reported in Table 3.1. Data (pmol/mg protein) represent mean ± S.E.M. (n=3 SCH preparations in 
triplicate per group). 
 
  
 117 
 
Figure 3.4. Inhibition of multidrug resistance-associated protein 4 (MRP4)-mediated transport of 
[3H]dehydroepiandrosterone sulfate (DHEAS) by troglitazone sulfate (TS) in membrane vesicles 
from MRP4-overexpressing and control human embryonic kidney cells. 
Effect of GSH (3 mM) on MRP4-mediated transport of 2 μM DHEAS and inhibition by 10 μM TS. (B) 
Effect of increasing concentrations of TS (0, 5, 10, and 50 μM) on MRP4-mediated DHEAS (2 min, 0.5 - 
20 μM) transport in the absence of GSH. Each point represents mean±S.D.  
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Figure 3.5. Impact of impaired function of canalicular and/or basolateral efflux transporters on 
hepatic TCA exposure. 
Cellular TCA concentrations in human and rat SCH were simulated based on the TCA model scheme 
depicted in Figure 3.2 and parameter estimates (Table 3.1). Parameters representing transport-mediated 
efflux (CLBL and CLBile) were decreased by 10-fold in isolation, or in combination, to represent impaired 
function of canalicular efflux transporters (solid line with open circle), basolateral efflux transporters 
(dashed line), and both pathways (dashed line with closed circle). Simulations were performed for 200 
minutes to obtain steady-state intracellular concentrations; the time to reach steady-state was longer when 
efflux pathways were impaired compared to control. 
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Figure 3.6. Net effects of inhibition of uptake and efflux transporters on hepatic TCA exposure. 
Cellular TCA concentrations in human SCH were simulated as a function of decreased (10- to 100-fold) 
CLUptake and CLEfflux (CLBL + CLBile); both efflux pathways (CLBL and CLBile) were assumed to be impaired 
to the same extent. The Z-axis represents the fold-change in steady-state hepatic TCA concentrations; 10 
to 100-fold (orange), 5 to 10-fold (yellow), 1 to 5-fold (light green), 0.1 to 1-fold (dark green), and 0.001 
to 0.1-fold (blue). 
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CHAPTER 4.  An Experimental Approach to Evaluate the Impact of Impaired Transport Function 
on Hepatobiliry Drug Disposition using Mrp2-deficient TR- Rat Sandwich-Cultured Hepatocytes in 
Combination with Bcrp Knockdown1  
 
INTRODUCTION 
Hepatocytes are polarized cells with distinct apical and basolateral domains. Transport proteins 
on the apical membrane are responsible for excretion of compounds into the bile canaliculus, whereas 
basolateral transport proteins mediate influx into hepatocytes and efflux back to sinusoidal blood. Hepatic 
canalicular and basolateral transport proteins play important roles in regulating the pharmacologic and 
toxicologic effects of many drugs by modulating hepatocellular exposure. Breast cancer resistance protein 
(BCRP), a member of the ATP-binding cassette (ABC) transporter family, is a half-transport protein that 
forms a functional homodimer or oligomer (1, 2). BCRP is highly expressed in the canalicular membrane 
of hepatocytes as well as in the intestine, breast, and placenta (3). BCRP substrates include glucuronide 
and sulfate conjugates [e.g., estrone-sulfate, estradiol-17β-D-glucuronide (E217G), SN-38 glucuronide], 
anticancer drugs (e.g., irinotecan, SN-38, methotrexate, daunorubicin, doxorubicin), and some statins 
[e.g., pitavastatin, rosuvastatin (RSV)] (4-9). The pharmacokinetics and pharmacodynamics of these 
drugs may be affected by modulation of BCRP expression and/or function resulting from genetic 
polymorphisms or drug-drug interactions (DDIs). 
Multidrug resistance-associated protein 2 (MRP2), is another member of the ABC transporter 
family that is expressed in the canalicular membrane of hepatocytes. Many drugs are substrates for both 
BCRP and MRP2 including RSV, methotrexate, doxorubicin, SN-38, and SN-38 glucuronide. 
                                                     
1This chapter has been published in Molecular Pharmaceutics, and is presented in the style of that Journal: Mol 
Pharm 2014 Jan 30 [Epub ahead of print, doi: 10.1021/mp400471e]. 
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Overlapping substrate specificity can make it challenging to predict the impact of altered function of one 
or more transport proteins on the hepatic and systemic exposure of substrates. A significant change in 
drug exposure is expected following loss-of-function of one or more transport pathways when clearance 
by that particular pathway (apical or basolateral) exceeds 50% of total clearance (10). Moreover, altered 
drug exposure as a result of impaired transport function depends on the remaining excretion routes, such 
as complimentary efflux transporters on the same membrane (e.g., canalicular excretion into bile) or 
alternative efflux transporters on the opposite membrane (e.g., basolateral excretion into sinusoidal 
blood). Thus, in vitro and in vivo models to assess changes in hepatocellular accumulation and routes of 
excretion of compounds in the setting of impaired transport function are greatly needed. 
Several model systems have been proposed to assess the role of BCRP and MRP2 in the 
disposition of a substrate. One approach is the use of specific BCRP and MRP2 inhibitors in hepatocytes. 
However, inhibitors of BCRP (e.g., GF120918, Ko134, fumitremorgin C, mitoxantrone, novobiocin) and 
MRP2 (e.g., MK-571, benzbromarone) may not be specific enough to allow assessment of the role of 
individual proteins (11-13). Similarly, specific substrates have been employed in hepatocytes and 
transport protein overexpressing cells to evaluate quantitatively the contribution of an individual hepatic 
uptake transporter [i.e., relative activity factor (RAF) method] (14), but “specific” BCRP and MRP2 
substrates are lacking due to the aforementioned overlapping substrate spectrum of these transport 
proteins. Although the use of transient or stably transfected cell lines expressing one or more transport 
proteins is a popular approach to assess the role of individual proteins in substrate disposition, this 
approach may be misleading. Expression levels of transport proteins in these in vitro systems may not be 
representative of the true physiologic state, and metabolic systems as well as other regulatory factors 
impacting hepatobiliary disposition of substrates may be absent or present at low levels, depending on the 
in vitro system. Thus, transport of substrates by a specific protein in transporter-expressing cells in vitro 
does not guarantee that the transporter will play a key role in substrate disposition in vivo.     
Another approach is the use of naturally occurring, genetically-deficient rodents or genetically 
engineered animals lacking a specific transport protein. Mrp2-deficient Wistar (TR-) rats and 
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Eisai-hyperbilirubinemic Sprague-Dawley rats have been used to delineate the role of Mrp2 in drug 
disposition in vivo (15, 16). Likewise, Bcrp knockout (Abcg2-/-) mice have been used to investigate 
whether Bcrp is involved in the disposition of drugs such as RSV, methotrexate, mitoxantrone, and 
pitavastatin (8, 17-19). Recently, Mrp2 knockout rats and Bcrp knockout rats were generated using zinc 
finger nuclease technology, and knockout phenotypes in these rats were characterized using sulfasalazine 
and 5-(and 6)-carboxy-2’,7’-dicholorofluorescein as probes for Bcrp and Mrp2 function, respectively (20, 
21). While in vivo pharmacokinetic studies in these models provide insight regarding overall drug 
distribution and excretion, sandwich-cultured hepatocytes (SCH) prepared from rodents lacking a specific 
transport protein allow assessment of altered hepatobiliary disposition in isolation from other organs (22-
24).   
RNA interference (RNAi) is one approach to explore the consequences of impaired protein 
function, and has been used to knock down transport proteins in the SCH system. Tian et al. transfected 
rat SCH with synthetic small interfering RNA (siRNA) to specifically knock down protein levels of Mrp2 
and Mrp3; approximately 50% knockdown was achieved using this approach (25). Knockdown of mRNA 
and protein levels of OATP1B1, OATP1B3, and OATP2B1 using siRNA has been reported in human 
SCH (26). In primary cells, it is technically challenging to reach high transfection efficiency. Delivery of 
short hairpin (sh) RNA using an adenoviral vector system resulted in high infection efficiency leading to 
high knockdown efficiency (27). Rat SCH infected with adenoviral vectors expressing shRNA targeting 
Bcrp exhibited a significant decrease in protein expression and activity of this canalicular transport 
protein; the disposition of digoxin, a P-gp substrate, and the expression of some other transport proteins 
was not affected (28). 
To date, primary hepatocyte models lacking multiple transport proteins have not been established. 
Such a model may be of particular importance if it mimics the physiological condition when an 
administered drug inhibits the function of multiple transporters due to the non-specific nature of transport 
inhibitors. The purpose of this investigation was to develop an in vitro model system to assess the 
consequences of altered transport function when multiple proteins are involved in hepatic excretion. 
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Knockdown of Bcrp in SCH from TR- and wild-type (WT) rats was developed as an in vitro system to 
assess the impact of impaired function of Bcrp and/or Mrp2 using probe substrates. RSV, a Bcrp and 
Mrp2 substrate, and taurocholate (TC), a model bile acid that is not transported by Bcrp and Mrp2, were 
selected as probe substrates for investigation. This report describes a two-stage statistical analysis strategy 
for optimizing the knockdown system. 
 
EXPERIMENTAL METHODS 
Chemicals   
Penicillin-streptomycin solution, dexamethasone, Hanks’ balanced salt solution (HBSS; with or 
without Ca2+ and Mg2+), collagenase (type IV), and Triton X-100 were purchased from Sigma-Aldrich 
(St. Louis, MO). Dulbecco’s modified Eagle’s medium (DMEM) and MEM nonessential amino acids 
were purchased from Invitrogen (Carlsbad, CA). Insulin/transferrin/selenium culture supplement, BioCoat 
culture plates, and MatrigelTM extracellular matrix were purchased from BD Biosciences Discovery 
Labware (Bedford, MA). [3H]TC (5 Ci/mmol; purity >97%) and [3H]E217G (50.3 Ci/mmol; purity >97%) 
were purchased from Perkin Elmer (Waltham, MA). [3H]RSV (10 Ci/mmol; purity >99%) was purchased 
from American Radiolabeled Chemicals (St. Louis, MO). All other chemicals and reagents were of 
analytical grade and were readily available from commercial sources. 
Packaging of Recombinant shRNA-Expressing Adenoviral Vectors   
Adenoviral vectors expressing small hairpin RNA (shRNA) targeting rat Bcrp (Ad-siBcrp), rat 
Mrp2 (Ad-siMrp2) or a non-targeted control shRNA (Ad-siNT) were packaged as published previously 
using the Adeno-XTM ViralTrak DsRed-Express Promoterless Expression System 2 (Clontech 
Laboratories, Mountrain View, CA)(28). The titer of adenoviral vectors was measured using Adeno-X 
Rapid Titer Kit (Clontech Laboratories, Mountain View, CA). siRNA sequences targeting the rat Bcrp 
gene at positions 288-306 relative to the start codon were published previously(28); siRNA sequences 
targeting rat MRP2 at positions 4257-4275, and a non-target siRNA (Ad-siNT) control sequence 
(ATGTATTGGCCTGTATTAG) were obtained from Darmacon (Chicago, IL).  
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Isolation and Culture of Rat SCH   
Primary rat hepatocytes were isolated from male Wistar (220 – 300 g, Charles River Laboratories, 
Inc., Wilmington, MA) and TR- (220 – 300 g, bred in-house; breeding stock obtained from Dr. Mary 
Vore, University of Kentucky, Lexington, KY) rats and seeded onto 24-well collagen-coated plates at a 
density of 0.35×106 cells/well in seeding medium (DMEM containing 5% fetal bovine serum, 10 µM 
insulin, 1 µM dexamethasone, 2 mM L-glutamine, 1% MEM nonessential amino acids, 100 units of 
penicillin G sodium, and 100 µg of streptomycin). One hour after seeding, hepatocytes were infected with 
Ad-siBcrp, Ad-siMrp2, or Ad-siNT at multiplicity of infection (MOI) of 1, 3, 5, and 10 by replacing the 
seeding medium with fresh seeding medium containing virus. On the next day, medium including viruses 
was removed, and cells were overlaid with MatrigelTM at a concentration of 0.25 mg/ml in 0.5 ml/well 
ice-cold culture medium (DMEM supplemented with 0.1 µM dexamethasone, 2 mM L-glutamine, 1% 
MEM nonessential amino acids, 100 units of penicillin G sodium, 100 µg of streptomycin, and 1% 
insulin/transferrin/selenium). Culture medium was changed every 24 h until experiments were performed 
on day 4.    
Quantitative Real-Time Polymerase Chain Reaction (RT-PCR)   
Total RNA was isolated from cell lysates using the ABI RNA isolation system (Applied 
Biosystems, Foster City, CA). mRNA levels of rat Bcrp and β-actin (internal control) were measured by 
TaqMan real-time RT-PCR using an ABI Prism 7700 System (Applied Biosystems) as described 
previously (29). The TaqMan probe and primer sequences (5’-3’) used for rat Bcrp were as follows: 
Forward (TGGATTGCCAGGCGTTCATT), Reverse (GTCCCAGTATGACTGTAACAA), and Probe 
(CTGCTCGGGAATCCTCAAGCTTCTG). Rat β-actin was detected using the following probe and 
primer sequences: Forward (TGCCTGACGGTCAGGTCA), Reverse 
(CAGGAAGGAAGG-CTGGAAG), and Probe (CACTAATCGGCAATGAGCGGTTCCG). Fold 
changes in mRNA levels of Bcrp were evaluated after normalizing the gene expression levels by those of 
β-actin (2−ΔΔCt method) as previously described (30). 
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Immunoblots   
Cells were washed with HBSS and lysis buffer containing 1% NP-40, 0.1% Na+-deoxycholate, 1 
mM EDTA, and complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) was 
applied. Protein concentrations were measured by the BCA assay (Pierce, Rockford, IL). Whole-cell 
lysates (15 µg) were resolved on NuPAGE 4 to 20% Bis-Tris gel (Invitrogen, Carlsbad, CA), and the 
proteins were transferred to nitrocellulose membranes. After blocking in 5% non-fat milk in Tris-buffered 
saline with Tween 20 (TBST) for 30 min, blots were incubated overnight at 4°C with the following 
antibodies: Bcrp (BXP-53), Mrp2 (M2III-6), Mrp4 (M4I-10), and P-gp (C219) (Alexis Biochemicals, San 
Diego, CA); Oatp1a1 (AB3570P, Millipore, Billerica, MA); Bsep (K44, kind gift from Drs. Bruno Stieger 
and Peter Meier); and β-actin (C4, Chemicon, San Francisco, CA). After incubation with HRP-conjugated 
secondary antibody, signals were detected by chemiluminescent substrate Supersignal West Duro (Pierce, 
Rockford, IL) with a Bio-Rad VersaDoc imaging system; densitrometry analysis was performed using 
Quantity One V4.1 software (Bio-Rad Laboratories, Hercules, CA). 
Accumulation Studies in Rat SCH   
Accumulation studies were conducted in SCH on day 4 as described previously (31). Briefly, 
cells were washed twice with 0.3 mL warm standard (Ca2+-containing) or Ca2+/Mg2+-free HBSS with 0.38 
g/L EGTA (hereafter referred to as Ca2+-free) and incubated in the same buffer for 10 min at 37ºC to 
maintain or disrupt tight junctions, respectively. Subsequently, cells were incubated at 37ºC for 10 min 
with 0.25 ml standard HBSS containing [3H]TC, [3H]RSV, or [3H]E217G at 1 µM (100 nCi/ml). After 10 
min, cells were washed 3x with ice-cold standard HBSS and lysed with 0.25 ml 0.5% (v/v) Triton X-100 
in phosphate-buffered saline. Samples were quantified by a Tri-Carb 3100 TR liquid scintillation analyzer 
(Perkin Elmer, Waltham, MA). Transport function was normalized to the protein content of each 
preparation using the BCA protein assay. The biliary excretion index (BEI; %) was calculated using 
B-CLEAR® technology (Qualyst Transporter Solutions, Research Triangle Park, NC) as follows:  
100
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onAccumulationAccumulati
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Experimental Design   
SCH were obtained from n=3 WT rats and n=3 TR- rats. From each rat, sets of 3 SCH samples 
(“triplicates”) were systematically assigned by plate location to each of the 36 combinations of virus (Ad-
siBcrp, Ad-siNT, non-infected), MOI (1, 3, 5, 10), and evaluation procedure (RT-PCR, immunoblots, 
RSV accumulation, TC accumulation, as noted in Figures 4.1, 4.2, 4.3).  For each level of MOI, 
triplicates were assigned to the three levels of virus (Ad-siBcrp, Ad-siNT, non-infected) in ratios of 1:1:1.  
For RT-PCR and immunoblot assays, two of the triplicate samples were measured, which provided 2 
numerical assay values that were averaged together as a preliminary step for statistical analysis. For the 
accumulation studies of probe substrates, triplicate samples provided 3 numerical assay values that were 
averaged together as a preliminary step for statistical analysis. MOI of 1 was intentionally not studied by 
RT-PCR and immunoblots; otherwise, the experimental design produced complete data (i.e., no missing 
values for any assays).  
Auxiliary Experimental Designs   
Preliminary experimentation briefly explored two alternatives to the recommended knockdown 
system: (1) a system using Ad-siMrp2 for knockdown as an alternative to relying on TR- rat SCH, and 
(2) a system using Ad-siBcrp with Ad-siMrp2 for double-knockdown. SCH obtained from n=4 WT rats 
were systematically assigned to selected combinations of three factors: virus (Ad-siMrp2, Ad-siBcrp with 
Ad-siMrp2, Ad-siNT, non-infected), MOI (5, 10, 15, 20), and evaluation procedure (RT-PCR, 
immunoblots, probe accumulation). Intentionally, the combinations studied were assigned to either 
triplicate or duplicate sets of SCH samples from 2, 3, or 4 rats (as noted in Supplement Figures 4.1, 4.2, 
4.3); otherwise, the design produced complete data (i.e., no missing values for the assays.)    
Two-Stage Statistical Analysis Strategy   
The “dose-finding” analyses of stage 1 (Figures 4.1, 4.2, 4.3) explored the dose-response 
relationship between MOI and measures of the resulting on-target and off-target effects.  For the MOI 
‘dose’ selected as optimal, stage 2 (Table 4.1) summarized for each of two probes, RSV and TC, the 
effects of suppressing Bcrp and/or Mrp2 function. Stages 1 and 2 illustrate proposed approaches for 
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MOI-selection and characterization of the effects of impaired transporter function on the disposition of 
compounds of interest.   
In stage 1, the extent of Bcrp knockdown (Figure 4.1) was evaluated in terms of Bcrp mRNA 
expression, and separately in terms of Bcrp protein: the primary inferential analysis of Bcrp expression 
relied on a univariate repeated-measures analysis of variance model (unirep-ANOVA) assuming that 
mean expression was a function of seven categories defined by virus [Ad-siBcrp, Ad-siNT, and non-
infected (MOI=0 only)] and MOI (3, 5, 10 for Ad-siBcrp and Ad-siNT). The model was fit to the TR- rat 
SCH data, and separately to the WT rat SCH data yielding statistical estimates of mean expression [with 
95% confidence intervals (CIs)], residual variance, and within-rat correlation.  The extent of Bcrp 
knockdown was defined by the three mean differences between Ad-siBcrp infected (MOI=3, 5, 10) and 
non-infected (MOI=0) SCH.  The null hypothesis “all three differences are exactly zero” was rejected if 
any of the three sub-hypotheses were rejected by the (modified-Bonferroni) Hochberg test procedure 
(=0.05). The same strategy was applied to similar hypothesis tests regarding Ad-siNT. The graphical 
summary was computed in terms of relative expression; specifically, the values for each rat type (WT or 
TR-) were expressed as a percent of the average that was observed in that non-infected SCH samples. 
Continuing stage 1, potential off-target knockdown (Figure 4.2) was explored for a selection of 
six other proteins (Oatp1a1, Ntcp, Bsep, P-gp, Mrp4, and Mrp2) using the same graphical summary 
method and the same inferential analysis methods that were applied to Bcrp protein expression. For each 
protein, the unirep-ANOVA model was used to obtain point and confidence interval estimates of mean 
expression as a function of five categories defined by virus [Ad-siBcrp, Ad-siNT, and non-infected 
(MOI=0 only)] and MOI (5, 10 for Ad-siBcrp and Ad-siNT). The hypothesis testing strategy was as 
described above for Bcrp protein.  
Completing stage 1, the dose-response relationship (Figure 4.3) between MOI and disposition of 
RSV and TC was explored in terms of total substrate accumulation (uptake in pmol/mg protein) and 
biliary excretion index (BEI %). The analysis relied on a unirep-ANOVA model assuming that the mean 
was a function of nine categories defined by virus [Ad-siBcrp, Ad-siNT, and non-infected (MOI=0 only)] 
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and MOI (1, 3, 5, 10 for Ad-siBcrp and Ad-siNT). The model was fit to the TR- rat SCH data, and 
separately to the WT rat SCH data, yielding statistical estimates of mean levels of response (total 
accumulation and BEI), residual variance and within-rat correlation. Estimates of mean responses 
(individual and marginal) and differences among mean marginal responses were all tabulated together 
with 95% CIs. The off-target effects of Ad-siNT were defined by the four mean differences between Ad-
siNT infected (MOI=1, 3, 5, 10) and non-infected (MOI=0) SCH. The null hypothesis “all four 
differences are exactly zero” was rejected if any of the four sub-hypotheses were rejected by the 
Hochberg test procedure (=0.05). The targeted effects of siBcrp expression were defined by the four 
MOI-specific mean differences between Ad-siBcrp and Ad-siNT infected SCH. The null hypothesis “all 
four differences are zero” was rejected if any of the four sub-hypotheses were rejected by the Hochberg 
test procedure (=0.05). The results from all eight unirep-ANOVA models are summarized in a graphical 
illustration (Figure 4.3). 
In stage 2, best estimates (Table 4.1) of effects on the disposition of probes attributable to 
impaired Bcrp function and/or absence of Mrp2 function were obtained for total substrate accumulation 
(uptake in pmol/mg protein) and BEI (%) using the responses from the SCH samples that were non-
infected compared to those administered virus at the MOI level selected as optimal ‘dose’. This stage 2 
analyses relied on a unirep-ANOVA model assuming mean response was a function of the six categories 
of virus (Ad-siBcrp, Ad-siNT, non-infected) and WT or TR- status. For probes RSV and TC, the resulting 
estimates of category means, marginal means, and contrasts thereof were tabulated with their SEs and 
95% CIs. The null hypothesis tested via an F-test procedure (=0.05) included “effects of the viruses do 
not depend on WT or TR- status”, “no difference between the marginal means for WT and TR- rat SCH”, 
and “no differences among three virus-specific marginal means”. If and only if virus effects were 
detected, then an F-test procedure (=0.05) was performed for the two sub-hypotheses regarding marginal 
means: “off-target effects are zero (siNT vs. non-infected)”, “targeted effects are zero (siBcrp vs. siNT)”.  
The results from all four unirep-ANOVA models were summarized in Table 4.1. 
 133 
 
For stages 1 and 2, auxiliary analyses were performed to more fully explore the data and to 
evaluate the robustness of the main results to reasonable perturbations of the statistical modeling 
assumptions and methods. For example, in stage 1, unirep-ANOVA models accounting for all three 
factors (WT or TR- status, virus, and MOI) were evaluated and interactions were explored.  
All statistical computations were performed using SAS software v9.2 (SAS Institute Inc., Cary, 
NC).   
 
RESULTS 
Targeted Knockdown of Bcrp in WT and TR- Rat SCH   
Relative to non-infected hepatocytes, mean levels of Bcrp mRNA (Figure 4.1A) decreased with 
increasing MOI of Ad-siBcrp in both WT and TR- rat SCH. For MOI 10, the mean was only 12% and 
6.5% of that in non-infected WT and TR- rat SCH, respectively. In contrast, Ad-siNT infection had 
negligible impact on mean Bcrp mRNA. Similarly, for Bcrp protein (Figure 4.1B) the mean level 
decreased with increasing MOI of Ad-siBcrp in both WT and TR- rat SCH relative to non-infected 
hepatocytes. In WT rat SCH, the mean decreased by 61%, 66%, and 81% with Ad-siBcrp at MOI of 3, 5, 
and 10, respectively. In TR- rat SCH, the mean decreased by 33%, 65%, and 70%, respectively. In 
contrast, Ad-siNT infection had much less impact on the mean level of Bcrp protein in TR- and WT rat 
SCH; however, for MOI of 10 in WT, the mean level was decreased by 47%, suggesting that off-target 
(non-specific) effects of viral infection can exist at high MOI (≥10) under the conditions of the proposed 
SCH knockdown system. 
Off-Target Effects of Bcrp Knockdown on the Levels of Other Transport Proteins   
For TR- rat SCH, no off-target effects were detected for Oatp1a1, Ntcp, Bsep, P-gp, Mrp4, and 
Mrp2 proteins at MOI of 5 and 10 (Figure 4.2). For WT rat SCH, off-target effects (Ad-siNT vs. non-
infected) were detected only for Mrp4 and Mrp2 proteins. Mean levels of Mrp4 protein were decreased by 
30% and 55% with Ad-siNT at MOI of 5 and 10, and by 55% and 56% with Ad-siBcrp at MOI of 5 and 
10, respectively, relative to non-infected SCH samples. For Mrp2 protein, an off-target effect was 
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statistically significant for Ad-siNT at MOI of 5, but not at MOI of 10, and not for Ad-siBcrp at either 
MOI level. 
Effects of Impaired Transporter Function on Probe Disposition  
Based on stage 1 analyses, MOI=5 was selected as the optimal ‘dose’ for stage 2 analyses of 
probes RSV and TC. 
RSV Total Accumulation.  Mean total accumulation of RSV was similar in WT and TR- rat SCH, 
and minimally altered by viral infection. Stage 1 analyses (Figure 4.3A) did not detect off-target effects 
(siNT vs. non-infected), targeted effects (siBcrp vs. siNT), nor any effects with increasing MOI. In 
stage 2 analysis (Table 4.1), targeted and non-targeted effects were not detected in samples administered 
virus at the MOI of 5. 
RSV BEI.  MOI-dependent effects of virus and WT or TR- status were observed in stage 1 
analyses (Figure 4.3B). For WT rat SCH, a mean decrease in BEI due to off-target effects (siNT vs. non-
infected) was detected at MOI of 5 and 10 only, and a mean decrease in BEI due to targeted effects 
(siBcrp vs. siNT) was detected at MOI of 5 and 10 only.  For TR- rat SCH, the pattern of response was 
similar but no effects were statistically significant. Stage 2 analyses (Table 4.1) detected effects for both 
factors. The marginal mean for TR- was smaller than for WT rat SCH by 28.6% with 95% CI [5.8, 51.3]. 
The targeted and non-targeted effects were statistically significant: relative to non-infected samples, siNT 
reduced the marginal mean BEI by 7.8% [3.2, 12.4]; relative to siNT, siBcrp reduced the marginal mean 
BEI by 13.3% [7.5, 19.1]. The difference in BEI between non-infected and siBcrp was 21% [16.5, 25.7]. 
TC Total Accumulation.  MOI-dependent effects were found in stage 1 analyses (Figure 4.3C): 
for WT rat SCH, the dose-dependent off-target effects were statistically significant for MOI of 3, 5 and 
10. For TR- rat SCH, off-target effects were not detected.  For both WT and TR- rat SCH, targeted effects 
were statistically significant only for MOI of 10. In stage 2 analyses (Table 4.1), focusing on MOI = 5, 
the marginal means were decreased by non-targeted and targeted effects: relative to non-infected samples, 
siNT reduced the marginal mean by 4.8 pmol/mg protein [1.9, 7.7]; relative to siNT, siBcrp reduced the 
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marginal mean by 5.1 pmol/mg protein [1.4, 8.8].  The difference between non-infected and siBcrp was 
9.9 pmol/mg protein [7.0, 12.8]. 
TC BEI.  In stage 1 analyses (Figure 4.3D) for TR- rat SCH, off-target effects and targeted effects 
were statistically significant at an MOI of 10.  In stage 2 analyses (Table 4.1), an off-target effect was 
evident: relative to non-infected samples, siNT reduced the marginal mean BEI by 6.3% [2.5, 10.1]. The 
targeted effect was not detected, as in comparison to siNT, siBcrp reduced the marginal mean BEI by 
only 1.2% [-3.7, 6.1]; however, the difference in BEI between non-infected and siBcrp, 7.5% [3.7, 11.3], 
was statistically significant. The difference in BEI between TR- and WT, 12.6% [-2.1, 27.3], was not 
statistically significant.  
Sensitivity Analyses and Exploratory Analyses.  The main results of stage 1 and stage 2 analyses 
were robust to perturbations of the modeling assumptions (e.g., variance homogeneity across WT and 
TR- rat SCH). In stage 1, a MOIbyWT or TR- interaction was observed in 3-factor models for the 
analyses of TC BEI (p=0.0038) and RSV total accumulation (p=0.0460); however, inclusion or exclusion 
of interactions and commonality assumptions yielded negligible changes in the main results of interest 
(data not presented).   
Ancillary Study of Knockdown of Mrp2 in WT Rat SCH  
Infection with Ad-siMrp2 decreased mean relative levels of Mrp2 protein by 45%, 79%, and 78% 
at MOI of 5, 10 and 15, respectively, compared to non-infected SCH (Supplement Figure 4.1). Infection 
with Ad-siNT decreased the mean by 39% at MOI of 10, suggesting that some off-target effects may exist 
for large MOI. In contrast, Ad-siNT or Ad-siMrp2 at MOI of 5, 10 and 15 had little influence on the mean 
relative level of Bcrp protein.   
Mean total accumulation of E217G (Supplement Figure 4.2A) showed little evidence of targeted 
or off-target effects. Mean BEI values for E217G (Supplement Figure 4.2B) appeared to decrease slightly 
with increasing MOI. Mean total accumulation of TC (Supplement Figure 4.2C) was decreased by 
Ad-siNT and Ad-Mrp2 at MOI of 10, suggesting again that off-target effects become more prevalent at 
MOI ≥ 10. Mean BEI values for TC (Supplement Figure 4.2D) were influenced least by viral infection. 
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Due to the off-target effects on TC total accumulation at an MOI of 10, an MOI of 5 was selected for the 
double knockdown study. 
Ancillary Study of Double Knockdown of Mrp2 and Bcrp in WT Rat SCH   
To suppress both Mrp2 and Bcrp (Supplement Figure 4.3), SCH were infected with Ad-siNT at 
MOI of 10, Ad-siMrp2 and Ad-siBcrp (MOI of 5 each; total MOI=10), or not infected. The targeted 
effects (double knockdown vs. Ad-siNT) decreased the mean relative levels of Mrp2 protein and Bcrp 
protein by 67% and 64%, respectively, relative to non-infected control. However, off-target effects also 
were observed: Ad-siNT infection at MOI of 10 decreased the mean levels of Mrp2 protein and Bcrp 
protein by 47% and 30%, respectively, relative to non-infected SCH samples. MOI of 10 also induced 
off-target effects in Bcrp knockdown SCH described elsewhere in this report; at MOI=10, Ad-siNT 
decreased mean relative levels of Bcrp (Figure 4.1B) and Mrp4 (Figure 4.2) in WT rat SCH, and altered 
hepatobiliary disposition of probe substrates [i.e. TC total accumulation in WT SCH (Figure 4.3C), RSV 
BEI in WT SCH (Figure 4.3B), and TC BEI in TR- SCH (Figure 4.3D)].  
 
DISCUSSION 
Protein knockdown in cultured primary hepatocytes is challenging because it is difficult to reach 
high transfection efficiency using conventional transfection reagents. Our laboratory previously had 
established an efficient and specific Bcrp knockdown system in WT rat SCH in 6-well plates using 
adenoviral vectors to deliver shRNA into hepatocytes (28). In the present study, that work was extended 
to establish an in vitro system exhibiting impaired function of multiple specific transport proteins in the 
24-well plate format. Scaling from 6-well to 24-well plates enabled more efficient use of hepatocytes and 
other resources required for the study. Initially, double knockdown of both Mrp2 and Bcrp was attempted.  
However, off-target effects in 24-well rat SCH were noted at the higher MOI required to knock down 
multiple transport proteins. Because an MOI of 5 was required for efficient knockdown of each transport 
protein (Mrp2 and Bcrp), the combination of two different shRNA targeting different transport proteins 
required an MOI of 10, at which off-target effects were prevalent. Use of a tandem plasmid vector that 
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expresses two different shRNA to facilitate the simultaneous double knockdown of genes has been 
applied in stable cell lines (32). However, plasmid DNA has low transfection efficiency into primary 
hepatocytes (27), and adenoviral vectors that similarly express tandem expression shRNA are not 
commercially available. Therefore, efficient double-knockdown of transport proteins using the adenoviral 
vector approach necessitated a higher viral load in hepatocytes. In order to circumvent this problem, 
Mrp2-deficient TR- rat SCH were employed in combination with Bcrp knockdown using adenoviral 
infection of shRNA targeting Bcrp.  
To validate this in vitro system, the impact of Bcrp knockdown on the hepatobiliary disposition of 
RSV and TC was examined in the absence and presence of functional Mrp2. RSV and TC were selected 
as probe substrates because different mechanisms dominate their hepatocellular uptake and biliary 
excretion. The results, for a range of MOI ‘doses’ with multiple viral vectors (siNT vs. siBcrp or siMrp2), 
demonstrated the importance of optimizing the system when an RNAi approach is employed to knock 
down transport proteins. This approach allows greater confidence in identification of off-target effects and 
interactions among factors that might otherwise have been dismissed as spurious if evaluated at only one 
level of MOI. This report demonstrates the use of a two-stage statistical analysis: stage 1 evaluated 
targeted and off-target effects for a range of MOI in order to identify dose-response relationships and 
select an optimal MOI ‘dose’ for the system. Stage 2 summarized for each of two probes, RSV and TC, 
the effects of impaired Bcrp and/or Mrp2 function. Results of stages 1 and 2 analyses demonstrated 
MOI-selection and characterization of the effects of impaired transporter function on the disposition of 
compounds of interest. Since changes in protein levels may not always translate to changes in protein 
activity, use of relevant probe substrates (positive and negative controls; TC and RSV in this study) to 
assess changes in protein activity is strongly recommended.  
The MOI of 5 was chosen as the optimal ‘dose’ for use in stage 2 analyses of the relative 
contributions of Mrp2 and Bcrp to the hepatobiliary disposition of the probe substrates. The main 
considerations in choosing the optimal MOI ‘dose’ were the MOI-dependent patterns of targeted and off-
target effects observed in stage 1. For example, targeted effects on RSV BEI were observed at MOI of 5 
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and 10. In analysis of total accumulation of TC, off-target effects were evident at MOI of 3, 5, and 10. At 
MOI of 10, off-target effects were maintained or increased based on immunoblots and TC BEI. These 
data suggest that an MOI of 5 is a better choice than an MOI of 3 or 10. 
In stage 1 analyses, some evidence of interactions between MOI and WT or TR- status were 
observed in auxiliary unirep-ANOVA models for TC BEI and RSV total accumulation. Such interactions 
are biologically plausible because loss of Mrp2 function (as in TR- rats) may alter the regulatory 
machinery of the cell due to accumulation of endogenous substances such as bilirubin and bile acid 
conjugates. This study is consistent with the premise that altered function of individual transport proteins 
does not occur in isolation.  Rather, as a result of overlapping substrate specificity and reliance on 
multiple mechanisms for vectorial transport from blood to bile, a complex network of cellular regulation 
is perturbed along with transport function, leading to compensatory changes. If so, it is advantageous to 
use an organ-specific in vitro model system, such as SCH, which recapitulates the relevant disposition, 
regulatory mechanisms and interplay expected in vivo. 
At MOI of 5, viral infection had minimal effects on RSV total accumulation. The non-targeted 
effect (siNT vs. non-infected) statistically significantly decreased the mean BEI of RSV, and the targeted 
effect (siBcrp vs siNT) further reduced mean BEI of RSV, consistent with the statistically significant 
mean decrease in Bcrp protein attributed to siBcrp. Mean BEI of RSV was decreased further by 
TR- status, suggesting an additive effect of targeted Bcrp knockdown and loss of Mrp2 function. Since 
Bcrp expression and function are decreased significantly in TR- rat SCH (33), reduced RSV BEI in Bcrp 
knockdown TR- rat SCH resulted from the combined effects of lack of Mrp2, an inherent decrease in Bcrp 
expression, and targeted knockdown of Bcrp. This is consistent with the known role of Bcrp and Mrp2 in 
the biliary excretion of RSV in vivo in rats (17).  
For TC, mean total accumulation and mean BEI values were decreased after viral infection 
relative to non-infected hepatocytes. TC is a bile acid that is not transported by Bcrp and Mrp2. This 
finding may be attributed to off-target effects of viral infection on uptake and efflux pathways involved in 
the hepatobiliary disposition of bile acids. If so, Ntcp function or Bsep function might also be altered by 
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viral infection. Although the immunoblot analysis failed to detect off-target effects for Ntcp and Bsep 
proteins, this system should be used with caution when testing the hepatobiliary disposition of Ntcp 
and/or Bsep substrates. Since RSV is transported by human NTCP, but not by rat Ntcp (34), RSV uptake 
was not influenced by potential off-target effects on Ntcp function in this system.  
Viral infection appeared to exert differential off-target effects on individual transport proteins. 
Mean levels of Mrp4 protein were decreased in siNT- and siBcrp-infected hepatocytes at MOI of 5 and 
10. Viral infection also decreased mean levels of Mrp2 protein in siNT-infected rat SCH, whereas off-
target effects of viral infection were not detected on other transport proteins. Notably, off-target effects on 
Mrp4 were observed in WT, but not in TR- SCH. Mrp4 is known to be induced by constitutive androstane 
receptor (CAR) (35), which is activated by bilirubin and bile acids (36, 37). Thus, it is plausible that 
accumulation of organic anions such as bilirubin and bile acids in TR- rat hepatocytes due to lack of Mrp2 
prevents viral infection-mediated down-regulation of Mrp4 through nuclear receptor regulation. However, 
further studies are needed to investigate the mechanism(s) of differential down-regulation of Mrp4 in WT 
and TR- rats. RSV undergoes biliary and basolateral efflux to a quantitatively similar extent; MRP4 
contributes to basolateral efflux of RSV (38). However, RSV total accumulation was not altered by 
decreased Mrp4 protein expression in siNT- and siBcrp-infected WT rat SCH, suggesting minimal 
changes in Mrp4 function or the presence of other basolateral efflux transport proteins that can 
compensate for impaired Mrp4 function.  
Recombinant adenovirus has been used widely as a gene delivery vector because of its high 
infection efficiency and high transgene capacity compared to other viral vector systems (i.e. lentivirus, 
retrovirus) (27). Thus, it provides a useful tool to deliver siRNA to primary cells, for which gene delivery 
is challenging. Recently, Hollingshead et al., reported a high-throughput gene silencing method in mouse 
SCH using transfection reagents (39). To increase transfection efficiency, a “reverse” transfection method 
was employed that initiated the transfection of suspended hepatocytes prior to plating. This approach 
resulted in a significant decrease in mRNA levels of Cyp3a11/13. Although this approach provides a 
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high-throughput method for functional studies, the expression and function of proteins-of-interest, as well 
as potential off-target effects, needs to be investigated further.   
There is increasing evidence that membrane transport proteins play an important role in the 
pharmacokinetics of many drugs. Effects of altered function of uptake transporters often are reflected in 
systemic drug exposure. However, it is more challenging to assess the consequences of altered function of 
efflux transporters because changes in cellular (e.g., hepatocyte) exposure, which may be important in 
predicting efficacy and toxicity, may not lead to changes in systemic exposure (40-42). The SCH model is 
an experimental tool that retains hepatic transport and metabolic capabilities, and provides information 
about hepatic exposure (intracellular concentration), systemic exposure (medium concentration), and 
biliary excretion (BEI, biliary clearance) in isolation from other organs. The current study assessed the 
utility of RNAi in SCH from hepatocytes lacking specific transport proteins (e.g., Mrp2-deficient TR- rat 
hepatocytes), as an in vitro tool to predict altered accumulation or disposition of drugs when multiple 
efflux transporters are impaired. This approach requires initial efforts for optimization, but once 
optimized, it has potential utility for rapid screening of a number of compounds. Concerns regarding 
possible off-target effects should be addressed further with validation of the system using additional 
compounds. Recently, Mrp2- and Bcrp-knockout rats have been shown to possess modest compensatory 
changes in expression of ADME-related genes, providing a useful in vivo system to explore the 
contribution of these transporters to drug disposition (43). However, results obtained from preclinical 
species may not necessarily translate to humans because of species differences in transport protein 
expression, regulation and function. To address this question, RNAi also can be applied to human SCH 
and future technologies in development (e.g., induced pluripotent stem cells, bioengineered 
culture systems such as HepatoPacTM and the Liver Chip) to assess species differences in transporter 
function and altered drug disposition. However, for knockdown of multiple transport proteins in human 
SCH, alternative approaches (e.g., tandem plasmid vector that can express two different siRNA in one 
vector) should be developed to minimize potential off-target effects.   
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Table 4.1. Total Accumulation and BEI (mean ± SEM) of probe substrates at MOI=5 vs. non 
infected control. 
Means were estimated via a univariate repeated-measures ANOVA model. Estimates of marginal means 
are least squares means (LSM) ± SEM. 
 
(A) [3H]Rosuvastatin: 
  Total Accumulation 
(pmol/mg protein) 
 
Biliary Excretion Index 
(BEI; %) 
  WT or TR- status   WT or TR- status  
Viral Treatment  Wild-Type TR- LSM  Wild-Type TR- LSM 
Non-infected  181 (25) 182 (29) 181 (13)  54.3 (8.2) 24.6 (11.0) 39.4 (4.1) 
Non-targeted 
(Ad-siNT) 
 
207 (48) 174 (47) 190 (14) 
 
45.4 (6.6) 17.9 (12.7) 31.7 (4.5)* 
Ad-siBcrp  184 (30) 171 (45) 177 (14)  30.8 (7.5) 5.9 (3.0) 18.4 (4.5)*† 
LSM  187 (18) 180 (18)   44.1 (5.8) 15.5 (5.8)#  
 
(B) [3H]Taurocholate: 
  Total Accumulation 
(pmol/mg protein) 
 Biliary Excretion Index 
(BEI; %) 
  WT or TR- status   WT or TR- status  
Viral Treatment  Wild-Type TR- LSM  Wild-Type TR- LSM 
Non-infected  27.1 (6.3) 41.7 (11.8) 34.4 (5)  83.1 (5.9) 72.6 (5.5) 77.8 (2.7) 
Non-targeted 
(Ad-siNT) 
 
21.2 (5.7) 38.0 (14.3) 29.6 (5)* 
 
78.6 (8.3) 64.5 (9.0) 71.5 (3.0)* 
Ad-siBcrp  18.0 (5.6) 31.0 (8.7) 24.5 (5)*†  80.1 (5.5) 60.6 (3.1) 70.3 (3.0)* 
LSM  22.1 (6) 36.9 (6)   79.5 (3.8) 66.9 (3.8)  
*: p<0.05 compared to non-infected 
†: p<0.05 compared to non-targeted 
#: p<0.05 compared to Wild-Type 
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Figure 4.1. Efficient knockdown of Bcrp in WT and TR- rat SCH. 
(A) Mean relative levels of Bcrp mRNA in SCH samples infected with Ad-siNT (solid bar) or Ad-siBcrp 
(open bar) at MOI of 3, 5, and 10. Each bar represents mean ± SEM of n=3 rat livers. Duplicate SCH 
samples from each liver were analyzed; mRNA levels were expressed as a percent of the mean for non-
infected hepatocytes and averaged together as a preliminary step for statistical analysis. The hypothesis 
testing procedure relied on a univariate repeated-measures ANOVA model for mean response as a 
function of MOI and virus. The model was fit separately to WT and TR- rat SCH data.  (B) Mean relative 
levels of Bcrp protein in SCH samples infected with Ad-siNT (solid bar) or Ad-siBcrp (open bar) at MOI 
of 3, 5 and 10. Representative blots from three independent studies are shown. -actin was used as the 
loading control for each blot. Each bar represents mean ± SEM of n=3 rat livers. Duplicate SCH samples 
from each liver were analyzed; protein levels were expressed as a percent of the mean for non-infected 
hepatocytes and averaged together as a preliminary step for statistical analysis. The hypothesis testing 
procedure relied on a univariate repeated-measures ANOVA model for mean response as a function of 
MOI and virus. The model was fit separately to WT and TR- rat SCH data. 
*, statistically significantly different from non-infected hepatocytes (P < 0.05). 
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Figure 4.2. Effects of Bcrp knockdown on mean relative levels of Oatp1a1, Ntcp, Bsep, P gp, Mrp4, 
and Mrp2 proteins in WT and TR- rat SCH infected with Ad siNT Ad siBcrp. 
(A) Representative blots from three independent studies are shown. -actin was used as the loading 
control for each blot. Mrp2 was evaluated only in WT SCH because it is not expressed in TR- rat SCH. 
(B) Each bar represents mean ± SEM of n=3 rat livers. Duplicate SCH samples from each liver were 
analyzed; protein levels after infection with Ad-siNT (solid bar) or Ad-siBcrp (open bar) at MOI of 5 and 
10 were expressed as a percent of the mean for non-infected hepatocytes and averaged together as a 
preliminary step for statistical analysis. The multiple hypothesis testing procedure relied on a univariate 
repeated-measures ANOVA model for mean response as a function of MOI and virus.  The model was fit 
separately to WT and TR- rat SCH data. 
*, statistically significantly different from non-infected hepatocytes (P < 0.05). 
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Figure 4.3. Effects of non-targeted and targeted adenoviral infection in WT and TR- SCH at 
increasing MOI. 
(A) Total accumulation and (B) biliary excretion index (BEI) of [3H]rosuvastatin; (C) total accumulation 
and (D) BEI of [3H]taurocholate. Mean values represent the responses of SCH preparations from n=3 WT 
(squares) and TR- (circles) rat livers, respectively, infected with non-targeted (Ad-siNT, closed symbols) 
or targeted (Ad-siBcrp, open symbols) adenoviral vectors. Triplicate SCH samples from each liver were 
measured and averaged together as a preliminary step for statistical analysis. Estimation of means and 
differences between means relied on a univariate repeated-measures ANOVA model for mean response as 
a function of MOI and virus.  The model was fit separately to WT and TR- rat SCH data.   
*, statistically significant off-target effect [siNT vs. non-infected (MOI of 0)].  
†, statistically significant targeted effect (siBcrp vs. siNT). 
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Supporting Information 
Supporting figures include 1) Mrp2 and Bcrp protein levels, 2) hepatobiliary disposition of 
[3H]estradiol-17β-D-glucuronide (E217G) and [3H]taurocholate (TC) in Mrp2 knockdown WT rat SCH, 
and 3) Mrp2 and Bcrp protein levels in Mrp2/Bcrp double knockdown WT rat SCH.  
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Supplement Figure 4.1. Knockdown of Mrp2 in WT rat SCH by adenoviral vector-mediated RNAi.  
Mean relative levels of Mrp2 and Bcrp protein in WT rat SCH infected with Ad-siNT (solid bar) or 
Ad-siMrp2 (open bar) at MOI of 5, 10, and 15. (A) Representative blots from n=2-4 independent studies 
are shown. β-actin was used as the loading control for each blot. (B) Each bar represents mean ± SEM of 
n=4 (MOI 5) or n=4 (MOI 10) or n=3 (MOI 15) rat livers. Triplicate SCH samples from each liver were 
analyzed; protein levels were expressed as a percent of the mean for non-infected hepatocytes and 
averaged.   
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Supplement Figure 4.2. Effect of non-targeted (Ad-siNT, closed symbols) and targeted (Ad-siMrp2, 
open symbols) adenoviral infection in WT rat SCH at increasing multiplicity-of-infection (MOI).  
(A) Total accumulation and (B) biliary excretion index (BEI) of [3H]estradiol-17β-D-glucuronide 
(E217G); (C) Total accumulation and (D) biliary excretion index (BEI) of [3H]taurocholate. Mean values 
represent the responses of SCH preparations from n=2 rat livers. Triplicate SCH samples from each liver 
were measured and averaged. 
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Supplement Figure 4.3. Double-knockdown of Mrp2 and Bcrp by adenoviral vector-mediated 
RNAi. Mean relative levels of Mrp2 and Bcrp proteins in WT rat SCH infected with Ad-siNT (solid bar, 
MOI of 10) or Ad-siMrp2 + Ad-siBcrp (open bar, MOI of 5 each). (A) Representative Mrp2 and Bcrp 
blots from three independent studies are shown. β-actin was used as the loading control for each blot. (B) 
Each bar represents mean ± SEM of n=3 rat livers. Duplicate (MOI 5) or triplicate (MOI 10) SCH 
samples from each liver were analyzed; protein levels were expressed as a percent of the mean for non-
infected hepatocytes and averaged. 
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CHAPTER 5.  Hepatocellular Exposure of Generated Metabolites, Troglitazone Sulfate and 
Glucuronide, is Determined by the Interplay between Formation and Excretion in Rat Sandwich-
Cultured Hepatocytes Lacking Selected Canalicular Transporters1  
 
INTRODUCTION 
Drug-induced liver injury (DILI) is one of the primary reasons for withdrawal of approved drugs 
from the market (1); however, the ability to accurately predict a drug’s propensity for DILI is limited due 
to a lack of understanding of the underlying mechanism(s). One important proposed mechanism of DILI 
is inhibition of bile salt export pump (BSEP)-mediated excretion of bile acids, which may increase 
hepatic exposure to bile acids, ultimately leading to necrotic and/or apoptotic cell death (2-5). Many drugs 
that cause either cholestatic or mixed hepatocellular/cholestatic liver injury [e.g., troglitazone (TGZ), 
bosentan, cyclosporine, rifampin, sulindac, and glibenclamide) inhibit BSEP/Bsep-mediated biliary 
excretion of bile acids (6-11). However, only a small fraction of patients treated with BSEP inhibitors 
develop DILI, suggesting that injury is driven by a combination of drug- and patient-specific risk factors. 
For drugs with a rare incidence of DILI, hepatic exposure to the causative drugs/metabolites may be high 
in the subset of patients who develop DILI. It is also possible that toxic reactions triggered by drug 
exposure may develop into severe liver injury in a subset of susceptible patients. Potential patient-specific 
risk factors that may influence drug disposition and/or toxicity include age, gender, activation of the 
innate immune system, co-medications, underlying disease, and/or genetic predisposition.  
TGZ was the first marketed thiazolidinedione, approved for the treatment of type II non-insulin-
dependent diabetes. However, 2% of TGZ-treated patients developed serum ALT elevations more than 3-
                                                     
1This work has been presented, in part, at the 2011 AAPS Annual Meeting and Exposition, Washington, DC, 
October 23-27, 2011, and has been submitted to Drug Metabolism and Disposition. 
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fold greater than the upper limit of normal (12, 13).  Subsequent to reports of lethal DILI in humans, TGZ 
was withdrawn from worldwide markets. Several mechanisms have been proposed to explain TGZ-
mediated DILI including formation of reactive metabolites, mitochondrial toxicity, apoptosis, and 
inhibition of bile acid transport (14, 15). Clinical observations and in vivo studies in rats have implicated 
that a cholestatic mechanism is involved in TGZ-induced hepatotoxicity (9, 16-18). In vitro vesicular 
transport assays demonstrated that TGZ and its major metabolite, TGZ sulfate (TS), are potent inhibitors 
of bile acid efflux transporters, supporting the involvement of cholestasis in TGZ-induced hepatotoxicity; 
TGZ inhibits human BSEP- and rat Bsep-mediated bile acid transport with IC50 values of 2.7–5.9 and 
3.9–10.6 µM, respectively (2, 3, 9). TS is a 10-fold more potent inhibitor of ATP-dependent transport of 
taurocholate in rat liver canalicular membrane vesicles compared to TGZ (9). Data from our laboratory 
demonstrated that TS also inhibits hepatic basolateral efflux transport proteins, multidrug resistance 
protein 4 (MRP4) (19).   
In rats and humans, TGZ is metabolized extensively in the liver, primarily by sulfation, with 
glucuronidation and oxidation as successively less prominent metabolic pathways; TS exhibited 10-fold 
higher plasma concentrations than TGZ, and was excreted primarily into bile, suggesting that TGZ 
metabolism and excretion were similar in humans and male rats (20-22). Previously published data 
suggested that TS is excreted into bile predominantly via breast cancer resistance protein (Bcrp) and 
multidrug resistance protein 2 (Mrp2) (23, 24).  Extensive hepatic accumulation of TS (20, 25), coupled 
with the finding that TS potently inhibits bile acid transporters (e.g., BSEP, MRP4), led to the hypothesis 
that TS is primarily responsible for altered bile acid disposition and subsequent hepatotoxicity; impaired 
function of Bcrp and Mrp2 (e.g., due to underlying disease, genetic variations, and drug-drug interactions) 
would increase hepatocellular TS accumulation and enhance inhibition of bile acid transport (Figure 5.1). 
To test this hypothesis, the hepatobiliary disposition of TGZ and generated metabolites, TS and TG, was 
examined in rat sandwich-cultured hepatocytes (SCH) using a novel experimental system developed in 
our laboratory (26) to quantitatively assess the effects of impaired function of Bcrp (using RNA 
interference technique) and/or Mrp2 (using Mrp2-deficient TR- rats). Differential metabolism of TGZ 
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also was investigated using S9 fractions prepared from liver tissues of WT and TR- rats. This work 
highlights the importance of considering both metabolic and transport pathways when predicting 
hepatocellular exposure to generated metabolites. 
 
METHODS 
Materials 
TGZ was purchased from Cayman Chemical Company (Ann Arbor, MI). TS, TGZ glucuronide 
(TG), and TGZ quinone (TQ) were kindly provided by Daiichi-Sankyo Co., Ltd. (Tokyo, Japan). TS also 
was synthesized from TGZ in-house (27). [3H]Taurocholate (5 Ci/mmol; purity > 97%) was purchased 
from Perkin Elmer (Waltham, MA). Taurocholate, Triton X-100, Hanks’ balanced salt solution (HBSS) 
premix, HBSS modified (with no calcium chloride, magnesium sulfate, phenol red, and sodium 
bicarbonate) premix, dexamethasone, penicillin-streptomycin solution, and collagenase (type IV) were 
purchased from Sigma-Aldrich (St. Louis, MO). Dimethyl sulfoxide (DMSO) was obtained from Fisher 
Scientific (Fairlawn, NJ). GIBCO brand fetal bovine serum, recombinant human insulin, and Dulbecco’s 
modified Eagle’s medium (DMEM), and membrane vesicles prepared from rat Bsep-overexpressing Sf9 
cells (Sf9-Bsep) and control Sf9 cells (Sf9-control) were purchased from Life Technologies (Carlsbad, 
CA). Insulin/transferrin/selenium (ITS) culture supplement, BioCoatTM culture plates, and MatrigelTM 
extracellular matrix were purchased from BD Biosciences Discovery Labware (Bedford, MA). GF120918 
(elacridar) was a generous gift from GlaxoSmithKline (Research Triangle Park, NC). All other chemicals 
and reagents were of analytical grade and were readily available from commercial sources. 
Hepatocyte Isolation and Culture in a Sandwich Configuration  
Hepatocytes were isolated from male Wistar rats (270–300 g, Charles River Laboratories, Inc., 
Wilmington, MA) and TR- rats (220 – 300 g, bred in-house; breeding stock obtained from Dr. Mary Vore, 
University of Kentucky, Lexington, KY) using a two-step collagenase perfusion method previously 
described (LeCluyse et al., 1996). Animals had free access to water and food before surgery and were 
allowed to acclimate for at least five days. All animal procedures complied with the guidelines of the 
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Institutional Animal Care and Use Committee (University of North Carolina, Chapel Hill, NC). 
Hepatocytes were seeded onto 24-well BioCoatTM culture plates at a density of 0.35×106 cells/well in 
seeding medium (DMEM containing 5% fetal bovine serum, 10 µM insulin, 1 µM dexamethasone, 2 mM 
L-glutamine, 1% MEM nonessential amino acids, 100 units of penicillin G sodium, and 100 µg of 
streptomycin) as described previously (28). Hepatocytes were incubated for 1 h at 37ºC in a humidified 
incubator (95% O2, 5% CO2) and allowed to attach to the collagen substratum, after which time the 
medium was aspirated to remove unattached cells, and replaced with fresh medium. On the next day, cells 
were overlaid with BD MatrigelTM at a concentration of 0.25 mg/ml in ice-cold feeding medium (DMEM 
supplemented with 0.1 µM dexamethasone, 2 mM L-glutamine, 1% MEM nonessential amino acids, 100 
units of penicillin G sodium, 100 µg of streptomycin, and 1% ITS). The culture medium was changed 
daily until experiments were performed on day 4. 
Knockdown of Bcrp Protein in WT and TR- Rat SCH  
Adenoviral vectors expressing short hairpin RNA targeting Bcrp (Ad-siBcrp) or a non-target 
control (Ad-siNT) were prepared as described previously (29). One hour after seeding on day 0, 
hepatocytes were infected with Ad-siBcrp or Ad-siNT at multiplicity of infection (MOI) of 5 by replacing 
the seeding medium with fresh seeding medium containing virus. On the next day, medium including 
viruses were removed, and cells were overlaid with MatrigelTM as described above. 
Accumulation of TGZ and Generated Metabolites in WT and TR- Rat SCH in the Absence or 
Presence of Bcrp Knockdown  
Following 30 min exposure to 0.5 ml feeding medium containing 10 µM TGZ, 0.2 ml aliquots of 
medium were collected from day 4 WT and TR- rat SCH in the absence or presence of Bcrp knockdown.  
The remaining culture medium was completely aspired, and SCH were rinsed with 0.5 ml/well of warm 
standard (Ca2+-containing) or Ca2+-free HBSS buffers. After rinses, HBSS buffers were aspired, and SCH 
were incubated with 0.5 ml of HBSS buffers (standard or Ca2+-free) at 37°C for 5 min. After incubation, 
the HBSS buffers were aspired from all wells. Plates were sealed and stored at -80°C until analysis. 
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Membrane Vesicle Assay   
Membrane vesicles (Sf9-control and Sf9-Bsep, 10 and 25 µg/reaction for taurocholate and TS 
uptake, respectively) were incubated at 37°C with the substrate (5 µM taurocholate or 100 µM TS) in tris-
sucrose buffer (TSB) containing MgCl2 (10 mM), creatine phosphate (10 mM), creatine kinase (100 
µg/ml), adenosine triphosphate (ATP) or adenosine monophosphate (AMP) (4 mM) in a final volume of 
50 µl. The assays were performed on three separate experiments in triplicate. After incubation for 5 min, 
the reaction was stopped by addition of 800 µl ice-cold TSB and immediately filtered using Type A/E 
glass fiber filter (PALL Corportion, Ann Arbor, MI) presoaked in TSB overnight. Under aspiration, the 
filters were washed twice with ice-cold TSB using a vacuum filtration system. Glass filters were 
transferred to glass vials, and 1 ml Bio-Safe IITM (Research Products International, Mount Prospect, IL) 
was added before counting radioactivity of taurocholate using the Tri-Carb 3100 TR liquid scintillation 
analyzer (PerkinElmer, Waltham, MA). For liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS)  analysis of TS, glass filters were dissolved with 1 ml methanol including 1 
nM ethyl warfarin (internal standard). Following vortex mixing and sonication, the supernatant was 
transferred to microcentrifuge tubes and centrifuged for 20 min at 4°C. After centrifugation, 500 µl of 
supernatant was transferred to 96-well LC-MS/MS plate, evaporated using SPE Dry 96 (Biotage, 
Uppsala, Sweden), and reconstituted with 100 µl 1:1 mixture of methanol and DMSO. The ATP-
dependent uptake of substrate was calculated by subtracting substrate uptake in the presence of AMP 
from substrate uptake in the presence of ATP. 
Effects of GF120918 on the Biliary Excretion of TS in WT and TR- Rat SCH   
WT and TR- rat SCH were pre-incubated with 0.5 µM GF120918 or vehicle control for 10 min 
followed by 30-min exposure to 0.5 ml feeding medium containing 10 µM TGZ and 0.5 µM GF120918 
(or vehicle control). After incubation, the culture medium was completely aspired, and SCH were rinsed 
with 0.5 ml/well of warm standard or Ca2+-free HBSS buffers. After the second rinse, HBSS buffers were 
aspired, and SCH were incubated with 0.5 ml of HBSS buffers (standard or Ca2+-free) at 37°C for 5 min. 
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After incubation, the HBSS buffer was aspired from all wells. Plates were sealed and stored at -80°C until 
analysis. 
In Vitro Metabolism of TGZ in S9 Fraction  
S9 fractions were prepared from liver tissues of WT and TR- rats (n=3, respectively) according to 
standard procedures and stored at -80°C until used (30). Protein concentration was determined by the 
BCA protein assay (Pierce Chemical., Rockford, IL) using human serum albumin (standard solution; 
Sigma) as a standard. Reaction mixture [95 µl of Tris-HCl buffer (pH 7.5, 0.1 M) containing 3’-
phosphoadenosine-5’-phosphosulfate (PAPS; final concentration 0.1 mM), uridine 5’-
diphosphoglucuronic acid (UDPGA; final concentration 2 mM), nicotinamide adenine dinucleotide 
phosphate (reduced, NADPH; final concentration 1 mM), alamethicin (final concentration 25 µl/ml), and 
TGZ (final concentrations of 1 or 10 µM)] was pre-incubated for 5 min at 37°C. TGZ was dissolved in 
DMSO; the final concentration of DMSO in the reaction mixture was 0.2%.  TGZ concentrations of 1 and 
10 µM were selected for investigation because they yielded unbound concentrations of TGZ in the S9 
fraction that were similar to the unbound concentrations in hepatocytes. Intracellular total concentrations 
of TGZ ranged from 100 – 250 µM after a 30-min incubation of WT and TR- rat SCH with 10 µM TGZ 
(25). Assuming that the intracellular unbound fraction (fu) is equal to the plasma fu of 0.000921 (31), 
intracellular concentrations of unbound TGZ would be in the range of 0.9–0.23 µM. TGZ also is highly 
bound to microsomal and cytosolic protein (TGZ fu was 0.01 and 0.03 in 2 mg/ml rat liver microsomes 
and 0.5 mg/ml rat liver cytosol, respectively) (32); therefore, 1 and 10 µM total TGZ in S9 fraction would 
result in TGZ unbound concentrations of ~ 0.1–1 µM, which covered the range of intracellular unbound 
TGZ concentrations in rat SCH. The reaction was started by adding 5 µl of the S9 fraction (final 
concentration 1 mg/ml). The reaction was stopped after 3 min by mixing with 200 µl ice-cold acetonitrile 
containing 15 nM ethyl warfarin (analytical internal standard). The 3-min time point was chosen based on 
the reported linear range to calculate the initial velocity of TS and TG formation (32). The reaction 
mixture was centrifuged for 20 min at 4°C, and the supernatant was transferred to 96-well LC-MS/MS 
plates for analysis. To determine desulfation of TS, 5 µl of TS (final concentration of 100 µM) was 
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incubated with 95 µl of 0.1M Tris-HCl buffer (pH 7.5) containing S9 fraction (final concentration 1 
mg/ml) for 30 min, and the same procedure was followed as detailed above. 
LC-MS/MS Analysis  
TGZ and generated metabolites were analyzed by LC-MS/MS as described previously (25). 
Briefly, the medium and cells or cells+ bile lysate samples were centrifuged at 12,000g for 10 min at 4°C, 
and the supernatant was diluted 1:6 (v/v) with 79%:21% (v/v) methanol/water containing the internal 
standard (ethyl warfarin). An Applied Biosystems API 4000 triple quadruple mass spectrometer with a 
TurboSpray ion source (Applied Biosystems, Foster City, CA) was used for analysis in negative 
ionization mode. The ranges of the standard curves were extended by adding additional points to the 
previously reported range (25); eleven point (5 – 10000 nM; TGZ) or ten point (5–5000 nM; TS, TG, and 
TQ) calibration curves were constructed as composites of TGZ (440.0→397.1), TS (520.2→440.1), TG 
(616.2→440.1), and TQ (456.1→413.1) by using peak area ratios of analyte and ethyl warfarin 
(320.8→160.9). All points on the curves back-calculated to within 15% of the nominal value. Care was 
taken to minimize the light-sensitive degradation of TGZ during all experimental procedures. 
Data Analysis and Statistics 
TGZ accumulation was corrected for nonspecific binding to the BioCoatTM plate without cells, 
and normalized to protein concentration measured by the BCA protein assay (Pierce Chemical., Rockford, 
IL). To account for the incompatibility of the protein assay with methanol, the average protein 
concentration for standard HBSS or Ca2+-free HBSS incubations in a representative plate from the same 
liver preparation was used to normalize accumulation. The biliary excretion index (BEI; %), defined as 
the percentage of accumulated substrate residing within the bile canaliculi, was calculated using B-
CLEAR® technology (Qualyst, Inc. Durham, NC) according to the following equation (Liu et al., 1999b): 
BEI (%) =  
AccumulationStandard HBSS − AccumulationCa2+−free HBSS
AccumulationStandard HBSS
 × 100 
Effects of viral infection (non-infected vs. Ad-siNT vs. Ad-siBcrp) and rat type (WT vs. TR-) on 
hepatobiliary disposition (accumulation in cells+bile, cellular accumulation, and BEI) and recovery of 
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TGZ and its metabolites were evaluated using a two-way ANOVA followed by Tukey’s post-hoc test. 
Two-way ANOVA also was used to evaluate the effects of GF120918 and rat type (WT vs. TR-) on 
hepatobiliary disposition of TS and TG. Student’s t-test was used to compare ATP-dependent substrate 
transport in Sf9-Bsep vs. Sf9-control, and the initial velocity of TS/TG formation in S9 fractions prepared 
from livers of WT and TR- rats. In all cases, p < 0.05 was considered statistically significant. All analyses 
were performed using SigmaStat 3.5 (San Jose, CA). 
 
RESULTS 
Hepatobiliary Disposition of TGZ and Generated Metabolites in WT and TR- Rat SCH in the 
Absence or Presence of Bcrp    
Loss-of-function of Mrp2 and Bcrp was validated in this experiment using rosuvastatin, a dual 
substrate of Mrp2 and Bcrp; rosuvastatin BEI was significantly decreased by impaired function of Mrp2 
or Bcrp, and biliary excretion was almost ablated in Bcrp knockdown TR- rat SCH (26). Accumulation of 
TGZ and generated metabolites in cells + bile, cells, and medium after a 30-min incubation of WT and 
TR- rat SCH with 10 µM TGZ is shown in Figures 5.2 and 5.3. BEI values of TS and TG in non-infected 
WT hepatocytes were 24 and 49 %, respectively (Figures 5.2B and 5.2C); biliary excretion of TGZ 
(Figure 5.2A) and TQ (data not shown) was negligible, consistent with previously published data (Lee et 
al., 2010a). The hepatobiliary disposition of TGZ and generated metabolites was not affected by infection 
of the non-target control adenoviral vector (Ad-siNT), confirming that off-target effects of viral infection 
were negligible in these studies. Unexpectedly, the BEI of TS was not altered by impaired Mrp2 (TR-) 
and/or Bcrp function (Ad-siBcrp), suggesting that other biliary transporters may compensate for the 
impaired function of Mrp2 and Bcrp (Figure 5.2B). Interestingly, TS accumulation in cells+bile, cells, 
and medium was decreased in TR- rat SCH compared to WT rat SCH (Figures 5.2B and 5.3B). Bcrp 
knockdown did not significantly alter TS accumulation in cells+bile, cells, or medium (Figures 5.2B and 
5.3B). The BEI of TG was significantly decreased in TR- rat SCH compared to WT rat SCH, but was not 
influenced by knockdown of Bcrp (Figure 5.2C). TG cellular accumulation was significantly increased in 
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TR- rat SCH compared to WT rat SCH, whereas TG accumulation in cells+bile was not altered (Figure 
5.2C). In TR- rat SCH, TG medium concentrations were significantly higher compared to WT rat SCH 
(Figure 5.3C). TG accumulation in cells+bile, cells, and medium was not significantly altered by Bcrp 
knockdown (Figures 5.2C and 5.3C). TQ accumulation in cells and cells+bile was significantly increased 
in TR- rat SCH in the absence and presence of Bcrp knockdown compared to WT rat SCH, but medium 
concentrations were not significantly different (data not shown). 
Differential Metabolism of TGZ in WT and TR- Rat SCH 
Cumulative recovery of TGZ and generated metabolites from medium, hepatocytes, and bile was 
comparable among all groups (92.3 – 99.6 %) (Figure 5.4A). After a 30-min incubation, more than 80% 
of the TGZ dose remained as parent compound in both WT and TR- SCH. Among three generated 
metabolites, TS was predominant (4.8 % of the dose recovered in cells, bile, and medium), followed by 
TQ (1.5 % of the dose) and TG (0.9 % of the dose) in non-infected WT rat SCH (Figure 5.4A). In TR- rat 
SCH, total recovery (medium, hepatocytes, and bile) of TS was significantly lower compared to WT rat 
SCH (Figure 5.4A). Total recovery of TG was significantly greater in TR- compared to WT rat SCH 
(Figure 5.4A). TS primarily was recovered from hepatocytes, while TG was recovered primarily from the 
medium (Figures 5.4B and 5.4C).  
Transport of TS in Membrane Vesicles from Bsep-overexpressing Sf9 Cells  
To investigate the transport protein(s) involved in the compensatory biliary excretion of TS in the 
absence of Mrp2 and Bcrp, ATP-dependent uptake of 10 µM taurocholate (positive control) and 100 µM 
TS was determined in Sf9-control and Sf9-Bsep vesicles. ATP-dependent taurocholate transport was 60-
fold greater in Sf9-Bsep vesicles compared to Sf9-control vesicles (Figure 5.5). However, ATP-dependent 
TS transport was comparable between Sf9-control and Sf9-Bsep vesicles, indicating that TS is not 
transported by Bsep. 
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Effects of GF120918 on the Hepatobiliary Disposition of TGZ and Generated Metabolites in WT 
and TR- Rat SCH   
The BEI of TS was not significantly altered by GF120918, a potent inhibitor of Bcrp and P-gp, 
nor by rat type (WT vs. TR-) (Figure 5.6A). The accumulation of TS in cells+bile and cells was 
significantly decreased in TR- rat SCH compared to WT rat SCH as shown in Figure 5.2B, but was not 
altered by the presence of GF120918. The BEI of TG was significantly decreased in TR- rat SCH 
compared to WT rat SCH, consistent with Figure 5.2C, but was not altered by the presence of GF120918 
(Figure 5.6B). TG accumulation in cells+bile and cells was not influenced significantly by GF120918 or 
by rat type, but there was a trend towards an increase in cellular TG accumulation in TR- compared to WT 
rat SCH (Figure 5.6B). 
TGZ Metabolism in S9 Fraction Prepared From Liver Tissues of WT and TR- Rats   
To investigate the differential metabolism (i.e. sulfation and glucuronidation) of TGZ in WT and 
TR- rats, formation of TS and TG was quantified after incubating 1 or 10 µM TGZ with S9 fraction 
prepared from liver tissues of WT and TR- rats for 3 min. These concentrations were selected for 
investigation because they yielded unbound concentrations of TGZ in the S9 fraction that were similar to 
the unbound concentrations in hepatocytes (see Methods for details). The initial velocity of TS formation 
in S9 fraction from WT and TR- rats was comparable after incubation with 1 and 10 µM TGZ, indicating 
that the activity of sulfotransferases was not altered in TR- rats (Figure 5.7). The initial velocity of TG 
formation was increased by 1.5- and 6.5-fold in TR- rats after incubation with 1 and 10 µM TGZ, 
respectively, consistent with the increased recovery of TG in TR- SCH (Figure 5.7). TS did not undergo 
de-sulfation after incubation of 100 µM TS with S9 fractions over a 30-min period (data not shown). 
 
DISCUSSION 
TGZ is metabolized by Phase I and II enzymes and the generated metabolites are eliminated by 
multiple transport proteins. Consequently, defects in relevant metabolic enzymes and/or transport proteins 
due to genetic polymorphisms, underlying disease, or co-administered drugs may predispose certain 
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patients to TGZ-induced hepatotoxicity. Hewitt et al. demonstrated that low CYP3A4 and UGT activity 
combined with high SULT activity was associated with TGZ toxicity in human hepatocytes (33). 
Pharmacokinetic modeling and Monte Carlo simulations in rat SCH revealed that intracellular 
concentrations of TS may increase up to 5.7-fold when biliary excretion of TS is decreased 10-fold (25), 
but effects of altered function of biliary transporters on TS disposition have not been evaluated 
experimentally. TS, a potent inhibitor of bile acid efflux transporters, is extensively excreted into bile via 
Mrp2 and Bcrp (23, 24). Thus, we hypothesized that loss-of-function of Bcrp and/or Mrp2 would result in 
decreased biliary excretion and increased cellular accumulation of TS, which may lead to further 
inhibition of bile acid transport and hepatotoxicity. This study examined the effects of impaired function 
of Bcrp and/or Mrp2 on the hepatobiliary disposition of TGZ and generated metabolites, TS and TG; 
although TQ was measured, this investigation did not focus on TQ because it is a minor metabolite that 
also is formed by phototoxidation (34). A recently established novel in vitro system, rat SCH lacking 
Mrp2 (using Mrp2-deficient TR- rat) and Bcrp (using adenoviral vectors expressing shRNA targeting 
Bcrp), was employed (26). 
Unexpectedly, biliary excretion of TS was not altered by loss-of-function of Bcrp and Mrp2, 
potentially due to the presence of a compensatory canalicular protein that transports TS in the absence of 
Mrp2 and Bcrp. It is unlikely that residual Bcrp expression played a role in TS transport because loss-of-
function of Mrp2 and Bcrp in this experimental system was validated using rosuvastatin, a dual substrate 
of Mrp2 and Bcrp.  Biliary excretion of rosuvastatin was almost ablated in Bcrp knockdown TR- rat SCH. 
Thus, Bsep and P-gp were investigated as potential compensatory transporters mediating the biliary 
excretion of TS. Results from membrane vesicle studies demonstrated that TS is not transported by Bsep. 
P-gp is not likely to be involved in TS biliary excretion because excretion of TS into bile was not altered 
in the presence of GF120918, a potent inhibitor of P-gp and Bcrp (35, 36), in WT and TR- rat SCH. Other 
hepatic canalicular transporters such as multidrug and toxin extrusion protein 1 (MATE1) or multidrug 
resistance protein 2 (Mdr2) might be involved in compensatory TS biliary excretion. MATE1 transports a 
wide range of chemicals including hydrophilic organic cations with low molecular weight (e.g., 
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metformin, tetraethylammonium, 1-methyl-4-phenylpyridinium, oxaliplatin), anionic compounds (e.g., 
acyclovir, ganclyclovir, estrone sulfate), and zwitterions (e.g., cephalexin, cephradine) (37, 38), so it is 
plausible that MATE1 contributes to TS biliary excretion. Mdr2 is the rodent ortholog of human MDR3, a 
phosphatidylcholine flippase, which also transports paclitaxel, digoxin, and verapamil (39). As expected, 
the biliary excretion of TG was significantly decreased in TR- rat SCH compared to WT rat SCH, but was 
not altered by Bcrp knockdown, consistent with previous data that Mrp2 plays a major role in the biliary 
excretion of TG (24).  
Even though the BEI of TS remained the same, the total recovery of TS was decreased in TR- 
compared to WT rat SCH based on decreased TS cellular accumulation and medium concentrations. 
These data suggest that TGZ sulfation was decreased, or de-sulfation of TS was increased in TR- rat SCH. 
TGZ is metabolized to TS primarily by SULT1A1 and also by SULT1E1 in humans (40). In rats, TS 
formation is four times faster in male rats compared to female rats, which is consistent with greater 
expression of Sult1a1 and Sult1e1 in male rats (41, 42). Interestingly, protein levels of hepatic Sult1a1 
and Sult1e1 were comparable between WT and TR- rats (43, 44), and our in vitro metabolism study using 
S9 fractions from livers of WT and TR- rats revealed that TS formation rates were comparable. A 
decrease in net sulfation of estradiol-17β-glucuronide (E217G) reported in TR- rats was attributed to 
increased desulfation of estradiol-3-sulfate-17β-glucuronide (44). However, desulfation of TS to TGZ 
was not observed in S9 fraction from livers of WT or TR- rats. It is possible that the availability of 3'-
phosphoadenosine-5'-phosphosulfate (PAPS) is less in TR- compared to WT rat SCH. In rats and humans, 
sulfation can be limited by the availability of the cofactor PAPS. PAPS is synthesized rapidly by ATP-
sulfurylase and APS-kinase, but its availability is limited by hepatic sulfate concentrations, which are 
largely dependent on circulating levels of inorganic sulfate (45). TR- rat SCH may have lower levels of 
PAPS precursors or lower activity of enzymes involved in PAPS synthesis. These differences would not 
be detected in the current experimental design where adequate PAPS was added exogenously to the in 
vitro metabolism system. TR- rat SCH also may have higher cellular concentrations of endogenous 
substrates (e.g., bile acids) that deplete PAPS, leading to decreased recovery of TS. Compared to WT rats, 
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hepatic sulfation activities in TR- rats have been reported to be modestly increased (i.e., acetaminophen, 
4-methylumbelliferone), similar (i.e., harmol, E217G), or decreased (i.e., resveratrol) in isolated perfused 
liver (IPL) studies (44, 46-50). However, except for the harmol and E217G studies, recovery was 
measured only in perfusate and bile, and mass balance did not account for recovery in the liver tissue. 
Further studies are warranted to investigate the mechanisms of altered sulfation in TR- rats and the 
underlying reason for decreased recovery of TS in TR- rat SCH.   
The increase in total recovery of TG in cells, bile, and medium of TR- rat SCH compared to WT 
rat SCH can be explained by increased activity of UGT enzymes, as shown in the in vitro S9 metabolism 
study. Species differences exist between humans and rats in UGT isozymes responsible for TGZ 
glucuronidation. TG formation is mediated primarily by UGT1A1 in humans whereas Ugt2b2 is the 
major isozyme responsible for TGZ glucuronidation in rats (51, 52). Expression of hepatic Ugt1a protein 
was increased in TR- rats (43). Although expression of hepatic Ugt2b2 in TR- rats has not been 
characterized, the present in vitro S9 metabolism data suggest that expression and/or activity of Ugt2b2 is 
increased in TR- rats. Overall, decreased biliary excretion combined with increased glucuronidation led to 
significantly increased cellular accumulation of TG in TR- compared with WT rat SCH. Medium 
concentrations of TG also were increased in TR- rat SCH, consistent with increased glucuronidation and 
increased expression of the basolateral efflux transporter Mrp3 (43, 44). 
The present study demonstrated that biliary excretion of TS was not altered by loss-of-function of 
Mrp2 and/or Bcrp, apparently due to a compensatory biliary transporter(s). These data suggest that loss-
of-function of Mrp2 and Bcrp is not a risk factor for increased hepatocellular TS accumulation in rats. 
Interestingly, hepatocellular accumulation of TS was decreased in TR- compared to WT rat SCH due to 
decreased TGZ sulfation. TR- rats have been employed widely to investigate the contribution of Mrp2 to 
drug disposition, but loss-of-function of Mrp2 in TR- rats leads to altered expression of several enzymes 
and transporters (e.g., decreased Bcrp, increased Mrp3, differential expression of CYP isoforms) (43, 53, 
54). Results from the present study demonstrated for the first time that in TR- rat SCH, TGZ sulfation was 
decreased, but these changes were not due to altered sulfotransferase activity. TGZ glucuronidation was 
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significantly increased, and TG biliary excretion was negligible, leading to increased cellular and medium 
TG concentrations in SCH from TR- compared to WT rats. Evaluation of hepatocellular exposure of a 
drug may be important in predicting efficacy and/or toxicity if the liver is the site of action, or the parent 
drug and/or generated metabolites elicit hepatotoxic effects. These data suggest that altered hepatocellular 
exposure of hepatically-generated metabolites is determined by both formation and excretion, and that 
compensatory mechanisms may play important roles when elimination pathways are impaired. 
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Figure 5.1. Proposed mechanism of troglitazone (TGZ)-mediated hepatotoxicity. 
Impaired BCRP and/or MRP2 function (1) causes accumulation of TGZ sulfate (TS; the major TGZ 
metabolite and a potent inhibitor of bile acid transport proteins) in hepatocytes (2), which inhibits bile 
acid excretion leading to bile acid accumulation (3) and hepatotoxicity (4). 
  
 168 
 
Figure 5.2. Intracellular accumulation of troglitazone (TGZ) and generated metabolites [TGZ 
sulfate (TS) and TGZ glucuronide (TG)] in WT and TR- rat SCH in the absence or presence of 
Bcrp Knockdown. 
WT and TR- rat SCH were treated with 10 μM TGZ for 30 min in the absence [CTL (non-infected cells) 
and Ad-siNT (non-target control)] or presence (Ad-siBcrp) of Bcrp knockdown. Hepatobiliary disposition 
of (A) TGZ, (B) TS, and (C) TG were measured in cells+bile (solid bars) and in cells (open bars). Effects 
of Bcrp knockdown (CTL vs. Ad-siNT vs. Ad-siBcrp) and rat type (WT vs. TR-) on accumulation and 
biliary excretion index (BEI; diamonds) of TGZ and generated metabolites were evaluated using two-way 
ANOVA. Data represent mean±S.E.M.; †, P < 0.05, significantly different from WT (cells+bile); ‡, P < 
0.05, significantly different from WT (cell); *, P < 0.05, significantly different from WT (BEI). 
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Figure 5.3. Accumulation of troglitazone (TGZ) and generated metabolites [TGZ sulfate (TS) and 
TGZ glucuronide (TG)] in the medium of WT and TR- rat SCH in the absence or presence of Bcrp 
Knockdown. 
WT and TR- rat SCH were treated with 10 μM TGZ for 30 min in the absence [CTL (non-infected cells) 
and Ad-siNT (non-target control)] or presence (Ad-siBcrp) of Bcrp knockdown. Concentrations of (A) 
TGZ, (B) TS, and (C) TG were measured in medium. Effects of Bcrp knockdown (CTL vs. Ad-siNT vs. 
Ad-siBcrp) and Mrp2 deficiency (WT vs. TR-) on media concentrations of TGZ and generated 
metabolites were evaluated using two-way ANOVA. Data represent mean±S.E.M.; *, P < 0.05, 
significantly different from WT. 
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Figure 5.4. Recovery of troglitazone (TGZ) and generated metabolites [TGZ sulfate (TS), TGZ 
glucuronide (TG), and TGZ quinone (TQ)] in WT and TR- rat SCH in the absence or presence of 
Bcrp Knockdown. 
WT and TR- rat SCH were treated with 10 μM TGZ for 30 min in the absence (CTL and Ad-siNT) or 
presence (Ad-siBcrp) of Bcrp knockdown. Total recovery of TGZ and generated metabolites in cells, bile, 
and medium are presented as % of the TGZ dose. *, P < 0.05, significantly different from WT. 
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Figure 5.5. Bsep-mediated transport of taurocholate (TC) and troglitazone sulfate (TS) in 
membrane vesicles. 
ATP–dependent transport of taurocholate and TS in membrane vesicles prepared from Sf9 cells 
overexpressing Bsep (Sf9-Bsep; open bars) or mock controls (Sf9-control; solid bars). The data represent 
mean±S.E.M. (n=3 in triplicate). *, P < 0.05, significantly different from mock controls. 
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Figure 5.6. Hepatobiliary disposition of troglitazone (TGZ) and generated metabolites [TGZ sulfate 
(TS) and TGZ glucuronide (TG)] in WT and TR- rat SCH in the absence or presence of GF120918. 
WT and TR- rat SCH were incubated with 10 μM TGZ for 30 min in the absence or presence of 
GF120918. Hepatobiliary disposition of (A) TS and (B) TG were measured in cells+bile (solid bars) and 
in cells (open bars). Effects of GF120198 and rat type (WT vs. TR-) on accumulation and the biliary 
excretion index (BEI) of TS and TG were evaluated using two-way ANOVA. †, P < 0.05, significantly 
different from WT (cells+bile); ‡, P < 0.05, significantly different from WT (cell); *, P < 0.05, 
significantly different from WT (BEI). 
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Figure 5.7. Metabolism of troglitazone (TGZ) in S9 fraction prepared from liver tissues of WT and 
TR- rats. 
The initial velocity of TGZ sulfate (TS) and TGZ glucuronide (TG) formation was obtained after 
incubation of 1 and 10 µM TGZ with S9 fractions prepared from liver tissues of WT (solid bars) and TR- 
(open bars) rats. *, P < 0.05, significantly different from WT. 
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CHAPTER 6.  Quantitative Relationship between Intracellular Lithocholic Acid, Chenodeoxycholic 
Acid and Toxicity in Sandwich-Cultured Hepatocytes; Incorporation into a Mechanistic Model of 
Drug-Induced Liver Injury1 
 
INTRODUCTION 
Drug-induced liver injury (DILI) is the most common cause of acute fulminant hepatic failure (1), 
and is one of the primary reasons for withdrawal of approved drugs from the market. Currently, only 50% 
of clinical DILI is predicted from standard preclinical testing in rodents (2), and mechanisms underlying 
interspecies differences have not been fully elucidated. One proposed mechanism of DILI is inhibition of 
bile acid (BA) efflux in hepatocytes by drugs, which may result in intracellular accumulation of 
potentially toxic BAs (3, 4). Specifically, there is increasing evidence that inhibition of bile salt export 
pump (BSEP)-mediated biliary excretion of BAs by drugs is a risk factor for cholestatic or mixed 
hepatocellular/cholestatic DILI (5, 6). BAs play important roles in the body as key signaling molecules as 
well as lipid solubilizers, but can be cytotoxic when present at supraphysiologic concentrations in 
hepatocytes (7). BA toxicity is highly correlated with hydrophobicity; lithocholic acid (LCA), 
chenodeoxycholic acid (CDCA), and deoxycholic acid (DCA) are more cytotoxic than less hydrophobic 
BAs, cholic acid (CA) and ursodeoxycholic acid (UDCA) (3, 8, 9).  Mechanisms of BA-induced 
hepatotoxicity include disruption of cell membranes due to their detergent-like properties, disruption of 
mitochondrial ATP synthesis, necrosis, and apoptosis (3). 
In vitro screening for BSEP inhibition demonstrated the importance of BSEP inhibition in 
cholestatic/mixed type DILI (5, 6), but predictability of hepatotoxic potential of new chemical entities 
                                                     
1This work has been presented, in part, at the 2013 SOT Annual Meeting and Toxpo, San Antonio, TX, March 10-
14, 2013, and will be submitted to Toxicological Sciences. 
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using this isolated transporter system is limited due to the artificial nature of this membrane vesicle 
system (e.g., lack of metabolic enzymes), the complexity of hepatobiliary BA disposition, and our lack of 
understanding about the physiology of BA homeostasis. Hepatocellular accumulation of BAs is 
dependent upon both uptake and efflux (basolateral and canalicular) processes, and thus, data obtained 
from BSEP membrane vesicles may not represent the drug-BA interaction in the whole cell. For example, 
inhibition of BSEP-mediated biliary excretion by drugs may not lead to hepatocellular accumulation of 
BAs if the drug also significantly inhibits hepatic BA uptake (10). In this case, demonstration of BSEP 
inhibition in membrane vesicles can be a false safety signal because in the whole hepatocyte, BA 
concentrations may be decreased or unchanged. Therefore, net effects on the whole cell are important to 
accurately predict drug-induced hepatotoxicity.  Furthermore, BA transport inhibition potential should be 
considered in terms of drug exposure at the site of interaction (e.g., systemic/portal vein exposure for 
uptake, hepatocellular exposure for canalicular/basolateral efflux). The situation is further complicated 
because BA homeostasis is tightly regulated by several nuclear receptors including farnesoid X receptor 
(FXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), and cell surface BA receptor 
TGR5 (11-14).  
Mechanistic modeling is a useful approach to interpret and extrapolate data obtained from 
different stages of drug development by integrating knowledge obtained at different scales of biological 
complexity (e.g., molecules, cells, organs, organisms, and populations) and different species. DILIsym® is 
a predictive, mechanistic, mathematical model based on the physiological processes involved in DILI that 
is under development as a public-private initiative (http://dilisym.com/) (15, 16). The model includes 
both physiology and drug disposition at multiple scales, ranging from molecular/cellular interactions to 
organ-tissue level considerations. Data from multiple species including humans, rats, and dogs, are 
incorporated in the model to explain interspecies differences in susceptibility to DILI and improve 
prediction of human DILI risk based on preclinical data. The current DILIsym® model includes 
components to predict and further explore reactive metabolite-mediated, mitochondrial, and BA-mediated 
toxicity. The BA homeostasis sub-model includes hepatobiliary disposition and enterohepatic 
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recirculation of LCA, CDCA, and respective metabolites, in addition to all other (“bulk”) BAs (17). LCA 
and CDCA were chosen because they are known to be hydrophobic and potentially toxic BA species; 
LCA is a secondary BA formed by bacterial metabolism of CDCA in the intestinal lumen (3). CDCA is 
the most widely implicated BA in cholestatic liver injury (18).  An overview of the BA transport 
inhibition model within DILIsym® is presented in Figure 6.1. Altered BA disposition by 
drugs/metabolites can be simulated by combining physiologically-based pharmacokinetic predictions of 
hepatocellular drug/metabolite exposure with experimentally-derived estimates of transporter inhibition 
constants (e.g., IC50 or Ki). Accumulation of hepatocellular BAs will lead to decreased hepatocyte ATP, 
which is an important determinant of necrotic cell death in DILIsym®; hepatocyte death will result in 
increased serum biomarkers of hepatocellular injury and function (e.g., ALT, AST, bilirubin). Loss of 
hepatocytes will subsequently influence drug and BA disposition, allowing dynamic interaction between 
kinetics and toxicity mechanisms.   
It has been widely accepted that intracellular accumulation of BAs results in hepatotoxicity but, 
surprisingly, the relationship between hepatocellular BA accumulation and toxicity has not been assessed 
quantitatively until recently. Chatterjee et al. measured CDCA and DCA toxicity and intracellular 
accumulation in rat SCH (19), but similar data are not available for humans and other species. To fill this 
data gap, which is essential to link BA kinetics to toxicity in a BA transport inhibition model within 
DILIsym®, studies were undertaken in sandwich-cultured hepatocytes (SCH) from human, rat, mouse, 
and dog, and quantitative relationships between intracellular LCA and CDCA exposure and toxicity were 
established. SCH, which maintain metabolic and transporter function as well as regulatory machinery (20-
22), were chosen for the current study since direct quantification of intracellular BA and ATP 
concentrations are possible with this system model. SCH are useful to investigate species differences in 
hepatobiliary disposition and hepatototoxicity of drugs and endogenous compounds such as BAs. This 
study also provides insight into species differences in the hepatocellular disposition and toxicity of LCA 
and CDCA. 
 
 182 
 
METHODS 
Chemicals  
LCA, CDCA, taurolithocholic acid (TLCA), taurohyodeoxycholic acid (THDCA), and Triton X-
100 were purchased from Sigma-Aldrich (St. Louis, MO). Lactate dehydrogenase (LDH)-Cytotoxicity 
Detection Kit and CellTiter-Glo® Luminescent Cell Viability Assay Kit were purchased from Roche 
Applied Science (Indianapolis, IN) and Promega (Fitchburg, WI), respectively. Culture medium, standard 
Hanks balanced salts solution (HBSS), and Ca2+-free HBSS (HBSS without Ca2+ and Mg2+, with 0.38g/L 
ethylene glycol tetraacetic acid) were provided by Qualyst Transporter Solutions, LLC (Durham, NC). 
The d8-taurocholic acid (d8-TCA) was purchased from Martrex, Inc. (Minnetonka, MN); d5-TCA, d5-
taurochenodeoxycholic acid (d5-TCDCA), and d4-glycochenodeoxycholic acid (d4-GCDCA) were 
purchased from Toronto Research Chemicals, Inc. (Toronto, Ontario, Canada). The d4-glycocholic acid 
(d4-GCA), d4-CDCA, and d4-CA (cholic acid) were purchased from CDN Isotopes, Inc. (Pointe-Claire, 
Quebec, Canada), and glycolithocholic acid (GLCA), glycohyodeoxycholic acid (GHDCA), and -
tauromuricholic acid (-TMCA) were purchased from Steraloids, Inc. (Newport, RI). All other chemicals 
and reagents were of analytical grade and were readily available from commercial sources. 
Cytotoxicity assay and data analysis 
Rat, human, mouse, and dog SCH were purchased from Qualyst Transporter Solutions (Durham, 
NC). Human hepatocytes were obtained from one African American male (51 years old, BMI 
30.86kg/m2), one Caucasian male (78 years old, BMI 33.1kg/m2), and one Caucasian female (62 years 
old, BMI 24kg/m2). Prior studies have reported that the culture days required for SCH to regain polarity 
varies among species. Thus, cytotoxicity and BA disposition studies were performed on the culture days 
optimized for each species: days 3–4, 6–8, 2–3, and 3–5, for rat, human, mouse, and dog, respectively 
(20). On day 3 (rat), 6 (human), 2 (mouse), or 4 (dog) of culture, cells were incubated with LCA (25, 50, 
100, 125, 150, and 200μM), 0.1% DMSO (vehicle control), or 2% Triton-X (positive control) for 6, 12, 
and 24hr. CDCA toxicity was tested only in rat and human SCH; day 3 rat and day 6 human SCH were 
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incubated with CDCA (50, 100, 250, 375, 500, and 1000μM for rat SCH; 250, 375, 500, 650, 800, and 
1000μM for human SCH), 0.1% DMSO (vehicle control), or 2% Triton-X (positive control) for 6, 12, and 
24hr. Cytotoxicity was assessed by LDH release from damaged cells using the LDH-Cytotoxicity 
Detection Kit according to the manufacturer’s protocol. Briefly, after incubation of SCH with BA for 
designated times, culture medium was collected and aliquots were placed in individual wells of a 96-well 
plate. The substrate mixture was added to the culture medium and incubated for 15min. During this time, 
tetrazolium salt 2-(4-iodophenyl)-3-(4-nitrophynel)-5-phenyl-2H-tetrazolim chloride (INT) in the 
substrate mixture was reduced to formazan by enzymatic reaction mediated by LDH in the culture 
medium. Then formazan formation was measured using PowerWaveTM XS Microplate Spectrophotometer 
(BioTek, Winooski, VT) at 492 nm. Data were corrected for baseline levels in vehicle control (0.1% 
DMSO-treated SCH) and presented as a percentage of positive control (2% Triton X-100-treated SCH) 
using the following equation; 
Cytotoxicity (%) =  
absorbance of samples−absorbance of vehicle control
absorbance of positive control−absorbance of vehicle control
 × 100            (1) 
The values measured after complete cell lysis using 2% Triton X-100 were considered as 
maximum cell death (100% cytotoxicity). 
Intracellular ATP levels were measured using CellTiter-Glo® Luminescent Cell Viability Assay 
Kit according to the manufacturer’s protocol. Briefly, after incubation of SCH with BAs for designated 
times, culture medium was collected for LDH analysis, and the remaining medium was aspirated from 
each well twice, and cells were washed with phosphate-buffered saline. Equal volumes of fresh culture 
medium and CellTiter-Glo reagent (prepared by adding lyophilized CellTiter-Glo substrate to CellTiter-
Glo buffer) were added to each well, and plates were placed on an orbital shaker for 2min to induce cell 
lysis. After incubating plates at room temperature for 10min to allow the luminescent signal to stabilize, 
luminescence was measured (TopCount NXTTM; Packard, Meriden, CT). Standard samples with known 
ATP concentrations (0.01–1µM ATP) were measured coincident with SCH samples for absolute 
quantification of ATP concentrations in the hepatocytes. Intracellular ATP concentrations were calculated 
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by dividing ATP amount (pmol/well) by cellular volume (1.26µl/well) (23), and corrected for cell 
viability obtained from the LDH assay using the following equations; 
Cellular ATP concentration of viable cells (mM) =  
ATP amount 
Cellular volume 
×  
1
Fraction viable cells
         (2) 
Fraction viable cells =  
100 − % cytotoxicity 
100
                                                            (3) 
The relationship between medium concentrations BA (LCA or CDCA) and intracellular ATP 
concentrations were evaluated using linear regression analysis. The least-squares estimates for the slope 
and intercept for the estimated regression lines were obtained using the following model; Y = α + β * X, 
where Y represents intracellular ATP concentrations (mM) and X represents medium concentrations of 
BA (µM). The null hypothesis was β=0, and the alternative hypothesis was β≠0. The concentration 
required to kill one-half of the cells, LC50, was estimated by performing non-linear regression analysis on 
BA medium concentration-LDH leakage data using the following equation:  
Y = Y0 +
Yinf−Y0
1+10(logLC50−logX)∗HillSlope
                                                          (4) 
where Y represents the measured LDH leakage presented as % of positive control and X 
represents medium concentrations of BA, Y0 represents LDH leakage in the absence of exogenous BAs, 
Yinf represents the LDH leakage at infinite BA medium concentrations, LC50 represents the BA medium 
concentration that gives a response half way between Y0 and Yinf, and the Hill Slope is the slope at the 
point of inflection. The data analysis was performed using GraphPad Prism (version 6, La Jolla, CA). 
LC-MS/MS analysis of intracellular LCA, CDCA, and their metabolites 
After incubation of SCH with LCA and CDCA for designated times, medium was removed and 
cells were washed with Ca2+-free HBSS. Then hepatocytes were incubated with Ca2+-free HBSS for 5min 
to open tight junctions using B-CLEAR® technology (Qualyst Transporter Solutions, LLC, Durham, NC). 
Cell lysate samples were prepared and analyzed using liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) analysis as described previously (Marion 2011). TCA, GCA, TCDCA, 
GCDCA, CA, and CDCA were measured using calibration curves prepared with stable isotope 
equivalents to avoid any background contribution from these endogenous BAs. It was not necessary to 
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use stable isotope equivalents for LCA, TLCA, GLCA, THDCA, and GHDCA. The calibration curve 
using -TMCA to measure /-TMCA was prepared using a non-rodent analytical plate to avoid 
background contribution of this endogenous BA in rodents. Under the chromatographic conditions used 
for this study, the stereoisomers - and -TMCA were not separated and were, thus, measured 
collectively and designated as /-TMCA. GMCA values were estimated using TMCA calibration curves 
and correction factor for the difference in molar response observed between d8-TCA and d4-GCA. The 
concentration ranges of the cell lysate calibration curves and the transitions monitored at unit resolution 
are listed in Supplementary Table 6.1. LC-MS/MS analysis was performed as described previously with 
the following exceptions; injection volume ranged from 5–20l, depending on the specific analyte; 
injection rinse solutions were composed of 50:50 methanol:acetonitrile; and chromatographic separation 
was achieved using a gradient with mobile phase consisting of methanol and 0.5mM ammonium acetate 
over a 20–25min run time. The transitions monitored at unit resolution are listed in Supplementary Table 
6.2. Intracellular BA concentrations were calculated by dividing the amount of BA (pmol/well) by the 
cellular volume (1.26µl/well) (23), and corrected for cell viability obtained from the LDH assay, as 
described above for intracellular ATP calculations. 
LCA and CDCA toxicity modeling 
A model incorporating intracellular LCA and CDCA concentrations, which change over time and 
serve as the toxicity signal, and inhibition of ATP production was constructed using the existing cellular 
ATP model within DILIsym® v1A, which describes ATP production and utilization (Figure 6.1) (15, 16). 
A continuous function describing the intracellular concentration of the LCA or CDCA over time was 
generated from the in vitro SCH data. This function was used to generate a signal for inhibition of ATP 
production by the following three equations: 
d[TS]
dt
=  k([BA] − [TS])     (5) 
IF =  
Vmax,tox∗[TS]
γ
Km,tox
γ
+[TS]γ
      (6) 
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FATP prod =  
1
1+IF
      (7) 
where [BA] is the intracellular BA concentration, and [TS] is the toxicity signal, which was 
incorporated in the model to account for the delay between intracellular BA accumulation and the decline 
in ATP; k represents the time constant for the delayed relationship between the BA concentration and the 
ATP decline. Vmax,tox, Km,tox, and  are the Hill equation parameters for the relationship between [TS] 
(delayed BA concentrations) and the inhibition factor (IF), and FATP prod is the fraction by which ATP 
production is multiplied to produce the observed toxicity. The parameters Vmax, tox, Km, tox, , and k were fit 
to the in vitro SCH data. These equations were incorporated into the DILIsym® model and link 
hepatocellular BA concentrations and toxicity in DILIsym® v2A. 
 
RESULTS 
Toxicity and intracellular accumulation of BAs in LCA-treated rat, human, mouse, and dog SCH 
In rat SCH treated with LCA, cellular ATP levels decreased in a concentration-dependent manner 
with respect to LCA concentrations in medium (Figure 6.2A); the linear regression analysis indicated that 
the slopes were significantly different from zero at 6hr (p=0.0001, r2=0.59), 12hr (p=0.0057, r2=0.70), and 
24hr (p<0.0001, r2=0.86). In human SCH, intracellular ATP levels decreased in a concentration-
dependent manner with respect to LCA concentrations in medium (Figure 6.2A); the slopes were 
significantly different from zero at 6hr (p=0.0001, r2=0.55), 12hr (p=0.0057, r2=0.34), and 24hr 
(p<0.0001, r2=0.62) based on liner regression analysis. In human SCH exposed to LCA, ATP decline 
>50% was not observed until 24hr, suggesting a delayed response compared to the observed ATP decline 
in rat SCH by 6hr. In mouse SCH, a significant linear relationship between intracellular ATP levels and 
LCA medium concentrations was found only at 12hr (p=0.003, r2=0.37), and in dog SCH, only at 24 
(p<0.0001, r2=0.60) (Figure 6.2A). In rat SCH, LDH leakage was observed at LCA medium 
concentrations above 100µM (Figure 6.2A); LC50 values were 168, 143, and 130µM at 6hr, 12hr, and 
24hr, respectively. Minimal LDH leakage was observed in human and mouse SCH (Figure 6.2A); in dog 
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SCH, LDH leakage was observed only at the highest LCA concentration (200µM) at 24hr (Figure 6.2A). 
LCA concentrations greater than 200µM were not tested because of the limited solubility of LCA in 
culture medium.  
To establish the quantitative relationship between LCA-induced toxicity and hepatocellular 
exposure to LCA species, cellular accumulation of LCA and its conjugates were measured in LCA-treated 
SCH. Because no LDH leakage was observed at all the LCA concentrations tested in human and mouse 
SCH, and LDH leakage was observed only at the highest LCA concentration in dog SCH, cellular LCA 
species were measured only in human, mouse, and dog SCH treated with 100–200µM of LCA. 
Unconjugated LCA accumulated extensively (in low mM ranges) in rat, human, mouse, and dog SCH 
(Figure 6.2B). Cellular LCA concentrations increased in rat SCH with increasing LCA medium 
concentrations, whereas cellular TLCA and GLCA concentrations decreased at LCA medium 
concentrations above 100μM at which toxicity was observed (Figure 6.2B). Intracellular accumulation of 
LCA and GLCA in human SCH was comparable to those in rat SCH, whereas TLCA concentrations in 
human SCH were ~100-fold lower than rat SCH (Figure 6.2B). Unlike rat SCH, intracellular TLCA and 
GLCA concentrations increased with increasing LCA medium concentrations up to 200µM in human 
SCH. In mouse SCH, intracellular LCA concentrations were modestly lower compared to rat and human 
SCH (Figure 6.2B). TLCA concentrations were comparable to, or modestly higher than, GLCA 
concentrations in mouse SCH. In dog SCH, intracellular LCA concentrations were comparable to, or 
slightly lower than, rat and human SCH, and TLCA concentrations were ~10-fold lower than LCA 
concentrations; GLCA was below the calibration range at all the LCA medium concentrations analyzed 
(100–200µM)  (Figure 6.2B).  
In order to explore the metabolism of LCA in SCH, cellular accumulation of other BAs 
potentially derived from LCA (e.g., conjugates of CA, CDCA, MCA, and HDCA) were measured or 
estimated (GMCA) in rat, human, mouse, and dog SCH after LCA incubation. In rat SCH, intracellular 
TCDCA, GCDCA, and GMCA were increased after LCA treatment compared to endogenous levels in 
vehicle-treated hepatocytes, suggesting that LCA is metabolized to CDCA and MCA (Supplement Figure 
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6.1A). In human SCH, MCA species were not detected. Instead, GHDCA accumulated extensively in the 
cells in a concentration-dependent manner with respect to LCA concentrations in medium (Supplement 
Figure 6.1B). In mouse SCH, TCDCA and GCDCA increased after LCA treatment compared to vehicle-
treated hepatocytes, indicating that CDCA species are formed from LCA (Supplement Figure 6.1C). In 
dog SCH, there were no significant increases in any measured BAs after LCA treatment (Supplement 
Figure 6.1D).  
Toxicity and intracellular accumulation of BAs in CDCA-treated rat and human SCH  
In rat SCH treated with 0–1000µM CDCA, cellular ATP levels decreased in a concentration-
dependent manner with respect to CDCA concentrations in medium (Figure 6.3A); the slopes were 
significantly different from zero at 6hr (p<0.0001, r2=0.80), 12hr (p<0.0001, r2=0.68), and 24hr 
(p<0.0001, r2=0.82) based on linear regression analysis. In human SCH, intracellular ATP levels 
decreased in a concentration-dependent manner with respect to CDCA concentrations in medium (Figure 
6.3A); the linear regression analysis indicated that the slopes were significantly different from zero at 6hr 
(p<0.0001, r2=0.89), 12hr (p<0.0001, r2=0.84), and 24hr (p<0.0001, r2=0.85). In both rat and human SCH, 
LDH leakage was increased in a concentration-dependent manner with respect to CDCA concentrations 
in medium (Figure 6.3A); LC50 values were lower in rat SCH (383, 258, and 243µM at 6hr, 12hr, and 
24hr, respectively) compared to human SCH (727µM at 24hr; the model did not converge at 6hr and 
12hr). In rat SCH, the maximum toxic responses (both ATP and LDH) at each CDCA concentration were 
achieved after 6–12hr incubation. In human SCH, cellular ATP levels were decreased to a minimum after 
6–12hr, but increases in LDH leakage were time-dependent, indicating that the toxic responses were 
delayed in human compared to rat SCH (Figure 6.3A). 
To establish a quantitative relationship between CDCA-induced toxicity and hepatocellular 
exposure to CDCA species, cellular accumulation of CDCA and its conjugates were measured in CDCA-
treated SCH. In both rat and human SCH, unconjugated CDCA accumulated extensively (in low mM 
ranges), and intracellular GCDCA concentrations were greater by an order of magnitude than TCDCA 
(Figure 6.3B). In rat SCH, cellular CDCA and TCDCA concentrations increased with increasing CDCA 
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medium concentrations, whereas cellular GCDCA concentrations decreased at CDCA medium 
concentrations above 100–250μM (Figure 6.3B). Cellular accumulation of unconjugated CDCA increased 
over time at the highest CDCA medium concentration (1000µM) in rat SCH (Figure 6.3B). In human 
SCH, cellular CDCA and GCDCA concentrations increased with increasing CDCA medium 
concentrations up to 375μM, and then decreased at CDCA medium concentrations above 375μM, where 
toxicity was observed (Figure 6.3B). Cellular TCDCA concentrations were lower than endogenous levels 
at all CDCA concentrations tested in human SCH (Figure 6.3B).  
In order to explore CDCA metabolism in SCH, cellular accumulation of other BAs potentially 
derived from CDCA (e.g., CA, MCA) and their conjugates also were measured (TMCA) or estimated 
(GMCA) in CDCA-treated rat and human SCH. In rat SCH, cellular MCA species (MCA, TMCA, and 
GMCA) increased after CDCA treatment compared to vehicle-treated control, indicating that MCA 
species are formed from CDCA (Supplement Figure 6.2A). Formation/conjugation of MCA appeared to 
be saturated at CDCA medium concentrations above 50–375µM. Intracellular GCA increased in rat SCH 
treated with CDCA concentrations of 100-250µM compared to vehicle-treated control only at 6hr; CA 
and TCA were below the calibration range. In CDCA-treated human SCH, unconjugated CA increased, 
whereas TCA and GCA concentrations decreased compared to vehicle-treated control (Supplement 
Figure 6.2B).  
Parameterization of the relationship between hepatocellular LCA and CDCA concentrations and 
ATP  
Models describing the relationship between intracellular LCA and CDCA, and ATP 
concentrations in rat and human SCH were constructed using the existing model of cellular ATP within 
DILIsym® (Figure 6.4A). Toxicophores were determined to be unconjugated LCA and CDCA in rat and 
human SCH. The representative model-generated fit of cellular ATP after LCA exposure in rat SCH is 
presented in Figure 6.4B. Parameter values (Km,tox, Vmax,tox, γ, and k) obtained by fitting the models to the 
data generated from LCA- and CDCA-treated rat and human SCH are presented in Table 6.1. The Km,tox 
values represent the approximate concentration at which toxicity begins to occur; a lower Km, tox value 
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suggests a greater susceptibility to intracellular buildup of that particular BA. This sub-model was 
incorporated into the BA transport inhibition model within DILIsym® to mathematically link 
hepatocellular BA accumulation (BA Homeostasis Model) and intracellular ATP concentrations (Cellular 
ATP Model; Figure 6.1). 
 
DISCUSSION 
 Accumulation of toxic BAs in hepatocytes is involved in the pathogenesis of cholestatic diseases 
(18, 24, 25). The relative potency of BAs with respect to hepatotoxicity has been investigated using in 
vitro and in vivo systems (26, 27), but the relationship between hepatocellular BA concentrations and 
toxicity has not been determined quantitatively. Recently, Chatterjee et al. reported cytotoxicity and 
intracellular accumulation of CDCA and DCA in rat SCH (19). However, intracellular BAs were 
measured at CDCA or DCA medium concentrations up to 100µM, where minimal toxicity was observed. 
Thus, it is difficult to quantify direct relationships between BA accumulation and toxicity using this data. 
BA concentrations at the site of toxicity (liver or hepatocytes) rarely have been measured because 
sensitive and specific LC-MS/MS analyses are required. Most studies have reported apparent LC50 values 
based on the BA concentrations administered to animals and/or medium concentrations for in vitro 
cytotoxicity studies. BAs exist as anions at physiologic pH, and are substrates of hepatic transporters 
[e.g., sodium-taurocholate cotransporting polypeptide (NTCP), BSEP, and multidrug resistance-
associated protein (MRP)3 and 4] (28-30). As a result, medium (plasma) concentrations cannot be 
assumed to represent actual hepatocellular BA exposure. For example, intracellular LCA concentrations 
were more than 10-fold higher than medium concentrations in rat SCH incubated with 200µM LCA 
(Figure 6.2B). Given the same medium (plasma) exposure, intracellular accumulation of BA species may 
vary depending on the expression and/or function of uptake/efflux transporters and metabolic enzymes. 
For example, mouse SCH accumulated considerably less LCA than other species (Figure 6.2B).  In this 
study, we established a quantitative relationship between intracellular BA concentrations and toxicity 
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using in vitro data obtained from SCH isolated from different species. This is the key information that 
connects BA kinetics and toxicity in DILIsym®, a mechanistic model of DILI. 
LCA, which is formed by bacterial 7α-dehydroxylation of CDCA in the gut lumen, has been 
reported to be the most hydrophobic and toxic BA species, and animals administered LCA have been 
used as a model of intrahepatic cholestasis (31, 32). In the present study, LCA showed differential 
toxicity in SCH from different species; treatment with 0–200µM LCA exerted a concentration-dependent 
decrease in ATP in rat SCH, whereas the same medium concentrations showed a delayed decrease in ATP 
in human and dog SCH, and negligible/minimal toxicity in mouse SCH. In rat SCH exposed to LCA 
medium concentrations above 100µM, ATP levels already were decreased by 6hr compared to the 
vehicle-treated control, whereas LDH showed a time-dependent increase from 6–24hr, indicating that a 
delay existed between decreased ATP and LDH leakage (indicator of membrane integrity) in rat SCH. 
This is consistent with a previous report demonstrating a time delay between ATP depletion and a 
decrease in hepatocyte viability in rat primary hepatocytes (33). LDH leakage was not observed in human 
SCH, potentially due to delayed ATP decline and a delay in the time between ATP depletion and loss of 
cell viability. Toxicity may have been observed if human SCH had been incubated with LCA without 
daily medium changes. However, this hypothesis was not tested because SCH require daily medium 
changes to maintain viability due to high metabolic activity. In rat SCH, intracellular unconjugated LCA 
concentrations correlated with the observed toxicity. Interestingly, TLCA and GLCA cellular 
concentrations were decreased at LCA medium concentrations greater than 100µM, potentially due to 
altered (e.g., saturation, depletion) glycine- or taurine-conjugation, adaptive increases in hepatic efflux of 
these conjugates, or further metabolism (e.g., sulfation); similar trends were shown for intracellular 
TCDCA, GCDCA, and GMCA. Lower intracellular unconjugated LCA concentrations in LCA-treated 
mouse SCH may explain the lack of toxicity in this species. In human and dog SCH, intracellular 
unconjugated LCA concentrations were comparable to rat SCH at medium LCA concentrations up to 
150µM, but no/minimal LDH leakage was observed, suggesting that human and dog SCH are more 
resistant to LCA-mediated toxicity given the same exposure. Although mechanisms of observed species 
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differences in the onset and potency of LCA toxicity remain to be investigated, a plausible hypothesis is 
that intracellular unbound LCA concentrations may differ among different species, potentially due to the 
differential intracellular binding/disposition/sequestration of LCA. It is also possible that differential 
accumulation of LCA at the site of toxicity (e.g., mitochondria) exists among different species. In 
addition to species differences in BA disposition, pathophysiological processes involved in the induction 
of LCA toxicity (e.g., mitochondrial function, induction of necrosis/apoptosis) downstream of BA 
exposure may contribute to differential sensitivity/resistance to BA toxicity.  
CDCA is the dominant BA in humans, whereas it contributes a smaller proportion of the BA pool 
in rats and mice. Trihydroxy BAs (e.g., CA) are more abundant in rodents. After incubation with 0–
1000µM CDCA, medium concentration-dependent toxicity was observed in both rat and human SCH. 
Human SCH showed delayed toxicity with a higher LC50, suggesting that CDCA-mediated toxicity is less 
potent compared to rat SCH. In rat SCH, unconjugated CDCA and TCDCA increased with increasing 
CDCA medium concentrations, consistent with the observed toxicity. Cellular TCDCA was ~100-fold 
lower compared to CDCA; thus, it is plausible that unconjugated CDCA is associated with the observed 
toxicity in rat SCH. However, in human SCH, intracellular concentrations of all the measured CDCA 
species decreased at high CDCA medium concentrations, where toxicity was observed, so it is not clear 
which BA caused toxicity in human SCH. Further investigation of other CDCA metabolites may provide 
additional insight.  
Results of the present studies demonstrated that rat was the most sensitive species to LCA 
toxicity in SCH, and CDCA induced toxicity at lower medium concentrations in rat SCH compared to 
human SCH. The fitted parameters (Km,tox) also suggest that LCA and CDCA elicit toxicity at similar 
intracellular concentrations in rat SCH, and that human SCH are less susceptible to LCA and CDCA 
toxicity than rat SCH given the similar intracellular exposure.  However, this does not necessarily mean 
that rats are the most sensitive species to DILI in vivo. To translate this in vitro data to in vivo, species 
differences in the in vivo BA profile and hepatocellular accumulation of individual BAs in the setting of 
drug administration needs to be considered. For example, even if toxicity was observed in rat SCH, 
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intracellular LCA concentrations that exert toxicity in rat SCH may be difficult to achieve in vivo in rats 
even after administration of a potent BA efflux inhibitor; typical rat hepatocellular LCA concentrations 
are in the low nM range whereas concentrations in the low mM range were required to elicit toxicity in rat 
SCH (34, 35). Also, systemic and hepatic CDCA concentrations observed in vivo in humans are higher 
compared to those in rats (34, 36-38). Mechanistic modeling is a useful tool that can incorporate 
information regarding drug pharmacokinetics and BA physiology/pathophysiology to predict in vivo liver 
injury across species. To build this mechanistic model, a quantitative empirical exposure-toxicity 
relationship was established using the data obtained from the current in vitro study. Toxic effects of BAs 
were linked to decreases in cellular ATP, which is an important determinant of cellular necrosis in 
DILIsym®; in the current model, reactive metabolite-mediated interference with mitochondrial respiration 
also is linked to cellular ATP levels.  
Several assumptions were made when the present data was incorporated into the mechanistic 
model. First, unconjugated LCA and CDCA were assumed to be associated with the observed toxicity 
because cellular unconjugated LCA/CDCA concentrations were correlated with observed toxicity in rat 
SCH.  However, it is possible that conjugated LCA and CDCA might cause toxicity. Conjugation of LCA 
(amidation, sulfation, and glucuronidation) increases solubility and facilitates biliary/urinary excretion; 
thus, LCA conjugation generally is considered to be a detoxification pathway.  However, LCA conjugates 
also cause cholestasis (39-41). GCDCA induces apoptosis in primary hepatocytes and mitochondrial 
permeability transition in isolated mitochondria (42, 43). Additional experiments (e.g., treatment of SCH 
with conjugates) would be needed to establish the relationship between LCA/CDCA conjugates and 
toxicity. Also, in vitro toxicity was measured after short-term exposure to high concentrations of BAs, 
assuming that toxicity was associated with direct effects on hepatocytes. A different experimental 
approach would be necessary to examine the acute effects of BAs on non-parenchymal cells, as well as 
the effects of long-term exposure to low concentrations of BAs on both parenchymal and non-
parenchymal cells.  
 194 
 
The present study also demonstrated that the SCH system could reproduce the previously 
reported species differences in LCA and CDCA hydroxylation. In rats, LCA and CDCA primarily 
undergo 6β-hydroxylation to form MDCA and αMCA, respectively (Supplementary Figure 6.3) (44, 45). 
LCA also is metabolized to a lesser extent to HCDA, CDCA, and UDCA by 6α-, 7α-, and 7β-
hydroxylation, respectively (46). In the present study, CDCA formation was observed in LCA-treated rat 
SCH. Even if HDCA, MDCA, and UDCA were not detected, MCA, which is formed by subsequent 
hydroxylation of MDCA and CDCA, significantly accumulated in LCA-treated rat SCH. MCA also was 
found in CDCA-treated rat SCH. In humans, sulfate conjugation is the major LCA detoxification 
pathway, but LCA also undergoes CYP3A4-mediated hydroxylation (32). Unlike rats, LCA and CDCA 
are hydroxylated preferentially at the 6α-position to form HDCA and hyocholic acid (HCA; γMCA), 
respectively (Supplementary Figure 6.3) (47-49). HDCA and HCA species are found in small amounts in 
bile, serum and urine of healthy adult humans, but excretion of these BAs was increased in cholestatic 
patients (50-52) presumably due to adaptive up-regulation of CYP3A enzymes (Xie 1999). Consistent 
with these reports, intracellular GHDCA was increased in LCA-treated human SCH in a concentration-
dependent manner with respect to LCA concentrations in medium.  
To our knowledge, this is the first investigation that has established quantitative relationships 
between intracellular LCA and CDCA exposure, and hepatocyte toxicity in multiple species. These 
relationships were incorporated into DILIsym® to link BA homeostasis and ATP dynamic sub-models, 
and can be used to predict DILI mediated by interruption of BA transport. Species differences in 
intracellular concentrations and toxic effects of LCA and CDCA after exposure to the same medium 
concentrations of these BAs were noted in the present studies. Due to species differences in BA 
metabolism, substrate/inhibitor specificity of BA transporters, BA composition and toxic effects of BAs 
reported here and elsewhere, preclinical species do not reliably predict BA-mediated DILI in humans (10, 
12, 32, 53). Mechanistic modeling incorporating data generated from human-derived in vitro systems  
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including human SCH and membrane vesicles expressing human transporters would be expected to 
provide a more accurate approach to predict altered hepatic BA disposition and subsequent DILI in 
humans. 
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Table 6.1. Parameter values describing the relationship between hepatocellular lithocholic acid 
(LCA) and chenodeoxycholic acid (CDCA) concentrations, and intracellular ATP. 
A model incorporating intracellular LCA and CDCA concentrations, the toxicity signals, and inhibition of 
ATP production was constructed using the existing cellular ATP model within DILIsym® (Figure 6.4; 
equations described in the Methods section). Parameter values were generated by fitting this model to 
hepatocellular bile acid (BA) concentrations and toxicity data obtained from in vitro rat and human 
sandwich-cultured hepatocytes incubated with LCA and CDCA. Vmax,tox, Km,tox, and γ are the Hill equation 
parameters for the relationship between toxicity signal (TS; delayed BA concentration) and the inhibition 
factor (IF). Km,tox (µM), the delayed BA concentration producing half-maximal IF; Vmax,tox 
(dimensionless), the maximal IF generated by TS; γ (dimensionless), Hill coefficient; k (1/hour), the time 
constant for the delayed relationship between the intracellular BA concentration and the ATP decline. 
 LCA CDCA 
 Rat Human Rat Human 
Km,tox (µM) 1000 2300 1000 4000 
Vmax,tox 
(dimensionless) 
2.25 3 8 2 
γ  (dimensionless) 1.5 1.5 1.5 1.5 
k (1/hour) 0.05 0.07 0.5 0.1 
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Figure 6.1. Schematic overview of the bile acid (BA) transport inhibition model in DILIsym®. 
Hepatic and systemic disposition of drugs/metabolites after intravenous (iv) and oral (po) administration 
are simulated using a physiologically-based pharmacokinetic (PBPK) model (Drug PBPK Model). The 
Bile Acid Homeostasis Model represents hepatobiliary disposition and enterohepatic recirculation of 
lithocholic acid (LCA) and chenodeoxycholic acid (CDCA) species, and all other (bulk) BAs (17); for 
simplicity, only the CDCA species are depicted in Figure 6.1. Using BA transport inhibition constants of 
drugs/metabolites (e.g., Ki, IC50), altered BA disposition is simulated. Increased hepatocellular 
accumulation of BAs disrupts cellular energy balance and decreases intracellular ATP concentrations 
(Cellular ATP Model), leading to necrotic cell death (Hepatocyte Life Cycle Model) and elevations in 
serum biomarkers of hepatocellular injury and function (e.g., ALT, AST, bilirubin) (Biomarker Model) 
(15, 16).  
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Figure 6.2. Toxicity and bile acid (BA) accumulation in lithocholic acid (LCA)-treated rat, human, 
mouse, and dog sandwich-cultured hepatocytes (SCH).  
(A) Effects of LCA exposure on intracellular ATP and lactate dehydrogenase (LDH) release. Day 3 
rat, day 6 human, day 2 mouse, and day 4 dog SCH were incubated with LCA (0–200µM) for 6hr (●), 
12hr (○), and 24hr (♦). Representative data (mean±SD of triplicate determinations) from n=2 (rat, human, 
and dog) or n=1 (mouse) independent studies. (B) Intracellular concentrations of LCA and LCA 
metabolites, glycolithocholic acid (GLCA) and taurolithocholic acid (TLCA).  Day 3 rat, day 6 
human, day 2 mouse, and day 4 dog SCH were incubated with LCA (0–200µM) for 6hr (●), 12hr (○), and 
24hr (♦). Intracellular LCA and LCA metabolites were measured by LC-MS/MS analysis of lysate after 
hepatocytes were incubated for 5min with Ca+2-free HBSS buffer to open tight junctions using B-
CLEAR®. Representative data (mean±SD of triplicate determinations) from n=1 (rat, mouse, and dog) or 
n=2 (human) independent studies. 
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Figure 6.3. Toxicity and bile acid (BA) accumulation in chenodeoxycholic acid (CDCA)-treated rat 
and human sandwich-cultured hepatocytes (SCH).  
Day 3 rat and day 6 human SCH were incubated with CDCA (0–1000µM) for 6hr (●), 1hr (○), and 24hr 
(♦). Representative data (mean±SD of triplicate determinations) from n=2 independent studies. (B) 
Intracellular concentrations of CDCA and CDCA metabolites, glycochenodeoxycholic acid 
(GCDCA) and taurochenodeoxycholic acid (TLCA). Day 3 rat and day 6 human SCH were incubated 
with CDCA (0–1000µM) for 6hr (●), 12hr (○), and 24hr (♦). Intracellular CDCA and CDCA metabolites 
were measured by LC-MS/MS analysis of lysate after hepatocytes were incubated for 5min with Ca+2-free 
HBSS buffer to open tight junctions using B-CLEAR®. Representative data (mean±SD of triplicate 
determinations) from n=1 (rat) or n=2 (human) independent studies. 
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Figure 6.4. Relationship between intracellular lithocholic acid (LCA) and chenodeoxycholic acid 
(CDCA) concentrations and ATP. 
(A) A model incorporating intracellular LCA/CDCA concentrations, the toxicity signals, and inhibition of 
ATP production was constructed using the existing Cellular ATP Model within DILIsym®. The Hill 
relationship between the toxicity signals (represented by delayed cellular LCA or CDCA concentrations) 
and inhibition of ATP production was parameterized by fitting the model to the data obtained in LCA and 
CDCA-treated rat and human SCH. (B) Representative model-generated fit (red curve) and observed 
(black square) mean cellular ATP levels (expressed as percent of control) as a function of time after LCA 
exposure in rat SCH. 
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SUPPLEMENTARY MATERIALS 
Supplementary Table 6.1.  Calibration curve ranges. CA, cholic acid; CDCA, chenodeoxycholic acid; 
GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; GHDCA, glycohyodeoxycholic acid; 
GLCA, glycolithocholic acid; GMCA, glycomuricholic acid; LCA, lithocholic acid; TCA, taurocholic 
acid; TCDCA, taurochenodeoxycholic acid; THDCA, taurohyodeoxycholic acid; TLCA, taurolithocholic 
acid; TMCA, tauromuricholic acid; d4-/d5-/d8-, deuterated. 
Analyte Species 
Calibration Curve Range 
(pmol/well) 
d5-TCA All internal standard 
β-TMCA rat, mouse 0.5 – 500 
d8-TCA All 0.25 - 500 
d4-GCA All 0.25 - 500 
d4-TCDCA All 0.25 - 500 
d4-GCDCA All 0.25 - 500 
THDCA human 0.25 - 100 
GHDCA human 0.25 - 100 
d4-CA human, rat 0.25 - 500 
d4-CDCA human 100 – 10,000 
 rat 0.5 - 500 
LCA human, dog, mouse 100 – 10,000 
 rat 1000 – 50,000 
TLCA human, rat, dog 1.0 – 1000 
 mouse 1 – 1000 
GLCA human 100 – 10,000 
 rat 10 – 10,000 
 dog, mouse 1 - 1000 
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Supplementary Table 6.2. Transitions monitored at unit resolution for LC-MS/MS analysis. CA, 
cholic acid; CDCA, chenodeoxycholic acid; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic 
acid; GHDCA, glycohyodeoxycholic acid; GLCA, glycolithocholic acid; GMCA, glycomuricholic acid; 
LCA, lithocholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; THDCA, 
taurohyodeoxycholic acid; TLCA, taurolithocholic acid; TMCA, tauromuricholic acid; d4-/d5-/d8-, 
deuterated. 
 
  
Analyte Precursor (m/z) Product (m/z) 
TCA 514.3 124.1 
α/β-TMCA 514.3 124.1 
d8-TCA 522.3 128.1 
d5-TCA 519.3 124.1 
GCA 464.3 74.1 
α/β -GMCA 464.3 74.1 
d4-GCA 468.3 74.1 
TCDCA 498.3 80.1 
THDCA 498.3 80.1 
d4-TCDCA 503.3 80.1 
GCDCA 448.3 74.1 
GHDCA 448.3 74.1 
d4-GCDCA 452.3 74.1 
CA 407.3 n/a (MS only) 
d4-CA 411.3 n/a (MS only) 
CDCA 391.3 n/a (MS only) 
d4-CDCA 395.3 n/a (MS only) 
LCA 375.2 n/a (MS only) 
TLCA 482.3 80.1 
GLCA 432.2 74.1 
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Supplementary Figure 6.1. Intracellular concentrations of bile acids (BAs) in lithocholic acid 
(LCA)-treated rat (A), human (B), mouse (C), and dog (D) sandwich-cultured hepatocytes (SCH).  
Day 3 rat, day 6 human, day 2 mouse, and day 4 dog SCH were incubated with LCA (0–200 µM) for 6hr 
(●), 12hr (○), and 24hr (▲). Intracellular BAs were measured by LC-MS/MS analysis of lysate after 
hepatocytes were incubated for 5min with Ca+2-free HBSS buffer to open tight junctions using B-
CLEAR®. Representative data (mean±SD of triplicate determinations) from n=1 (rat, mouse, and dog) or 
n=2 (human) independent studies. TMCA represents α/β-TMCA because the stereoisomers α- and β-
TMCA were measured collectively. GMCA values were estimated using TMCA calibration curves. GCA, 
glycocholic acid; GCDCA, glycochenodeoxycholic acid; GHDCA, glycohyodeoxycholic acid; GMCA, 
glycomuricholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TMCA, 
tauromuricholic acid. 
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Supplementary Figure 6.2. Intracellular concentrations of bile acids (BAs) in chenodeoxycholic acid 
(CDCA)-treated rat (A) and human (B) sandwich-cultured hepatocytes (SCH).  Day 3 rat and day 6 
human SCH were incubated with CDCA (0–1000 µM) for 6hr (●), 12hr (○), and 24hr (▲). Intracellular 
BAs were measured by LC-MS/MS analysis of lysate after hepatocytes were incubated for 5min with 
Ca+2-free HBSS buffer to open tight junctions using B-CLEAR®. Representative data (mean±SD of 
triplicate determinations) from n=1 (rat) or n=2 (human) independent studies. TMCA represents α/β-
TMCA because the stereoisomers α- and β-TMCA were measured collectively. GMCA values are 
estimates calculated using TMCA calibration curves. CA, cholic acid; GCA, glycocholic acid; GMCA, 
glycomuricholic acid; MCA, muricholic acid; TCA, taurocholic acid; TMCA, tauromuricholic acid. 
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Supplementary Figure 6.3. Hepatic metabolic pathways of lithocholic acid (LCA) and 
chenodeoxycholic acid (CDCA).  Schematic overview of previously reported metabolic pathways of 
LCA and CDCA in the liver. Conjugation pathways are only shown for LCA and CDCA, but other bile 
acids are also subject to glycine-, taurine-, sulfate-, or glucuronide-conjugation. (H) major pathway in 
humans; (R) major pathway in rats; 3-KCA, 3-ketocholic acid; 6-KLCA, 6-ketolithocholic acid; BAAT, 
bile acid:amino acid transferase; BACS, bile acid:coA synthase; CA, cholic acid; CDCA, 
chenodeoxycholic acid; CDCA-Glc, chenodeoxycholic acid-glucuronide; CDCA-S, chenodeoxycholic 
acid-sulfate; CYP, cytochrome P450; GCDCA, glycochenodeoxycholic acid; GLCA, glycolithocholic 
acid; HCA, hyocholic acid; HDCA, hyodeoxycholic acid; ILCA, isolithocholic acid; LCA, lithocholic 
acid; LCA-Glc, lithocholic acid-glucuronide; LCA-S, lithocholic acid-sulfate; αMCA, α-muricholic acid; 
βMCA, β-muricholic acid; γMCA, γ-muricholic acid; MDCA, murideoxycholic acid; SULT, 
sulfotransferase; TCDCA, taurochenodeoxycholic acid; TLCA, taurolithocholic acid; TLCA-S, 
taurolithocholic acid-sulfate; UDCA, ursodeoxycholic acid; UGT, UDP glucuronosyltransferase. 
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CHAPTER 7.  Mechanistic Modeling of Drug-Induced Liver Injury Predicts Delayed Presentation 
and Species Differences in Bile Acid -Mediated Troglitazone Hepatotoxicity1  
 
INTRODUCTION 
Drug-induced liver injury (DILI), a frequent cause of liver injury, is manifested as a broad range 
of illnesses from temporal changes in serum biochemistry to acute hepatitis or cholestasis. DILI is one of 
the primary reasons for the failure of pharmaceutical agents during drug development as well as 
withdrawal of approved drugs from the market (1). Unfortunately, current in vitro screening approaches 
or in vivo preclinical studies do not adequately predict the DILI liability of new chemical entities. Rare 
incidences of severe drug-related hepatotoxicity typically are not detected in the Phase III clinical trials 
that involve a few thousand patients, and may not be detected until the drug has been approved and 
administered to tens or hundreds of thousands of patients. These unexpected findings have led to 
blackbox warnings (e.g., bosentan, diclofenac, ketoconazole, isoniazid), or in severe cases, withdrawal of 
the drug from the market (e.g., troglitazone, bromfenac).  
Troglitazone (TGZ) was the first of the thiazolidinedione class drugs approved in worldwide 
markets for the treatment of insulin resistance occurring in type 2 diabetes. During the clinical trials that 
led to the approval of TGZ, ALT elevations >3X upper normal limit (ULN) in about 2% of patients and 2 
cases of jaundice were reported (2). All of these patients recovered without permanent clinical 
complications, and the TGZ was approved. However, after the release of TGZ on the market, 2 cases of 
liver failure related to TGZ were reported, and it was given a blackbox warning status with requirement of 
monthly monitoring of liver enzymes. Over the next three years, 43 cases of liver failure and 21 deaths 
                                                     
1This work has been accepted for podium presentation, in part, at the ASCPT 2014 Annual Meeting, Atlanta, GA, 
March 18-22, 2014, and will be submitted to Clinical Pharmacology and Therapeutics: Pharmacometrics and 
Systems Pharmacology. 
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related to TGZ therapy were reported (3). With the arrival of rosiglitazone and pioglitazone, drugs from 
the same class that demonstrated less concerns about hepatotoxicity, TGZ was withdrawn from the 
market (4).  
Fourteen years have passed since the withdrawal of TGZ, but the mechanism(s) of TGZ-mediated 
hepatotoxicity have not been fully elucidated. Although numerous mechanisms have been postulated, one 
proposed mechanism is inhibition of bile acid transport inhibition by TGZ and its major metabolite, TGZ 
sulfate (TS) (5, 6), which may cause accumulation of toxic bile acids in hepatocytes and subsequent 
toxicity (7, 8). The bile salt export pump (BSEP) is a canalicular transporter that is predominantly 
responsible for biliary excretion of bile acids. Impaired BSEP function due to genetic polymorphisms 
induces liver injury (9, 10), and BSEP inhibition mediated by drugs has been associated with 
cholestatic/mixed type DILI (11, 12). In vitro vesicular transport assays revealed that TGZ and TS are 
potent inhibitors of BSEP and multidrug resistance-associated protein 4 (MRP4), hepatic transporters that 
mediate biliary and basolateral efflux of bile acids, respectively (11, 13, 14). TGZ is also shown to inhibit 
NTCP-mediated bile acid uptake (15). However, the involvement of bile acid inhibition in TGZ-mediated 
hepatotoxicity has not been demonstrated in vivo in humans. Also, hepatotoxicity signals were not 
detected during preclinical testing of TGZ, even though TGZ and TS are potent inhibitors of rat Bsep 
(13). While it is challenging to translate the results from isolated in vitro studies to in vivo, and preclinical 
studies to humans, mechanistic modeling is a useful approach to integrate data from different 
experimental systems and species, and biological knowledge, to predict human DILI. 
In the current study, a mechanistic model of DILI (DILIsym, http://www.dilisym.com) was used 
to investigate the role of bile acid transport inhibition in TGZ hepatotoxicity and underlying mechanisms 
for species differences. DILIsym includes sub-models representing disposition of drugs and metabolites, 
physiology and pathophysiology of bile acids, the hepatocyte life cycle, and biomarkers of liver injury 
(e.g., serum ALT and bilirubin) (Figure 7.1) (16-19). TGZ-mediated DILI responses were simulated in 
the human and rat populations (SimPops); these simulated populations included variability in key model 
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parameters describing bile acid and drug disposition. Potential risk factors for TGZ-induced 
hepatotoxicity in humans in the context of bile acid inhibition also were assessed in human SimPops.  
 
RESULTS 
Physiologically-based pharmacokinetic (PBPK) modeling 
A PBPK model was developed to describe the disposition of TGZ and TS in humans and male 
rats (Supplementary Figure 7.2). Simulated TGZ and TS plasma concentration-time profiles in humans 
following a single oral dose of 400 mg TGZ (Figure 7.2A), and in male rats following a single 
intravenous dose of 5 mg/kg TGZ (Figure 7.2B) were within 2-fold of the mean observed concentrations 
measured by high performance liquid chromatography (HPLC) (20-22). In male rats administered a single 
oral dose of 5 mg/kg TGZ, the simulated TGZ plasma concentration-time profile was within 2.6-fold of 
the mean observed concentrations measured by HPLC (Figure 7.2B) (21).  
Simulations of TGZ hepatotoxicity in human and rat populations (SimPops)  
The baseline human simulation did not include population variability; as expected, no DILI 
responses (i.e., decreased hepatic ATP, decreased viable liver mass, or increased serum ALT) were 
observed (data not shown) based on the rare incidence of TGZ-mediated hepatotoxicity in the clinic. To 
explore TGZ hepatotoxicity at the population level, human and rat SimPops that included variability in 
bile acid and drug disposition were constructed using the parameters listed in Table 7.2. Several TGZ 
dose levels were employed for the human SimPops (n=331) [once daily oral doses of 200, 400, or 600 mg 
for 6 months (clinically used doses)] and rat SimPops (n=191) [once daily oral doses of 5 mg/kg 
(equivalent to the clinical dose) or 25 mg/kg for 6 months]. TGZ-mediated perturbations in bile acid 
disposition and DILI responses in the human and rat SimPops are presented in Figure 7.3. In the human 
SimPops, hepatic accumulation of chenodeoxycholic acid (CDCA) and lithocholic acid (LCA) species 
(sum of LCA, CDCA, and their conjugates) and subsequent DILI responses were dependent on TGZ 
dose. In the human SimPops, the simulated median (range) maximum hepatic concentrations of CDCA 
and LCA species post-dose were 203 µM (76–1057), 272 µM (108–1431), and 312 µM (128–1646) at 
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TGZ doses of 200, 400, and 600 mg/day, respectively, compared to a baseline value of 44 µM. Baseline 
human hepatic ATP concentration in the current model was 4.2 mM. Hepatic bile acid accumulation led 
to a decrease in hepatic ATP and a decrease in viable liver mass in a subset of the human SimPops; 
simulated median (range) values of minimum hepatic ATP concentrations post-dose were 4.14 mM 
(3.49–4.19), 4.10 mM (3.22–4.18), and 4.07 mM (3.00–4.17) at TGZ doses of 200, 400, and 600 mg/day, 
respectively. Corresponding values for fractional viable liver mass were 1.00 (0.92–1.00), 1.00 (0.45–
1.00), and 1.00 (0.33–1.00). The incidence of elevated serum ALT, serum total bilirubin, and Hy’s Law 
cases (serum ALT >3X ULN and serum bilirubin >2X ULN) in the human SimPops are summarized in 
Table 7.1; the reported incidence of ALT elevations and jaundice in the clinical trials also are listed (2, 3). 
In the human SimPops, TGZ doses of 200, 400, and 600 mg/day induced elevations in serum ALT >3X 
ULN in 0, 2.4, and 4.2% of the population; Hy’s Law cases were observed in 0.9 and 3.0% of the 
population treated with 400 and 600 mg/day TGZ, respectively. This is similar to observations from the 
clinical trials where TGZ (200–600 mg/day) induced serum ALT elevations >3X ULN in 1.9% of treated 
patients, and 2 cases of jaundice (0.08%) were reported (2). The time to peak ALT in the human SimPops 
with ALT elevations >3X ULN was 1.3–6 months at TGZ doses of 400 and 600 mg/day; these are 
comparable to 3–7 months observed in the clinical trials (Table 7.1) (3). Simulated time-course dynamics 
of serum ALT and viable liver mass in susceptible individuals (serum ALT >3X ULN) are presented in 
Figure 7.4.  
In the rat SimPops, the simulated median (range) maximum hepatic concentrations of CDCA and 
LCA species post-dose were 26 µM (11–179) and 41 µM (11–179) at TGZ doses of 5 and 25 mg/kg/day, 
respectively, compared to baseline values of 8 µM. The baseline rat hepatic ATP concentration was 2.0 
mM. Simulated median (range) minimum hepatic ATP concentrations after TGZ doses of 5 mg/kg/day 
and 25 mg/kg/day were 1.96 mM (1.68–2.00) and 1.93 mM (1.50–1.99), respectively. The corresponding 
values for fractional viable liver mass were 1.00 (1.00–1.00) and 1.00 (0.92–1.00), respectively. None of 
the rat SimPops exhibited serum ALT elevations >3X baseline (21 U/L).  
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Sensitivity analysis  
To investigate the sensitivity of DILI responses to transporter inhibition constants, simulations 
were performed with 10-fold smaller and larger inhibition constants for BSEP, MRP4, and NTCP. 
Simulated maximum serum ALT levels in human and rat SimPops treated with TGZ (600 mg/day for 
humans; 5 mg/kg/day for rats) for 1 month are presented in Figure 7.5. In the human SimPops, serum 
ALT levels were sensitive to the Ki value of TGZ and TS for BSEP inhibition; when BSEP Ki was 
decreased by 10-fold (assuming 10-fold more potent inhibition), 14.2% of the population exhibited serum 
ALT >3X compared to only 2.7% of the population with the measured BSEP Ki. None of the individuals 
showed elevated serum ALT >3X when BSEP Ki was increased 10-fold (assuming 10-fold less potent 
inhibition). The Ki of TGZ and TS for MRP4 inhibition also influenced serum ALT elevations, but to a 
smaller extent compared to BSEP Ki; 3.0% and 1.8% of the population exhibited a serum ALT >3X when 
the MRP4 Ki was decreased and increased by 10-fold, respectively, compared to an incidence of 2.7% 
with the measured MRP4 Ki. Modulation of the Ki for NTCP inhibition by TGZ and TS led to opposite 
effects compared to modulation of BSEP and MRP4 Ki; a decrease in the NTCP Ki by 10-fold led to a 
decreased incidence of elevations in serum ALT >3X (1.5% of the population), whereas an increase in the 
NTCP Ki by 10-fold increased the incidence of elevations in serum ALT >3X (3.6% of the population), 
compared to an incidence of 2.7% with the measured NTCP Ki. This confirms the suggested protective 
role of bile acid uptake inhibition in hepatic bile acid accumulation and subsequent DILI. In the rat 
SimPops, simulated serum ALT levels did not exceed 3X baseline values (21 U/L) even when the Ki for 
BSEP or MRP4 were decreased by 10-fold, or the Ki for NTCP was increased 10-fold. These results give 
confidence that TGZ is not expected to be hepatotoxic in rats.   
Multiple regression analysis 
Hepatotoxicity was not predicted in the baseline human simulation, which did not include 
population variability, whereas simulations with human SimPops revealed a subset of individuals 
susceptible to TGZ-mediated hepatotoxicity. To identify the most important parameters in our model in 
the context of bile acid-mediated DILI, multiple regression analysis was performed with the lowest 
 216 
 
hepatic ATP post-dose as the predicted outcome and the 16 parameters used to develop the human 
SimPops as independent variables. Hepatic ATP was selected because perturbations in cellular ATP 
synthesis is the first step in the development of bile acid-mediated DILI in the current model (Figure 7.1), 
and thus is the most sensitive and variable model output compared to other DILI responses (i.e., serum 
ALT, fractional viable liver mass). Table 7.2 shows the statistical significance (p-values) and standardized 
coefficients of parameters varied in human SimPops. Among the 16 parameters used to construct human 
SimPops, seven parameters were statistically significant predictors of hepatic ATP levels; the maximum 
rate of LCA-sulfate biliary excretion was the most important variable influencing hepatic ATP decline 
followed by the maximum rate of LCA synthesis in the intestinal lumen, canalicular efflux regulation 
scaling factor, the maximum rate of CDCA-amide biliary excretion, biliary clearance of TS, body weight, 
and the maximum velocity of CDCA-amide basolateral efflux. 
 
DISCUSSION 
Bile acid transport inhibition by TGZ and its major metabolite, TS, is one proposed mechanism of 
TGZ-mediated hepatotoxicity. Although TGZ and TS are potent inhibitors of bile acid transporters in 
isolated membrane vesicle systems, the relationship between bile acid transport inhibition and in vivo 
hepatotoxicity has not been evaluated. In the current study, a mechanistic model of DILI was used to 
investigate the hepatotoxic potential of TGZ via bile acid transport inhibition in humans and rats. It is 
important to consider population variability when predicting bile-acid mediated hepatotoxicity due to 
large variability in bile acid exposure and the low incidence of hepatotoxicity (2, 23). Lack of TGZ-
mediated DILI in the baseline human model in the current study also supports the necessity of population-
based analysis. Thus, human and rat SimPops that included variability in key parameters in bile acid 
disposition, TGZ and TS disposition, body weight, and sensitivity of ATP synthesis to hepatic bile acid 
accumulation were constructed to investigate the hepatotoxic potential of TGZ at the population level.  
In the clinic, TGZ was administered at oral doses of 200, 400, or 600 mg once daily. Thus, each 
dose level was employed in the human SimPops. The simulated incidences of elevated serum ALT >3X 
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ULN was 2.4–4.2%, which were similar to 1.9–2.1% that had been observed in clinical trials and a 
retrospective study of 291 patients with type 2 diabetes (2, 24) (Table 7.1). Hy’s Law cases were observed 
in 0.9–3.0% of human SimPops, whereas 2 cases of jaundice (0.08%, both Hy’s Law cases) relevant to 
TGZ treatment were reported in clinical trials (Table 7.1). The incidence of serum bilirubin elevations 
might have been overestimated in the simulations because TGZ was not discontinued even when serum 
ALT was increased, in contrast to the clinical situation. Simulations also adequately predicted the delayed 
time to peak ALT observed in the clinical trials (3–7 months) (Table 7.1). The duration of therapy before 
ALT elevation in a retrospective study was longer and more variable (413±256 days), which might be 
explained, in part, by different dosing schemes. In the clinic, patients were administered lower doses and 
then titrated up to 600 mg/day if they did not respond to TGZ therapy. In the current simulations, a single 
dose level was administered throughout the simulation, and thus, human SimPops administered 600 
mg/day TGZ were exposed from the beginning to the high dose level. Since the incidence of ALT 
elevations increased with increasing dose in the current simulations, the onset of ALT elevations would 
have been delayed further if doses had been escalated in the simulations. Also, the estimation of time to 
peak ALT in the clinic depends on the monitoring frequency. If patients were not monitored routinely, 
earlier signals may have been missed, resulting in a longer than expected reported time to peak. Although 
mechanisms underlying delayed presentation of TGZ hepatotoxicity remain unclear, delayed ALT 
elevations in the present mechanistic model were driven by a delayed build-up of toxic bile acids in 
hepatocytes. After initiating TGZ administration in the human SimPops, hepatic TS concentrations 
reached steady-state within 2 weeks (data not shown). However, it took 0.5–3 months before the toxic 
bile acids accumulated to a high enough concentration in hepatocytes to cause hepatotoxicity because of 
the dynamic interaction between hepatic bile acid disposition and ATP concentrations in the current 
model (19); hepatic accumulation of toxic bile acids inhibited ATP synthesis, and ATP depletion in turn 
decreased function of ATP-dependent bile acid efflux transporters (25, 26), further increasing hepatic bile 
acid accumulation. The extent of bile acid accumulation and the sensitivity of ATP synthesis to hepatic 
bile acid accumulation determined the level of hepatic injury (i.e., decreased hepatic ATP and loss of 
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viable liver mass). In the human SimPops, extensive liver injury led to a marked and early rise in serum 
ALT, whereas lower level injury resulted in mild and further delayed increases in serum ALT (Figure 
7.4).  
Currently, only approximately one-half of drugs that cause human DILI exhibit detectable liver 
injury in preclinical testing (27). Specifically, preclinical animals are less sensitive to bile acid-mediated 
DILI compared to humans, and thus, do not reliably predict human hepatotoxicity that involves bile acid 
transport inhibition (28, 29). Toxicity signals for TGZ were not detected during the standard preclinical 
toxicity testing before approval, and minimal hepatotoxicity was observed in 104 weeks of long-term 
toxicity studies (30). Potential reasons include species differences in toxic bile acid composition, substrate 
and/or inhibitor specificity of bile acid transporters, and metabolism/detoxification pathways of bile acids 
(28, 31-33). For example, bosentan was a more potent inhibitor of rat Ntcp-mediated bile acid uptake 
compared to human NTCP, which may prevent hepatic accumulation of bile acids despite inhibition of 
Bsep in rats (12, 28). However, unlike bosentan, TGZ was reported to be a more potent inhibitor of 
human NTCP relative to rat Ntcp, and inhibition potency was similar for human BSEP and rat Bsep (12, 
15). A unifying hypothesis is that differential hepatotoxicity of TGZ could be attributed to species 
differences in toxic bile acid profiles. Rats have a hydrophilic, and thus less toxic, bile acid pool; CDCA, 
the most widely implicated bile acid in cholestatic liver injury (34), is one of the dominant bile acids in 
humans, whereas it contributes a smaller proportion of the bile acid pool in rats and mice (23, 35). Tri-
hydroxy bile acids such as cholic acid and muricholic acid are more abundant in rodents (35). LCA, the 
most hydrophobic and potentially toxic bile acid, is predominantly sulfated in humans, whereas LCA 
primarily undergoes 6β-hydroxylation to form murideoxycholic acid in rats (32). Conjugation (i.e., 
amidation, sulfation, and glucuronidation) increase solubility and facilitate biliary/urinary excretion, and 
is generally considered as a detoxification pathway. However, LCA conjugates also cause cholestasis (36-
38), and the glycine conjugate of CDCA induces mitochondrial permeability transition and apoptosis in 
isolated mitochondria and primary hepatocytes, respectively (39, 40). In DILIsym, CDCA, LCA, and 
their conjugates were exclusively modeled as the toxic bile acids. Simulated maximum hepatic 
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concentrations of CDCA and LCA species in the human SimPops administered 200–600 mg/day TGZ 
were 74–1646 µM (Figure 7.3A). Although hepatic bile acid concentrations after administration of bile 
acid transport inhibitors to humans have not been investigated, several investigations revealed that 
concentrations of hepatic bile acids increased up to 215 ± 39.1 µM and 1960.5 µM in patients with end-
stage chronic cholestatic liver disease and hepatolithiasis, respectively (41, 42), suggesting that simulated 
hepatic bile acid concentrations are not physiologically unrealistic. In rat SimPops administered 5–25 
mg/kg/day TGZ, simulated maximum hepatic concentrations of CDCA and LCA species ranged 11–179 
µM (Figure 7.3B). This is much lower compared to humans due to the hydrophobic bile acid pool and 
detoxification of LCA by hydroxylation (19), and led to a lack of hepatotoxicity in the rat SimPops. These 
results demonstrated that a mechanistic model which incorporates species differences in bile acid 
homeostasis correctly predicted differential hepatotoxicity of TGZ in humans versus rats. Sensitivity 
analysis also revealed that rat SimPops did not exhibit hepatotoxicity even with 10-fold lower (more 
potent) inhibition constants for bile acid efflux transporters, suggesting that the differential bile acid 
profile, rather than inhibitor specificity of drugs, is the main contributor to species difference (Figure 7.5). 
Only a small subset of patients treated with TGZ experience elevated serum ALT, suggesting that 
certain patients are more susceptible to TGZ-mediated toxicity. A multiple linear regression analysis 
showed that in the current model, decreased biliary excretion of LCA-sulfate and CDCA-amide, 
decreased TS biliary clearance, decreased hepatic basolateral efflux of CDCA-amide, increased LCA 
synthesis in the gut, decreased feedback regulation on hepatic efflux transporters, and decreased body 
weight were key risk factors for TGZ-mediated hepatotoxicity associated with bile acid transport 
inhibition. Decreased biliary excretion of bile acids and TS represents decreased expression and/or 
function of hepatic canalicular transporters, which will increase hepatic exposure of toxic bile acids as 
well as perpetrator drugs/metabolites. Decreased function of basolateral efflux transporters, which serve 
as an important compensatory pathway for bile acid excretion when biliary excretion is impaired (43), 
could potentiate hepatic accumulation of toxic bile acids. Thus, impaired expression and/or function of 
these transporters by concomitant drugs, disease states, or genetic polymorphisms would be expected to 
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predispose a subset of patients to DILI. Functional variants in BSEP are a known susceptibility factor for 
the development of estrogen- and fluvastatin-induced cholestasis (44, 45), indicating that patients with 
impaired BSEP function might be at greater risk of DILI. Hepatocyte exposure to bile acids and 
perpetrator drugs/metabolites as well as hepatocyte susceptibility to bile acids (e.g., mitochondrial 
function) also might be altered in liver disease (e.g., non-alcoholic steatohepatitis, cirrhosis), which often 
are associated with diabetes (46). However, quantitative data relating the extent of functional impairment 
to the progress and severity of disease are needed to support this. LCA is synthesized in the intestine by 
bacterial modification of CDCA, which is known to be affected by environmental factors such as diet. 
However, the rate and variability of LCA synthesis have not been well characterized, and thus further data 
are needed to evaluate the effects of environmental factors on bile acid-mediated hepatotoxicity using 
mechanistic modeling. Adaptive response to hepatic bile acid accumulation (e.g., altered bile acid 
synthesis, metabolism, and transport) is another important unknown for which quantitative data are 
lacking (47). Predictability of the model will be improved further with advances in our knowledge about 
bile acid physiology, patient- and disease-specific risk factors. 
Increasing evidence supports the hypothesis that drug-mediated functional disturbances in hepatic 
bile acid transporters leads to intracellular accumulation of potentially harmful bile acids and subsequent 
development of hepatic injury. Systematic investigation of a panel of drugs for their inhibitory effects on 
bile acid efflux transporters using isolated membrane vesicles and hepatotoxic potential demonstrated that 
inhibition of bile acid efflux transporters is associated with DILI (11, 12, 48, 49).  More sophisticated 
model systems such as sandwich-cultured hepatocytes have been used to assess effects of drugs and 
generated metabolites on hepatic accumulation of bile acids (49-51). However, bile acid-drug interactions 
may be more complicated due to vectorial transport and enterohepatic recirculation of bile acids, dynamic 
changes in the systemic as well as hepatic exposure of drugs/metabolites and bile acids, and feedback 
regulation of bile acid synthesis and transport as an adaptive response to hepatic bile acid accumulation 
(52). It is of note that knowledge gaps exist in bile acid homeostasis as discussed above and elsewhere 
(19), which may limit accurate, quantitative prediction of bile acid-mediated DILI. Nonetheless, 
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mechanistic modeling incorporating 1) physiology and pathophysiology of bile acids in humans and rats, 
2) systemic and hepatic disposition of TGZ and TS, and 3) in vitro inhibition potency data reasonably 
predicted altered bile acid disposition in rats administered glibenclamide (19), and also adequately 
predicted delayed presentation and species differences in TGZ hepatotoxicity. These findings suggest that 
mechanistic modeling combined with population analysis may provide a useful tool to integrate our 
current knowledge about physiological and experimental data obtained during the drug development 
process, and prospectively predict hepatotoxic potential of new chemical entities that are in the drug 
development pipeline.  
 
METHODS 
Physiologically-based pharmacokinetic (PBPK) model development 
A PBPK model was developed to describe the distribution of TGZ and TS in humans and male 
rats (Figure 7.2) after intravenous (rat) and oral (human and rat) administration. Only male rat data were 
employed in the current study because gender differences were observed in TGZ and TS 
pharmacokinetics in rats, but not in humans; plasma TS concentrations in female rats were ~3-fold lower 
compared to male rats, and female rats did not mimic TGZ and TS disposition observed in humans (53, 
54). Details regarding the construction and final structure of the PBPK model are provided in the 
supplementary material (Supplementary Figure 7.2). Briefly, the TGZ PBPK model consisted of a central 
compartment representing the blood, as well as hepatic and extrahepatic tissues (e.g., muscle, intestine) 
linked to the central compartment by blood flow. It was assumed that TGZ metabolism occurred mainly 
in the liver by sulfation and glucuronidation; the quinone metabolite was not included because this is a 
minor pathway of metabolism and the current investigation was not focused on quinone-mediated toxicity 
(53, 55). Disposition of TS was described using a semi-PBPK model, which consisted of a central 
compartment representing the blood, hepatic tissue, and extrahepatic tissues lumped into one 
compartment. Chemical-specific kinetic parameters (e.g., tissue partition coefficients, rate of metabolite 
formation, fraction unbound in plasma, biliary and renal clearances) were obtained from the literature or 
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optimized using TGZ and TS plasma concentration versus time data obtained from the in vivo 
experiments (Supplementary Table 7.1).  
Construction of human and rat population samples (SimPops) 
To account for inter-individual variability in the model parameters governing bile acid and drug 
disposition, human and rat SimPops were constructed previously within DILIsym using the genetic 
algorithm in MATLAB (19). Human (n=331) and rat (n=192) population samples (Simpops) were 
generated by varying parameters 10 (human) or 11 (rat) parameters,  as listed in Table 7.2, in the bile acid 
homeostasis sub-model; these bile acid Simpops are “system-specific” and were used to simulate 
hepatotoxic potential of different compounds. In the current study, parameters governing TGZ and TS 
disposition (human and rat), body weight (human), and sensitivity of hepatic ATP decline to hepatic bile 
acid accumulation (human) also were varied using the probability distribution of  each parameter obtained 
from the literature. Details related to construction of the SimPops can be found in the supplementary 
material. 
Simulation of DILI responses 
Perturbation of bile acid disposition and DILI responses after TGZ administration in human (200, 
400, or 600 mg/day for 6 months) and rat (5 or 25 mg/kg/day for 1 month) SimPops were simulated using 
PBPK model predictions of TGZ and TS disposition, a previously developed bile acid homeostasis sub-
model (19), and bile acid transport inhibition constants for TGZ and TS (i.e., Ki, IC50) measured in 
isolated membrane vesicle transport systems (supplemental Table 7.2). To assess the sensitivity of DILI 
responses to inhibition constants, simulations were performed with 10-fold smaller or greater inhibition 
constants for BSEP, MRP4, and NTCP in human and rat SimPops administered 600 mg/day (highest dose 
used in the clinic) and 5 mg/kg/day (equivalent to the clinical dose) TGZ, respectively. Simulations for 
the sensitivity analysis studies were performed for only 1 month due to the extensive computational time 
required for long-term (6 month) simulations, and also because even for the individuals with delayed 
presentation of hepatotoxicity, slight increases (<3X ULN) in serum ALT could be detected within 1 
month of simulation. To identify the most important parameters in the context of bile acid-mediated DILI, 
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a multiple regression analysis was performed with minimum hepatic ATP as the predicted outcome; 16 
parameters were used to develop human SimPops as independent variables. Because the units of 
independent variables were different by orders of magnitude, standardized coefficients were calculated to 
determine which of the independent variables have a greater effect on the minimum hepatic ATP. 
Statistical analyses were performed using JMP 10 (SAS, Cary, NC). 
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Table 7.1. Summary of troglitazone-mediated hepatotoxicity in human SimPops and clinical trials. 
 Simulationsa Clinical Trials (2, 3)  
 TGZ  
200 mg 
(n=331) 
TGZ 
400 mg 
(n=331) 
TGZ 
600 mg 
(n=331) 
TGZ  
200 – 600 mg 
(n=2510) 
Placebo 
 (n=475) 
ALT > 3X ULN (%)b  0c 2.4 4.2 1.9 0.6 
ALT > 5X ULN (%)b  0 1.2 3.0 1.7 N/A 
ALT > 8X ULN (%)b  0 0.9 2.4 0.9 0 
ALT > 30X ULN (%)b  0 0 0.3 0.2 0 
Time to peak ALT (Days)d N/A 128 ± 61 110 ± 62 147 ± 86 N/A 
Total Bilirubin > 2X (%)e 0 0.9 3.0 N/A N/A 
Hy’s Law cases (%) 0 0.9 3.0 0.08 N/A 
Jaundice (%) N/A N/A N/A 0.08 0 
a Each dose level was simulated for 6 months. 
b ULN (upper limit of normal) was 34 U/L in the clinical trials. Baseline serum ALT in human SimPops 
was 30 U/L. 
c 1 individual with ALT >2X ULN. 
d Mean ± S.D. 
e Baseline serum total bilirubin in human SimPops was 0.55 mg/dL. 
N/A, not available. 
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Table 7.2. List of parameters varied in the human and rat SimPops and results of multiple 
regression analysis in human SimPops administered 600 mg/day troglitazone (TGZ) for 6 months. 
Human and rat population samples incorporating variability in parameters governing bile acid 
homeostasis (Bile Acid Homeostasis Sub-model) have been constructed previously (19). Four parameters 
in the Drug PBPK Sub-model and two system-specific parameters also were varied. (See supplementary 
material for methods and data used for construction of SimPops). In the human SimPops, a multiple 
regression analysis was performed to identify the most important parameters in TGZ-mediated 
hepatotoxicity using 16 varied parameters as independent variables and minimum hepatic ATP as the 
predicted outcome. Statistical significance and standardized coefficients were calculated using JMP 10. 
Parameter Name Parameter Description Significance Standardized 
Coefficienta 
Bile Acid Homeostasis Sub-model 
LCA-sulfate uptake Vmax Maximum velocity of hepatic uptake 
of LCA-sulfate 
N/S -0.07 
 
LCA-sulfate canalicular 
efflux Vmax 
Maximum velocity of biliary 
excretion of LCA-sulfate 
P < 0.001 
 
0.43 
 
CDCA-amide uptake Vmax Maximum velocity of hepatic uptake 
of CDCA-amide 
N/S 0.00 
 
CDCA-amide canalicular 
efflux Vmax  
Maximum velocity of biliary 
excretion of CDCA-amide 
P < 0.001 
 
0.21 
 
CDCA-amide basolateral 
efflux Vmax 
Maximum velocity of hepatic 
basolateral efflux of CDCA-amide 
P < 0.05 
 
0.08 
 
CDCA amidation Vmax Maximum velocity of CDCA 
amidation in hepatocytes 
N/S 0.04 
 
LCA-amide sulfation Vmax Maximum velocity of LCA-amide 
sulfation in hepatocytes 
N/S -0.03 
 
LCA synthesis Vmax  Maximum velocity of LCA 
synthesis in the intestinal lumen 
P < 0.001 
 
-0.26 
 
Uptake regulation scaling 
factor  
Scaling factor governing the 
magnitude of feedback regulation of 
hepatic uptake transporter function 
by hepatic bile acid accumulation  
N/S 0.04 
 
Canalicular efflux regulation 
scaling factor 
Scaling factor governing the 
magnitude of feedback regulation of 
hepatic canalicular transporter 
function by hepatic bile acid 
accumulation 
P < 0.001 
 
0.24 
 
 
LCA hydroxylation Vmaxb  Maximum velocity of LCA 
hydroxylation in hepatocytes 
N/A N/A 
Drug PBPK Sub-model  
TGZ intestinal absorption Kab First-order rate constant for TGZ 
absorption from intestine 
N/S -0.01 
 
TGZ hepatic uptake Vmax  Maximum velocity of TGZ hepatic 
uptake  
N/S -0.04 
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TGZ sulfation Vmax Formation rate of TGZ-sulfate (TS)  N/S -0.06 
TS biliary clearance  Biliary clearance of TS  P < 0.001 0.18 
Other system-specific parameters  
Body weightc Body weight P < 0.001 
 
0.15 
 
Toxicity Km for CDCA and 
LCA speciesc 
Intracellular bile acid concentrations 
that induce half-maximal inhibition 
of ATP synthesis  
N/S 0.02 
 
a Parameter estimates that would have resulted from the regression if all of the variables had been 
standardized to a mean of 0 and a variance of 1. The greater the absolute value of the standardized 
coefficient, the greater the effects of the independent variable on the model output.  
b Used in rat SimPops only. 
c Used in human SimPops only. 
N/S, not significant. 
N/A, not available. 
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Figure 7.1. Schematic overview of the bile acid transport inhibition module in DILIsym. 
Hepatic and systemic disposition of drugs/metabolites are simulated using a physiologically-based 
pharmacokinetic (PBPK) model (Drug PBPK Model). The Bile Acid Homeostasis Model represents 
hepatobiliary disposition and enterohepatic recirculation of lithocholic acid (LCA) and chenodeoxycholic 
acid (CDCA) species, and all other (bulk) bile acids (19). Using bile acid transport inhibition constants of 
drugs/metabolites (e.g., Ki, IC50), altered bile acid disposition is simulated. Increased hepatocellular 
accumulation of bile acids inhibits hepatic ATP synthesis and decreases intracellular ATP concentrations 
(Cellular ATP Model), leading to necrotic cell death (Hepatocyte Life Cycle Model) and elevations in 
serum biomarkers of hepatocellular injury and function (e.g., ALT, AST, bilirubin) (Biomarker Model). 
Loss of hepatocytes will subsequently influence drug and bile acid disposition (dashed lines), allowing 
dynamic interaction between kinetics and toxicity mechanisms. Details regarding the construction and 
structures of sub-models can be found in the supplementary materials. 
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Figure 7.2. Predicted and observed plasma concentration of troglitazone (TGZ) and TGZ sulfate 
(TS) in humans and rats. 
Solid and dashed lines represented plasma concentrations of TGZ and TS, respectively, predicted based 
on a PBPK model (Supplementary Figure 7.2). Closed and open symbols represent observed plasma 
concentrations of TGZ and TS, respectively, in (A) humans (triangles) administered 400 mg oral TGZ 
(20), and (B) male rats administered 5 mg/kg intravenous (circles) or oral (triangles) TGZ (21, 22). 
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Figure 7.3. Simulated DILI responses in human and rat populations (SimPops) at specified 
troglitazone (TGZ) dose levels. 
Predicted maximum hepatic accumulation of CDCA and LCA species and DILI responses (i.e., minimum 
hepatic ATP, minimum viable liver mass, maximum serum ALT) post-dose in human SimPops at oral 
doses of 200 (green triangle), 400 (blue circle), or 600 (red diamond) mg/day TGZ for 6 months (A), and 
rat SimPops at oral doses of 5 (blue circle) or 25 (red diamond) mg/kg/day for 6 months (B). 
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Figure 7.4. Simulated serum ALT and viable liver mass in susceptible individuals. 
In human SimPops administered 400 (A) or 600 (B) mg/day troglitazone for 6 months, individuals with 
serum ALT elevations > 3X (n=8 at 400 mg/day; n=14 at 600 mg/day) are presented. 
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Figure 7.5. Sensitivity analysis of transporter inhibition constants. 
Inhibition constants for BSEP, MRP4, and NTCP were altered 10-fold in either direction of the values 
measured in isolated transport systems (Supplementary Table 7.3). Predicted maximum serum ALT 
concentrations in human and rat SimPops after an oral dose of 600 mg/day and 5 mg/kg/day TGZ, 
respectively, for 1 month are presented. Dashed lines represent 3X baseline ALT in human (90 U/L) and 
rat (63 U/L) SimPops. 
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SUPPLEMENTARY MATERIAL 
DILIsym v2 
DILIsym is a mechanistic, mathematical model of DILI, which is organized into various sub-
models that represent physiological processes involved in DILI and drug disposition (16) 
(http://www.dilisym.com). These sub-models are mathematically integrated to simulate response in the 
intact organism. Data from multiple species including humans, rats, mouse, and dogs, are incorporated in 
the model to explore species differences in DILI susceptibility and interpret preclinical data to improve 
prediction of human DILI risk. Currently, DILIsym includes components to predict reactive metabolite-
mediated, mitochondrial, and bile acid-mediated toxicity.  
Physiologically-based Pharmacokinetic (PBPK) Sub-model  
The structure of the PBPK model depicting disposition of troglitazone (TGZ) and TGZ sulfate 
(TS) is presented in Supplementary Figure 7.2. The PBPK model of TGZ consisted of a central 
compartment representing the blood, as well as hepatic and extrahepatic tissues (e.g., muscle, intestine) 
linked to the central compartment by blood flow. The size of the liver and the volume of blood are subject 
to change from baseline values based on the amount of cellular necrosis. Hepatic uptake of TGZ was 
represented using saturable Michaelis-Menten kinetics representing transport-mediated processes (56). 
Biliary excretion of TGZ was reported to be negligible (53, 57, 58). Distribution of TGZ to extra-hepatic 
tissues was assumed to be perfusion-limited and was represented by tissue partition coefficients. TGZ 
metabolism, represented by Michaelis-Menten kinetics, was assumed to occur primarily in the liver by 
sulfation and glucuronidation (22). The quinone metabolite was not included due to its minimal (<10%) 
contribution to total systemic exposure in humans, and total recovery in feces and urine in rats (53, 55).  
The possibility that systemic and hepatic concentrations of TGZ quinone in vivo might have been lower 
than measured due to photooxidation of TGZ to TGZ quinone during analysis cannot be excluded (59). 
TGZ quinone also has been shown to induce hepatotoxicity, but quinone-mediated hepatotoxicity is not 
the focus of the current investigation (6). TGZ glucuronide is formed in the liver, but disposition of TGZ 
glucuronide was not modeled because TGZ glucuronide does not inhibit bile acid transport. TS moved 
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from the periportal zone into the midlobular zone, then into the centrilobular zone, and then into the 
central (blood) compartment, in the direction of blood flow. TS disposition was described using a semi-
PBPK model, which consisted of a central compartment representing the blood, hepatic tissue, and 
extrahepatic tissues lumped into one compartment. TS was reported to be a substrate of hepatic uptake 
and biliary transporters, but hepatic TS disposition was represented by liver partition coefficients because 
1) the semi-PBPK model structure of the metabolites in the current DILIsym does not include active 
transport of metabolites, and 2) existing data suggest that the ratio of hepatic and plasma concentrations 
of TS remained constant over time and could thus be represented by a partition coefficient (53). Biliary 
excretion of TS also was accounted for in the model. Drug-specific parameters, attained from the 
literature or estimated using available plasma TGZ/TS concentration versus time data, are listed in 
Supplementary Table 7.1. Physiological parameters for tissue volumes and blood flows in the PBPK 
module of DILIsym can be found in the supplementary materials of Howell et al. (17). 
Bile Acid Homeostasis Sub-model 
The sub-model of bile acid homeostasis in humans and rats has been constructed within DILIsym 
(19). This sub-model includes 1) the synthesis and metabolism of bile acids in hepatocytes, 2) the biliary 
excretion and basolateral efflux of bile acids via hepatic transporters, 3) the release of bile acids from the 
gallbladder (humans and dogs only), 4) the synthesis of secondary bile acids and deconjugation of 
conjugated bile acids in the gut lumen, 5) reabsorption of bile acids from the gut and subsequent uptake 
into the liver, and 6) the regulatory effects of bile acids on the expression of hepatic transporters and bile 
acid synthesis (19). Hepatic uptake, basolateral efflux, and biliary excretion of bile acids are transporter-
meditated processes which might be interrupted by drugs and/or metabolites. Inhibition constants of TGZ 
and TS for bile acid transport proteins used in the current investigation are listed in Supplementary Table 
7.2. The model represents LCA, CDCA, and respective metabolites, in addition to all other (“bulk”) bile 
acids. LCA and CDCA were chosen because they are hydrophobic and known to be potentially toxic bile 
acids. The quantitative relationship between hepatocellular unconjugated LCA and/or CDCA 
concentrations and ATP concentrations was constructed using the data obtained from human and rat 
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sandwich-cultured hepatocytes (60). Conjugates of LCA and CDCA were assumed to be equally as toxic 
as their unconjugated counterpart.  
Cellular ATP Sub-model 
The cellular ATP model has been constructed previously in DILIsym (17) (Supplementary Figure 
7.4). Briefly, basal ATP turnover was designed to include zero order production and first order utilization. 
The steady-state ATP turnover rate was calculated based on the measured whole body basal metabolic 
rate (61-64), the fraction of the basal metabolic rate from the liver (65), the mass of the liver, and the 
weighted average of the energetic cost of synthesizing ATP from fatty acids, carbohydrates, and amino 
acids (66, 67).  Baseline hepatic ATP levels in the DILIsym model were based on Ghosh 2010 (68) and 
Kaminsky 1984 (69) for the rat, and Noren 2005 (70) and Meyerhoff 1990 (71) for the human. 
Hepatocyte Life Cycle Sub-model 
The hepatocyte life cycle sub-model has been constructed previously in DILIsym (17) 
(Supplementary Figure 7.5). Hepatocytes can undergo death by apoptosis or necrosis; both are 
components of DILI. A variety of determinants push a stressed cell towards apoptosis or necrosis; one of 
the predominant factors is the energy state of the cell. Without sufficient ATP, the cell cannot support 
energy-requiring reactions (including apoptosis), and necrosis will result. Apoptosis can be initiated by 
signals originating in mitochondria or elsewhere. Mitochondrial signals arise when the permeability of the 
outer mitochondrial membrane and/or the number of open inner mitochondrial pores (due to the 
mitochondrial permeability transition-mPT) are increased. Extra-mitochondrial apoptotic signals come 
from “death receptors” and/or ER stress. In addition to the cellular energy state, other factors contribute to 
necrosis. Increased levels of oxidative species, such as reactive metabolites of drugs or endogenous 
compounds, can compromise the integrity of the plasma membrane and cause hepatocytes to rupture. 
Proteases released by Kupffer cells and neutrophils also can elicit necrosis. 
Explicit tracking of individual hepatocyte pools (necrotic, apoptotic and mitotic) is done with 
DILIsym, as it enables comparisons with histological data. Mature and young hepatocytes may have 
different rates of necrosis and apoptosis, and non-viable cells are cleared with specified half-lives. With 
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appropriate internal and external cues, mature hepatocytes can commit to mitosis and divide into young 
hepatocytes. Cell division can be slowed by crowding signals resulting in cell cycle arrest. Oval cells 
contribute to hepatocyte populations in the periportal zone and hepatocytes may 'stream' (i.e., migrate 
over time) from periportal to midlobular and then to centrilobular zones. The contributing rates of cell 
turnover are regulated by mediators (described below in the 'Mediator Production and Regulation' and 
'Regulation of Hepatocyte Rates' sections). 
All zones are assumed to have the same density of hepatocytes, and hepatocytes have the same 
volume.  In all species, centrilobular (CL) is 1/9, midlobular (ML) is 3/9 and periportal (PP) is 5/9 of total 
liver volume, based on a 'cake-slice' like three dimensional configuration of the average acinus (72-74). 
The CL zone is perfused by the venous blood and a decreasing oxygen gradient exists from PP to CL. 
However in practice, some of the 'inter-septal' hepatocytes in the PP zone also may be poorly perfused 
and have slightly different properties (75). While inter-septal morphology is not explicitly modeled, a 
fraction of poorly perfused PP hepatocytes is factored in when interpreting histological data. 
The baseline homeostasis rates associated with the hepatocyte life cycle are calculated such that the 
fraction of hepatocytes that should be young, mature, mitotic, and apoptotic at baseline are consistent with 
the user defined inputs for these values.  Hepatocytes have a long life cycle in the baseline, homeostatic 
state, living 180-365 days or 6-12 months (76). The default values used in the DILIsym model for these 
fractions are from the references listed below. 
1.  The fraction of mitotic and apoptotic hepatocytes at homeostasis was based on Grisham 1962 
(77). Necrosis is assumed not to occur at homeostasis. 
2.  The rate of removal of apoptotic cells was based on Bursch 1990 (78) in rats. This rate is not 
available for other species. In the current version of the model, the cell removal rates do not 
further affect rates of necrosis, apoptosis, and/or proliferation.  Future versions may include 
this type of feedback, however. 
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3.  The rate constant for removal of necrotic cells is calibrated in the rat based on time-series data 
of necrotic hepatocytes after acetaminophen treatment (79). Similar data were not available for 
other species, so the same rate constant was used for other species. 
4.  The rate of cell cycle progression is based on Chanda 1996 (80). 
5.  At baseline, the rate of maturation to go from young to mature hepatocytes is rapid compared 
to other rates.  The differences in the model between young and mature hepatocytes are in 
their rates of necrosis and apoptosis in each zone.  This effect can be explored further with the 
model. 
Biomarker Sub-model 
The biomarker sub-model previously has been constructed in DILIsym (17). Several clinical 
biomarkers are included in the model including alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), prothrombin time, total plasma bilirubin, keratin 18, and high mobility box 
group 1 protein (HMGB1). The ALT and bilirubin sub-models are discussed in more detail below, since 
data from these sub-models is included in this manuscript. 
ALT is an intracellular enzyme responsible for amino acid metabolism and gluconeogenesis in 
the liver and other tissues. In DILI, circulating ALT serves as a marker of hepatocellular injury. An 
increase in ALT is thought to represent compromised hepatocellular membrane integrity due to necrosis. 
Care must be taken when using ALT as a biomarker for DILI, however, because increases in ALT have 
been observed in situations unrelated to DILI. For example, ALT levels may be increased due to release 
from muscle following high intensity exercise (81). 
ALT levels in DILIsym are driven primarily by the rate of hepatocyte necrotic flux 
(Supplementary Figure 7.6). The intermediate ALT compartment was required to adequately describe 
observed ALT profiles in response to other hepatotoxic drugs (e.g., acetaminophen), and may represent 
interstitial space, the Space of Disse, or liver sinusoids. The clearance of ALT has a specified half-life. 
The half-life of ALT is altered by reductions in the number of viable hepatocytes, i.e. less hepatocytes 
lead to a longer ALT half-life. Cellular ALT levels were calculated from the literature and used to 
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estimate the amount of ALT released per necrotic cell (82, 83). More details can be found in the 
supplementary material of Howell et al. (17). 
Combined monitoring of ALT and bilirubin levels often is used as a diagnostic test for DILI. Hy's 
law, for example, includes the combination of ALT (or AST) increases > 3-fold the upper limit of normal 
(ULN) with increases of serum total bilirubin > 2-fold ULN. For this reason, and because total plasma 
bilirubin is an important clinical marker for liver function, a bilirubin sub-model was included in 
DILIsym. 
Bilirubin is a byproduct of red blood cell lysis and serves as a marker of hepatocellular function. 
Bilirubin is derived from the heme molecule, which is abundant in red blood cells. Bilirubin is released to 
the circulation with red blood cell lysis and is cleared by hepatocytes. Once inside the hepatocyte, 
bilirubin is conjugated (to glucuronide, primarily) and exported to bile for excretion, which is an ATP-
dependent process. Bilirubin levels correlate well with the change in hepatic glutathione (84, 85).  
Moreover, hepatic glutathione correlates well with hepatic ATP levels (86, 87). ATP reductions are the 
likely mechanistic link underlying the correlation between bilirubin and glutathione levels. Increases in 
unconjugated or total bilirubin are used in DILI as a marker of compromised hepatic function. Like ALT, 
caution must be taken when using bilirubin as a diagnostic test for DILI, because bilirubin levels may 
increase due to increases in red blood cell lysis or competition for uptake by OATPs instead of decreased 
hepatocellular function (88). 
Bilirubin levels in the model are regulated by changes in clearance, as the input is constant and 
determined by literature values. The primary regulator of hepatocellular bilirubin uptake is the number of 
viable hepatocytes (current hepatocyte number as a fraction of baseline) (89). Glucuronidation and 
transport of bilirubin out of hepatocytes is regulated by cellular ATP levels; this regulation mechanism 
correlates well with changes in bilirubin prior to cell loss. Conjugated bilirubin is not currently included 
in the model, but is likely to be integrated into the bile acid transport model in future versions of 
DILIsym.  A schematic of the bilirubin model is shown in Supplementary Figure 7.7. 
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Construction of human and rat simulated Populations (SimPops) 
Human and rat population samples incorporating variability in the most sensitive parameters 
(n=10 in human, n=11 in rat; Bile Acid Homeostasis Sub-model parameters in Table 7.2) governing bile 
acid homeostasis were constructed previously in DILIsym using a genetic algorithm in MATLAB (Bile 
Acid SimPops). The data and genetic algorithm methods used for construction of the Bile Acid SimPops 
are described in Woodhead et al., and Howell et al., (17, 19). In the human and rat SimPops used in the 
current study, additional variability was incorporated in four drug-specific parameters (the first-order rate 
constant for TGZ absorption from intestine, maximum velocity of TGZ hepatic uptake, formation rate of 
TGZ-sulfate, and biliary clearance of TS). Two system-specific parameters (body weight and sensitivity 
of mitochondrial toxicity to hepatic bile acid accumulation) also were incorporated in the human 
SimPops. A list of parameters varied in human and rat SimPops is presented in Table 7.2. Data used for 
six additional parameters in human and rat SimPops are presented in Supplementary Table 7.3.  
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Supplementary Table 7.1. Troglitazone (drug-dependent) parameters used for the construction of the 
physiologically-based pharmacokinetic model. 
Parameter Values Methods/references 
Troglitazone 
Molecular weight (g/mol) 441.5 ChEMBL 
Log P 4.69 ChEMBL 
pKa 6.35 ChEMBL 
Blood to plasma total concentration ratio 0.55 (Human) 
0.60 (rat) 
(21) 
fu,p (plasma unbound fraction) 0.2 Parameter estimation* 
Kliver (liver to blood partition coefficient) 1 Parameter estimation* 
Kgut (gut to blood partition coefficient) 0.47 Predicted based on pKa 
and logP (90) 
Kmuscle (muscle to blood partition coefficient) 0.15 Predicted based on pKa 
and logP (90) 
Kother (other tissues to blood partition coefficient) 0.61 Predicted based on pKa 
and logP (90) 
Hepatic uptake Vmax (mg/hr) 50.1 Parameter estimation* 
Hepatic uptake Km (mg/ml) 0.0035 (56) 
Hepatic permeability (ml/hr) 1590 Assumed to be 10% of 
total hepatic uptake (91) 
TS formation Vmax (mol/hr/kg^0.75) (maximum velocity 
of TGZ sulfation) 
3.34E-05 (22) 
TS formation Km,u (mol/ml) (unbound Michaelis 
Menten constant of TGZ sulfation) 
1.66E-11 (22) 
TG formation Vmax (mol/hr/kg^0.75) (maximum 
velocity of TGZ glucuronidation) 
7.60E-05 (22) 
TG formation Km,u (mol/ml) (unbound Michaelis 
Menten constant of TGZ glucuronidation) 
7.00E-10 (22) 
CLbile (ml/hr/kg^0.75) 0 (53, 57, 58) 
CLrenal 
(ml/hr/kg^0.75) 
0 (55, 58) 
Kab (1/hr) (the first order rate constant for intestinal 
absorption) 
0.08 (hu) Parameter estimation* 
Kout_gut (1/hr) (the first order rate constant for 
elimination from intestinal lumen to feces) 
0.033 (hu) Parameter estimation* 
Troglitazone Sulfate 
Molecular weight (g/mol) 521.6 ChEMBL 
Blood to plasma total concentration ratio 0.55 (Human) 
0.60 (rat) 
Assumed to be the same 
as TGZ 
fu,p 0.2 Parameter estimation* 
Kliver (liver to blood partition coefficient) 15 (53) 
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Vd_wt (mg/kg) (volume of distribution per kg weight) 380 Parameter estimation* 
CLbile (ml/hr/kg^0.75) 19.5 (57) 
CLrenal (ml/hr/kg^0.75) 0 (55, 58) 
*Optimized using TGZ and/or TS plasma concentration versus time data (20-22, 53, 92). 
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Supplementary Table 7.2. Inhibition constants of TGZ and TS for bile acid transport proteins. 
  Rat Inhibition Constant (µM) Human Inhibition Constant (µM) 
 TGZ TS TGZ TS 
BSEP 1.3a  0.23 a 1.3b 0.23b 
MRP4 21 (IC50)c 8c 31 (IC50)d  8e 
NTCP 2.3 (IC50)f  2.3 (IC50)g 0.33 (IC50)f 0.33 (IC50) g  
Ki unless indicated. 
a, (13) 
b, assumed to be the same as rat because IC50 values of TGZ for human BSEP and rat Bsep are similar 
(12). 
c, assumed to be the same as human 
d, (11) 
e, Yang et al., in preparation 
f, (15) 
g, assumed to be the same as TGZ 
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Supplementary Table 7.3. DILIsym model parameters used to generate human (A) and rat (B) 
simulated populations (SimPops) to explore troglitazone (TGZ)-mediated hepatotoxicity.  
 Human SimPops  
Parameter Name Parameter description Lower/upper 
bounds (%) 
References 
Body weight (kg) Body weight 64/141 (93) 
Toxicity Km for CDCA and LCA 
species 
Intracellular bile acid 
concentrations that induce half-
maximal inhibition of ATP 
synthesis  
50/150  Nadanaciva 
et al., 
unpublished 
TGZ intestinal absorption Kab First-order rate constant for TGZ 
absorption from intestine 
50/150  
TGZ hepatic uptake Vmax (mg/hr) Maximum velocity of TGZ 
hepatic uptake mediated by 
OATP1B1 
13/454* (94) 
TGZ sulfation Vmax (mol/hr/kg^0.75) Formation rate of TGZ-sulfate 
(TS) mediated by 
SULT1A1/1E1 
35/248* (95) 
TS biliary clearance (mL/hr/kg^0.75) Biliary clearance of TS mediated 
by canalicular transport proteins, 
BCRP and MRP2 
29/281* (94) 
  Rat SimPops 
Parameter Name Parameter description Lower/upper 
bounds (%) 
References 
TGZ intestinal absorption Kab First-order rate constant for TGZ 
absorption from intestine 
50/150  
TGZ hepatic uptake Vmax (mg/hr) Maximum velocity of TGZ 
hepatic uptake mediated by 
Oatp1b1 
51/184* (96) 
TGZ sulfation Vmax (mol/hr/kg^0.75) Formation rate of TS mediated 
by Sult1a1/1e1 
51/183* (97) 
TS biliary clearance (mL/hr/kg^0.75) Biliary clearance of TS mediated 
by canalicular transport proteins, 
Bcrp and Mrp2 
51/184* (96) 
The lower and upper bounds give the maximum and minimum values used for the SimPops generation 
relative to baseline parameter values of 100%. The baseline values were taken from the literature or 
obtained through optimization using in vivo data (See Methods).  
Unless specified, a normal distribution was assumed. The standard deviation of the parameters used to 
generate the population samples were assumed to be the differences between the upper or lower bound 
and the baseline value divided by a factor of 2.5. Under this assumption with normal distribution, the 
above bounds include 98.8% of the population. 
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*Log-normal distribution was assumed. Mu (µ) and sigma (σ) (mean and standard deviation of log-
transformed data) were obtained from mean (m) and variance (v) of non-transformed distribution data 
using the following equations: = log(
𝑚2
√𝑣+𝑚2
) , 𝜎 = √log (
𝑣
𝑚2+1
)   
Upper and lower bounds were assumed to be the exponential of µ ± 2.5 × 𝜎. Under this assumption with 
log-normal distribution, the above bounds include 98.8% of the population. 
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Supplementary Figure 7.1. Diagram of the overall structure of DILIsym. 
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Supplementary Figure 7.2. Diagram of PBPK sub-model.  The PBPK model of TGZ consisted of a 
central compartment representing the blood, as well as liver and extrahepatic tissues (e.g., muscle, 
intestine) linked to the central compartment by blood flow. Metabolism of TGZ occurred exclusively in 
the liver. Disposition of TS was described using a semi-PBPK model, which consisted of a central 
compartment representing the blood, extrahepatic tissues, which were lumped into one compartment, and 
liver tissue. 
  
 247 
 
Supplementary Figure 7.3. Diagram of bile acid homeostasis sub-model. The model represents LCA, 
CDCA, and respective metabolites, in addition to all other (“bulk”) bile acids. For simplicity, only the 
CDCA species in the periportal zone are depicted here. Pathways represented as dashed lines are subject 
to feedback regulation mediated by nuclear receptors such as farnesoid X receptor. 
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Supplementary Figure 7.4. Diagram of cellular ATP sub-model. ATP is modeled with a simple 
production and utilization balance, with hepatic bile acid accumulation causing a disruption in ATP 
production. 
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Supplementary Figure 7.5. Diagram of hepatocyte life cycle sub-model. Mature hepatocytes can 
undergo necrosis, apoptosis, or move to the mitotic state where they subsequently divide into two young 
cells. For simplicity, only hepatocytes in the centrilobular zone of the liver are depicted here. 
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Supplementary Figure 7.6. Diagram of ALT sub-model. ALT levels in the model are driven largely by 
the rate of hepatocyte necrotic flux. The intermediate ALT compartment represents extrahepatic space 
including interstitial space, the Space of Disse, and liver sinusoids, and was incorporated to adequately 
describe observed serum ALT profiles in response to other model hepatotoxic drugs (e.g., 
acetaminophen). The clearance of ALT is driven by the specified half-life. The half-life of ALT is altered 
by reductions in the number of viable hepatocytes, i.e. less hepatocytes leads to a longer ALT half-life. 
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Supplementary Figure 7.7. Diagram of bilirubin sub-model. Bilirubin levels in the model are 
regulated by changes in clearance, as the source of bilirubin is constant and determined from published 
data (see the text above for details). The primary regulator of hepatocellular bilirubin uptake is the 
number of viable hepatocytes. Glucuronidation and transport of bilirubin out of hepatocytes is regulated 
by cellular ATP levels; this regulation mechanism correlates well with changes in bilirubin prior to cell 
loss. 
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CHAPTER 8.  Summary and Future Directions 
 
The objectives of this dissertation research were to characterize the mechanisms of drug-induced 
liver injury (DILI) that involve bile acid transport inhibition, and to develop a novel strategy to predict 
liability of drugs for human DILI. DILI is of paramount concern in drug development, but is not well 
predicted from in vitro assay or standard preclinical testing (1, 2).  The rare incidence of DILI, and the 
fact that DILI may not be detected during clinical trials, suggests that in addition to drug-specific risk 
factors, patient-specific risk factors also exist that make a subset of patients more susceptible to DILI. To 
improve our understanding of species differences and patient specific risk factors for bile acid-mediated 
DILI, a variety of model systems [e.g., membrane vesicles, sandwich-cultured hepatocytes (SCH) isolated 
from multiple species] and methods (e.g., RNA interference, pharmacokinetic and mechanistic modeling 
and simulation) were employed in this dissertation project. This research project focused on the model 
bile acids taurocholic acid (TCA), chenodeoxycholic acid (CDCA), and lithocholic acid (LCA). 
Troglitazone (TGZ), an antidiabetic drug that was withdrawn from worldwide markets due to sever DILI, 
was employed as a model hepatotoxic drug. Although numerous mechanisms of TGZ-mediated 
hepatotoxicity have been postulated, one proposed mechanism is inhibition of bile acid transport by TGZ 
and its major metabolite, TGZ sulfate (TS) (3, 4). Inhibition of hepatic bile acid efflux might result in 
hepatic accumulation of harmful bile acids and subsequent hepatotoxicity (5). 
In Aim #1 of this dissertation research, species differences in humans and rats were characterized 
with respect to the hepatobiliary disposition of bile acids and the interaction of hepatotoxic drugs with 
bile acids at hepatic transport proteins. TCA is a prototypical bile acid that has been used widely as a 
probe substrate in transporter inhibition assays (4, 6-8). There exists a wealth of data regarding TCA 
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kinetics and the interaction of TCA with drugs and/or metabolites, which is a great advantage of using 
TCA as a model bile acid. In this aim, hepatic uptake, biliary excretion, and basolateral efflux of TCA 
were characterized using data obtained from human and rat SCH combined with pharmacokinetic 
modeling. Inhibitory effects of TGZ and TS on hepatobiliary disposition of TCA were also investigated 
using SCH and isolated membrane vesicles (Chapter 3). 
Aim #2 investigated the patient-specific risk factors for DILI, focusing on the altered 
hepatobiliary disposition of drugs/metabolites in the setting of impaired function of canalicular 
transporters. Only about 2% of the patient treated with TGZ developed hepatotoxicity, suggesting that 
liver injury was driven by a combination of drug- and patient-specific risk factors. TS, a potent inhibitor 
of bile acid transporters, is predominantly excreted into by Breast cancer resistance protein (Bcrp) and 
multidrug resistance-associated protein 2 (Mrp2). Thus, impaired function of these canalicular 
transporters may cause hepatocellular TS accumulation and lead to hepatotoxicity. To test this hypothesis, 
an in vitro model system lacking specific Bcrp and Mrp2 was established using SCH (Chapter 4), and 
altered hepatic exposure to TGZ and generated metabolites was assessed in this system (Chapter 5).  
Lastly, a mechanistic model of DILI was developed in Aim #3 to improve our understanding 
about, and predictability of, DILI that involves inhibition of bile acid transport. Experiments were 
performed to define the quantitative relationship between intracellular bile acid concentrations and 
hepatotoxicity, which is essential for model development (Chapter 6). Although TCA is commonly used 
as a model bile acid, it is a hydrophilic, less toxic bile acid (5, 9) that is not predominant in humans, and 
may not be suitable as the sole bile acid to investigate toxicity studies. Therefore, CDCA and LCA, which 
are hydrophobic and potentially toxic bile acids (10, 11), were chosen for toxicity studies and were 
modeled exclusively in the mechanistic DILI model. This mechanistic model was used to assess the 
contribution of bile acid transport inhibition associated with TGZ-mediated hepatotoxicity in humans and 
to investigate the mechanism(s) for differential hepatotoxicity of TGZ in humans and rats (Chapter 7).   
The results of this comprehensive dissertation project improved the current understanding about 
mechanisms, species differences, and patient-specific risk factors in bile acid-mediated DILI, and 
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developed a mechanistic model to provide a novel framework to predict human DILI. The following is a 
summary of the findings of the current project and opportunities for future investigation that were 
identified as a result of this research. 
 
Species Differences in Hepatobiliary Disposition of Taurocholic acid in Human and Rat Sandwich-
Cultured Hepatocytes; Implications for Drug-Induced Liver Injury (Chapter 3) 
The bile salt export pump (BSEP) plays an important role in biliary excretion of bile acids. Liver 
diseases caused by functional defects in BSEP due to genetic polymorphisms (e.g., progressive familial 
intrahepatic cholestasis type 2, benign recurrent intrahepatic cholestasis type 2) emphasize the importance 
of BSEP in bile acid excretion and demonstrate toxic consequences of bile acid retention in hepatocytes 
(3, 5, 12). In addition to biliary excretion, bile acids also undergo basolateral efflux via MRP3, MRP4, 
and potentially organic solute transporter (OST)α – OSTβ (13-15). The contribution of basolateral efflux 
to hepatocellular bile acid excretion has been thought to be minimal under normal conditions due to 
extensive biliary excretion of bile acids. However, as proposed in the “hepatocyte hopping” theory of 
bilirubin glucuronides (16), it is possible that bile acids may undergo extensive basolateral efflux, and 
then be taken up into downstream hepatocytes, until they are eventually excreted into bile. So far, the 
relative contributions of biliary versus basolateral efflux clearances to hepatocellular bile acid excretion 
have not been determined precisely.  
In the present study, the hepatobiliary disposition (basolateral uptake and efflux, biliary 
excretion) of TCA was characterized using the uptake and efflux data in human and rat SCH combined 
with pharmacokinetic modeling. The results from this study revealed for the first time that species 
differences exist in hepatocellular efflux pathways of TCA in human versus rat SCH; biliary excretion of 
TCA predominated in human SCH, whereas biliary excretion and basolateral efflux contributed equally to 
hepatocellular TCA excretion. This has important implications in DILI mediated by interruption of bile 
acid transport. Simulations demonstrated that BSEP inhibition alone led to greater hepatic TCA 
accumulation in human SCH compared to rat SCH. This explains, in part, why rats are less sensitive to 
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bile acid-mediated DILI compared to humans after administration of BSEP inhibitors. Additionally, 
inhibition of both basolateral and biliary excretion pathways led to exponential increases in hepatic TCA 
exposure in both human and rat SCH, suggesting that a drug that inhibits both excretion pathways will 
have greater DILI liability. This also implies that impaired function of the alternate pathway due to co-
administered drugs, genetic polymorphisms, and/or disease may predispose patients to DILI when 
administered a drug that inhibits only one pathway.  
Bile acids undergo extensive enterohepatic recirculation (17), and thus, hepatic bile acid exposure 
is modulated by hepatic uptake transporters as well as canalicular and basolateral efflux transporters. 
While inhibition of bile acid efflux transporters are known to be associated with cholestatic/mixed type 
DILI (4, 8), inhibition of bile acid uptake has been suggested to exert protective effects (1). If a drug 
inhibits both hepatic uptake and efflux of bile acids, hepatic bile acid accumulation will be determined by 
the relative potency of uptake inhibition versus efflux inhibition. Simulations in the present study showed 
that inhibition of TCA uptake clearance by greater than 60% prevents hepatic TCA exposure form 
increasing by more than 10-fold in human SCH, thereby confirming the protective effects of uptake 
inhibition. It is of note that simulations in the current study were performed using a hypothetical inhibitor, 
of which concentrations in the medium and in the cells were assumed to be at steady-state. Based on this 
assumption, a constant fractional inhibition of uptake and efflux transporters was employed throughout 
the simulation. In reality, drug concentrations in the hepatocytes and medium might change over time due 
to metabolism and transport. Incorporation of a model describing drugs/metabolites disposition will allow 
prediction of dynamic interactions between drugs/metabolites and bile acids; thus, this would be the 
natural next step to accurately predict altered bile acid disposition by a specific drug.  
The present study was the first investigation to establish that TS is an inhibitor of basolateral bile 
acid efflux in addition to biliary bile acid excretion. Parameter estimates recovered from the 
pharmacokinetic modeling revealed that pre-incubation with TGZ tended to decrease basolateral efflux 
clearance of TCA in human and rat SCH. TGZ has been reported to inhibit basolateral efflux transporters, 
MRP3 and MRP4 (4). However, hepatic concentrations of TGZ were minimal, whereas TS accumulated 
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extensively in hepatocytes (18, 19). TS was reported to be a more potent inhibitor of BSEP compared to 
TGZ (18), suggesting that TS is likely to inhibit basolateral efflux of TCA. To test this hypothesis, in 
vitro transporter inhibition studies were performed using membrane vesicles prepared from HEK293T 
cells overexpressing MRP4; TS was found to be a noncompetitive inhibitor of MRP4 with a Ki value of 8 
µM. Uptake clearance also was significantly decreased (in human SCH) or showed trends towards a 
decrease (in rat SCH) compared to control after TGZ pre-incubation. Although TGZ is a potent inhibitor 
of NTCP/Ntcp-mediated bile acid uptake (20), TGZ concentrations in the buffer during the uptake phase 
were minimal because TGZ-containing buffer was replaced with TGZ-free buffer during the 10-min pre-
incubation (with standard or Ca2+-free standard buffers) as well as during the 20-min uptake phase.  This 
suggests that TGZ might inhibit NTCP/Ntcp by mechanisms other than direct inhibition. For example, 
intracellular TGZ and/or TS may interact with the intracellular domain of NTCP/Ntcp thereby inhibiting 
TCA uptake similar to trans-inhibition of BSEP by estradiol-17β-D-glucuronide (21). It is also possible 
that intracellular accumulation of TGZ and/or TS leads to retrieval of NTCP/Ntcp from the basolateral 
plasma membrane by modulation of intracellular signaling pathways (i.e., short-term regulation) (22). 
Another hypothesis is that irreversible binding of TGZ and/or its metabolites to NTCP/Ntcp might exert 
long-lasting inhibitory effects. Indirect inhibitory mechanisms for transporters are not well understood 
currently, and further studies are needed to elucidate the mechanism(s) for long-lasting inhibition of TCA 
uptake by TGZ observed in the current study. 
Mathematical modeling often requires simplification of biological systems, and thus, several 
assumptions were made during model development. In this modeling project, the hepatocyte compartment 
was assumed to be a homogenous, well-stirred compartment, which clearly is an over-simplification of 
the complex subcellular structure of hepatocytes. Although the current model reasonably explained the 
observed data in human and rat SCH, a slight overestimation of cellular TCA concentrations at earlier 
time points during the uptake phase was noted. Vectorial transport of bile acids from sinusoidal blood to 
bile canaliculi suggests that intracellular trafficking of bile acids may be mediated by vesicular transport 
or carrier-mediated transport rather than simple diffusion of bile acids in the cytosol (23). Intracellular 
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trafficking of BSEP-containing vesicular structures has been shown by confocal imaging using yellow 
fluorescent protein-tagged BSEP (24). Bile acids also can be distributed into and sequestered within 
subcellular organelles. For example, bile acids are ligands of nuclear receptors such as farnesoid X 
receptor and pregnane X receptor, which translocate into the nucleus after activation (25); a time-
dependent increase in nuclear fluorescence was shown after treatment of rat hepatocyte couplets with 
fluorescent bile acids (26). However, the current body of information is not enough to fully understand 
intracellular transport of bile acids, and the quantitative data necessary for mathematical model 
development are lacking. Characterization of the intracellular disposition and transport of bile acids and 
how drugs modulate these processes would be an important next step to improve our understanding of 
bile acid-drug interactions.  
This research demonstrated the utility of pharmacokinetic modeling and simulation in 
understanding differential drug-bile acid interactions in humans and rats, and predicting altered 
hepatobiliary bile acid disposition in the setting of drug-bile acid interactions at multiple hepatic 
transporters. This approach can be used to predict dynamic interactions when combined with 
pharmacokinetic data for drugs and metabolites. The current study provided a framework to investigate 
hepatobiliary disposition of bile acids using TCA, a non-toxic, prototypical bile acid that has been 
employed widely in investigations of drug effects on bile acid transport. The present work needs to be 
expanded to cytotoxic bile acids such as CDCA, LCA, and deoxycholic acid (DCA) in order to improve 
our understanding and predictability of bile acid-mediated DILI.   
 
An Experimental Approach to Evaluate the Impact of Impaired Transport Function on 
Hepatobiliry Drug Disposition using Mrp2-deficient TR- Rat Sandwich-Cultured Hepatocytes in 
Combination with Bcrp Knockdown (Chapter 4) 
Predicting drug disposition in the setting of altered transport function has important clinical 
significance in terms of drug efficacy and safety. BCRP and MRP2 are members of the ATP-binding 
cassette transporter family located in the canalicular membrane of hepatocytes; these hepatic efflux 
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transporters have overlapping substrate specificity. Modulation of expression and/or function of these 
transporters due to genetic polymorphisms, drug-drug interactions, or disease may alter the 
pharmacokinetics and pharmacodynamics of substrates. However, it is challenging to predict the impact 
of altered function of one or more transporters on the hepatic and systemic exposure of substrates due to 
overlapping substrate specificity. In this project, an in vitro model system was established to evaluate the 
impact of impaired Mrp2 and Bcrp function on hepatobiliary drug disposition; Bcrp knockdown was 
achieved by using RNA interference (RNAi) technique, and SCH from Mrp2-deficient (TR-) rats were 
employed to mimic the loss-of-function of Mrp2. To our knowledge, this was the first investigation that 
established an approach to develop a primary hepatocyte model lacking multiple specific transporters.     
This work also emphasized the importance of optimizing the system using a range of multiplicity 
of infection (MOI) when knocking down a protein by RNAi in hepatocytes, and established a strategy for 
optimization of the knockdown system. A two-stage statistical analysis approach was employed in this 
study  that included 1) selection of an optimal MOI by identification of a dose (MOI) – response 
relationship based on the targeted and off-target effects over a range of MOI, and 2) characterization of 
the impact of impaired transporter function at selected MOI. This two-stage analysis approach allowed a 
thorough characterization of the system including off-target effects and interactions among factors that 
might not be revealed by testing only one level of MOI. It is important to note that optimization and 
characterization in the current study were based on functional changes in the transporter using the probe 
substrates rosuvastatin (RSV) and TCA. RSV (a dual substrate of Bcrp and Mrp2) and TCA (a model bile 
acid that is not transported by Bcrp and Mrp2) represented positive and negative controls, respectively, to 
evaluate the functional changes in the transporter knockdown system. Changes in mRNA or protein levels 
may not always translate to functional changes, and altered localization of transporters may not be 
reflected in protein expression levels in the whole cells lysate. Thus, use of relevant probe substrates to 
evaluate changes in protein activity is strongly recommended when establishing a knockdown system.  
It is challenging to knock down proteins in primary cultured hepatocytes because high 
transfection efficiency is difficult to achieve using conventional transfection reagents. To attain efficient 
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knockdown, adenoviral vectors were employed to deliver shRNA into hepatocytes in the present study. 
Recombinant adenovirus had demonstrated high infection efficiency and high transgene capacity, and has 
been used widely as a gene deliver vector (27). Previous work had revealed that adenoviral vectors 
expressing shRNA targeting Bcrp exhibited a significant decrease in protein expression and activity of 
Bcrp in SCH (28). In the current study, double knockdown of Bcrp and Mrp2 using RNAi was attempted 
initially. However, off-target effects on other transporters were noted at the higher MOI required to knock 
down both transporters; an MOI of 5 was required for efficient knockdown of Bcrp and Mrp2, 
respectively, and thus, a combination of shRNA targeting two different transporters required an MOI of 
10, at which off-target effects were predominant. To circumvent this issue, SCH from TR- rats were 
employed in combination with Bcrp knockdown using adenoviral infections of shRNA targeting Bcrp. 
Alternatively, tandem plasmid vectors that express multiple different siRNA in one vector can be used to 
achieve double knockdown with minimal off-target effects. This might be of great importance when 
RNAi is applied to human-derived cells such as human SCH or other technologies in development (e.g., 
induced pluripotent stems cells, bioengineered culture systems) because it is difficult to obtain human 
cells naturally lacking specific transporters (e.g., hepatocytes from patients with Dubin-Johnson 
syndrome). Often, preclinical data do not translate to humans due to species differences in transporter 
expression and regulation, and substrate/inhibitor specificity and affinity. Therefore, development of a 
human-derived system lacking multiple transporters would be the next step necessary to reliably predict 
drug disposition in patients with altered hepatobiliary transporter function. The current study established a 
strategy for optimization of the knockdown system, and demonstrated the potential use of RNAi in SCH 
as an in vitro tool to predict altered hepatobiliary drug disposition when transporter function is impaired. 
This research with rat SCH provides a stepping stone for development of a transporter knockdown system 
in human-derived cells.  
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Hepatocellular Exposure of Generated Metabolites, Troglitazone Sulfate and Glucuronide, is 
Determined by the Interplay between Formation and Excretion in Rat Sandwich-Cultured 
Hepatocytes Lacking Selected Canalicular Transporters (Chapter 5) 
TGZ caused hepatotoxicity only in a small fraction of treated patients, suggesting that injury was 
driven by a combination of drug- and patient-specific risk factors. In hepatocytes, TGZ is extensively 
metabolized to TS, which is excreted into bile predominantly via Bcrp and Mrp2 (29, 30). TS 
accumulates extensively in hepatocytes (19, 31), and also is a potent inhibitor of bile acid efflux 
transporters such as BSEP and MRP4 (18). This suggests that TS may be an important mediator of altered 
bile acid disposition and subsequent hepatotoxicity. The impaired function of Bcrp and Mrp2 would be 
expected to increase hepatocellular TS accumulation and enhance inhibition of bile acid efflux, which 
might predispose a subset of patients to TGZ-mediated hepatotoxicity. To test this hypothesis, the 
hepatobiliary disposition of TGZ and generated metabolites, TS and TGZ glucuronide (TG), was 
examined in rat SCH lacking Bcrp and/or Mrp2, as established in the previous chapter. The results from 
the present study revealed that biliary excretion of generated TS was not significantly altered by impaired 
Bcrp and/or Mrp2 function, suggesting that loss-of function of Bcrp and/or Mrp2 would not be a risk 
factor for increased hepatocellular TS accumulation in rats. This might be due to a compensatory 
transporter(s) that can excrete TS into bile in the absence of Mrp2 and Bcrp. Bsep and P-glycoprotein (P-
gp) were investigated as potential compensatory transporters using membrane vesicles overexpressing 
Bsep, and GF120918, which is a potent inhibitor of P-gp and Bcrp, in rat SCH, respectively. However, 
results suggested that Bsep and P-gp were not likely to be involved in TS biliary excretion. Other hepatic 
canalicular transporters such as multidrug and toxic extrusion protein 1 (MATE1) or multidrug resistance 
protein 2 (Mdr2) might contribute to TS biliary excretion. Further investigations are needed to elucidate 
the compensatory transporter(s) responsible for TS biliary excretion. 
Although TS biliary excretion was not altered, hepatocellular TS accumulation was significantly 
decreased in TR- rat SCH compared to WT rat SCH. A decrease in the total recovery of TS (in cells, bile, 
and media) indicated that sulfation was decreased, or de-sulfation was increased, in TR- rat SCH 
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compared to WT rat SCH. TS de-sulfation was not observed in the S9 fraction from WT or TR- rat livers, 
suggesting that decreased hepatocellular TS accumulation might be due to decreased sulfation rather than 
increased de-sulfation.  Interestingly, TS formation rates were comparable in S9 fractions from WT and 
TR- rat livers.  The expression levels of sulfotransferase (Sult) 1a1 and Sult1e1 were comparable in livers 
from WT and TR- rats (32, 33). One hypothesis to explain decreased total TS recovery is that the 
availability of 3’-phosphoadenosine-5’-phosphosulfate (PAPS), an important cofactor for sulfation, is less 
in TR- compared to WT rat SCH. In vitro metabolism experiments using S9 fractions were performed 
with adequate amount of PAPS added exogenously, but sulfation might have been limited by the 
availability of PAPS in TR- hepatocytes. It is possible that TR- rat SCH may have lower levels of PAPS 
precursors or lower activity of enzymes involved in PAPS synthesis. This could be tested in future studies 
by quantifying PAPS biosynthesis from inorganic [35S]sulfate in hepatocytes using a high-performance 
liquid chromatography (HPLC) radiometric procedure (34). Alternatively, TR- rat SCH may have higher 
cellular concentrations of endogenous substrates that deplete PAPS, resulting in decreased sulfation of 
TGZ. Although the mechanisms still remain to be elucidated, the present data demonstrated for the first 
time that sulfation of TGZ was decreased in TR- rat SCH. TR- rats have been employed widely to 
investigate the contribution of Mrp2 to drug disposition, but altered expression of several enzymes and 
transporters in TR- rats has been noted (32, 35, 36). Thus, accurate characterization of altered function of 
enzymes and transporters in TR- rats is required to correctly interpret the results from TR- rats. The results 
from the present study suggest that further investigation of mechanisms underlying altered sulfation of 
TGZ in TR- rat SCH, and the potential impact on sulfation of other compounds, is warranted.  
Altered disposition of TS and TG revealed in the present study also confirms that hepatocellular 
exposure of hepatically-generated metabolites is determined by both formation and excretion. Even 
though TS biliary excretion was not altered, hepatocellular TS accumulation was decreased in TR- rat 
SCH as a result of decreased sulfation of TGZ. In contrast, hepatocellular TG accumulation was 
significantly increased in TR- compared to WT rat SCH as a result of increased glucuronidation of TGZ 
combined with negligible TG biliary excretion. Loss-of-function of Mrp2 in TR- rats led to altered 
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expression of several enzymes and transporters as a compensatory mechanism (32, 35, 36). Likewise, 
changes in function of one pathway might lead to altered function of other enzymes and/or transporters. 
Therefore, to accurately predict changes in the hepatic exposure of metabolites, altered formation as well 
as excretion of metabolites needs to be considered. This is important in predicting efficacy and/or toxicity 
of metabolites if the liver is the site of action or the generated metabolites elicit hepatotoxic effects.  
The present study demonstrated that biliary excretion of TS was not altered by loss-of-function of 
Mrp2 and/or Bcrp, suggesting that loss-of-function of these hepatic efflux proteins is not a risk factor for 
increased hepatocellular TS accumulation in rats. However, these data might not be directly translated to 
humans due to species differences in abundance, substrate specificity and/or affinity for canalicular 
transporters. To characterize risk factors for human DILI, the results from the current study need to be 
evaluated in primary human hepatocytes or human-derived cell systems. As discussed in the previous 
chapter, this would require double knock-down of transporters in human systems using tandem vectors, or 
more advanced technology to minimize the off-target effects on other transporters.  
 
Quantitative Relationship between Intracellular Lithocholic Acid, Chenodeoxycholic Acid and 
Toxicity in Sandwich-Cultured Hepatocytes; Incorporation into a Mechanistic Model of Drug-
Induced Liver Injury (Chapter 6) 
Increasing evidence supports the hypothesis that drug-mediated functional disturbances in hepatic 
bile acid transporters can induce hepatotoxicity by hepatocellular accumulation of harmful bile acids. 
Inhibition of bile acid efflux transporters by drugs has been demonstrated to be associated with DILI 
based on the systematic investigation of a panel of drugs for their inhibitory effects on bile acid efflux 
transporters using isolated membrane vesicle systems (4, 6, 8). However, results from the isolated 
transporter system cannot be translated directly to in vivo hepatotoxicity due to the complexity of bile 
acid homeostasis (i.e., vectorial transport, enterohepatic recirculation), dynamic changes in the systemic 
as well as hepatic exposure of drugs/metabolites and bile acids, and feedback regulation of bile acid 
synthesis and transport as an adaptive response to hepatic bile acid accumulation. While in vivo 
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preclinical models predictive of bile acid-mediated DILI are lacking, mechanistic modeling that 
incorporates biological processes involved in DILI as well as the disposition of drugs and metabolites is a 
useful approach to translate in vitro data to in vivo and make predictions about human DILI.  
The objective of Aim 3 was to develop a mechanistic model of DILI that involves interruption of 
bile acid transport by drugs. It has been widely accepted that intracellular accumulation of bile acids 
results in hepatotoxicity. However, the relationship between hepatocellular bile acid accumulation and 
toxicity, which is essential to link bile acid kinetics to toxicity in the mechanistic model of DILI, has not 
been assessed quantitatively. In the present study, we established for the first time the relationship 
between intracellular bile acid concentrations and toxicity in multiple species. Quantification of 
intracellular concentrations of bile acids and ATP, which is difficult to measure in vivo especially in 
humans, was possible by using SCH. SCH maintain metabolic and transporter function as well as 
regulatory machinery, and thus mimic bile acid metabolism and transport in vivo (37-39). The results 
revealed that unconjugated LCA and CDCA were correlated with observed toxicity (i.e., depletion of 
intracellular ATP, LDH leakage).  Based on these results, LCA and CDCA were selected as the 
toxicophores for subsequent investigations. Using the in vitro data obtained from SCH, mathematical 
models describing the relationship between intracellular unconjugated LCA and CDCA, and ATP 
concentrations were constructed.  
This study also provided insight into species differences in toxicity of LCA and CDCA. After 
incubation with LCA, differential toxicity was noted in SCH from different species. LCA exerted a 
concentration-dependent decrease in hepatocellular ATP in rat SCH, whereas human and dog SCH were 
more resistant to LCA-mediated toxicity given the same hepatocellular exposure. Minimal toxicity was 
observed in mouse SCH treated with LCA, potentially due to lower intracellular unconjugated LCA 
concentrations compared to other species treated with the same LCA medium concentrations. CDCA 
induced medium concentration-dependent toxicity in both rat and human SCH. However, human SCH 
showed delayed toxicity with a higher LC50 value compared to rat SCH, suggesting that CDCA-mediated 
toxicity is less potent in humans compared to rats. Although mechanisms of observed species differences 
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remain to be investigated, a plausible hypothesis is that intracellular unbound bile acid concentrations 
may differ among different species, potentially due to the differential intracellular binding, disposition, 
and/or sequestration of bile acids. It is also possible that differential accumulation of toxic bile acids at the 
site of toxicity exists among different species. For example, bile acids are known to induce mitochondrial 
toxicity by inducing mitochondrial permeability transition (40, 41). Thus, mitochondrial accumulation of 
toxic bile acids might be different in humans and rats, leading to the observed species difference. 
However, little is known about intracellular distribution and transport of bile acids, and further studies are 
warranted. One approach would be isolation of subcellular factions after incubation of human and rat 
hepatocytes with bile acids. However, isolation of subcellular fractions of membrane-bound organelles 
using differential centrifugation has limitations due to potential redistribution of compounds during 
fractionation (42). Use of fluorescent bile acids would allow real-time imaging of intracellular 
localization of bile acids (43, 44). However, such data should be interpreted with caution because tagging 
bile acids with a fluorophore might alter the intracellular distribution of bile acids. In addition to species 
differences in bile acid disposition, pathophysiological processes involved in the induction of bile acid 
toxicity (e.g., mitochondrial function, induction of necrosis/apoptosis) downstream of bile acid exposure 
may contribute to differential sensitivity/resistance to bile acid toxicity, and further investigations are 
warranted to fully characterize the underlying mechanisms. 
Interestingly, cellular concentrations of LCA conjugates were decreased at LCA medium 
concentrations greater than 100 µM in rat SCH. Similar trends were observed for intracellular TCDCA, 
GCDCA, TMCA, and GMCA in rat SCH treated with CDCA, and GCDCA in human SCH incubated 
with CDCA. This is potentially due to saturation of enzymes involved in bile acid amidation (i.e., bile 
acid-CoA synthase, bile acid-CoA:amino acid N-acyltransferase) and/or depletion of co-substrates (i.e., 
glycine, taurine). However, concentration-dependent formation of conjugates alone would be expected to 
cause intracellular concentrations of conjugates to plateau, rather than decrease as observed, as 
unconjugated bile acid concentrations in the medium increased. Observed decreases in intracellular 
conjugate concentrations at higher concentrations of unconjugated bile acids suggests that other changes 
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are occurring, such as adaptive increases in hepatic efflux and/or further metabolism (e.g., sulfation) of 
these conjugates. Short-term regulation of efflux transporters due to cytokine-mediated insertion and 
retrieval of transporters into and from plasma membranes might be involved because incubation times of 
6 to 24 hr was not long enough to cause transcriptional changes in transporter expression levels. It is also 
possible that sulfation of glycine and taurine conjugates of LCA might have been increased at higher 
medium concentrations of unconjugated LCA, but testing this would require quantification of sulfate 
conjugates. 
In the present study, unconjugated LCA and CDCA were assumed to be associated with the 
observed toxicity in SCH because cellular unconjugated LCA and CDCA concentrations were correlated 
with observed toxicity. However, it is possible that conjugated LCA and CDCA might also cause toxicity.  
For example, LCA conjugates have been shown to cause cholestasis (45-47). GCDCA induces apoptosis 
in primary hepatocytes and mitochondrial permeability transition in isolated mitochondria (40, 41, 48). In 
addition, other hydrophobic bile acid species such as DCA might also contribute to bile acid-mediated 
DILI. Measurement of intracellular bile acid concentrations and toxicity in SCH incubated with 
concentration ranges of CDCA conjugates, LCA conjugates, or other potentially toxic bile acids would 
help elucidate the contribution of other bile acids to DILI and improve the predictability of the 
mechanistic model. Also, toxicity measured in the current study was the direct effect of bile acids on 
hepatocytes after short-term (6 to 24 hr) exposure to high concentrations of bile acids. Different 
experimental approaches would be necessary to examine the contribution of non-parenchymal cells to bile 
acid-mediated toxicity, as well as the toxic effects of long-term exposure to low concentrations of bile 
acids.  
Results from the present study revealed that rat was the most sensitive species to LCA toxicity in 
SCH, and that CDCA induced toxicity at lower medium concentrations in rat SCH compared to human 
SCH. However, this does not indicate that rats are more susceptible to bile acid-mediated hepatotoxicity 
compared to other species. Actually, rats are less sensitive to hepatotoxicity induced by bile acid transport 
inhibitors (1, 2). To accurately translate the in vitro toxicity data generated in the present study to in vivo, 
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species differences in the in vivo bile acid profile, bile acid disposition and regulation, as well as 
hepatocellular accumulation of toxic bile acids in the setting of drug administration needs to be 
considered. This can be accomplished by developing a mechanistic model of DILI that incorporates the 
physiology and pathophysiology of bile acids and the disposition of drugs and metabolites, which will be 
discussed in the next chapter. The relationships between intracellular bile acid exposure and hepatocyte 
toxicity in humans and rats established in this chapter were incorporated into the mechanistic model to 
link bile acid homeostasis and cellular ATP dynamic sub-models, and predict DILI mediated by 
interruption of bile acid transport.  
 
Mechanistic Modeling of Drug-Induced Liver Injury Predicts Delayed Presentation and Species 
Differences in Bile Acid -Mediated Troglitazone Hepatotoxicity (Chapter 7) 
In this chapter, a mechanistic model of DILI (DILIsym®) that involves drug-bile acid interactions 
was developed to incorporate current knowledge about the biological system and in vitro data to improve 
the predictability of human DILI. DILIsym® incorporates sub-models representing drug and metabolite 
disposition, the physiology and pathophysiology of bile acids, cellular ATP dynamics, the hepatocyte life 
cycle, and biomarkers of liver injury (e.g., serum ALT and bilirubin). The quantitative relationships 
between intracellular bile acid concentrations and toxicity established in the previous chapter were 
employed to link the bile acid homeostasis model and hepatotoxicity. Population variability also was 
incorporated into model predictions because of the large variability that exists in bile acid exposure and 
because incidence rates of bile acid-mediated hepatotoxicity are low (49, 50). DILIsym® was used to 
investigate the role of bile acid transport inhibition in TGZ-mediated hepatotoxicity in humans, and to 
explore the mechanisms for species differences in hepatotoxicity in humans and rats administered TGZ. 
Although TGZ and TS were identified as potent inhibitors of bile acid transporters in isolated 
membrane vesicle systems (4, 7, 20), the implications of these finding with respect to in vivo 
hepatotoxicity have not been evaluated. Results from the current study demonstrated for the first time that 
bile acid transport inhibition alone, without other mechanisms of toxicity (e.g., reactive metabolite, 
 276 
 
mitochondrial toxicity), can explain species differences and the lag time in TGZ-mediated hepatotoxicity. 
In the simulated human population (SimPops) administered 400 – 600 mg/day TGZ for 6 months, 2.4 – 
4.2% of individuals exhibited elevations in serum ALT >3X ULN, and Hy’s Law cases were identified in 
0.9 – 3.0% of the population. This is similar to observations during the clinical trials, where 2% of treated 
patients experienced elevated serum ALT >3X ULN, and two patients presented with jaundice (50). 
Simulations also adequately predicted the delayed time to peak ALT elevations observed in the clinic 
(50). Although the underlying mechanism(s) remain unclear, the mechanistic modeling suggested that 
delayed bile acid accumulation due to the dynamic interaction between hepatobiliary bile acid disposition 
and hepatic ATP concentrations might contribute to the delayed presentation of TGZ-mediated toxicity.  
DILIsym®, which incorporates species differences in bile acid homeostasis, correctly predicted 
the differential hepatotoxicity of TGZ in humans versus rats. Rats have a more hydrophilic, less toxic bile 
acid pool compared to humans. For example, CDCA, the most widely implicated bile acid in cholestatic 
liver injury (10), is one of the dominant bile acids in humans, whereas it contributes a smaller proportion 
to the total bile acid pool in rats and mice (49, 51). LCA, the most hydrophobic bile acid, is primarily 
sulfated in humans, but undergoes extensive hydroxylation in rats (11). The DILIsym® bile acid 
homeostasis sub-model incorporated these species differences in the bile acid profile, which led to lower 
hepatic accumulation of toxic bile acids in rats compared to humans, and thus, no apparent toxicity in rats. 
Sensitivity analysis demonstrated that rat SimPops did not exhibit hepatotoxicity even for compounds 
with 10-fold lower (more potent) inhibition constants for bile acid efflux transporters, suggesting that the 
differential bile acid profile, rather than inhibitor specificity and/or potency of drugs, is the main 
contributor to species differences in DILI.  
As shown in the clinic and simulated results, only a small subset of patients treated with TGZ 
experienced serum ALT elevations, suggesting that certain patients are more susceptible to TGZ-
mediated hepatotoxicity (50). Multiple linear regression analysis of DILI responses in the human 
SimPops enabled identification of potential risk factors; the results suggested that impaired function of 
hepatic efflux transporters responsible for excretion of bile acids (LCA-sulfate, CDCA-amide) as well as 
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perpetrator drugs/metabolites (TS) might predispose a subset of patients to DILI. It is possible that 
diseases (type 2 diabetes and associated conditions such as non-alcoholic steatohepatitis and cirrhosis) 
might make a subset of patients more susceptible to hepatotoxicity due to functional changes in enzymes 
and/or transporters, underlying liver injury, and compromised compensatory hepatocyte proliferation and 
tissue repair (52). However, mechanistic and quantitative assessment of functional impairment of 
enzymes and/or transporters as well as impaired tissue injury with regard to the progress/severity of 
disease will be required. Increased LCA synthesis in the intestinal lumen as also identified as a risk factor 
for DILI. LCA is synthesized in the intestine by bacterial modification of CDCA, which is known to be 
affected by environmental factors such as diet. However, the rate and interindividual variability of LCA 
synthesis have not been well characterized, and thus further studies are needed to evaluate the effects of 
environmental factors on bile acid-mediated hepatotoxicity using the mechanistic modeling. 
The current mechanistic model combined with population analysis was able to reasonably predict 
altered bile acid disposition in rats administered glibenclamide (53), and also correctly predicted species 
differences in TGZ-mediated hepatotoxicity. This suggests that the mechanistic model can be used to 
qualitatively predict a drug’s propensity to cause bile acid-mediated hepatotoxicity. However, it is of note 
that there exist knowledge gaps in bile acid homeostasis and bile acid-drug interactions that limit the 
accurate prediction of bile acid-mediated DILI. For example, quantitative data regarding feedback 
regulation of bile acid synthesis and/or transport currently are lacking. Intestinal transporters that mediate 
bile acid reabsorption recently have been characterized, and there has been increasing evidence that 
enterocytes play important roles in feedback regulation of bile acid synthesis, metabolism, and transport 
(54). However, this is an emerging area of research, and more information (both qualitative and 
quantitative) needs to be generated to fully characterize intestinal bile acid transport and regulation. Other 
important unknowns include hepatocyte drug and bile acid concentrations that are relevant to drug-bile 
acid interactions at the hepatic efflux transporters. Total hepatic concentrations may not accurately 
represent the concentrations of drug and/or metabolite available to inhibit transporters. Alternatively, 
unbound cytosolic concentrations might represent the drug and/or metabolite(s) concentrations that are 
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capable of exerting inhibitory effects based on the free-drug hypothesis (55). However, if bile acids 
undergo carrier- or vesicle-mediated intracellular transport, unbound cytosolic drug concentrations might 
not be relevant. Therefore, intracellular transport and localization of bile acids needs to be elucidated first, 
and then development of experimental methods to reliably measure the relevant concentrations should 
follow in order to accurately characterize relevant hepatocyte drug concentrations for inhibition of bile 
acid efflux.  
Although the current model reasonably predicted incidence rates and delayed presentation of 
serum ALT elevations induced by TGZ treatment, “adaptation” to liver injury was not predicted. Once the 
injury is initiated (e.g., by drug-mediated hepatic bile acid accumulation), the prognosis of liver injury is 
determined by biochemical mechanisms that lead to progression or regression of injury and compensatory 
liver repair. In most patients who experienced TGZ-mediated elevations in serum ALT, enzyme levels 
returned to normal after discontinuation of the drug or even with the continuing use of TGZ (50), and 
only a small percentage of patients developed liver failure that led to encephalopathy, transplant or death 
(56). This suggests that most of the patients who experienced serum ALT elevations were able to adapt to 
the liver injury, whereas patients who did not adapt progressed to severe hepatotoxicity (2). Although 
mechanisms underlying adaption are poorly understood, several studies suggest that regulation of 
multiple genes including drug metabolizing enzymes and transporters are critical. For example, hepatic 
basolateral efflux transporters are upregulated under cholestatic conditions when biliary bile acid 
excretion is impaired, serving as a compensatory elimination pathway of bile acids (57). Genetic defects 
in this regulatory pathway might make a subset of population more sensitive to bile acid-mediated DILI. 
Secondary inflammation, oxidative damage, and enzymatic degradation via proteases also are postulated 
to be involved in the progression of hepatotoxicity (52). Idiosyncratic toxicities are not driven solely by 
drug exposure, but rather depend on several drug- and patient-related risk factors. Lack of a mechanistic 
understanding of the adaptation process, a paucity of existing animal models, and the absence of specific 
and sensitive biomarkers impedes the identification of susceptible patients to idiosyncratic severe liver 
injury. Validity and predictability of the mechanistic model depend largely on existing data and 
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knowledge. However, even in the absence of data, mechanistic modeling can be used to test different 
hypotheses regarding susceptibility factors associated with different biological processes that contribute 
to severe liver injury beyond serum ALT elevations.  
In the present study, a mechanistic model was developed to predict DILI that involves inhibition 
of hepatic bile acid transport. Results from the current study demonstrated for the first time that bile acid 
transport inhibition alone could predict the delayed hepatotoxicity observed after TGZ treatment. Also, 
the mechanistic model incorporating physiology and pathophysiology of bile acids in humans and rats 
correctly predicted differential TGZ hepatotoxicity in humans and rats. Although development of a 
mechanistic model is limited by currently available data and knowledge, modeling can define knowledge 
gaps, prioritize identified knowledge gaps, and guide study design. In the process of model development, 
a missing link was found between intracellular bile acid concentrations and toxicity, and experiments 
were performed (LCA and CDCA toxicity studies, as discussed in the previous chapter) to fill this data 
gap. Data generated from these experiments served as model input, and then the developed model was 
used to simulate DILI responses in populations. Simulation results were validated against the existing 
clinical data, and at the same time, used to identify risk factors for DILI, which generated new hypotheses 
that can be tested by experiments. The current study demonstrated that mechanistic models can be useful 
to predict hepatotoxic potential of compounds and aid in decision-making throughout drug development. 
Initially, predictions are based on in vitro and preclinical data. The mechanistic models can be refined 
iteratively to incorporate additional information generated during the drug development process (e.g., 
drug disposition and safety data in healthy volunteers during phase I clinical trials) as it becomes 
available. Refined models can be used to inform the safety profile of drugs in larger populations and/or 
patients, and identify patients who may be susceptible to toxicity.  
 
CONCLUSION 
This dissertation research focused on DILI that involves drug-bile acid interactions at hepatic 
transport proteins. Various experimental systems and approaches were employed to answer important 
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questions regarding species differences and patient specific risk factors for bile acid-mediated DILI. A 
mechanistic, multi-scale model that incorporates information about biological processes involved in DILI 
was developed to translate experimental data from in vitro systems and preclinical species to humans to 
improve predictability of human DILI. Although many fundamental questions remain to be answered, the 
integrative approach employed in these studies established a framework to incorporate knowledge about 
physiology and experimental data obtained during the drug development process to prospectively predict 
hepatotoxic potential of chemical entities.  
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Figure 3.3. 
Human Control 
 
Taurocholic Acid Accumulation (pmol/mg protein) 
Lysate Buffer 
Study Phase 
Time (minute) Standard HBSS Ca2+-free HBSS Standard HBSS Ca2+-free HBSS 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 48.0 14.8 20.5 7.2     
5 5 95.4 18.6 32.9 8.0     
10 10 136.9 20.8 44.6 6.5     
20 20 318.6 6.1 116.7 37.2     
Efflux 
2 23 220.4 49.3 65.7 9.6 42.9 28.2 34.8 7.1 
3.5 24.5 211.9 31.1 56.4 16.2 49.8 21.7 43.6 5.1 
5 26 217.5 55.9 48.3 16.7 69.0 32.2 51.4 8.5 
10 31 218.1 61.0 41.9 26.0 101.0 31.8 82.0 13.5 
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Human +TGZ 
 
Taurocholic Acid Accumulation (pmol/mg protein) 
Lysate Buffer 
Study Phase 
Time (minute) Standard HBSS Ca2+-free HBSS Standard HBSS Ca2+-free HBSS 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 6.8 0.6 6.3 4.4     
5 5 12.4 0.8 11.0 8.0     
10 10 15.9 0.7 8.5 4.9     
20 20 33.3 4.0 22.1 14.1     
Efflux 
2 23 22.4 2.8 8.6 3.9 8.3 3.7 14.7 17.4 
3.5 24.5 22.7 0.9 6.0 3.0 11.1 3.2 11.9 10.3 
5 26 15.3 3.1 4.7 2.9 12.2 4.4 18.5 19.9 
10 31 15.3 0.6 3.2 1.9 23.1 7.0 22.3 17.7 
 
 
Rat Control 
 
Taurocholic Acid Accumulation (pmol/mg protein) 
Lysate Buffer 
Study Phase 
Time (minute) Standard HBSS Ca2+-free HBSS Standard HBSS Ca2+-free HBSS 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 21.8 4.7 4.9 0.8     
5 5 37.5 10.2 5.9 2.6     
10 10 54.7 9.6 10.5 3.0     
15 15 73.1 19.1 11.5 1.5     
20 20 85.3 21.5 13.8 0.9     
Efflux 
2 23 72.2 10.6 4.5 1.2 19.3 4.9 9.1 3.7 
3.5 24.5 57.8 12.6 3.9 2.0 25.7 8.4 9.0 3.7 
5 26 49.3 11.3 1.9 0.8 31.4 9.2 8.7 2.5 
10 31 40.3 14.0 1.3 0.6 45.7 21.3 12.5 4.0 
15 36 33.0 6.0 0.5 0.1 51.8 15.5 11.6 0.6 
 
  
 
2
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Rat + TGZ 
 
Taurocholic Acid Accumulation (pmol/mg protein) 
Lysate Buffer 
Study Phase 
Time (minute) Standard HBSS Ca2+-free HBSS Standard HBSS Ca2+-free HBSS 
(in phase) (cumulative) Mean SEM Mean SEM Mean SEM Mean SEM 
Uptake 
2 2 5.0 1.8 2.5 0.5     
5 5 7.5 0.6 2.7 1.0     
10 10 9.2 0.8 3.2 0.8     
15 15 11.5 0.6 4.2 0.7     
20 20 12.9 0.9 5.0 1.1     
Efflux 
2 23 6.5 1.6 0.9 0.1 4.7 0.5 2.9 0.1 
3.5 24.5 4.6 1.0 0.7 0.2 5.9 0.3 4.3 1.4 
5 26 4.4 1.1 0.5 0.2 8.0 0.6 4.4 0.3 
10 31 2.6 0.9 0.2 0.1 8.7 1.3 5.1 2.0 
15 36 1.7 0.3 0.1 0.1 9.5 0.5 5.7 2.3 
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Figure 3.4. 
(A) 2 µM DHEAS 
 ATP-dependent DHEAS transport 
(pmol/min/mg protein) 
 - GSH + GSH 
Mean SD Mean SD 
Control 127.3 55.3 276.0 25.0 
50 µM TS 29.3 3.1 79.0 4.5 
 
(B) Concentration-dependent transport of DHEAS 
 
ATP-dependent DHEAS transport 
(pmol/min/mg protein) 
DHEAS 
Concentration 
(µM) 
Control 5 µM TS 10 µM TS 50 µM TS 
Mean SD Mean SD Mean SD Mean SD 
0.5 79.6 3.6 72.1 2.5 28.0 1.3 3.2 3.3 
2 240.2 21.4 233.8 7.0 105.5 6.6 21.7 5.3 
5 462.4 24.6 415.3 34.5 176.7 28.4 32.2 8.5 
10 614.6 28.7 634.6 47.1 318.4 40.5 21.5 7.5 
20 737.3 143.6 593.9 88.3 330.3 82.9 133.9 45.9 
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Figure 4.1. 
(A) Bcrp mRNA  
 
(B) Bcrp protein 
 Bcrp protein (% non-infected control) 
MOI 
WT TR- 
Ad-siNT Ad-siBcrp Ad-siNT Ad-siBcrp 
Mean SEM Mean SEM Mean SEM Mean SEM 
3 66.6 18.8 39.4 20.6 131.8 76.4 66.7 26.0 
5 76.9 16.5 33.6 15.0 86.8 15.8 35.3 19.9 
10 53.3 16.0 19.4 10.1 82.4 10.8 30.1 11.0 
 
  
 Bcrp mRNA (% non-infected control) 
MOI 
WT TR- 
Ad-siNT Ad-siBcrp Ad-siNT Ad-siBcrp 
Mean SEM Mean SEM Mean SEM Mean SEM 
3 108.1 26.6 41.0 10.4 98.2 38.9 23.4 10.0 
5 98.3 12.6 23.5 6.8 118.5 7.7 14.2 4.0 
10 124.2 6.5 11.6 3.5 117.7 35.0 6.5 0.9 
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Figure 4.2.  
(B) Transport protein expression 
 Protein (% non-infected control) 
Protein MOI 
WT TR- 
Ad-siNT Ad-siBcrp Ad-siNT Ad-siBcrp 
Mean SEM Mean SEM Mean SEM Mean SEM 
Oatp1a1 
5 142.5 32.3 165.8 41.8 97.0 32.5 94.2 61.4 
10 157.0 55.9 139.0 82.0 85.0 76.3 71.3 46.4 
Ntcp 
5 106.6 46.2 113.4 44.2 102.4 33.5 74.7 22.0 
10 109.3 56.8 73.9 43.5 96.7 20.4 55.9 15.5 
Bsep 
5 62.9 45.8 50.2 41.3 101.8 46.5 142.0 42.4 
10 43.8 37.6 59.6 64.5 94.2 32.4 126.7 65.9 
Pgp 
5 114.3 42.5 96.6 31.1 110.3 15.9 111.0 64.2 
10 85.2 22.2 94.2 39.2 76.0 46.8 96.4 57.9 
Mrp4 
5 70.2 6.9 45.2 0.0 90.8 27.1 77.5 35.7 
10 45.2 12.9 44.7 27.6 75.0 10.8 78.6 24.8 
Mrp2 
5 50.5 13.7 117.6 81.4     
10 74.6 61.5 84.3 53.0     
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Figure 4.3.  
(A) Rosuvastatin accumulation (Cells+Bile) 
 Accumulation in Cells+Bile (pmol/mg protein) 
MOI 
WT TR- 
Ad-siNT Ad-siBcrp Ad-siNT Ad-siBcrp 
0 180.9 182.2 
1 200.2 181.9 180.7 173.7 
3 197.3 190.3 169.6 156.1 
5 206.9 184.0 173.7 170.9 
10 190.3 181.0 149.8 126.1 
 
(B) Rosuvastatin BEI 
 BEI (%) 
MOI 
WT TR- 
Ad-siNT Ad-siBcrp Ad-siNT Ad-siBcrp 
0 54.3 24.6 
1 53.1 54.5 20.1 21.0 
3 49.6 44.5 18.7 14.1 
5 45.4 30.8 17.8 5.9 
10 40.0 29.4 19.2 7.7 
 
(C) Taurocholic acid accumulation (Cells+Bile) 
 Accumulation in Cells+Bile (pmol/mg protein) 
MOI 
WT TR- 
Ad-siNT Ad-siBcrp Ad-siNT Ad-siBcrp 
0 27.1 41.7 
1 27.8 26.0 39.3 33.9 
3 22.3 19.7 37.1 32.1 
5 21.1 18.0 38.1 30.9 
10 21.3 16.4 40.3 26.7 
 
(D) Taurocholic acid BEI 
 BEI (%) 
MOI 
WT TR- 
Ad-siNT Ad-siBcrp Ad-siNT Ad-siBcrp 
0 83.0 72.6 
1 89.2 85.2 73.4 66.5 
3 82.7 81.7 70.4 67.2 
5 78.6 80.1 64.5 60.6 
10 80.8 77.4 56.8 45.8 
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Supplement Figure 4.1. 
(B) Mrp2 and Bcrp protein 
MOI 
Mrp2 protein (% non-infected control) Bcrp protein (% non-infected control) 
Ad-siNT Ad-siBcrp Ad-siNT Ad-siBcrp 
Mean SEM Mean SEM Mean SEM Mean SEM 
5 109.1 42.1 60.4 30.0 97.9 14.2 114.0 22.1 
10 59.7 49.5 17.1 13.6 102.6 27.9 88.2 10.5 
15 106.1 0.0 32.7 0.0 104.7 0.0 104.7 0.0 
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Supplement Figure 4.2. 
(A) Estradiol-17β-D-glucuronide accumulation (Cells+Bile) 
 
Accumulation in Cells+Bile  
(pmol/mg protein) 
MOI Ad-siNT Ad-siMrp2 
0 1015.1 
5 1224.1 1031.8 
10 992.4 1078.7 
15 967.5 788.5 
20 1146.6 1039.2 
 
(B) Estradiol-17β-D-glucuronide BEI 
 BEI (%) 
MOI Ad-siNT Ad-siMrp2 
0 23.8 
5 19.6 10.5 
10 4.1 0.0 
15 7.6 0.0 
20 11.7 7.3 
 
(C) Taurocholic acid accumulation (Cells+Bile) 
 
Accumulation in Cells+Bile  
(pmol/mg protein) 
MOI Ad-siNT Ad-siMrp2 
0 34.4 
5 33.5 22.7 
10 20.2 11.0 
15 26.1 19.9 
20 24.7 16.2 
 
(D) Taurocholic acid BEI 
 BEI (%) 
MOI Ad-siNT Ad-siMrp2 
0 90.8 
5 91.1 88.4 
10 90.2 86.5 
15 88.9 87.5 
20 86.3 83.0 
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Supplement Figure 4.3. 
(B) Mrp2 and Bcrp protein expression 
 Protein (% non-infected control) 
 Ad-siNT Ad-siBcrp + Ad-siMrp2 
 Mean SEM Mean SEM 
Mrp2 53.4 19.8 32.9 8.8 
Bcrp 70.5 5.6 36.0 4.0 
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Figure 5.2. 
(A) TGZ 
Rat 
Viral 
Infection 
Cells+Bile 
(pmol/mg protein) 
Cells 
(pmol/mg protein) 
Mean SEM Mean SEM 
WT 
CTL 406.0 301.0 629.1 330.6 
Ad-siNT 431.5 324.6 585.8 335.1 
Ad-siBcrp 529.6 375.3 704.7 405.1 
TR- 
CTL 927.2 624.2 1069.7 593.9 
Ad-siNT 902.1 630.3 1026.2 607.1 
Ad-siBcrp 1096.0 737.4 1261.0 795.7 
 
(B) TS 
Rat 
Viral 
Infection 
Cells+Bile 
(pmol/mg protein) 
Cells 
(pmol/mg protein) 
BEI 
(%) 
Mean SEM Mean SEM Mean SEM 
WT 
CTL 1067.4 95.3 812.8 212.7 24.3 14.9 
Ad-siNT 1270.0 83.5 949.9 156.5 25.5 8.1 
Ad-siBcrp 1311.7 214.3 1005.6 236.3 23.4 10.9 
TR- 
CTL 717.5 60.8 575.0 51.4 19.1 13.5 
Ad-siNT 739.9 112.0 606.6 17.3 16.6 14.0 
Ad-siBcrp 771.1 143.6 593.2 65.5 22.1 10.0 
 
(C) TG 
Rat 
Viral 
Infection 
Cells+Bile 
(pmol/mg protein) 
Cells 
(pmol/mg protein) 
BEI 
(%) 
Mean SEM Mean SEM Mean SEM 
WT 
CTL 92.6 71.3 41.8 32.0 49.3 14.7 
Ad-siNT 151.1 117.7 64.3 53.2 58.5 7.7 
Ad-siBcrp 137.1 109.1 60.5 50.8 55.6 5.3 
TR- 
CTL 64.8 22.5 70.8 19.6 1.0 1.7 
Ad-siNT 134.4 18.4 141.7 32.0 2.3 4.0 
Ad-siBcrp 117.4 23.2 115.3 9.9 7.9 7.2 
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Figure 5.3. 
(A) TGZ 
Rat 
Viral 
Infection 
Medium  
(pmol/mg protein) 
Mean SEM 
WT 
CTL 7163.3 1740.0 
Ad-siNT 7206.7 1855.8 
Ad-siBcrp 7260.0 2014.3 
TR- 
CTL 6776.7 1585.9 
Ad-siNT 7256.7 1856.1 
Ad-siBcrp 7233.3 2140.0 
 
(B) TS 
Rat 
Viral 
Infection 
Medium 
(pmol/mg protein) 
Mean SEM 
WT 
CTL 121.9 24.6 
Ad-siNT 101.8 8.5 
Ad-siBcrp 92.3 19.0 
TR- 
CTL 81.6 21.8 
Ad-siNT 76.0 17.4 
Ad-siBcrp 63.6 16.8 
 
(C) TG 
Rat 
Viral 
Infection 
Medium 
(pmol/mg protein) 
Mean SEM 
WT 
CTL 60.3 49.0 
Ad-siNT 76.3 62.3 
Ad-siBcrp 58.9 48.8 
TR- 
CTL 103.9 26.9 
Ad-siNT 157.1 47.3 
Ad-siBcrp 113.8 17.5 
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Figure 5.4. 
(A) Total recovery 
  Total recovery (% of TGZ Dose) 
Rat 
Viral 
Infection 
TGZ TS TG TQ 
WT 
CTL 91.1 4.8 0.9 1.5 
Ad-siNT 91.3 5.1 1.3 1.5 
Ad-siBcrp 92.3 5.2 1.0 1.3 
TR- 
CTL 86.9 2.8 1.5 1.2 
Ad-siNT 92.6 2.9 2.3 1.3 
Ad-siBcrp 92.4 2.8 1.7 1.4 
 
(B) TS Recovery  
  TS recovery (% of TGZ Dose) 
Rat 
Viral 
Infection 
Medium Cells Bile 
WT 
CTL 1.61 2.36 0.85 
Ad-siNT 1.32 2.78 1.01 
Ad-siBcrp 1.22 2.94 1.01 
TR- 
CTL 1.01 1.42 0.42 
Ad-siNT 0.95 1.52 0.41 
Ad-siBcrp 0.80 1.52 0.47 
 
(C) TG Recovery 
  TG recovery (% of TGZ Dose) 
Rat 
Viral 
Infection 
Medium Cells Bile 
WT 
CTL 0.69 0.11 0.13 
Ad-siNT 0.87 0.16 0.22 
Ad-siBcrp 0.68 0.15 0.20 
TR- 
CTL 1.30 0.17 0.00 
Ad-siNT 1.94 0.34 0.01 
Ad-siBcrp 1.43 0.28 0.03 
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Figure 5.5. 
 
ATP-dependent transport  
(pmol/min/mg protein) 
Compound 
Control Bsep 
Mean SEM Mean SEM 
TC 7.8 13.0 326.6 18.4 
TS 479.8 336.4 532.1 355.0 
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Figure 5.6. 
(A) TS 
Rat 
Viral 
Infection 
Cells+Bile 
(pmol/mg protein) 
Cells 
(pmol/mg protein) 
BEI 
(%) 
Mean SEM Mean SEM Mean SEM 
WT 
CTL 1059.6 212.7 880.2 288.2 18.1 13.1 
GF120918 1058.0 163.5 903.0 191.4 14.4 13.2 
TR- 
CTL 588.8 73.7 508.8 68.2 13.5 7.3 
GF120918 602.9 77.7 535.9 64.5 10.7 8.4 
 
(B) TG 
Rat 
Viral 
Infection 
Cells+Bile 
(pmol/mg protein) 
Cells 
(pmol/mg protein) 
BEI 
(%) 
Mean SEM Mean SEM Mean SEM 
WT 
CTL 89.6 89.4 43.9 56.2 59.9 13.9 
GF120918 86.6 90.4 44.7 59.7 64.5 23.5 
TR- 
CTL 78.8 9.9 77.5 15.8 1.5 16.3 
GF120918 84.9 8.1 85.1 15.4 3.2 8.1 
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Figure 5.7. 
1 µM TGZ 
 Velocity (pmol/min/mg protein) 
Compound 
WT TR- 
Mean SD Mean SD 
TS 88.6 24.4 101.8 57.5 
TG 4.9 4.8 75.0 48.7 
 
10 µM TGZ 
 Velocity (pmol/min/mg protein) 
Compound 
WT TR- 
Mean SD Mean SD 
TS 251.6 109.8 291.6 93.8 
TG 95.6 44.6 616.7 190.6 
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Figure 6.2. 
(A) ATP  
LCA Medium 
Concentration 
(µM) 
Rat ATP (mM) Human ATP (mM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 2.79 0.13 3.74 0.54 3.33 0.04 5.23 0.07 4.15 0.31 3.63 0.63 
25 3.13 0.29 3.39 0.05 2.91 0.21 4.83 0.33 4.06 0.18 3.14 0.67 
50 3.17 0.24 3.57 0.27 2.96 0.20 4.73 0.12 4.31 0.27 2.49 0.53 
100 3.04 0.33 2.98 0.07 2.75 0.15 4.36 0.57 3.69 0.41 2.46 0.61 
125 2.43 0.13 3.05 0.84 1.84 0.29 4.49 0.08 3.97 0.17 2.78 0.61 
150 2.22 0.21 2.16 0.23 1.63 0.34 4.28 0.38 3.51 0.23 1.85 0.33 
200 1.81 0.23 1.81 0.40 0.87 0.52 4.20 0.14 3.71 0.23 1.11 0.46 
 
LCA Medium 
Concentration 
(µM) 
Mouse ATP (mM) Dog ATP (mM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 2.22 0.12 2.55 0.20 1.48 0.22 2.38 0.87 3.76 0.67 3.63 0.63 
25 2.25 0.19 2.76 0.46 1.91 0.66 2.78 1.15 4.15 1.36 3.19 0.68 
50 2.14 0.18 2.59 0.13 1.42 0.15 2.11 0.85 3.85 1.16 2.51 0.53 
100 2.27 0.29 2.49 0.28 1.33 0.61 1.97 0.87 3.79 0.62 2.50 0.62 
125 2.30 0.40 2.46 0.16 1.29 0.21 2.22 0.26 3.36 0.10 2.75 0.60 
150 2.10 0.25 2.43 0.20 1.42 0.06 2.18 0.63 3.45 1.04 1.84 0.33 
200 2.17 0.53 1.95 0.06 1.16 0.25 2.08 0.72 2.91 0.40 1.29 0.53 
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LDH 
LCA Medium 
Concentration 
(µM) 
Rat LDH (% Control) Human (% Control) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.73 0.00 1.95 0.00 0.83 0.00 0.62 0.00 0.77 0.00 0.62 
25 0.00 0.56 0.71 0.84 1.37 0.81 0.00 1.28 0.00 1.67 0.00 1.28 
50 0.00 0.43 0.00 0.83 0.00 0.19 0.00 0.99 1.01 0.74 0.00 0.99 
100 0.00 0.68 1.46 0.74 0.09 0.62 0.00 1.71 0.00 0.89 0.00 1.71 
125 1.05 0.97 17.23 6.70 32.85 5.87 1.10 3.06 0.00 0.70 1.10 3.06 
150 4.68 1.48 38.65 3.58 65.62 5.98 0.08 2.05 0.80 2.29 0.08 2.05 
200 15.65 3.66 61.93 7.07 80.05 12.41 0.00 0.39 1.46 1.17 0.00 0.39 
 
LCA Medium 
Concentration 
(µM) 
Mouse (% Control) Dog (% Control) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.78 0.00 1.37 0.00 3.52 0.00 2.08 0.00 2.66 0.00 3.47 
25 1.65 0.83 4.56 2.55 5.81 3.56 0.00 4.35 0.00 2.42 0.00 6.85 
50 0.70 0.49 1.72 2.55 0.74 1.71 0.00 3.48 0.21 3.35 0.00 3.98 
100 4.01 1.10 0.00 1.89 0.00 3.57 0.00 3.59 1.79 2.23 0.00 3.96 
125 0.35 1.36 1.42 1.00 0.00 1.97 0.00 0.41 0.00 0.57 0.00 0.53 
150 2.83 0.47 3.38 2.98 1.68 7.08 0.00 2.01 0.04 3.12 0.00 1.73 
200 2.42 1.35 2.43 3.35 3.00 3.36 0.00 3.57 0.00 1.46 13.23 1.19 
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(B)  LCA 
LCA Medium 
Concentration 
(µM) 
Rat LCA (mM) Human LCA (mM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.00 0.00 0.00 0.00 0.00       
25 0.01 0.00 0.01 0.00 0.00 0.00       
50 0.07 0.04 0.03 0.00 0.01 0.00       
100 0.93 0.06 0.84 0.01 0.03 0.00 2.36 0.16 1.24 0.08 0.11 0.02 
125 0.99 0.14 1.08 0.02 0.11 0.05 3.79 0.18 2.59 0.17 0.51 0.19 
150 1.08 0.15 1.54 0.06 2.67 0.15 4.29 0.31 3.22 0.10 1.05 0.23 
200 2.53 0.87 9.07 2.46 6.76 1.36 4.72 1.21 4.09 0.17 1.11 0.16 
 
LCA Medium 
Concentration 
(µM) 
Mouse LCA (mM) Dog LCA (mM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
100 0.41 0.05 0.26 0.02 0.55 0.03 0.94 0.29 0.97 0.07 0.33 0.04 
125 0.70 0.12 0.44 0.03 0.75 0.06 2.55 0.44 2.10 0.55 0.88 0.10 
150 0.73 0.22 0.59 0.17 1.02 0.15 1.66 0.92 1.39 0.30 0.48 0.07 
200 1.17 0.19 1.09 0.16 1.41 0.33 3.60 0.67 3.21 0.08 1.49 0.06 
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TLCA 
LCA Medium 
Concentration 
(µM) 
Rat TLCA (mM) Human TLCA (mM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.00 0.00 0.00 0.00 0.00       
25 0.46 0.17 0.50 0.16 0.34 0.20       
50 0.57 0.46 0.68 0.32 0.49 0.17       
100 0.82 0.24 0.85 0.25 0.56 0.10 0.0042 0.0005 0.0035 0.0002 0.0013 0.0003 
125 0.47 0.33 0.61 0.18 0.52 0.22 0.0054 0.0001 0.0051 0.0002 0.0027 0.0002 
150 0.54 0.11 0.48 0.16 0.21 0.10 0.0051 0.0007 0.0052 0.0003 0.0035 0.0004 
200 0.33 0.20 0.21 0.12 0.34 0.20 0.0063 0.0008 0.0071 0.0004 0.0057 0.0008 
 
LCA Medium 
Concentration 
(µM) 
Mouse TLCA (mM) Dog TLCA (mM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
100 0.08 0.02 0.43 0.23 0.46 0.03 0.12 0.04 0.18 0.04 0.15 0.04 
125 0.35 0.53 0.25 0.11 0.37 0.17 0.18 0.04 0.23 0.07 0.14 0.04 
150 0.04 0.01 0.08 0.05 0.32 0.18 0.13 0.08 0.20 0.04 0.11 0.05 
200 0.09 0.10 0.22 0.28 0.40 0.36 0.15 0.03 0.28 0.09 0.12 0.03 
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GLCA 
LCA Medium 
Concentration 
(µM) 
Rat GLCA (mM) Human GLCA (mM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.00 0.00 0.00 0.00 0.00       
25 1.17 0.29 1.65 0.08 1.00 0.62       
50 2.11 0.38 3.83 0.34 2.64 0.57       
100 3.42 0.94 7.80 1.21 5.94 0.82 1.00 0.04 0.93 0.09 0.36 0.14 
125 3.06 1.99 6.26 1.58 6.43 1.00 1.28 0.30 1.38 0.21 0.87 0.13 
150 2.81 0.15 5.28 2.10 3.24 1.61 1.07 0.13 1.23 0.11 1.05 0.08 
200 2.84 1.66 3.02 1.16 4.50 3.45 1.33 0.31 2.06 0.66 2.14 0.39 
 
LCA Medium 
Concentration 
(µM) 
Mouse GLCA (mM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD 
100 0.02 0.00 0.15 0.06 0.24 0.02 
125 0.06 0.08 0.10 0.03 0.18 0.08 
150 0.02 0.00 0.04 0.02 0.18 0.08 
200 0.02 0.01 0.07 0.06 0.17 0.12 
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Figure 6.3. 
(A) ATP  
Rat ATP (mM) Human ATP (mM) 
CDCA Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr CDCA Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 2.00 0.26 1.71 0.22 2.90 0.26 0 4.27 0.02 3.36 0.07 3.66 0.13 
50 2.06 0.18 1.74 0.15 2.79 0.13 250 4.35 0.08 3.39 0.03 3.81 0.07 
100 1.78 0.07 1.54 0.06 2.49 0.40 375 4.02 0.18 3.40 0.04 3.41 0.04 
250 1.21 0.25 1.67 0.35 1.86 0.33 500 3.50 0.14 2.94 0.05 2.95 0.06 
375 0.58 0.27 1.72 0.80 1.53 0.84 650 2.61 0.17 1.70 0.04 1.48 0.03 
500 0.94 0.12 0.73 0.10 0.70 0.03 800 1.41 0.06 0.67 0.07 0.14 0.01 
1000 0.15 0.02 0.15 0.05 0.21 0.01 1000 0.61 0.07 0.16 0.02 0.08 0.00 
 
LDH 
Rat LDH (% Control) Human LDH (% Control) 
CDCA Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr CDCA Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 1.55 0.00 2.67 0.00 2.73 0 0.00 0.57 0.00 1.36 0.00 0.10 
50 1.85 1.02 0.44 1.80 0.00 2.52 250 0.07 0.61 0.00 0.71 0.30 0.95 
100 2.49 0.98 3.84 0.69 3.71 4.92 375 0.00 0.60 0.00 0.27 0.81 0.15 
250 11.09 4.29 44.56 3.08 52.53 5.41 500 0.00 2.74 2.11 0.38 3.77 0.80 
375 43.45 8.07 83.79 4.43 88.50 5.55 650 3.13 1.44 5.35 0.73 19.89 1.10 
500 89.34 1.49 88.60 4.65 91.52 10.00 800 4.44 0.32 12.33 1.28 54.69 0.77 
1000 97.28 4.77 99.01 6.50 102.69 4.20 1000 10.82 1.66 44.70 3.09 72.80 4.26 
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(B) CDCA 
Rat CDCA (mM) Human CDCA (mM) 
CDCA 
Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr 
CDCA 
Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0 0.00 0.00 0.00 0.00 0.00 0.00 
50 0.00096 0.00044 0.00040 0.00038 0.00009 0.00015 250 2.96 0.05 2.80 0.06 2.05 0.27 
100 0.00565 0.00242 0.00 0.00 0.00 0.00 375 4.00 0.09 3.47 0.28 3.16 0.08 
250 0.10 0.01 0.06 0.01 0.04 0.00 500 3.95 0.10 2.18 0.38 1.99 0.27 
375 0.12 0.04 0.26 0.02 0.19 0.01 650 2.98 0.22 1.10 0.09 0.61 0.09 
500 0.35 0.04 0.70 0.16 0.68 0.16 800 2.62 0.18 0.82 0.04 0.90 0.04 
1000 1.25 0.17 2.89 0.52 6.80 0.98 1000 2.90 0.22 2.02 0.19 1.08 0.16 
 
TCDCA 
Rat TCDCA (mM) Human TCDCA (mM) 
CDCA  
Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr CDCA  
Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.0000 0.0000 0.0001 0.0001 0.0003 0.0001 0 0.0369 0.0004 0.0368 0.0006 0.0280 0.0005 
50 0.0038 0.0008 0.0008 0.0002 0.0005 0.0001 250 0.0058 0.0006 0.0047 0.0003 0.0051 0.0006 
100 0.0093 0.0046 0.0017 0.0004 0.0009 0.0001 375 0.0081 0.0005 0.0061 0.0005 0.0054 0.0005 
250 0.0050 0.0014 0.0024 0.0002 0.0029 0.0004 500 0.0109 0.0011 0.0044 0.0004 0.0050 0.0002 
375 0.0051 0.0009 0.0099 0.0029 0.0069 0.0020 650 0.0110 0.0007 0.0031 0.0003 0.0025 0.0000 
500 0.0074 0.0010 0.0112 0.0035 0.0109 0.0017 800 0.0113 0.0008 0.0028 0.0001 0.0014 0.0001 
1000 0.0102 0.0029 0.0171 0.0027 0.0387 0.0051 1000 0.0128 0.0016 0.0037 0.0005 0.0009 0.0002 
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GCDCA 
Rat GCDCA (mM) Human GCDCA (mM) 
CDCA 
Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr CDCA 
Medium 
Concentration 
(µM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0 0.032 0.001 0.035 0.002 0.033 0.000 
50 0.0010 0.0004 0.0004 0.0004 0.0001 0.0001 250 0.43 0.02 0.38 0.01 0.44 0.04 
100 0.0057 0.0024 0.00 0.00 0.00 0.00 375 0.54 0.02 0.42 0.01 0.37 0.01 
250 0.0961 0.0077 0.0633 0.0139 0.0397 0.0035 500 0.50 0.00 0.29 0.03 0.32 0.01 
375 0.12 0.04 0.26 0.02 0.19 0.01 650 0.35 0.01 0.14 0.01 0.15 0.01 
500 0.35 0.04 0.70 0.16 0.68 0.16 800 0.29 0.01 0.17 0.01 0.03 0.01 
1000 1.25 0.17 2.89 0.52 6.80 0.98 1000 0.25 0.01 0.13 0.02 0.01 0.00 
 
  
  
 
3
1
1
 
Supplementary Figure 6.1. 
(A) Rat 
LCA Medium 
Concentration 
(µM) 
TCDCA (µM) GCDCA (µM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.00 0.11 0.19 1.41 0.25 0.00 0.00 0.00 0.00 0.25 0.22 
25 1.02 0.19 1.71 0.34 2.91 0.68 1.11 0.04 2.23 0.45 2.59 0.58 
50 1.05 0.70 1.93 0.45 3.28 1.23 1.39 0.72 2.92 0.46 5.05 0.36 
100 0.67 0.27 1.25 0.21 1.56 0.38 1.12 0.41 2.37 0.08 4.67 0.78 
125 0.00 0.00 0.34 0.30 0.35 0.60 0.63 0.26 0.94 0.21 1.75 0.36 
150 0.00 0.00 0.00 0.00 0.00 0.00 0.69 0.17 0.73 0.23 0.33 0.57 
200 0.00 0.00 0.00 0.00 0.00 0.00 0.64 0.56 0.00 0.00 0.88 1.52 
 
LCA Medium 
Concentration 
(µM) 
TMCA (µM) GMCA (µM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.69 0.94 10.62 3.27 51.45 17.96 0.00 0.00 0.19 0.32 5.26 0.54 
25 11.64 2.01 13.91 3.58 18.68 7.56 10.58 0.46 11.38 1.65 11.27 1.61 
50 6.84 4.72 11.63 3.13 13.56 3.99 8.20 3.67 11.90 0.79 12.70 0.00 
100 2.58 1.46 3.55 1.05 4.16 1.30 7.72 1.68 10.47 1.61 9.80 0.46 
125 0.00 0.00 0.00 0.00 1.42 1.43 3.80 2.14 4.79 1.45 10.01 2.64 
150 0.00 0.00 0.00 0.00 0.00 0.00 3.69 1.01 3.41 1.60 2.39 2.70 
200 0.00 0.00 0.00 0.00 0.00 0.00 1.76 1.52 1.53 0.32 0.66 1.15 
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(B) Human 
LCA Medium 
Concentration 
(µM) 
TCDCA (µM) GCDCA (µM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0     9.70 1.69     14.28 2.93 
100 4.35 0.03 4.53 0.30 3.95 1.30 1.98 0.15 2.76 0.20 2.83 0.89 
125 4.09 0.67 3.44 0.26 3.05 0.36 2.10 0.16 2.38 0.16 2.16 0.31 
150 3.38 0.36 2.80 0.10 2.20 0.21 1.71 0.20 1.86 0.25 1.50 0.22 
200 3.76 0.83 3.25 0.09 2.29 0.16 2.28 0.51 2.22 0.14 1.66 0.14 
 
LCA Medium 
Concentration 
(µM) 
TCA (µM) GCA (µM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0     2.67 0.59     14.28 2.93 
100 0.23 0.04 0.21 0.03 0.13 0.12 0.60 0.10 0.63 0.03 0.61 0.15 
125 0.22 0.06 0.23 0.04 0.08 0.15 0.63 0.31 0.59 0.09 0.55 0.19 
150 0.19 0.01 0.07 0.13 0.00 0.00 0.54 0.14 0.41 0.12 0.34 0.05 
200 0.29 0.03 0.33 0.02 0.20 0.01 0.72 0.13 0.85 0.22 0.66 0.12 
 
LCA Medium 
Concentration 
(µM) 
GHDCA (µM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD 
0     0.00 0.00 
100 3.05 0.03 2.60 0.43 1.08 1.08 
125 6.90 2.00 6.50 1.83 1.84 3.18 
150 7.89 1.33 2.31 4.01 4.98 0.83 
200 13.65 5.90 16.62 14.59 18.75 3.31 
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(C) Mouse 
LCA Medium 
Concentration 
(µM) 
TCDCA (µM) GCDCA (µM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0     0.38 0.09     0.00 0.00 
100 13.56 2.20 19.20 4.52 26.33 5.57 0.96 0.20 1.31 0.11 1.48 0.27 
125 13.96 8.38 14.53 3.30 17.89 3.56 0.74 0.18 1.20 0.13 0.96 0.13 
150 8.28 1.89 8.35 2.02 12.47 1.04 0.70 0.05 0.92 0.21 1.04 0.14 
200 11.17 2.76 11.86 7.77 15.81 5.79 0.82 0.30 1.07 0.32 1.01 0.29 
 
LCA Medium 
Concentration 
(µM) 
TMCA (µM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD 
0     6.58 0.93 
100 1.34 0.64 3.68 1.00 1.93 0.58 
125 1.09 1.45 1.65 0.69 0.61 0.53 
150 0.00 0.00 0.41 0.37 0.00 0.00 
200 0.41 0.70 0.88 1.12 0.49 0.85 
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(D) Dog 
LCA Medium 
Concentration 
(µM) 
TCDCA (µM) GCDCA (µM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0     1.23 0.22     1.18 0.21 
100 0.94 0.09 0.71 0.06 0.40 0.05 0.97 0.21 0.83 0.12 0.54 0.10 
125 0.79 0.07 0.58 0.05 0.42 0.03 0.89 0.16 0.65 0.10 0.41 0.05 
150 0.70 0.17 0.73 0.12 0.36 0.06 0.79 0.35 0.78 0.15 0.41 0.11 
200 0.55 0.10 0.61 0.08 0.52 0.18 0.54 0.02 0.53 0.07 0.49 0.12 
 
LCA Medium 
Concentration 
(µM) 
TCA (µM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD 
0     0.48 0.08 
100 0.29 0.08 0.22 0.06 0.13 0.11 
125 0.25 0.06 0.24 0.09 0.16 0.13 
150 0.26 0.09 0.35 0.21 0.11 0.10 
200 0.30 0.13 0.14 0.13 0.00 0.00 
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Supplementary Figure 6.2. 
(A) Rat 
CDCA 
Medium 
Concentration 
(µM) 
MCA (µM) TMCA (µM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 3.45 1.05 5.74 2.49 14.00 3.94 
50 0.00 0.00 0.00 0.00 0.00 0.00 30.68 9.87 33.66 12.41 46.28 17.25 
100 24.12 9.33 0.00 0.00 0.00 0.00 28.23 2.55 13.18 4.16 18.37 3.02 
250 72.25 13.63 135.56 37.14 88.75 7.62 8.22 1.91 1.94 0.49 1.79 0.33 
375 63.87 24.68 113.44 18.10 55.44 12.66 7.12 2.80 0.00 0.00 0.00 0.00 
500 101.37 25.99 62.27 42.55 1.53 2.65 5.33 3.29 0.00 0.00 0.00 0.00 
1000 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
CDCA 
Medium 
Concentration 
(µM) 
GMCA (µM) GCA (µM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.00 0.00 0.00 0.00 0.87 0.10 0.00 0.00 0.00 0.00 0.00 0.00 
50 120.61 10.12 95.64 19.74 102.50 16.20 0.00 0.00 0.00 0.00 0.00 0.00 
100 305.97 15.05 127.47 13.50 115.58 12.55 0.36 0.03 0.00 0.00 0.00 0.00 
250 202.90 11.34 150.74 11.60 117.49 13.47 0.18 0.01 0.00 0.00 0.00 0.00 
375 117.37 25.60 44.25 6.11 12.22 5.38 0.00 0.00 0.00 0.00 0.00 0.00 
500 80.99 40.40 8.19 2.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1000 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
  
  
 
3
1
6
 
(B) Human 
CDCA 
Medium 
Concentration 
(µM) 
CA (µM) TCA (µM) 
6 hr 12 hr 24 hr 6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
0 0.59 0.04 0.75 0.06 0.62 0.08 5.88 0.25 7.31 0.38 8.33 0.67 
250 9.49 0.41 5.93 0.26 4.24 0.69 0.50 0.03 0.32 0.06 0.20 0.03 
375 10.95 0.58 6.60 0.66 3.99 0.45 0.58 0.02 0.26 0.04 0.19 0.03 
500 11.72 0.68 5.37 0.83 3.15 0.24 1.03 0.05 0.28 0.03 0.14 0.12 
650 7.85 0.66 2.94 0.32 1.71 0.09 1.44 0.09 0.32 0.01 0.00 0.00 
800 6.27 0.36 1.93 0.06 0.32 0.28 2.13 0.19 0.36 0.02 0.00 0.00 
1000 5.11 0.13 1.28 0.11 0.00 0.00 2.49 0.08 0.40 0.03 0.00 0.00 
 
CDCA 
Medium 
Concentration 
(µM) 
GCA (µM) 
6 hr 12 hr 24 hr 
Mean SD Mean SD Mean SD 
0 20.38 0.89 28.39 4.10 44.47 1.05 
250 2.22 0.15 1.25 0.03 1.01 0.11 
375 2.35 0.21 1.33 0.07 0.90 0.06 
500 2.78 0.22 1.17 0.04 0.87 0.07 
650 4.18 0.26 0.81 0.15 0.65 0.02 
800 6.11 0.49 1.27 0.10 0.00 0.00 
1000 8.93 0.41 1.40 0.15 0.00 0.00 
 
 
